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Children and young people are often administered medicines which are not tested or 
approved for use in this population. It is acknowledged that this use of off-label and 
unlicensed medicines to treat children can lead to over- or under-dosing, adverse drug 
reactions, and low treatment success (EMA, 2012). A key challenge to developing 
age-appropriate and acceptable medicines is that limited information is available for 
the development of paediatric medicines. Patient acceptability of medicines is thought 
to have a significant impact on treatment adherence and ultimately safety and efficacy. 
However, a lack of knowledge about what is considered acceptable to children and 
best practice methods to assess acceptability is limited and fragmented.  
Aim and objectives 
The aim of this study was to explore the experiences of children in relation to 
medicines, to incorporate their views to develop a better understanding of the 
acceptability of medicine, and to relate this to the tools that are used to assess the 
acceptability of medicines. 
Three objectives were proposed to ensure that the overall aim of the study was 
achieved. These were to: 
1. Explore children’s experiences of medicines to gain a better understanding 
about what is acceptable to children in formulations. 
2. Evaluate with children methods used to assess the acceptability of medicine. 
3. Use this new information to propose ways that existing tools used to assess 
acceptability of formulations in a paediatric population can be re-designed to 
better reflect children’s perspectives on the acceptability of medicine.  
 
Methods 
This study used a generic qualitative methodology and employed child-centred 
qualitative methods including activity booklets, drawing and ranking activities, 
interviews and participant observation to generate data with children aged 5-12 years 
in group workshops and one-to-one. Children were recruited through convenience 




One hundred and eleven children participated in the study. The findings are organised 
into six superordinate themes presented in two separate chapters clearly reflecting the 
children’s perspectives. The first findings chapter, Exploring Children’s Perspectives 
to Improve the Understanding of the Acceptability of Medicines, encompasses three 
major themes: 1) What children can tell us about the acceptability of medicines, 2) 
What helps improve the acceptability of medicines to children, and 3) What reduces 
the acceptability of medicines to children. The second findings chapter, Improving the 
Methods Used to Assess the Acceptability of Medicines, also has three key themes: 
4) Children’s experience and understanding of scales, 5) Children’s perceptions on 
and preferences for scales, and lastly, 6) Improving acceptability assessment.   
 
Conclusion 
The findings from the study present original contributions to knowledge of the 
acceptability of medicine in a child population, demonstrating that involving children in 
acceptability research provides a much-needed perspective on the acceptability of 
medicine and the factors thought to impact acceptability. A new definition of the 
acceptability of medicine is presented, grounded in data provided by the children. The 
“Framework of Children’s Medicine Acceptability”, provides a novel theoretical 
framework for the acceptability of medicine. Key recommendations address the factors 
that should be measured when assessing acceptability, improvements for 
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“Patient acceptability can be defined as the ability and 
willingness of a patient to self-administer, and also of any 
of their lay or professional caregivers, to administer a 





“a formulation whose pharmaceutical design makes it 
suitable for use in the target age group(s)” (EMA, 2013).  
Adverse Drug Event 
 
“an injury resulting from medical intervention related to a 





“Drug compounding is often regarded as the process of 
combining, mixing or altering ingredients to create a 
medication tailored to the needs of an individual patient” 




“An excipient is a constituent of a medicine other than the 
active substance, added in the formulation for a specific 
purpose. This may include colouring matter, preservatives, 
adjuvants, stabilisers, thickeners, emulsifiers, flavouring 




“A manipulation is defined as the physical alteration of a 
pharmaceutical drug dosage form for the purposes of 
extracting and administering the required proportion of the 
drug dose. Examples of the types of manipulation include: 
6 Tablets: split/broken/cut and a segment given, crushed 
and a proportion of the powder given, dispersed in liquid 
and a portion of the liquid given. Transdermal Patches: 
patch cut, and a portion of patch uncovered and applied.” 






“Adherence to medicines is defined as the extent to which 
the patient's action matches the agreed recommendations” 





“the extent to which the patient’s action matches the 
recommendation of the prescriber” (NCCSDO, 2005., p12) 
Medication Error 
 
“Medication errors are broadly defined as any error in the 
prescribing, dispensing, or administration of a drug, 
irrespective of whether such errors lead to adverse 





“Intentional non-adherence refers to non-adherence that is 
deliberate and largely associated with patient motivation 
whereas unintentional non-adherence is non-adherence 
that is largely driven by a lack of capacity or resources to 





“Means that the medicine is being used in a way that is 
different to that described in the licence. E.g. using a 
medicine for a different illness to that stated in the licence, 
using a medicine in an age group outside the licensed 
range, or using a medicine at a higher dose than stated” 




“treating and caring for people in a safe environment and 
protecting them from avoidable harm” (NHS, 2012/2013., 





“Means a medicine has a licence in other countries, but 
not in the UK; a medicine has a licence but needs to be 
made up to be taken as an unlicensed formulation” (i.e. a 
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specially prepared liquid for someone who has difficulty 
swallowing tablets); or a medicine that has no licence at all 
















































1 Introduction  
The aim of this chapter is to introduce the study and provide context and justification 
for the requirement of this research. In an attempt to contextualise this issue within the 
broader landscape, this chapter begins by exploring medicine usage within healthcare 
and the related patient safety concerns, it then focusses on paediatric formulation 
development and its associated challenges. The chapter emphasises the significance 
of the acceptability of formulations in paediatric medicine development and highlights 
what knowledge is currently available and where improvement is necessary. Finally, 
the chapter concludes by presenting the following structure of the thesis. 
 
1.1 Improving Acceptability and Adherence  
Improving the acceptability of medicinal products in the child population is crucial to 
ensuring adherence to medication regimes, reducing the risk of medication errors, and 
improving treatment success (Ranmal et al, 2018). For years, paediatric formulation 
development has been behind that of medicines development for adults. It is reported 
that 50-90% of drugs used in children have never been studied in the paediatric 
population as part of drug development, instead relying on adult participants for safety 
and efficacy studies (Bouzom and Walther, 2008), and in the United Kingdom, fewer 
than 60% of licensed medicines are approved for the paediatric population 
(Balakrishnan et al, 2006). This however varies depending on the setting that 
medicines are prescribed, it is reported that 10-20% of medicines prescribed for 
children by general practitioners have not been licensed for use in children, however 
this number rises up to 45% of medicines used in general paediatric wards and for 
children within neonatal intensive care this number can be over 90% (ABPI, 2004). 
 
Global regulatory initiatives have acknowledged the importance for the development 
of age-appropriate formulations to treat the child population (Gerrard et al, 2019), and 
it is understood that there are specific considerations required when developing 
formulations for children. As well as the diversity of childhood in physiological, 
biological and cognitive development, there are also patient compliance challenges 
such as the ability to take doses and taste preferences, as well as specific safety and 
efficacy concerns relating to the formulations (Sam et al, 2012; Klassen et al, 2008; 
Kearns, 2003). Additionally, issues related to ethical requirements, developmental 
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costs and a small, fragmented market also add to the challenge of developing 
appropriate dosage forms (Schirm et al, 2003; Balakrishnan et al, 2006). By 
developing age-appropriate formulations to treat children it is hoped that patient 
adherence will improve, resulting in positive treatment outcomes and ultimately 
effective treatment regimes.  
 
1.1.1  Improving patient adherence 
Prescribing, dispensing or reviewing medicines is made increasingly difficult for 
healthcare professionals (HCP’s) when accounting for complex medical needs and the 
use of multiple medications in different population groups. A large-scale report 
published by the National Collaborating Centre for Primary Care (NCPPC) in 2009 
outlined that in the UK between 2006-2007 around 10% of NHS expenditure was spent 
on medical care and drug costs, equating to £10.6 billion (O’Flynn, 2009). It is reported 
that patients do not take their medicines as prescribed or recommended and 
adherence figures can be anywhere between 33% to 67% (Elliot et al, 2015), and even 
with a disease as serious as breast cancer, adherence is on average only 70% 
(Philbin, 2019). This results in an estimated drug cost for unwanted or unused 
medications for the NHS in the UK of around £300 million annually (NHS, 2015). A 
systematic review focusing on interventions for enhancing medication adherence 
(Haynes et al, 2008) concluded that improving medicines-taking may have a bigger 
impact on positive clinical outcomes than adapting or improving the treatment itself.  
 
The fact that the cost of unwanted and unused medication is so high is indicative of 
both a lack of adequate communication between healthcare professionals and patients 
about their health problems and how they might be treated, and patients’ assessment 
and experiences of ongoing treatments (Nunes et al, 2009). Over the last decade, 
researchers are becoming more aware that addressing nonadherence might not be 
about getting patients to take more medicines, rather it should begin with an 
understanding of patients’ perspectives of medicines and the reasons why they might 
not want or are unable to use them (Suan et al, 2018; Pages-Puigdemont et al, 2016). 
 
Adherence to medication is multifaceted and involves the formulation, the patient and 
caregiver (where appropriate), and health care team. Within the literature the terms 
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‘medicine compliance’ and ‘medicine adherence’ are frequently used interchangeably 
(Jimmy & Jose, 2011). However, medicine compliance has previously been defined 
as “the extent to which the patient’s action matches the recommendation of the 
prescriber” (NCCSDO, 2005, p12), whereas medicine adherence is defined as “the 
extent to which the patient’s action matches the agreed recommendations of the 
prescriber” (NCCSDO, 2005, p12). Adherence therefore differs from compliance with 
the requirement for an agreement between the patient and the prescriber. The 
agreement of the patient to use the medicine, as intended, is an essential factor of 
treatment success (Brown and Bussell, 2011). Reasons for non-adherence include 
inappropriate formulations, cognitive and social factors. Within the child population 
additional factors impact on adherence including parental/caregiver involvement and 
the age of the child (Rachidi et al, 2017; Chappell, 2015; Gardiner, 2006).  
 
Nonadherence with medication can be due to a number of reasons, which typically fall 
into two categories: intentional and unintentional (O’Flynn, 2009). Unintentional 
nonadherence happens when the patient wants to follow the treatment regimen but 
cannot because of factors outside of their control, such as poor recall or instructions 
which make it difficult for those with intellectual difficulties to follow. Intentional 
nonadherence occurs when the person makes a conscious decision to not follow the 
treatment regimens that they have been prescribed, usually because the medication 
formulation or dosing regimen is perceived by the patient as being inappropriate in 
some way. It is well documented that nonadherence or poor adherence to medication 
regimes result in negative treatment outcomes (Kalogianni, 2011), and adherence is 
ultimately dependent on the patient’s willingness and ability to take the product as 
intended (Adeyemi et al, 2012; Drumond et al, 2017). Therefore, when developing 
medicines for children, it is crucial that formulations are age appropriate and 
acceptable if they are to be used and adhered to.  
 
1.2 The Development of Paediatric Medicines 
In their report Priority Medicines for Children the WHO (2013) states that despite the 
availability of effective molecules, formulations adapted for children are still lacking, 
and development falls behind that of formulations for adults. They note that: “children 
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are often either not treated or, based on anecdotal paediatric evidence, treated off 
label or off licence with formulations for adults” (WHO, 2013, p85). 
 
Compared to adults, there are a number of additional challenges to account for when 
developing and prescribing dosage formulations for children. During childhood there 
is a rapid rate of growth and development, and specific changes occur in the body that 
affect the how medicines are accepted and processed. The bodily organs, systems 
and enzymes change, affecting response to active drugs and adverse reactions and 
this happens at different rates depending on the individual child. Therefore, dosage 
requirements vary across the childhood and are dependent on body surface area and 
weight (Yewale & Dharmapalan, 2012) as well as other factors. Differences are also 
observed in children’s cognitive and motor skills, including co-ordination (EMA, 2006), 
which affects the administration of medicines and the ability to take formulations.  
 
Due to the differences and variability in the paediatric population, the magnitude of 
doses required through childhood can vary 100-fold and the ability to cope with 
different dosage forms can also vary considerably (EMA, 2006). Developers must 
consider a number of practicalities when creating or adapting formulations for children 
such as ensuring the safety of certain excipients (WHO, 2007), being conscious of 
adverse drug reactions (Ufer et al, 2007), and being aware of adherence issues related 
to unpalatable formulations (Ernest et al, 2007).  
 
1.2.1 Paediatric population  
Understanding that the paediatric population is not homogenous, and that maturation 
and development are continual processes in childhood are particularly important 
considerations in the application of physiological, pharmacological and 
pharmacokinetic characteristics to formulation development (RCPCH, 1999; Moore, 
1998; Fernandez et al, 2011; Ernest, 2007). Pharmacokinetics refers to the route of 
the drug through the body’s system and includes the absorption, distribution, 
metabolism and elimination (ADME) of the formulation. Pharmacodynamics comprises 
the physiological and biological response to the drug. The pharmacokinetics of drugs 
vary with age (Kearns, 1998), and one of the most difficult tasks for formulators and 
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developers is to account for the changes that occur during childhood in order to 
develop and provide safe and effective medication (NICE, 2015).  
 
Physiological changes in development impact on important pharmacokinetic 
differences such as intestinal transit, gastric pH and surface area:volume ratio, which 
all impact on the absorption of the drug. Differences have also been reported in drug 
distribution and elimination due to variance in body composition such as fat and water 
levels, and enzyme levels and activity. During infancy and childhood continuous 
change is observed in body water, fat, and protein levels, indicating that the distribution 
of drugs in newborns is significantly different to that in older children and adolescents 
(Ernest, 2006).  Between the ages of 2-11 years most drug clearance related 
processes have matured but these are still usually different to adults (Ernest, 2006). 
Furthermore, additional notable differences in growth and development in sub-groups 
within this 2-11year age range further highlight the requirement for dose variability in 
the infant and child population (Bartelink, 2006). Due to the variability in size, body 
composition, age and organ function that occurs across childhood, paediatricians and 
toxicologists cannot predict children’s reactions to drug therapy based on adult data 
(Kearns et al, 2003), and therefore are presented with challenges of prescribing safe 
and effective treatment for children (Milsap & Jusko, 1994).  
 
Consequently, a range of dosage forms should be available to prescribe a medicinal 
product allowing different strengths and concentrations to ensure every child can be 
treated. The International Council for Harmonisation (ICH) E11, classifies the 
paediatric population into several age groups, this aims to provide the pharmaceutical 
industry with approximate age bands based on relevant physiological and 
pharmacokinetic principals to rationalise and licence medicinal products, rather than 
age groups being ‘arbitrarily chosen’ (Conroy, 2003; pp49). These groups are preterm 
neonates (<36 weeks’ gestation, 1- 27 days), full term neonates (0-27 days), infants 
and toddlers (28 days- 23 months), children (2- 11 years old) and adolescents (12-18 
years old) (EMA CHMP, 2006). The ‘children’ category is further broken down into pre-
school children (2-5 years) and school age children (6- 11 years). These are the age 
categorisations commonly used across pharmaceutical development literature 
(Gauthier & Cardot, 2011; Walsh et al, 2011; Aiache & Gauthier, 2007; Batchelor & 
Marriot, 2013). Of these age bands, it is reported that more than 80% of the child 
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population is represented by children over the age of 2 years, and 50% of all children 
is comprised of preschool (2-5 years) and school age groups (6-11 years) (Gauthier & 
Cardot, 2011).  
 
Whilst classifying the paediatric population into age groups provides some guidance 
for research and development, these age groups do not necessarily adequately 
represent every child within those age brackets. Additionally, different end points may 
be established within the same age group, and there may be overlap between the age 
categories (EMA, 2006). A flexible approach, accounting for developmental biology 
and pharmacology is necessary to ensure that each individual is provided with the best 
possible treatment (EMA, 2006).  
 
1.3 Current Medicines Use 
Even when medicines are licensed for use in children, there are issues such as the 
suitability of formulations available for use in the paediatric population that limit the 
extent to which they can be effectively administered. Of the previously mentioned 60% 
approved medicines for children, 29% did not have a suitable formulation for children 
(Balakrishnan, 2006). Although a new medicine may not initially be expected to have 
paediatric licensing, if it is relevant for use in children, it should have the necessary 
licenses and formulations within a reasonable time frame (Balakrishnan, 2006). The 
lack of paediatric formulations is particularly telling in the availability of appropriate 
liquid dosage forms (Ainscough et al (2017). This is an issue for young children and 
neonates, who are often faced with inappropriate dosing and dosage forms (tablets, 
capsules, injections), harmful excipients and the stability of the formulation available 
to them (EMA, 2012; Nahata, 1999).   
 
1.3.1 Off-label and unlicensed medicines use 
As a consequence of the lack of paediatric formulations, it is commonplace for 
healthcare workers to prescribe off-label and unlicensed medicines for paediatric 
patients (Conroy, 2000; Turner, 1998). ‘Off-label’ use refers to medicine that is used 
in a way that is different to that described in the licence, for example, using a medicine 
to treat an illness it was not developed for or using a medicine in an age group outside 
of the licensed range. ‘Unlicensed’ medication is often a medicine that has a license 
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in another country that must be imported, a medicine that is adapted from one form to 
another (e.g. solid to liquid form), or a medicine that does not have a license at all 
(NHS, 2016).  
 
Whilst it is not illegal to prescribe unlicensed or off-label medicine, there are clinical 
and ethical issues associated with this practice. A medicine is approved through the 
licensing process to ensure its efficacy, safety and usability in the target population 
(Stegemann et al, 2016). When a medicine is prescribed outside of this licence, the 
clinical support of the treatment is missing, and the treatment of the illness is often 
based more on assumptions and extrapolations (Stegemann et al, 2016). This has 
obvious drawbacks in terms of validity and reliability because of the variance between 
children and adults, and the variability between child sub-populations that were 
discussed earlier, such as pharmacokinetic and pharmacodynamic differences (EMA, 
1997). There is also an increased risk when manipulating the medication from a solid 
or liquid formulation, or the splitting, crushing or cutting of medicines, as little is known 
about the quality standards or effects of manipulated drugs on therapeutic outcomes. 
Inappropriate use of medication can cause unnecessary risk rather than expected 
treatment benefits (Collier, 1999). Associations between the use of unlicensed drugs 
and dispensing and administration errors have been reported. In the child population 
an increase in medication errors and adverse reactions have been significantly more 
linked to unlicensed drug prescribing than licensed drugs (Conroy, 2011; Bellis et al, 
2014). Furthermore, ethical issues related to the off-label and unlicensed use of 
medications include the extent to which the patient is involved in decision-making 
about treatment, and the extent of information that can be provided to the patient to 
inform them of the medication (Stegemann et al, 2016). 
 
Despite the concerns related to the use of off-label or unlicensed products being 
prescribed for the paediatric population, there is often no other alternative medicine to 
treat children. The American Academy of Paediatrics (AAP) recently released a 
statement regarding this issue stating that “Paediatricians must prescribe drugs off-
label, simply because an overwhelming number of critical drugs still have no 
information on the label for use in children” (from Healthychildren.org, para 3). It is 
commonly agreed that this prescribing is best practice when no suitable alternative is 
available (GMC, 2013). 
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1.3.2 Compounding and manipulation of medicine 
Often, in order to prescribe medication in a suitable way for use in the paediatric 
population, the compounding and manipulation of drugs needs to take place. 
Compounding is regarded as the “process of combining, mixing, or altering ingredients 
to create a medication tailored to the needs of an individual patient” (FDA, 2018, p1). 
It is the creation of a particular medication which suits the unique needs of a patient, 
and the world compounding pharmacies market size was estimated over $9.5 billion 
in 2019 (Global Market Insights, 2019). There are differing understandings and 
definitions of drug manipulations (Ghaleb et al, 2006), but drug manipulation has been 
defined as the “physical alteration of a dosage form for the purpose of extracting a 
proportion of the drug dose (manipulation with the aim of achieving the required 
prescribed dose)” (Richey, 2013 p7).  The practice of manipulating medicines occurs 
in the UK and internationally (Bourlon et al, 2006; Kayitare et al, 2009), and there are 
many different reasons for doing this.  
 
Due to the majority of drugs being developed and tested for use in adults, the drug 
dose is often only available in dose units suitable for adults (Richey, 2013). In order to 
adapt these medications into age-appropriate dosage forms for children, manipulation 
of the existing medicine form may be required. This usually occurs at the point of 
administration, in the form of splitting, crushing or dispersing the dosage form to 
produce a smaller dose that matches the requirement of the child. However, this is 
further complicated considering the variance in dose requirement across childhood 
and the differences in a child’s ability to cope with different dosage forms (Rocchi & 
Tomasi, 2011). Extensive research and guidance have been developed by 
researchers at Alder Hey Children’s Hospital regarding the Manipulation of Drugs 
Required in Children (MODRIC). Whilst manipulations such as tablet cutting, crushing 
and opening capsules may be necessary to administer oral doses given to patients 
(Standing & Tuleu, 2005), there is a paucity of evidence on drug manipulations, and a 
review of the literature has found that there is a need for guidance to ensure dose 
accuracy (Richey et al, 2011). It is not uncommon for parents and caregivers who often 
have to crush or split oral dosage forms and mix them with food or drinks in order to 
mask the taste of the formulation to administer it to the child (Meirer et al, 2007). This 
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is also not limited to young children, with drug manipulations observed across a range 
of childhood ages (Skwierczynski & Conroy, 2008). 
 
Whilst drug manipulations are commonly required for clinical reasons (such as 
providing an age-appropriate form for children), there are also some instances where 
drug manipulation is driven by economic factors. There may be a considerable price 
difference between medication strengths and so it may be cheaper to split doses than 
buy the formulation with the optimal dose (Quinzler et al, 2006) Similarly, cheaper 
unlicensed formulations may be used to treat children to save on costs, even when a 
licensed, more expensive medication is available.  
 
There are numerous issues with the manipulation of medication, including time 
restraints, inaccuracies, lack of information on the stability and bioavailability of the 
drug (Nunn, 2003; Skwierczynski & Conroy, 2008). These manipulations may 
compromise drug efficacy and safety and increase the risk of dose calculation errors 
such as under or over-dosing (Richey, 2013). Under and overdosing are labelled as 
the most common medication error in neonatal and paediatric practice (Krzyzaniak & 
Bajorek, 2016). Although the requirement for drug manipulation is clear, there is little 
research on the subject, and the risks are not fully investigated in the paediatric 
population (Miller et al, 2007).  
 
1.3.3 Age-appropriate formulations 
Using adult studies to calculate safety and efficacy for the paediatric population based 
on age, body weight and/or body surface area is neither an accurate nor appropriate 
method to produce appropriate medicines for children. This method relies on the 
assumption that children are “small adults”, which is not the case (Yewale and 
Dharmapalan, 2012; p1). A clinical guideline published in 2009 from the National 
Institute for Health Care and Excellence (NICE) provides recommendations to 
formulators and developers for the development and prescription of appropriate 
medicines for children, conscious that inappropriate medicines have significant 
detrimental effects on children, the healthcare system and society. Similarly, there has 
been a global regulatory movement to improve medicines for children, fostering the 
development of patient-centric pharmaceutical products that account for the needs of 
children (Ranmal et al, 2018). 
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Past medication errors in paediatric patients have prompted the implementation of 
legal regulations and requirements in the development, approval, and use of paediatric 
formulations (Ward et al, 2017). Despite this, off-label, unlicensed, and manipulated 
medicines are still administered to the paediatric population.  
 
The misuse of formulations in the paediatric population has led to tragedies of infant 
illness and death, such as the misuse of morphine (Borchers et al, 2007), the tragedy 
of the polio clinical trials in 1954, in which more than 250 children were infected with 
the polio virus from a vaccine (FDA, 2006), the fatal use of diethylene glycol in 
sulphanilamide formulations (FDA, 1981), and the devastating effects on newborns of 
the use of thalidomide in pregnant women (McBride, 1961). Whilst the implementation 
of legal regulations to prevent tragedies such as these has made testing in children 
safer, children still do not have access to appropriate dosage forms and strengths 
across disease state and across the age range. Most dosage forms are limited in some 
way in regard to clinical use.  
 
Whilst oral dosage formulations are the most commonly used in the paediatric 
population (PDCO, 2013; Tuleu & Breikreutz, 2013), solid oral dosage forms have 
some risk of choking or inadvertent inhalation (Thompson et al, 2009). Liquid oral 
dosage forms, whilst posing less of a risk of choking, present issues such as 
measurement difficulties (Chappelle, 2015), palatability, as taste-masking becomes 
more difficult (Matsui, 2007), shorter shelf life, and increased prices (Reider, 2017). 
Non oral routes of administration include nasal, ocular, rectal, dermal, parenteral, and 
optic (Batchelor & Marriot, 2015). These provide difficulties in ease of use, adverse 
side effects, difficulties in administering, appropriateness of administration, and issues 
in paediatric distribution and absorption (Batchelor & Marriot, 2015).   
 
An additional issue in formulations administered to children are the excipients. 
Excipients are anything other than the active pharmaceutical ingredient in a medicine 
(Haywood & Glass, 2011), and are often used in oral formulations in order to improve 
palatability and shelf-life. Excipient choice in developing paediatric formulations, and 
formulation choice in administering formulations to children off-label is compounded 
because of the unavailability of information regarding what is “safe” or “approved” for 
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paediatric patients (WHO, 2012; EMEA, 2000). It is known that certain excipients 
including ethanol, propylene glycol, benzyl alcohol and parabens (Tuleu, 2013) should 
not to be used in children, due to adverse reactions in organ development.  Both the 
EU and US recognised the concerns of paediatric drug use and collaborated to 
develop the Safety and Toxicity of Excipients for Paediatrics (STEP) database (EUPFI. 
Salunke et al, 2012/2013), as well as for neonates with the European Study of 
Neonatal Exposure to Excipients: An Update (Turner et al, 2013). As well as this, the 
requirement for new paediatric regulatory guidance and legislation on the development 
and availability of age-appropriate formulations for children was recognised.  
 
The initiative to develop age appropriate medicine is now at the forefront of paediatric 
pharmaceutical development, an age appropriate medicine is defined as one that is 
“suitable for use in the target age group(s)” (EMA, 2013, p23). The WHO states that 
“the ideal children’s medicine is one that suits the age, physiological condition and 
body weight of the child taking them and is available in a flexible solid oral dosage 
form that can be taken whole, dissolved in a variety of liquids, or sprinkled on foods, 
making it easier for children to take” (WHO, 2010, online). 
 
1.3.4 Regulations and policy for developing paediatric drug formulations  
For decades, paediatric drug discovery, development, and regulation have been years 
behind adult therapies (Maron, 2017). This has resulted in products that do not go 
through the same rigorous safety and efficacy testing as adult formulations, leading to 
inappropriate and unacceptable drug products for the paediatric population. This 
means that doctors and pharmacists are presented with two options: to not treat the 
child or to prescribe off-label or unlicensed medication, which often carries unknown 
risks and side effects (AAP, 1995; Maron, 2017).  As well as the risk of complications, 
morbidities and mortality outlined above, this has also resulted in significant delays in 
drug discovery in this population.  
 
Over the last decade, policy and regulations for paediatric drug development have 
provided incentives and obligations for pharmaceutical companies to invest in the 
development of paediatric medicinal products (Penkov et al, 2017; Zisowsky et al, 
2010). Collectively with child advocacy groups, international consortia and paediatric 
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drug development networks, there has been a shift from research ‘in’ children to drug 
development research ‘for’ children (Bucci-Rechtweg, 2017).  
 
Specific legislation and policy in the EU and the US have driven the pharmaceutical 
industry to take a more active stance in the investment of time and resources to 
develop child appropriate formulations. 
 
1.3.4.1 US Food and Drug Administration (FDA) regulations  
The US was first to produce regulatory initiatives addressing paediatric pharmaceutical 
development (Penkov, 2017; Turner et al, 2014). In 1997, the Paediatric Labelling Rule 
was issued (FDA, 2010), outlining that manufacturers were to submit a new drug 
application (NDA) in order to have the labelling of an existing medication (developed 
for adults) amended to also include children in the drug labelling. Whilst this rule was 
designed to improve paediatric drug labelling, it was entirely voluntary, and so only a 
minority of studies resulted from it (NICH, 2010). This was amended and reauthorised 
as the Paediatric Rule (FDA, 2010), which required the manufacturer to submit safety 
and effectiveness information in the relevant paediatric groups before approval 
(CDER, 2010). Alongside this, the FDA produced the Food and Drug Administration 
Modernisation Act (FDAMA), which provided incentives for companies to develop 
specific products that were deemed beneficial for the paediatric population (FDA, 
1997). This was largely successful, and many drugs in the US have been labelled 
through this act (Zisowsky et al, 2010).  
 
Drawbacks with these early initiatives and regulations were identified in the early 
2000s and addressed within two following acts: Best Pharmaceuticals for Children Act 
(BPCA) in 2002, and Paediatric Research Equity Act (PREA), 2003. The BPCA 
provides the incentives for drug development; however, this act only refers to drugs 
and is voluntary. In contrast, the PREA includes the requirements for drug 
development, referring to both drugs and biologics and is mandatory (Zisowsky, 2010). 
Both acts provide encouragement for additional paediatric research and development 
in drug formulation. Both acts were amended and reauthorised in 2007 within the Food 
and Drug Administration Amendments Act (FDAAA), this ensured the acts were in use 
until 2012, when, with modifications, they were made permanent. These acts are the 
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current legislation in the US and are found in within the Food and Administration Safety 
and Innovation Act (FDASIA) (Penkov et al, 2017) (Table 1.1).  
 
Table 1.1: Regulatory milestones of paediatric legislation in the US and EU 
1994 1997 1998 2000-2001 2002 2003 2006 2007 























































1.3.4.2 European Medicines Agency (EMA) regulation 
Similarly, in the late 1990s the EU also recognised the necessity for pharmaceutical 
companies to be accountable to legal obligations in paediatric pharmaceutical 
development. In 1997, the first ‘round table’ talks were established to discuss 
paediatric medicines at the EMA (Zisowsky et al, 2017). In 2002, following a call from 
the European Health Council for action to be taken on the usage of unauthorised 
medicinal products in children, the consultation paper Better Medicines for Children 
was produced. This proposes specific regulatory actions on paediatric medicinal 
products. This was followed by a guidance note on the clinical investigations of 
medicinal products in children, and the need to strengthen legislation (EMEA, 2009). 
The International Conference on Harmonisation (ICH) discussions followed this, 
supporting the need for international discussion on the conduct of clinical trials in 
children (EMEA, 2009; CMPM, 2009), this preceded the official European ICH E11 
guidelines (EMEA, 2009; CMPM, 2009).  
 
Similarly, the European Council produced recommendations that the European 
Commission make appropriate proposals to develop governance and regulatory 
measures in respect of clinical trials on children, and to ensure that the specific needs 
of children are met in the newly developed medicinal products (The Council of the 
European Union, 2008(1); 2008(2)). The proposals for the new legislation were 
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assessed and accepted in June 2006 (EU Regulation, 2006), and the law was entered 
into force in all EU countries in January 2007 (Hawcutt & Smyth, 2008). The aim of the 
Paediatric Regulation is to improve the health of children by increasing the 
development of medicines for children and improving the available information on the 
information we have available about paediatric medicines (Hawcutt & Smyth, 2008).  
 
1.3.5 Additional considerations: acceptability to improve adherence  
The current regulations in the US and Europe help to provide developers with 
guidance in paediatric formulations. However, gaps still remain. Poor adherence is an 
issue for developers. It is reported that paediatric adherence rates in the paediatric 
population range from 11%-93%, with a median rate of 58% (Matsui, 2007). In regard 
to the factors that influence adherence, figures recently published as part of a 
systematic review (Brown & Bussell, 2011) state that in paediatric patients with 
asthma, less than 50% of medications are taken as prescribed, with the key reason 
for not taking their medicine being the taste.  
 
Of particular consideration is the draft European Regulation on Medicinal Products for 
Paediatric Use (2004). This requires that companies submitting Paediatric 
Investigation Plans (PIPs) should ensure they describe the measures taken to adapt 
the formulations to make their use in paediatric populations acceptable, easy, safe 
and effective. Similarly, pharmaceutical companies are also asked to submit a 
Paediatric Study Plan (PSP) when marketing a new formulation for children. PSP’s 
are documents that outline the safety and effectiveness of a medicine, and require 
pharmaceutical companies to consider the active ingredients, dosage form, dosing 
regimen or route of administration of the medicine in line with the study objective, age 
groups and appropriateness (Randovan & Beeby, 2018). Building on this, the 
regulatory guideline published by the EMA (2012) places emphasis on ensuring that 
the pharmaceutical design of the formulation is age-appropriate, highlighting the 
importance of acceptability and preference of dosage forms. It states that “the child’s 
age, individual health status, behaviour, disabilities, background and culture are 
currently considered as the most likely parameters determining the child’s acceptability 
and preference” of dosage forms (EMA/CHMP, 2012, p3). It also outlines that whilst 
ensuring the acceptability of formulations, attention should be paid to developing the 
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“minimum number of acceptable dosage forms which are capable of meeting the 
needs of the majority of the children in the target age groups” (EMA/CHMP, 2012, p3).  
 
Acceptability is key in the development of age-appropriate formulations, and this is 
well understood within regulations. In the same guideline paper, the EMA calls for 
pharmaceutical companies to account for acceptability when they are developing new 
dosage forms and to consider route(s) of administration, dosage form, dosing 
needs/flexibility and excipients (EMA/CHMP, 2012). If a medicine is not acceptable to 
a child, even when the formulation meets the requirements of safety, stability, 
absorption and cost, the child is unlikely to be willing to take the product, and therefore 
the treatment will not be effective. As knowledge on the factors that influence age-
appropriateness of paediatric formulations increases, the effectiveness and/or 
usefulness of the products should be re-evaluated in the interest of the children and 
their caregivers. This approach is in accordance with Article 23 of the Directive 
2001/83/EC which requires companies to monitor the progress of their formulations 
during the life cycle of a medicinal product, adapting and improving their products for 
the benefit of the patient.  
 
All medicines should be appropriately designed to meet the requirements of the patient 
and to consistently deliver the necessary treatment. However, there is currently only 
limited knowledge available to pharmaceutical developers and scientists about the 
acceptability of different dosage forms, administration volumes, dosage form sizes, 
tastes and excipients in relation to the age and development of children. Due to this 
lack of available information, practices mentioned earlier such as the manipulation, off 
label and unlicensed prescribing of drugs still takes place. Considerations of the 
acceptability of the formulation itself are essential due to its impact on adherence, and 
ultimately treatment effectiveness, success and safety (Jimmy & Jose, 2011).  
 
1.4 Improving Acceptability in the Paediatric Population 
As a result of the aforementioned legalities and policies, a new paediatric regulatory 
environment has been formed, implemented in the US and Europe and is under 
development in other parts of the world. This change in perception regarding the 
development and availability of age appropriate and acceptable medicines for children 
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has been a springboard for companies and researchers to create better medicines for 
children (BPCA, 2002; FDA, 2007).  
 
The purpose of the BPCA, PREA, and the EU Paediatric Regulation to promote clinical 
trials in children and produce safety and efficacy data has been relatively successful 
(BPCA, 2013; van Riet-Nales et al, 2011; Ivanovska, 2017). Between 1997 and 2016, 
over 620 products were studied in the paediatric population and now have new 
paediatric information in the label; of these, over 560 involved new paediatric studies 
(Califf, 2017). The importance of paediatric labelling relates to ensuring that 
pharmacists and doctors are provided with the necessary paediatric-specific 
information including relevant age range and dosing information (Mazer-Amirshahi, 
2014).  
 
Nevertheless, there are still substantial areas to improve upon in paediatric formulation 
development, such as concerns that the EU regulation and PIP’s have generated 
drugs for children which are driven by adult needs (because companies have to rely 
on adult participants in studies) rather than unmet paediatric needs. Similarly, 
reporting of efficacy data is often missing; negative results are often omitted or 
published at a substantially later date (IMNA, 2013; Benjamin et al, 2013). Additionally, 
despite the requirement for age-appropriate and child-acceptable medication, the 
heterogeneity of the child population is becoming increasingly recognised, and the 
selection of an appropriate paediatric formulation requires a case-by-case basis 
(CHMP; PDCO, 2013).  
 
Both the FDA and EMA (2013; 2018) have developed recommendations for designing 
age-appropriate formulations (Zisowsky et al, 2010). In a commentary on the EMA 
(EMA, 2013) guidelines, it is stated that “acceptability aspects should be evaluated, 
(preferably) during the clinical study (preferably) with patients from all target age 
groups” (Kosarevitz, 2014).  However, the lack of guidance from regulators about how 
exactly to undertake acceptability assessment provides issues for industry when 
developing medicines. Despite requiring that companies describe and justify their 
choice of formulation and acceptability assessment measures (Kosarevitz, 2014) for 
all target populations, this choice is left to the discretion of the companies. Therefore, 
the understanding and definition of acceptability is dependent on the questions asked 
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and the perspective adopted by each individual company. As the WHO (2007, p90) 
state, “the essential question is to determine whether a formulation proposed for 
registration is acceptable for the relevant target populations of children: can the claim 
for age appropriate medicines for children be effectively substantiated?”.  
 
Similarly, the way in which that acceptability assessment is carried out varies 
depending on the researcher and the methods used to assess it. There is a lack of 
standardisation in measures used, and a lack of coherence in which aspects of 
acceptability are assessed. The Literature Review in Chapter 2 addresses these 
issues and explores the variation in how acceptability of all dosage forms in the 
paediatric population are defined and assessed.  
 
1.5 Conclusion 
In summary, to provide medicines that are both acceptable and age appropriate to the 
paediatric population, it is crucial that formulators and regulators work together with 
children and their caregivers. Moreover, undertaking patient-centric practices in the 
development of paediatric formulations and collaboration will ensure that children’s 
voices are heard. Through an enhanced understanding of children’s acceptability of 
medicine, pharmacists and formulation scientists may be better informed on how to 
create medicines that are more appropriate and acceptable for children. Therefore, 
the following chapter addresses the literature evidence of the acceptability of 
medicines for children, and the methodology used to assess acceptability.  
 
Chapter 1: Introduction. This chapter has provided the background information on the 
core topic of this thesis. The following seven chapters provide details of literature, 
methodology, methods, findings, discussion and conclusions. In brief they are 
composed of:  
 
Chapter 2: Literature Review. This chapter presents an integrative literature review, 
synthesising and summarising the key literature related to the specific topic of the 
acceptability of medicine and the methods used to assess acceptability in a paediatric 
population. This chapter concludes with the identification of research gaps and 
outlines the research aim and objectives of the study.  
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Chapter 3: Methodology. This chapter outlines the methodology adopted by the 
research and provides a justification for the methodological approach.  
 
Chapter 4: Methods. This chapter describes the selected methods of data collection 
and analysis and explains the sampling and recruitment of the participants.  
 
Chapter 5: Improving Acceptability Understanding. This findings chapter begins by 
outlining the characteristics of the participants and presents the findings for the first 
objective of the study. The findings include super-ordinate that encompass 1) What 
children can tell us about the acceptability of medicines, 2) What helps improve the 
acceptability of medicines to children, and 3) What reduces the acceptability of 
medicines to children.  
 
Chapter 6: Improving Acceptability Assessment. This second findings chapter 
discusses the findings related to objectives two and three. These are presented in 
themes encompassing 1) Children’s experience and understanding of scales, 2) 
Children’s perceptions on, and preferences for scales, and lastly, 3) Improving 
acceptability assessment.   
 
Chapter 7: Discussion. This chapter presents the discussion and provides an in-depth 
synthesis and interpretation of the two findings chapters. The findings are critically 
discussed and applied in the context of existing literature.  
 
Chapter 8: Conclusion: This chapter concludes this study, including the strengths and 






















































2 Integrative Literature Review 
2.1 Introduction  
The previous chapter presented a comprehensive background to this study, outlining 
the development of, and specific considerations regarding paediatric formulation 
development. It also introduced the acceptability of paediatric medicine, the 
associated challenges and identified gaps where these challenges can be improved. 
One of the key barriers to developing acceptable medicines for children relates to the 
paucity of knowledge regarding what is considered acceptable to children in medicines 
and how the acceptability of paediatric formulations is assessed. Therefore, the 
overarching aim of this chapter is to review, update and summarise the literature that 
reports on the methods of measurement or assessment of paediatric formulations. 
This chapter begins with a description of the methodological approach to the literature 
review and then follows with a synthesised account of the literature focusing on the 
acceptability of paediatric formulations.  
 
2.1.1 Integrative literature review  
 
The purpose of a literature review is primarily to summarise the pre-existing knowledge 
that is already available of a research topic or question (Noble and Smith, 2018). The 
review can be used to provide an overview of existing information, make 
recommendations to support decisions in healthcare, and highlight gaps in knowledge 
to guide future research (Noble and Smith, 2018; Hart, 2018). The most common 
approach in healthcare is to conduct a systematic review to answer a specific clinical 
question, however, literature reviews are undertaken for a number of different 
purposes (Whittemore and Knafl, 2005). The integrative review is one of many 
approaches to conducting a literature review, its purpose is to summarise past 
literature to provide a more complete understanding of a topic or healthcare problem 
(Broome, 1993). Integrative reviews are argued to be the most comprehensive 
methodological approach of reviews, allowing for the inclusion of diverse 
methodologies including experimental and non-experimental research, as well as 
theoretical and empirical studies (Whittemore and Knafl, 2005; Tavares de Souza et 
al, 2010). In contrast to integrative reviews, systematic reviews focus more specifically 
on one primary research question and typically include only experimental studies. 
Additionally, systematic reviews are designed to overcome bias at every stage of the 
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review process, adhering to strict methods to search and select papers, assess 
relevance and validity, collect, synthesise and interpret data (Tavares de Souza, 
2010). A critique of integrative reviews is that they do not focus on the same rigorous 
procedures as systematic reviews and can therefore be at risk of increased errors 
during the review process (Dunkin, 1996).  
 
Overall, it was decided that an integrative review would be the most appropriate in the 
current study. A strength of this type of review relates to its inclusion of a broad range 
of research, and its wide range of purposes (Broome, 1993). Both of these factors 
have “the potential to result in a comprehensive portrayal of complex concepts, 
theories or health care problems of importance” (Whittemore and Knafl, 2005., p548). 
This seemed a suitable method for assessing the literature base regarding the 
acceptability of medicines. Whilst integrative reviews can be conducted in a number 
of ways, the author is still expected to follow structured processes to ensure the 
reduction of errors (Torraco, 2016). This relates to the processes of the methodology 
outlined, how the literature was identified, analysed, synthesised and reported. 
Therefore, the following section of this chapter will outline these processes and provide 
justification of the robustness of the literature review (Mallett et al., 2012).  
 
However, before outlining the processes of the current review, it is recommended that 
an integrative review broadly outlines the topic it is intending to address (Torraco, 
2016). There are, in general, two kinds of topics - mature topics and new emerging 
topics - and most are placed somewhere along this continuum. As a topic grows, the 
corresponding knowledge base also develops, this is where an integrative review of a 
mature topic would review, critique and reconceptualise the knowledge base as it 
develops. In contrast, an integrative review that addresses new or emerging topics 
benefits from a holistic synthesis of the overall literature to date (Torraco, 2016). The 
current topic relating to the methods used to assess the acceptability of medicines is 
somewhere along the continuum from new to mature, at the time of writing, no review 
has attempted to evaluate and synthesise the methods used to assess acceptability 
of all types of medicine formulation in a child population. However, it is acknowledged 
that two notable reviews, one systematic (Ranmal et al, 2018) and one systematically 
searched and narratively presented (Mistry & Batchelor, 2017) have been published 
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in the last two years that do partly address this topic, both specifically focussing solely 
on oral formulations.  
 
In line with Torraco’s (2016) recommendation of outlining the topic, the following 
section will provide a brief overview of what is already known about this topic and 
argue that the current review which addresses all formulations builds on these broader 
literature and the findings from the two recent reviews (Mistry & Batchelor, 2017; 
Ranmal et al, 2018) to provide an update and expanded review.  
 
2.1.2 Current knowledge of the topic 
Children’s acceptability of medicines has been defined as “the overall ability and 
willingness of the patient to use a medicinal product as intended and its care giver to 
administer the medicine as intended” (EMA, 2013, p20). Patient acceptability is 
thought to have a significant impact on treatment adherence and consequently the 
safety and efficacy of the medicine (EMA, 2013). Whilst the EMA states that patient 
acceptability is an integral part of pharmaceutical development that should be 
evaluated in children themselves (EMA, 2013), knowledge regarding best practice 
methods to do this is limited and fragmented (Bekele et al, 2014). Additionally, there 
is little knowledge about what is currently considered acceptable to the children 
(Drumond et al, 2017; Mistry & Batchelor, 2017; Walsh et al, 2017).  A recent review 
has presented evidence of acceptability of pharmaceutical formulations in children and 
older adult patients (Squires, 2013), and two notable reviews have provided a 
synthesis of literature focussed on the methodological approaches used to assess 
children’s, and children’s and older adults’ acceptance of oral formulations (Mistry & 
Batchelor, 2017; Ranmal, 2018).   
 
The systematic search and narrative review conducted by Mistry & Batchelor (2017) 
aimed to synthesise the currently available information regarding the acceptability of 
oral medicines for children. This review led to the identification of key gaps within the 
literature, specifically that methods to define what is classified as acceptable to 
children is still required. It was also reported that gaps specific to the acceptability of 
oral formulations, such as knowledge relating to the shape of tablets, minitablets and 
capsules, and the size and volume of multiparticulates is also necessary. This review 
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also identified that a standardised methodology or criteria was necessary to formally 
evaluate the acceptability of formulations within studies that could be used to 
standardise research reporting on acceptability.  
 
Building on this, a systematic review published by Ranmal et al (2018) identified 
papers reporting on formulation factors of oral medications that affect acceptability, 
with a particular emphasis on evaluating the methodologies employed within the 
studies. This paper focussed on both children and older adults and concluded that 
methodologies used within studies reporting acceptability vary considerably. A key 
finding of this review was that acceptability definitions and criteria used to assess 
acceptability varied significantly across the literature. This review mirrored the 
conclusions of the Mistry & Batchelor (2017) review, that the standardisation for 
reporting acceptability testing and study methodology would be beneficial.   
 
Building on the recommendations of these reviews, and acknowledging the limitations 
related to the focus of only one formulation type, the current review aims to review, 
update and summarise the available literature related to the methods used to assess 
acceptability of medicines in the paediatric population. Furthermore, this work differs 
from these previous works which focused on the application of adult tools to a 
paediatric population thus limiting their potential child-centeredness and value. This 
work specifically took this limitation into account with its ultimate aim and focus being 
on the development of age-appropriate tools; this focus makes this work unique. 
 
2.2 Methods  
2.2.1 Review aim and purpose 
As previously mentioned, an integrative literature review, whilst not typically 
systematic, is written in a structured manner. It is reported that specifying the topic or 
purpose of an integrative review leads to a coherent structure for presenting the 
findings (Torraco, 2016).  
 
Therefore, the overarching aim of this integrative literature review was to review what 
methods are used to assess the acceptability of medicines within the paediatric 
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population (0<18yrs). The purpose being to critically examine this in relation to the 
three main concepts which comprise the topic and which are outlined in section 2.4.  
 
2.2.2 Search Strategy  
A well-defined search strategy is reportedly critical for increasing rigor in any literature 
review (Cooper, 1998). Whittemore & Knafl (2005) report that ideally, all of the relevant 
literature should be included in the review. However, limitations associated with 
inconsistent search terminology and indexing problems can mean that only around 
50% of eligible studies are identified in computerised databases (Jadad, 1998; 
Whittemore & Knafl, 2005). Despite this, within an integrative review, at least two or 
three search databases should be used, and this should be accompanied by hand 
searching, networking or searching research registries (Conn et al, 2003).  
 
Therefore, in the current study the electronic literature search was initially performed 
in May 2018, updated in January 2019 and further updated in August 2020 using the 
PubMed, Scopus, and Embase databases. The search protocol adhered to the 
Population, Concept, Context (PCC) model (The Joanna Briggs Institute, 2015), which 
has roots in the PICO (population, intervention, comparator and outcome) framework 
commonly used to focus clinical questions and develop systematic literature search 
strategies.  
 
The electronic literature search followed the three-step search strategy outlined in the 
Joanna Briggs Methodology for Joanna Briggs Institute (JBI) Scoping Reviews (2015). 
The initial preliminary search was undertaken on the PubMed database, in line with 
the second step of this three-step process, the key words were then reviewed and 
amended to aim for the inclusion of all potentially relevant key text words in titles and 
abstracts of papers. The key terms used in this search strategy were further refined in 
collaboration with a health sciences librarian, and a table of all index terms used to 
search for papers in this study is presented below in Table 2.1. Thirdly, two additional 
searches were carried out on the Embase and Scopus databases, and the reference 
lists of all identified relevant papers were searched for additional studies. This is 
presented in Table 2.1.  
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Table 2.1: Search Terms 
Population  
 0-18 years 1. Paediatric OR pediatric OR child* OR infant OR newborn OR 
adolesc* OR teen* OR “young adult” OR “young person” 
Concept 
Acceptability of medicine 2.  Satisfaction OR acceptance OR preference OR approval OR 
acceptability OR palatability OR taste OR smell OR size OR 
shape OR appearance OR swallowability OR good OR bad OR 
ok 
3. Formulation OR “dosage form” OR medicine OR drug OR form 
OR dose 
Context  
Methods of assessment 4. Methods OR assessment OR methodologies OR development 
OR evaluation 
5. “Taste-test” OR “hedonic scale” OR “facial affective scale” OR 
observation 
 
2.2.3 Inclusion and exclusion criteria 
Criteria used to ascertain whether papers are included and excluded should be stated 
and consistent with the goals of the review (Torraco, 2016). The selection criteria in 
the current study was dependent on the language and accessibility of the papers, 
whether the paper stated the methodology/assessment measures used to evaluate 
acceptability, and the population. Papers were excluded if they were not a primary 
source, if they did not report the methodology or assessment of acceptability and if the 
population was outside of the relevant age range (Table 2.2).  
Table 2.2: Inclusion and exclusion criteria  
Inclusion criteria 
• Publications in English 
• Primary sources (excluding guidelines) 
• Primary articles relating to paediatric formulation development, specifically papers that 
reported the method/methodology used in acceptability assessment testing 
• Studies reporting on child population (<18 years old)  
• No limits were set for date of publication. 
Exclusion criteria 







2.3 Search Results 
In integrative reviews, although not essential, authors are encouraged to present a 
matrix or table of the papers identified and either included or rejected from the study 
(Torraco, 2016). The criteria that is used to retain or discard papers should be 
explained, and selection criteria may include populations of interest, time restraints or 
the research methods used (Torraco, 2016). In the current study, only primary papers 
that reported the methodology used to evaluate the acceptability of medicine in a child 
population were included. (Note: although the two reviews by Ranmal et al (2018) and 
Mistry & Batchelor (2017) were not included in the review itself, their reference lists 
were examined to provide a further means of checking that all eligible primary papers 
were included). 
 
Therefore, in the current study a total of 3712 papers were identified through the 
electronic searches, after all document titles and abstracts were manually screened 
for relevance, and duplicates were removed, the full text articles were accessed and 
evaluated for inclusion. Thirty-eight papers were eligible for inclusion, and an 
additional 26 papers were included following the manual screening of references 













































   
 
   





Articles identified through database searching 
PubMed (n= 2,858) 
Embase (n= 830) 
Scopus (n= 33) 
























Articles after duplicates removed 
PubMed (n= 2,001) 
 Embase (n= 22) 
Scopus (n= 33) 
Articles screened 
PubMed (n= 74) 
Embase (n=13) 
 Scopus (n= 6) 
 
Articles excluded 
(n = 31) 
No acceptability tests 
Population age range not 
eligible (adults) 
Methodology not relevant  
 
Full-text articles assessed for eligibility 
PubMed (n= 48) 
Embase (n= 11) 
Scopus (n= 3) 
 
Full-text articles excluded, 
with reasons 




Total studies included in integrative review  
(n = 64) 
Manual screening of 
references  
   (n= 26) 
 
 47 
2.4 Findings from the Review 
2.4.1 Structuring the findings  
As previously mentioned, specifying the topic and purpose of the literature review 
provides some guidance for the structure of presenting the review’s findings.  Whilst 
there is no one way of organising a literature review, it is suggested they can be 
organised by grouping articles dependent on similarities in concepts or theories, 
methodological similarities among studies or historical development (American 
Psychological Association, 2010). The current review has employed the conceptual or 
thematic structure. Conceptual structuring provides coherence and clarity about how 
the main themes of the topic come together as one combined piece and is key to how 
the literature review is organised (Torraco, 2016). Most healthcare topics are 
comprised of several key concepts (Torraco, 2016) or themes, and the current review 
is focussed around the key themes relating to the acceptability of medicines. 
 
This review focuses on how the acceptability of medicines is defined, the factors 
identified in the literature that impact on acceptability, and the methodology or 
assessments used to evaluate acceptability. A conceptual map (Figure 2.2) that 
represents the structure of the review has been created; this map presents the key 
themes identified in the literature relating to the acceptability of medicine. The purpose 
of this map is to demonstrate the connections between the themes and reflect how the 






Figure 2.2: Conceptual map of the key themes and sub-themes of the integrative literature review. 
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Although the EMA (2013) and WHO (2007) guidelines were not included in the main 
review, the definition of acceptability presented in this guideline is used as the ‘gold 
standard’ definition when presenting the findings of the review and the discussion. 
 
2.4.2 Data extraction  
Structured summary tables were created and key details from the literature were 
inputted; these details included author, year, participant age, who provided the 
assessment, outcome measures used for acceptability, threshold level of acceptability 
and method of measurement of acceptability (Table 2.3).  The papers presented in 
Table 2.3 are organised in chronological order (most recent to oldest publication 
dates). 
 
2.4.3 Overview of the papers in the review  
All 64 papers were empirical studies, with 27 using a randomised crossover design, 
15 using a randomised control trial (Angwa et al, 2020; Hofmanova et al, 2020; 
Klingmann e al, 2020; Purchase et al, 2019; Thompson, 2009; Kendall, 2001; 
Geltman, 2009; Cadwgan, 2017; Nahirya-ntege, 2012; Cristofides, 2005; Orlu, 2017; 
Mekmullica, 2003; Blume, 2018; Klingmann et al, 2018; Cohen, 2005), six using a 
prospective research design (Moniot-ville, 1998; Akhavan-Karbasi, 2010; Block, 2006; 
Amirav, 2014; Coleman, 2002; Jagani, 2016), three employed survey designs (Mulla, 
2016; Valovirta, 2009; Wallace et al, 2019), two employed a single subject 
experimental design (Babbitt, 1991; Beck, 2005), two observational studies (Cohen, 
2009; Ruiz et al, 2020), interview (Venebles, 2016), one observation and interview 
(Giralt et al, 2019), one interview and questionnaire (Bryson, 2014), one comparison 
study (Arapostathis, 2010), and one online survey (Lloyd, 2011). Six did not specify 
the study design further than empirical (Giralt, 2017; Verrotte, 2011; Polaha, 2008; 
Nasrin, 2005; Strehle, 2010; Pakalnis, 2003).  
 
The dates of publication ranged from 1984-2020, with 40 (63%) papers published 
since the year 2008, showing an increase in the number of published papers reporting 
on the methodology/methods used to assess acceptability in paediatric formulations 
in the last decade. The majority of studies were conducted in the UK, Europe and 
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American countries, this is generally in line with the focus on recent European 
initiatives, however an increase in the number of studies conducted globally in the last 
year, particularly in African countries such as South Africa, Kenya and Uganda reflects 
the efforts of global initiatives to improve acceptability (see Table 2.3). 
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used to assess 
acceptability  
Threshold level of 
acceptability  
Measurement or result of 
acceptability   



















defined as perception 
of taste of the 
formulation as same 
or better and 
expression of 
willingness of 
caregivers to use 
amoxicillin tablet in 
future.  
Dispersible tablets: 55% of 
caregivers perceived taste to be 
better than other medicines 
compared to oral suspension.  
Oral suspension: 60.5% believed 






















Marks on 5-point scale 
were translated to 
scores from 1-5 (1= 
negative, 5= positive).  
 
Comparison of tablets 
was done using 
statistical analysis on 
SPSS.  
62.4% of children swallowed at 
least one tablet.  
Success of swallowing was age 
related.  
Children who completely 
swallowed tablet tended to give 
higher scores for ease of 
swallowing.  
Researchers recorded negative 
facial expressions as indicative of 
aversion to tablet: lips pressed 
together, wrinkling nose, browns 
pulled together, voice disgust, 
eyes squeezed shut and head 







e film vs 
syrup. 









as aggregate of two 
variables: everything 
swallowed or chewed/ 
partially swallowed. 
Threshold endpoints transformed 
to statistics.  
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Caregivers. Palatability.  
Pleasant (positive 
hedonic pattern), no 
change (neutral 
hedonic pattern), and 
unpleasant (negative 
hedonic pattern).  
ODF- 143/150 (95.3%) 
Syrup- 121/150 (80.7%).  






























Result of intake. 
Patient reaction. 
Time needed to 
prepare. 





Dose fully taken, 
partly, or not at all. 
 










Dividing dose, use of 
food/drink, patient 
reward, use of 
restraint  
Multivariate mapping and 
clustering provided a score which 
resulted in either: positively or 
negatively accepted.  
















where formulation was 
regarded as: easier to 
administer and easier 
to store than liquid. 
Caregivers own beliefs (including 
competence and autonomy, future 
aspirations related to children’s 
health, self-experience and 
perceived HIV-related stigma). 
 
Mechanisms (including practical 
issues- storing/administrating, 




























point likert scales) 
Observations 
Caregiver responses. 92% felt volume of dispersion as 
acceptable. 
82% children swallowed dose. 
12% refused dose. 
1% spat it out. 
















Vaccine efficacy and 
safety. 
Trust. 
Benefits showed strongest 
association with vaccine uptake. 
Awareness weakest association.  
Past behaviour and trust: null 
association.  
Efficacy and safety most 











responses to medicine 
not defined. 
Children were scored to “swallow 
well” in 77-78% of the observers’ 
opinion and the tool developer.  
12% of children who showed 
negative behaviour were 
described as showing “refusal” by 
the observer, but “spitting” by the 
tool developer.  
Substantial concordance between 







Mini tablets  
Syrup  
Placebo 6-12 months 
2-5 years.  
Researcher. Observation  Acceptability is 
defined as an 




Swallowability: 16.1% children 
swallowed all 400 minitablets 
compared to 31.2% children 
swallowed all syrup.  
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68.8% chewed and/or had left-
over tablets, only 51.6% had left-
over syrup.  
53.9% of children that chewed 
tablets went on to completely 
swallow them all.  
When administered 100 
minitablets, 41.9% of children 
chewed/had leftovers. Of these, 
92.3% ultimately swallowed them 
all. 3.8% had less than 50% of 
minitablets left; 3.8% had more 
than 50% of minitablets left.  





















Ability to use as 
required and swallow 
the formulation. 
Swallowability: 92% in children  
Researchers observations of 
negative expressions: pursed lips 
(57%) children, nose wrinkle 
(30%), eyes squeezed (21%) 
Children less likely to show 
acceptance (72%). 
5-point hedonic scale (grittiness, 





























Patches well tolerated by children; 
however, liquid has fewer negative 
side effects for parents.  
Patches thought to be favoured 
because more effective and 
convenient (administering liquid 3x 
per day an issue) 






>3 years  Parents Interview  
Observations  
Caregiver factors that 
contribute to 
Information, motivation, self-
efficacy, skills, health beliefs, 





“factors that affect the 
ongoing treatment 
adherence”. 
caregiver-infant relationship will all 








unit dose.  
Equivalent 
syrup dose. 
Placebo 6 months-5yrs 
 
Age group 1: 
(6-23months) 
Age group 2: 
(2-5 yrs) 
Children  Observation  Aggregate of the 
evaluation criteria 
swallowed and 
chewed according to 
evaluation criteria 
from previous study. 
Swallowed minitabs or 
either completely 
swallowed or partially 
swallowed syrup.  
26.8% of children who took 
minitablets chewed or left some. 
43.5% of children left syrup.  
Children preferred drink over food 
to accompany tablet. 






ble tablets.  










5 years (n=13) 
Caregivers 
Nurses 









administration of ODT. 
2. Responses on 5point 
scale by children 
>3yrs. 
3. Responses on 5-point 
MAS by parents and 
caregivers. 
78% children rated dosage form 
as <3 on 5-point scale, 63% 
reported they ‘very much liked’ it. 
72% expressed willingness to take 
an ODT again. 
Caregivers: (child<2yrs) 79% 
scored 5 on MAS; (child >2yrs) 
86% scored 5 on MAS; (child 
>5yrs) 52% scored 5 on MAS.  














• 6-point facial 
hedonic scale (0- 
not difficult, 6- 






Pill Glide found to be safe, easy 
and effective to help children older 

























Infants 1-4 years caregiver 
preferences decreased after 12 
weeks. 
Older children’s preference for 
pellets continually decreased. But 
preference still higher than 
alternative formulation after 48 


















7-point FHS and 
observation 
Childs’ overall liking  
Spontaneous 
reactions  
No significant differences were 
observed for flavours or age 
groups between the two 
medicines. Mint flavour had the 
most negative reaction (40% 
rejection), neutral and strawberry 
taste did not differ significantly.  
Strawberry was most highly 
accepted (60% + 70%) for both 
formulations.  







Xaluprine 3-16 years Children and 






77% children rated the taste of the 
formulation ‘okay’ to ‘good’, 82% 
reported it was ‘easy to take all 
the time’ 












people (10+) and 
adults 




of dosage forms 
Acceptability defined 
as ability and 
willingness to take the 
formulation 
All ages show a preference for 
tablets over capsules, tablets 









0-18 years  Children and 
parents/carers 
Interviews  Barriers: age 
appropriateness, child 
88 reported barriers across 148 









65% participants reported at least 
one barrier to non-oral medication.  












2-3 years Paediatrician Observed and 
recorded  
Acceptance defined 
as swallowing in A or 
B categories. (A= 
smooth swallowing/ 
swallowing with 
choking reflex or 
cough, B = biting or 
chewing followed by 
swallowing).  
Median palatability score was 2.6.  
83% children able to swallow 5 or 
10 minitablets with fruit jelly as an 
aid.  








0-12 months Parents Observation Acceptance defined 
as no mask rejection 
and remaining asleep 
77% of infants successfully 
accepted the medication without 
waking. (1 woke during the 
observation, 1 did not go to sleep 







Not stated  Not stated  3-11 years Child  
Primary caregiver 
Hospital clinical 
and technical staff 
Interviews and 
questionnaires 
Focus groups   
Preferences.  Development of a Medication 
Adherence Prediction Tool 
(MedAPT) questionnaire.  
Child’s age, medical condition, 
taste/palatability. Colour, dose 
form, complexity of routine, and 












3 months- 13 
years 
Caregivers  Observation/feed





More problems reported with 
taking syrups than minitabs.  
Taste was most common issue 
with all formulations; worst in 
minitabs than tablets (50% vs 
0%), similar with minitabs and 
syrup (53% and 67%). Difficulty 
with swallowing reported for 20% 
minitabs, 60% syrups, 0% tablets.  
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Caregivers preferred minitabs 
over syrup.   












6-59 months Parent/caregiver  Caregiver 
questionnaire 
Adherence. 
Ease of use. 
Acceptability. 
Caregivers generally preferred the 
dispersible tablet (dissolved in a 
small volume of water or milk) 






















Score of >4 for 85.3% of subjects 
for strawberry and 49.0% for 
orange.  
Willingness to take again: 
strawberry (94%) orange (56%).  
Nahirya-











2.9 years Caregivers Questionnaires Preference. 74% of caregivers expected to 
prefer tablets, and 27% expected 
child to prefer tablets. After 8/24 
weeks, 94-97% caregivers 
preferred tablets and reported that 
57-59% of children did. 





vs syrup  
Placebo 0.5-6 years Children Observation Acceptance defined 
as swallowing and 
chewing for minitablet, 
not defined for syrup 
Minitablet acceptance was higher 
or equal to syrup in all age groups. 
Van Riet-










Placebo 1-4yrs Parents Observation and 
VAS (0-10). 
Result of intake. 
Report preference 
of child and 
themselves. 
Intake and preference. 
Mean VAS scores 
Children’s mean VAS scores. 
Tablet (9.39); powder (8.84); 
suspension (8.26); syrup (8.35) 










Median 12yrs Parents/carers Online survey Preference (not 
defined).  
Caregivers preferred transdermal 
patches compared to oral 
medications 
 59 




Oral drop vs 
oral filmstrip  





as ability and 









Overall preference of 85.4% 
observed for filmstrips (Not clear 
how this was calculated).  


























Palatability found to be the most 
important objective in treatment.  
Granule formulation was found to 
positively influence convenience 
of use 
Granules preferred over solution 
after 6 months by all participants.  
Akhavan-








6 months to 6 
years 
Parents 10-cm visual 
analogue scale  
Satisfaction. No significant differences in 
parental satisfaction between 















64 of 87 children stated they 
preferred the local injection (with 
needle) to INJEX (needle-less).  





Oral drop Vitamin K Infants Midwives Questionnaire  Acceptability (not 
defined).  
56% midwives reported use of oral 
drops as ‘quite unacceptable’ or 
‘completely unacceptable’, 33% 
undecided and 11% ‘not very 
acceptable’ 
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If entire treatment 
taken. 
Taste (5-face 
scale filled in by 
parents or child if 









would accept to 
treat their child 
again with the 
same medication.  
Main endpoint was 
taste assessment (5= 
very good, 1 = very 
bad). Faces 5-3 were 
considered a 
‘satisfactory taste’, 
faces 2 and 1 were 






considered good if at 
least 90% of product 
was taken.  
When both parents and children 
answered the taste scale, 
correlation between taste 










5-7months Parents Questionnaire Ease of 
administration. 
Parents in oral drop group more 
likely to report difficulty integrating 
administration into daily routine 







Minitablets Placebo  2-6 years Clinician  Observed  Ability to swallow. 46% of children aged 2 years 
swallowed tablet.  
53% children aged 3 years; 85% 









0-12 years Parents Questionnaire  ‘Preference measured 
against current 
medication- direct 
Parental preference ranged from 




















6-36 months Parents Which treatment 
did you prefer?  
Preference. 51% parents preferred CfC for 
practicality reasons and/or 
because their child had fewer 
symptoms 
23% preferred C10 because of 
practicality or less gastrointestinal 
symptoms  
No statistical significance between 
results 
Polaha et al. 
2008 
 
United States  







liquid / pill 
medication history 
and acceptance 
as well as 
parental interest 




30-40% of youth had 
rejected/refused a pill or liquid 
formulation. Half were unable to 
swallow a standard size pill or 











5-15 years Patients/children Diary card data  
100mm VAS for 
“ease of use” 





Ease of use. 
Compliance. 
Preference. 
55.7% preferred melt formulation, 
44.3% preferred tablet.  
Patient preference highly 
correlated to age but not dose.  
Compliance 94.5% in MELT and 
88.9% tablet.  
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of use, taste, if 
parents would use 
it again.  
Not defined.  Preferences defined by ease of 
administration, better taste, and 
caused less gastrointestinal 
distress.  







Valproate 5-14 years Children  
 
Parents  
Not stated. Preferences over 
alternate formulations. 
Preferences found for ‘chrono 
VPA once daily’ 






4-9 years  Clinician  Observation. Acceptance defined 
as child allowed pill to 
be in mouth within 10 
seconds of verbal 
prompt.  
 
Distress: 3-point rating 
scale (observed and 
filled in by therapist) 
All children were able to swallow 
mock tablets with a therapist 
following training. 7/8 children 
continued this at home  








n 4mg or 
placebo  




Willingness to take in 
the future.  
None of subjects rejected or spat 
out medication. 
12 children found the active tablet 
to not be as ‘good’ tasting 






Sprinkles  Placebo Infants 4-18 
months (mean 
11.76 months) 
Not defined  Not defined. 
(Adherence and 
side effects). 
Adherence. 3% were adherent100% of the 
time. 
40% adherent 75% of the time.  
65% adherent 50% of the time. 











measured on child’s 
behaviour when given 
the medicine- not 
defined.  
93.1% reported tablets were 
equally or more acceptable as 
other medicines 
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Parents and children preferred 
















Median = 15 
years 
Patients  Visual Analogue 
scale 
Acceptability defined 
as palatability, smell, 
ease of swallowing 
and gastrointestinal 
intolerance.  
In phase A patients scored mean- 
57, in phase B where the amino 
acids made up 40% of the protein 
substitute patients scored mean 
82.  
70% patients preferred the amino 










4-12 years old Children Observation Success defined as 
subjects being able to 
swallow all three 
capsules.  
Success rates 84.4% - 100% 





United States  
Nasal spray Sumatripta
n 




Bad taste, difficulty in use and off-









1-16 years Children 
Family 









Smaller tablets were generally 

















3-17 years Children Questionnaire  Preference with 
reference to ease of 
swallowing, presence 
of an aftertaste and 
feeling of fullness after 
taking the medicine. 
87% preference for creon 10,000 










6-59 months Parents  Diary and visual 




and acceptability of 
child (not defined). 
 
Parents preference on 
acceptability of nebuchamber in 
older children but not younger.  
No statistically sig differences on 
VAS scores for two treatments.  










3-16 years Children 
Parents 
Staff 
Wong Baker facial 
pain scale. 
Visual analogue 
(or OR both). 
Observation 
Patient’s reaction 
defined as no obvious 
discomfort, mild 









Patients reacted worse to the IMr 
treatment compared to nasal 
spray. 80% showed no discomfort 
with nasal spray compared to 9% 
of IM.  
Acceptability significantly greater 
with spray than IM treatment.  
Judged as ‘acceptable’ in 98% 
patients in spray compared to 
32% in IM by staff.  
Judged as acceptable in 97% 
cases for spray and 72% in IM for 
parents.  
Patients prepared to have the 
treatment again (94% for spray 













2-14 months  Independent 





Rated on five 
behavioural elements:  
cry, facial expression, 
body movement or 
level of agitation, 
reaction to placement 
Medibottle had advantages over 
oral syringe.  
Infants showed greater 
acceptance of medibottle with 
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of drug in the mouth, 
and swallowing of 
drug. 
higher MAS scores (9.0 compared 














12-17 years Children Questionnaire. Preference and ease 
of use (not defined). 
70% children preferred tablets. 










2-8 years Researcher Observation. 
6-point scale. 
Acceptability defined 
as child smiling or 
without making a face. 
Acceptability was good, fairly good 










10-18 years Children Logbook. Ease of use. 
Compliance (% of 
expected medication 
amount actually taken 
during the study 
interval). 
Form of the medication increased 
compliance by 25% in 42% of 
participants. 13 favoured pills and 
3 favoured powder.  

















Satisfaction defined as 
extremely satisfied 
and satisfied on the 
scale.  
  
Percentage satisfaction was 
reported as 89% amoxicillin, 81% 
trimethoprim, 74% 
sulfamethoxazole and 67% 
cefuroxime axetil.  






Valporate 5-16years Parents 
Children 
Questionnaires. Preference.  75% of parents and children 
















Acceptance. Swallowing skill acquisition 
clinically significant to treatment 
acceptance  











Younger group less able to 
discriminate between formulations 
than older group.  
In group younger than 6 years it 
was concluded that the FHS could 
not be used to discriminate 
between formulations as the 
results were similar for all tests.  
Older children able to discriminate 
in both verbal and scale methods.  
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2.4.4 Concept of acceptability assessment  
2.4.4.1 Acceptability definitions  
Although all papers in this review aimed to evaluate the acceptability of formulations 
in paediatric populations, 22 papers used ‘acceptability’ or ‘acceptance’ as an outcome 
measure (Babbit, 1991; Dagan, 1994; Moniot-ville, 1998; Kendall, 2001; Brand, 2001; 
Coleman, 2002; MacDonald, 2003; Beck, 2005; Nasrin, 2005; Araposthathis, 2010; 
Strehl, 2010; Rodd et al, 2011; Spomer et al, 2012; Amirav, 2014; Ogutu, 2014; Kluk, 
2015; Ranmal, 2016; Mulla, 2016; Venebles, 2016; Angwa et al, 2020; Klingmann et 
al, 2020; Giralt et al, 2019). Even within these 22 papers, a common definition of 
acceptability was not applied. Ten papers provided definitions or criteria to assess 
‘acceptability’ but these definitions widely varied (Table 2.2). Criteria included “no 
rejection” (Amirav, 2014), “child smiling” (Moniot-ville, 1998) and “swallowed with 
ease” (Kluk, 2015); four definitions included the word 'willingness' (Dagan, 1994; 
Rodd, 2011; Ranmal et al, 2016; Angwa et al, 2020). Two of the 64 papers defined 
‘acceptability’ as the “ability and willingness to take the formulation” (Rodd, 2011; 
Ranmal, 2016), and one paper used “willingness to swallow” (Moniot-ville, 1998).  
 
Table 2.4: Summary of acceptability definitions 
Author (year) Acceptance/Acceptability definition 
Dagan (1994) “willingness to swallow” and “occurrence of vomiting” 
Moniot-ville (1998) “child smiling” or “without making a face” 
Beck (2005) “child allowed pill to be in the mouth” 
Rodd (2011) “ability and willingness to take formulation” 
Spomer (2012) “swallowing” and “chewing and subsequently swallowing” 
Ranmal (2016) “ability and willingness to take formulation” 
Amirav (2014) “no rejection” 
Kluk (2015) “swallowing with ease” 
Giralt et al (2019) “formulation easier to administer and store” 
Klingmann (2018) “an aggregate of the evaluation criteria: everything 
swallowed or chewed and swallowed” 
Angwa (2020) “perception of taste” and “willingness of caregivers to use” 
 
Given that acceptability is understood to be a multi-dimensional construct, the majority 
of papers used a variety of outcome measures to assess acceptability (see Table 2.4). 
In thirty-six papers, two or more terms were used to assess acceptability (i.e. a 
combination of terms presented in Table 2.5). Four papers did not define any criteria 
or provide a definition about the assessment used to evaluate the acceptability of the 
formulation. The most common alternative assessment terms were preference, 
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amount swallowed/swallowability, ability to use/usability, and taste (Table 2.5). Patient 
preference, for example, is an individual’s evaluation of a specific element (in this 
case, formulation) over another element, and can only be used when more than one 
product is being assessed. Whilst there is an argument for the use of patient 
preference in health care decision making (Bryson, 2014), this will only provide the 
relative comparison rather than the actual acceptability of the formulation. Whilst 
factors such as ‘swallowability’ and ‘usability’ should be evaluated as part of 
acceptability assessment, it should be recognised that these factors alone cannot 
provide the full extent of acceptability.  
 
Table 2.5: Alternative acceptability terms 
Outcomes used to 
measure domain of 
acceptability 
Frequency of 
use in papers 
Author/year 
Preference 23 Klingmann et al (2017); van Riet-Nales et al (2012); 
Kekitiinwa et al (2016); Herranz et al (2006); Musiime 
et al (2014); Block et al (2006); Sjovall et al (1984); 
Cloyd et al (1992); Lottman et al, (2007); Macdonald 
et al (2003); Ogutu et al (2014); Munck et al (2008); 
Jagani et al (2016); Nahirya-Ntege et al (2012); Rodd 
et al (2011); Valorvita et al (2009); Patchell et al 
(2002); Weinberg et al (2000); Bukstein et al (2003); 
Lloyd, et al (2011); Venebles et al (2016); Brand et al 
(2001); Arapostathis et al (2010); Bryson et al, (2014); 
Hofmanova et al (2020). 
Amount swallowed/ 
swallowability 
9 Klingmann et al (2017); Musiime, et al (2014); Lopez 
et al (2018); Coleman et al (2002); Jagani, et al 
(2016); Thompson et al (2009), Kluk et al (2015); 
Dagan et al (1994); Purchase et al (2019); Klingmann 
et al (2018); Patchell et al (2002); Hofmanova, et al 
(2020); Klingmann, et al (2020). 
Ability to use/ usability 7 Lopez et al (2018); McCrindle et al,(1997); Lottman et 
al (2007); Ogutu et al (2014); Ranmal et al (2016); 
Weinberg et al (2000); Cadwgan et al (2017); Angwa 
et al (2020); Hofmanova, et al (2020.  
Taste 6 Musiime et al (2014); Sjovall (1984); Cohen et al 
(2005); Coleman et al, (2002); Jagani et al (2016); 
Patchell et al (2002); Angwa et al (2020); Hofmanova 
et al (2020). 
Child facial expression/ 
behaviour 
6 Blume et al (2018); Medeiros et al (2016); Beck 
(2005); Rodd et al. (2011); Nasrin et al (2005); Kendall 
et al (2001); Ruiz et al (2020).  
Satisfaction 6 Strehle et al (2010); Akhavan-Karbasi (2010); Dagan 
(1994); Orlu (2017); Bukstein et al (2003); Cadwgan et 
al (2017).  
Reported problems 5 Kekitiinwa et al (2016); Bukstein (2003); van Riet-
Nales et al (2012); Kendall et al (2001); Blume et al 
(2018). 
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Adherence to treatment 4  Cristofides (2005); Giralt (2017); Orlu, (2017); Strehle 
(2010). 
Ease of administration 3 Block (2006) et al; Geltman (2009 et al); Verrotti et al. 
et al (2011).  
Willingness to take  3 Cohen et al (2005); Dagan (1994); Ranmal et al 
(2016); Angwa, et al (2020).  
Tolerability 3 Verrotti et al. (2011); Cadwgan et al (2017). 
Successful 
administration  
2  Ogutu et al (2014); Geltman et al (2009).  
Compliance  2  Lottman et al (2007); Macdonald et al (2003). 
Palatability 1 Verrotti et al. (2011), Klingmann et al (2020). 
Time taken 1 Ruiz et al (2020).  
 
2.4.4.2  Formulation factors influencing acceptability  
Overall acceptability is reported to be ‘multidimensional’; the combination of several 
factors including palatability, swallowability, ease of administration, appearance, 
smell, administration device and convenience of administration (Ruiz et al, 2020). 
Therefore, whilst some alternative terms may reflect an overall evaluation of the 
product, some (swallowability, usability, taste and palatability) are individual factors 
that cannot accurately provide an overall acceptability measure. Therefore, focussing 
on only one or two of these in the evaluation of paediatric medicines fails to account 
for the complexity of acceptability (Vallet, et al 2017; Kozarewicz, et al 2014; Ranmal 
et al, 2016), and will provide incomplete acceptability assessments.  
 
Three of the alternative assessment factors (swallowability, taste and palatability), 
which account for almost a third of the outcome threshold levels used to assess 
acceptability, are specific to oral formulations and would not be meaningful if used in 
non-oral formulations. Consequently, whilst the EMA (2013) has defined acceptability, 
the implementation of this definition in the actual acceptability assessment of medicinal 
formulations has not been reported in twenty-two papers included in this review that 
were published after the definition was established (EMA, 2013). The criteria used to 
determine acceptability varies both between and within studies on oral and non-oral 
formulations and therefore it seems that the concept of ‘acceptability’ is open to 
interpretation.  
Within all 64 studies different stakeholders provided acceptability assessments; 
parents/caregivers were the most commonly used assessor (n=22 studies) (Rodd et 
al, 2011; van Riet-Nales, 2012; Kekitiinwa, 2016; Musiime, 2014; Blume, 2018; Block, 
2006; Giralt, 2017; Geltman, 2009; Ogutu, 2014; Akhavan-Karbasi, 2010; Munck, 
2008; Babbitt, 1991; Nahirya-Ntege, 2012; Nasrin, 2005; Dagan, 1994; Valovirta, 
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2009; Lloyd, 2011; Pakalnis, 2003; Amirav, 2014; Brand, 2001; Angwa, 2020; Wallace 
et al, 2019). Children were the primary assessor in 12 studies (Klingmann, 2017; 
McCrindle, 1997; Sjovall, 1984; Cohen, 2005; Lottman, 2007; Macdonald, 2003; 
Jagani, 2016; Mekmullica, 2003; Spomer, 2012; Patchell, 2002; Weinberg, 2000; 
Arapostathis, 2010). 
 
Health care staff including nurses, clinicians and researchers in seven studies (Moniot-
ville, 1998; Beck, 2005; Kluk, 2015; Thompson, 2009; Strehle, 2010; Klingmann et al, 
2018; Kraus, 2001) and a combination of children, parents/caregivers, and staff in 22 
studies (Angwa, 2020; Hofmanova et al, 2020; Klingmann et al, 2020; Ruiz et al, 2020; 
Giralt et al, 2019; Purchase et al, 2019; Bryson, 2014; Orlu, 2017; Herranz, 2006; 
Lopez, 2018; Cloyd, 1992; Coleman, 2002; Medeiros, 2016; Verrotti et al, 2011; 
Thompson, 2013; Polaha, 2008; Mulla, 2016; Ranmal, 2016; Bukstein, 2003; 
Venebles, 2016; Kendall, 2001; Cadwgan, 2017), and one study did not specify 
(Cristofides, 2005).  
 
Although children and caregivers were almost equally likely to be asked to provide 
acceptability assessment, caregivers were more likely to provide the assessment for 
children under the age of 6 years old. Typically, children between the ages of 6-18 
years old reported their own acceptability assessment. However, there were some 
exceptions with children aged from 4 years old providing their own feedback in some 
studies (Mekmullica, 2003; Ogutu, 2014; Lottman, 2007), and parents providing 
acceptability assessments for older children and teenagers up to <13 years old 
(Munck, 2008; Babbitt, 1991). Further clarification about the age at which children and 
adults should provide feedback on acceptability is required if acceptability testing is to 
be standardised.  
 
In 10 studies (Herranz, 2006; Cloyd, 1992; Coleman, 2002; Lottman, 2007; Verrotti et 
al, 2011; Mulla, 2016; Ranmal, 2016; Bukstein, 2003; Venebles, 2016; Kendall, 2001) 
both children and caregivers provided feedback. Whilst the EMA (2013) outlines that 
it expects acceptability testing to be conducted in children themselves, clarification on 
who should provide the response to the testing is required. It should not be overlooked 
that the acceptability definition includes both the ability and willingness of the patient 
to use and their caregiver (defined as ‘user’) to administer as intended. Therefore, it 
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could be argued that, in children of an appropriate age and capacity where a 
parent/caregiver is required to administer the medicine, only the responses of both 
child and caregiver would provide holistic acceptability assessment. Having two 
acceptability end-point assessments may also reduce bias of using one method to 
report acceptability assessment.  
 
2.4.4.3 Threshold of acceptability   
Clarification is also required regarding what limit of acceptance of a medicine is 
deemed as a success or acceptable. No criteria as such exist, and information 
regarding at what point a formulation is classed as acceptable is missing from the 
studies in the review. Within the papers there was at least two ways that researchers 
attempted to provide a threshold for acceptability. The first way is by calculating the 
proportion of participants who expressed a preference or similar positive reaction to 
the medicine and then arbitrarily defining a threshold limit of acceptability as 
somewhere between 0-100%. The second is by using a scale approach, and defining 
the limit of acceptability as a category, so acceptability for each participant is 
categorised independently.  
 
Apart from the arbitrary limit of ‘preference’, only sixteen studies provided information 
about a statistical threshold to define acceptability (Crisofides, 2005; Lottman, 2007; 
Strehle, 2010; Valvorita, 2009; Moniot-ville, 1998; Weinberg, 2000; Cloyd, 1992; 
Blume, 2018; Orlu, 2017; Mulla, 2016; Kendall, 2001; Nasrin, 2005; Dagan, 1994; 
Rodd, 2011; Lopez, 2018; Araposthathis, 2010). Within these sixteen studies, one 
study reported acceptability to be between 50%-100% adherence (Cristofides, 2005), 
this was the lowest accepted limit reported. Similarly, another study considered a 
medicine was acceptable when 55.7% of their participants expressed a preference for 
it (Lottman, 2007). Conversely, Strehle (2010), reported that 56% of midwives reported 
the treatment to be “unacceptable”, this was the only study to report the unacceptability 
as opposed to the acceptability of a treatment.  
 
One study considered 65% to be acceptable (Valvorita, 2009), whereas the remaining 
12 studies considered a preference of 70% or above to be acceptable. Both Moniot-
ville (1998) and Weinberg (2000) reported that 70% of children had a preference, after 
these four studies reported percentages of 75%-78% acceptance (Cloyd, 1992; 
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Blume, 2018; Orlu, 2017, Mulla; 2016). The remaining six papers judged acceptability 
as between 80% and 100% (Kendall, 2001; Nasrin, 2005; Dagan, 1994; Rodd, 2011; 
Lopez, 2018; Araposthathis, 2010).  
 
Alternatively, twelve studies used the point score or faces on the scales as a way to 
measure acceptability. On the 7-point scales (Thompson, 2013; Medeiros, 2016), a 
score of 4 or above, typically including the middle or neutral point/face e.g. 
“indifference” (Medeiros, 2016) was regarded as an acceptable score by the 
researchers. Similarly, on the 6-point scales, scores of 3 and above, i.e. “somewhat 
satisfied” (Bukstein, 2003), or “okay” (Moniot-ville, 2016) were regarded as acceptable. 
The 5-point scales provided slightly more variance, with five studies (Cohen, 2008; 
Mulla, 2016; Orlu, 2017; Ranmal, 2016; Hofmanova et al, 2020) regarding scores 3-5 
as acceptable, including one study which further grouped these into a “neutral” score 
(3), and a “positive score” (4, 5) (Ranmal, 2016). However, one study (Sjovall, 1984) 
only acknowledged a score of 4 or 5 to be acceptable. Two studies (Lopez, 2018; 
Verrotte, 2016) did not specify which scores they recognised as acceptable. Going 
forward, researchers should provide a rational for the reason they have decided which 
point or response equates to acceptability, and a universally agreed minimum level of 
acceptability would assist researchers in the reporting of their acceptability studies. 
 
2.4.5  Factors affecting the acceptability of children’s medicine 
2.4.5.1 Participant characteristics: age 
Articles were included in the review if the age of the study participants were children 
aged between 0 and <18 years; one study focussed specifically on neonates <4.3 
weeks (Rodd et al, 2011); and 38 studies spanned across at least two age groups 
(Table 2.6). Seven of these studies reported that they further subdivided these age 
groups during data collection (Klingmann et al, 2017, Ogutu, 2014, Lopez, 2018; Ruiz 
et al, 2020; Klingmann et al, 2018; Angwa, 2020; Hofmanova, 2020). Two of the 
studies included in this review included participants over the age of 18 years; 8-25 
years (Macdonald, 2003), the findings that could be isolated for <18 year olds from 
these studies were included, one paper did not specify ages but reported they were 
children (Polaha, 2008).  
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Despite the age guidelines issued by the WHO (2007) which sub-divides the paediatric 
population based on pharmacokinetic characteristics, practicality and age 
preferences, it is clear that almost half of studies did not stratify their sample in line 
with these guidelines. Whilst this may not necessarily have an impact on the 
administration of drugs (as the majority of drugs are administered on a weight basis), 
the acceptability and appropriateness of a formulation will almost certainly be 
influenced by the variability observed across ages, including child development, ease 
of administration and patient/care giver adherence (WHO, 2007). Therefore, the 
results from the papers which assessed acceptability across more than one age group, 
particularly those ranging from newborn/infants, may not provide an accurate 
representation of the acceptability of the product in each individual age sub-group. 
 
Table 2.6: Participants’ age range 
Age Number of 
studies 
Author 
Newborn/neonate/<4weeks 1 Rodd et al (2011) 
Infant 0-23 months 9 Dagan (1994); Strehle (2010); Blume (2018); Amirav 
(2014); Munck (2008); Cristofides (2005); Geltman 
(2009); Klingmann et al (2020); Kraus, (2001).  
Child 2-12 years 21 van Riet-Nales (2012); Kluk (2015), Thompson, 2009; 
Nahirya-Ntege (2012); Cadwgan (2017), Lopez (2018), 
Araposathis (2010), Verrotti et al (2011); Thompson 
(2013); Ranmal (2016); Bukstein, (2003); Cohen (2005); 
Beck (2005); Mekmullica (2003); Lloyd (2011); Pakalnis 
(2003); Giralt (2017); Angwa (2020); Hofmanova, 
(2020); Bryson, (2014); Cohen, (2009). 
Adolescent 12-18 years 1 Weinberg (2000) 
 
Infant to child 
 
14 Spomer (2012); Klingmann (2017); Orlu (2017); Block 
(2006); Moniot-ville (1998); Akhavan-Karbasi (2010); 
Nasrin (2005); Sjovall (1984); Ogutu (2014); Medeiros 
(2016), Valovirta (2009); Purchase et al, (2019); Wallace 
et al (2019); Klingmann et al (2018). 
 
Infant to adolescent 6 Kekitiinwa (2016); Musiime (2014); Coleman (2002); 
Venebles (2016); Brand (2001); Ruiz et al, (2020). 
Child to adolescent 
 
10 Herranz (2006); McCrindle (1997); Cloyd (1992); 
Lottman (2007); Macdonald (2003); Babbitt (1991); 
Jagani (2016); Patchell (2002); Kendall (2001); Mulla 
(2016). 
Not stated 2 Polaha (2008); Giralt et al (2019).  




2.4.5.2   Participant characteristics: disease status 
Acceptability of formulations is also likely to be influenced by disease status. Studies 
that included both healthy volunteers and patients were included in this review. In the 
reviewed papers, patients were enrolled from a range of pathologies, including 
asthma, arthritis and outpatient wards. In future studies where patients are all or part 
of a study population, the patient characteristics should be reported to at least disease 
level. Healthy volunteers evaluating the acceptability of formulations (either 
placebo/vitamin) accounted for participants in 12 studies (Klingmann, 2017; Orlu, 
2017; van Riet-Nales, 2012; Cristofides, 2005; Macdonald, 2003; Thompson, 2009; 
Rodd et al, 2011; Strehle, 2010; Spomer, 2012; Nasrin, 2005; Klingmann et al, 2018; 
Bryson, 2014). In 49 studies, samples comprised volunteers/patients already taking 
medicine, testing both active and placebo formulations (Pakalnis et al, 2003; Cohen 
et al, 2009; Ogutu et al, 2014; Kekitiinwa, 2016; Herranz, 2006; Musiime, 2014; Blume, 
2018; Block, 2006; Giralt, 2017; McCrindle, 1997; Sjovall, 1984; Cohen, 2005; Cloyd, 
1992; Coleman, 2002; Geltman, 2009; Lottman, 2007; Moniot-ville, 1998; Medeiros, 
2016; Akhavan-Karbasi, 2010; Verrotti et al, 2011; Munck, 2009; Beck, 2005; Jagani, 
2016; Kluk, 2015; Thompson, 2013; Polaha, 2008; Nahirya-Ntege, 2012; Mekmullica, 
2003; Dagan, 1994; Mulla, 2016; Valorvita, 2009; Patchell, 2002; Weinberg, 2000; 
Bukstein, 2003; Lloyd, 2011; Venebles, 2016; Amirav, 2014; Kendall, 2001; Cadwgan, 
2017; Brand, 2001; Arapostathis, 2010; Angwa et al, 2020; Hofmanova et al, 2020; 
Klingmann et al, 2020; Ruiz et al, 2020; Giralt et al, 2019; Purchase et al, 2019; 
Wallace et al, 2019; Kraus, 2001). Three studies did not define patients’ disease status 
or treatment administered (Lopez, 2018; Babbitt, 1991; Ranmal, 2016).  
 
The EMA has stated that it is preferable for acceptability studies to be conducted in 
the most relevant patient population as part of clinical trials (Kozarewicz, 2014). 
Additionally, testing the acceptability of a medicine that a patient has already been 
prescribed may increase the real-world application to the medicine. Therefore, those 
studies which test in a clinical population and are representative of the population the 
formulation is targeted to, may provide better validity. However, that is not to say that 
testing in a non-clinical sample is not beneficial; the testing of new, prospective 
formulations is necessary to develop and improve on existing products and 
formulations. Similarly, some aspects of acceptability, such as the size of a tablet could 
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be considered as disease-agnostic, and therefore there is merit in studying in ‘healthy’ 
children too.  
 
2.4.5.3 Formulation factors: type of formulation  
All papers included in this review measured the acceptability of medicines, both oral 
and non-oral, in a paediatric population. Twelve studies focussed solely on or 
compared the acceptability of non-oral formulations, five of these studies compared 
non-oral formulations with oral formulations including patch vs liquid (Cadwgan, 2017); 
patches vs tablets (Lloyd, 2011); tablets vs inhalers (Bukstein, 2003; Weinberg, 2000); 
gel vs injection vs needless-device (INJEX) (Arapostathis, 2010) and the remaining 
studies assessed/compared only non-oral formulations including vaccines, inhalers, 
rectal administrations, nasal spray, and spacer devices (Brand, 2001; Kendall, 2001; 
Amirav, 2014;  Pakalnis, 2003; Venebles, 2016; Kraus, 2001; Wallace et al, 2019). 
Fifty-one studies evaluated the acceptability of oral dosage formulations, the most 
common being tablets, suspensions, dispersible tablets, films, and syrups. Of these 
51 studies, 25 of them assessed the acceptability of one dosage form (Cohen et al, 
2009; Hofmanova, 2020; Orlu, 2017; Herranz, 2006; Blume 2018; Lopez, 2018; 
Cristofides, 2005; Block, 2006; Giralt, 2017; Cohen, 2005; Coleman, 2002; Moniot-
ville, 1998; Babbitt, 1991; Beck, 2005; Kluk, 2015; Thompson, 2009; Thompson, 2013; 
Mekmullica, 2003; Nasrin, 2005; Dagan, 1994; Strehle, 2010; Patchell, 2002; Ranmal, 
2016; Purchase, 2019; Giralt, 2019), whereas 26 evaluated or compared two or more 
types of dosage form such as film vs syrup or dispersible tablet vs suspension etc 
(Akhavan-Karbasi et al, 2010; Medeiros et al, 2016; Ogutu et al, 2014; Angwa, 2020; 
Klingmann, 2017; van Riet-Nales, 2012; Kekitiinwa, 2016; Musiime, 2014; McCrindle, 
1997; Cloyd, 1992; Geltman, 2009; Lottman, 2007; MacDonald, 2003; Verrotti et al, 
2011; Munck, 2008; Jagani, 2016; Polaha, 2008; Nahirya-Ntege, 2012; Rodd et al, 
2011; Mulla, 2016; Spomer, 2012; Valorvirta, 2009; Bryson, 2014; Klingmann et al, 
2018; Ruiz et al, 2020; Klingmann, 2020). 
 
The types of formulations assessed in acceptability studies will have an influence on 
the assessment criteria used, for example studies that compared more than one 
medicine typically used preference (Klingmann, 2017; van Riet-Nales, 2012) to 
evaluate acceptability, whereas studies that investigated tablet size or palatability 
generally opted to use swallowability (Lopez, 2017; Jagani, 2016). The formulation 
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type will impact on the criteria used to assess the acceptability of the medicine product. 
Therefore, this limits the extent to which acceptability can be compared within or 
across studies.  
 
2.4.6 Acceptability assessment measures and approaches 
The methods used to measure the acceptability of formulations varied widely in this 
review. The following section will provide a general outline of the prevalence of each 
method identified, followed by a more comprehensive overview of the most common 
assessment methods used.  
 
Overall, 19 different methods for assessing the acceptability of medicines in children 
were identified across the 64 papers. The most common methods were patient or 
caregiver preference, observations, questionnaires and scale methods (Table 2.6). 
Preference was reported in 24 studies; of these, reports were made by parents in eight 
studies (Kekitiinwa, 2016; Brand, 2001; Ogutu, 2014; Munck, 2008; Nahirya-Ntege, 
2012; Rodd et al, 2011; Valovirta, 2009; Lloyd, 2011),  by children in eight studies 
(Klingmann, 2017; Macdonald, 2003; Patchell, 2002; Ranmal, 2016; Weinberg, 2000; 
Arapostathis, 2010; Sjovall, 1984; Hofmanova, 2020) and by parents and children 
together in eight studies (Cloyd, 1992; Lottman, 2007; Bukstein, 2003; Venebles, 
2016; Cadwgan, 2017; Herranz, 2006; Kekitiinwa, 2016; Bryson, 2014).  
 
In 22 studies, ‘preference’ was paired with at least one other assessment method, 
including: questionnaires (Cadwgan, 2017; Valovirta, 2009; Nahirya-Ntege, 2012; 
Rodd, 2011; Bryson, 2014), visual analogue scales (Van-Riet Nales, 2012; Brand, 
2001; Akhavan-Karbasi, 2012; Lottman, 2007; Macdonald, 2003), Facial Hedonic 
Scales (Verrotte, 2011; Jagani, 2016; Hofmanova et al, 2020); observations (Rodd, 
2011) and self-report diary methods (Lloyd, 2011; Jagani, 2016). In six papers 
(Herranz, 2016; Sjovall, 1984; Cloyd, 1992; Munck, 2008; Arapostathis, 2010; 
Kekiniitwa, 2016) preference was used as a lone method of assessment. In 16 papers 
(Van Riet-Nales, 2012; Kekitiinwa, 2016; Sjovall, 1984; Cloyd, 1992; Lottman, 2007; 
Macdonald, 2003; Munck , 2008; Jagani, 2009; Nahirya-Ntege, 2012; Valovirta, 2009; 
Weinburg, 2000; Bukstein, 2003; Lloyd, 2011; Venebles, 2016; Cadwgan, 2017; 
Arapostathis, 2010) preference was used to assess the acceptability of one dosage 
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form over another e.g. intradermal patch vs liquid (Cadwgan, 2017) or tablets vs 
patches (Lloyd, 2011). In two papers (Patchell, 2002; Brand, 2001), preference was 
used to evaluate two different types of the same formulation (for example, in Brand’s 
(2001) study the comparison was between inhaler spacer devices (Nebuchamber vs 
Babyhaler). The remaining paper asked participants to evaluate preference between 
a new sustained release tablet compared to their typical medication (Herranz, 2006).  
Questionnaires were also commonly used as a method of acceptability testing in  19 
papers. Specific questionnaires such as the ‘Treatment Satisfaction Questionnaire for 
Medication (TSQM)’ (Cadwgan, 2017), and the 'Medicine Acceptance Scale (MAS)' 
(Kraus, 2001; Polaha, 2008; Orlu, 2017) were used. These are discussed in section 
2.4.6.6. One online questionnaire used a discrete choice experiment approach to 
explore factors that affected the health-related quality of life in children with ADHD 
(Lloyd, 2011). Similarly, the Caregiver Vaccine Acceptance Scale (Wallace, 2019) was 
used to elicit caregiver attitudes and beliefs. Studies which used questionnaires were 
most likely to ask parents to complete them alone (n=11 studies) (Valorvirta, 2009; 
Pakalnis, 2003; Blume, 2018; Block, 2006; Geltman, 2009; Ogutu, 2014; Akhavan-
Karbasi, 2010; Nihirya-Ntege, 2012; Rodd et al, 2011; Angwa, 2020; Wallace et al, 
2019). This was followed by parents and children completing together (n=7 studies) 
(Herranz, 2016; Cloyd, 1992; Cadwgan, 2017; Bukstein, 2003; Mulla, 2016; Ranmal, 
2016; Hofmanova, 2020), children alone (n=2 studies) (Weinberg, 2000; Patchell, 
2002) and parent and researcher or researcher alone (n=2 studies) (Orlu, 2017; 
Medeiros, 2016). In six studies, questionnaires were used as the sole instrument to 
measure acceptability (Nahirya-Ntege, 2012; Cloyd, 1992; Geltman, 2009; Ogutu, 
2014; Strehle, 2010; Pakalnis, 2003) but they were coupled with preferences in six 
other studies (Kekinittawa, 2016; Valorvirta, 2009; Patchell, 2002; Ranmal, 2016; 
Nasrin, 2005; Lloyd, 2011). Finally, scale methods such as Facial Hedonic scales 
(Cohen, 2008; Orlu, 2017) and Likert scales (Rodd, 2011) were used alongside 
questionnaires to measure acceptability. The remaining questionnaires were all 
developed for the purpose of the individual studies, and had different ‘acceptability’ 
end points, for example, the questionnaire developed by Bukstein et al (2003) 
measured ‘preference’ as a primary outcome for acceptance.  
 
Finally, observations were also used as a method of acceptability assessment and 
were typically undertaken by parents (n=8 studies) by observing children’s behaviour 
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and facial expressions (van Riet-Nales, 2012; Musiime, 2014; Blume, 2018; Giralt, 
2017; Babbitt, 1991; Rodd et al, 2011; Amirav, 2014; Angwa, 2020)  or healthcare staff 
(n=10 studies) (Orlu, 2017; Lopez, 2018; Moniot-ville, 1994; Medeiros, 2016; Beck, 
2005; Kluk, 2015; Thompson, 2009; Hofmanova, 2020; Klingmann, 2020; Klingmann 
et al, 2018). In six papers, observations were used as a lone method of assessment 
(Amirav, 2014; Spomer, 2012; Klingmann, 2017; Klingmann, 2018; Kluk, 2015; 
Thompson, 2009). They were also used alongside other assessment methods, 
including; Visual Analogue Scales (VAS) (Kendall, 2001; Orlu, 2017), Facial Hedonic 
scales (Blume, 2018; Lopez, 2018; Moniot-ville, 1998); Cohen, 2008); and 
Feedback/Preferences (Giralt, 2017; Musiime, 2017; Babbit; 1991). In four studies, 
(Orlu, 2017; Lopez, 2018; Ruiz et al; 2020; Giralt et al, 2019) observations from health-
care staff were used alongside caregiver observations. See section 2.4.6.4 for further 
details on observations. 
Table 2.7:  Frequency of acceptability measurements 





Treatment satisfaction questionnaire measurement (TSQM) 
Medicine Acceptance Scale (MAS) 






Facial Hedonic Scale 
3 point  
5 point 
6 point                                


















Baker Wong Pain scale 1 
Verbal self-report (child) 4 















2.4.6.1  Preferences 
Preferences were a common method used to evaluate how acceptable a formulation 
was in the review. Twenty-two studies (Van Riet-Nales, 2012; Kekitiinwa, 2016; 
Herranz, 2006; Sjovall, 1984; Cloyd, 1992; Lottman, 2007; Macdonald, 2003; Munck, 
2008; Jagani, 2009; Nahirya-Ntege, 2012;  Rodd et al, 2011; Valovirta, 2009; Patchell, 
2002; Weinberg, 2000; Bukstein, 2003; Lloyd, 2011; Brand, 2001; Cadwgan, 2017; 
Arapostathis, 2010; Venebles, 2016; Hofmanova, 2020; Bryson, 2014) used 
preferences of both parents and/or children to provide part, or all, of the assessment 
of the medicinal products. Preference has previously been found to be closely related 
to adherence of treatment in children. The Children’s Medication Preferences (CHIMP) 
study (Bryson, 2014) conducted at Alder Hey Children’s Hospital reported that choice 
(preference) of a formulation and associated factors have an influence on medication 
acceptability due to the premise that one formulation will not suit all children. 
Preference was found to be highly associated with medicine acceptance in children 
when they were given the choice, provided that an acceptable option was available 
(Bryson, 2014).  
 
In the current review, preferences were used as the endpoint or sole measure of 
evaluating the acceptability of a formulation in twelve of the 22 studies that used 
preferences. Five of these had parents or caregivers provide their own preference or 
their child’s perceived preference (Munck, 2008; Nahirya-Ntege, 2012; Valorvita, 
2009; Lloyd, 2011; Brand, 2001). Three studies used the preference of the child and 
their parents (Musiime, 2014; Cloyd, 1992; Bryson, 2014), and three studies used the 
preference of the children alone (Herranz, 2006; Patchell, 2002; Hofmanova, 2020).  
The remaining studies used preferences along with other evaluation end-points 
including the ease of use of the formulation (Lottman, 2007; Weinberg, 2000); 
compliance to treatment (Lottman, 2007; Macdonald, 2003), acceptance (Rodd, 2011; 
Ranmal, 2016; Arapostathis, 2010); satisfaction (Bukstein, 2003; Block, 2006), and 
appropriateness (Venebals, 2016), swallowability (Jagani, 2016; Kekitiinwa, 2016).  
 
Ultimately, preference has been demonstrated to distinguish between formulation type 
within a trial (tablet type/liquid type) (van Riet-Nales, 2012), alternative existing 
formulations (a new sustained release tablet compared to the typical tablet used to 
treat the children (Herranz, 2006), taste of oral formulations (Block, 2006), size of oral 
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tablet (Valovirta, 2009), oral vs non-oral routes (Weinberg, 2000; Lloyd, 2011), and 
between injection type (Arapostathis, 2010). This provides evidence that this method 
of assessment is useful and can account for the range of formulation factors and 
individual differences in children.  
 
Preferences were reported for oral formulations when compared with inhalers in two 
studies (Bukstein, 2003; Weinberg & Naya, 2000), reasons given were ease of use. 
Whereas preference was reported for other non-oral formulations, such as patches 
(Lloyd et al, 2011). Similarly, preference was marginally higher for alternative oral 
dosage forms such as filmstrips (Rodd et al, 2011) and melt formulations (Lottman et 
al, 2007) when compared with tablets, this was found to be reflective of compliance 
with treatment with higher percentages found for alternatives over tablets (Lottman et 
al, 2007). Parental preference differed depending on a number of factors, preferences 
were found to be variable depending on the country where the study was conducted 
e.g. preference was found to be 26% in Netherlands and 65% Spain (Valorvirta & 
Scadding, 2009) between ODT’s and oral solutions, this could be due to cultural 
differences. Similarly, the age of the child seemed to influence parents’ preference for 
formulation (Brand, 2001; Lottman, 2001). This could be due to the influence of 
parents’ perceptions or beliefs relating to their child’s age and their child’s abilities to 
take different formulations. In one study parents/caregivers were asked to report which 
formulation (syrup vs tablet) they expected themselves and their children to prefer. 
Seventy four percent of caregivers expected to prefer tablets, but only 27% expected 
their children to prefer tablets. Following the study, parents were again asked to report 
which formulation they preferred, 94-97% of parents expressed a preference for 
tablets, and reported that 57-59% of their children preferred tablets (Nahirya-Ntege et 
al, 2012). This is something that should be considered when parents are asked to 
provide acceptability assessments as proxy. Past experience, understanding and 
perceptions will all impact parents’ beliefs about the age at which children can, or 
should, take different medications.   
 
2.4.6.2 Facial Hedonic Scale (FHS) 
Hedonic scales refer to the pleasure or the perception of pleasure, of a given 
substance or experience. Researchers may select hedonic scales based on 
characteristics of their target population, for example, the details on the face (gender, 
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colour of hair or skin) and/or the number of faces to choose from. Also, the wording of 
the anchor phrases (the words used beneath categories or anchors on scales to 
explain what they relate to) can be selected dependent on the target population. 
Hedonic scales differed between studies on a number of aspects, e.g. number of 
points, faces used, facial expressions, colours, and the anchors/phrases included. A 
5-point scale was the most common scale (n=9 studies) (Dagan, 1994; Cohen, 2005; 
Mulla, 2016; Lopez, 2018; Verrotti, 2011; Strehle 2010; Orlu, 2017; Ranmal, 2016; 
Hofmanova, 2020), 7-point scales were used in two studies (Thompson, 2009, 
Medeiros, 2016), 6-point scales were used in three studies (Moniot-ville, 1998, Jagani, 
2016; Bukstein, 2003), and 3-point scales were used in one study (Dagan, 1994) (see 
Table 6). A 5-point hedonic scale was used with children as young as 3 (Orlu et al, 
2017) and 4 years old (Hofmanova, 2020; Cadwgan et al, 2017).  
 
Eleven studies in the review used a 'faces' scales and, of these, 7 used a simple emoji-
based image (Cohen, 2005; Mulla, 2016; Lopez, 2018; Jagani, 2016; Bukstein, 2003;  
Ranmal, 2016; Thompson, 2009), and one used a more realistic drawing of a child's 
face (Medeiros, 2016), three papers only explained the scale and no further details 
regarding the images on the scale are available (Hofmanova, 2020; Strehle, 2010; 
Moniot-ville, 1984). Figures 2.3 a-f show a selection of ‘faces’ used in some of the 
studies. When focusing solely on the emoji-based faces there are considerable 
differences between the characteristics of the faces. Although all faces include eyes 
and a mouth, some also include a nose, eyebrows, hair, hands, tears and all have 
slightly different expressions or intensity of expression (such as degree of downturn of 
the mouth). Some include other elements such as 'thumbs up and down' and noses 
being held to suggest distaste. The more realistic faces portray gender specific 
features. None of the studies provided information on how these faces/facial 
expressions or the accompanying text were chosen, and it is unclear whether any 













Figure 2.4: Facial Hedonic Scale (Ranmal, 2016) 
 
 

















Figure 2.7: Facial Hedonic Scale (Medeiros, 2016) 
 
Figure 2.8: Facial Hedonic Scale (Thompson, 2013) 
 
 
Different characteristics were measured across the studies (Table 2.8). Two FHS in 
the current review were reported as ‘age-adapted’ (Orlu, 2017; Ranmal, 2016). 
However, both studies used 5-point scales and the ‘age adaptation’ referred to the 
anchor phrases next to each face. Hedonic scales are sometimes used with ‘anchor 
phrases’ or verbal descriptors when used in child populations, this helps mitigate some 
of the issues with the understanding or comprehension of the interpretation of the 
scale. The anchor phrases used in the studies in this review were highly dependent 
on what the scale was measuring. For example, a scale with the ‘Ease of Swallowing’ 
as an end point for acceptability used “easy to take-not easy to take” as endpoints 
(Lottman et al, 2007), whereas a scale measuring ‘Taste’ as an endpoint, used “Very 
good-Very bad” (Cohen, 2008). The phrases/anchors varied widely across all of the 
FHS used, even when the endpoints of the scale were the same. Two of the studies 
used FHS to exclusively measure “overall satisfaction” (Dagan, 1994; Strehle, 2010). 
Even between these two studies, the terminology differed, with Strehle (2010) using 




Table 2.9: Characteristics of measures use 
Author 
(year) 
Age Measuring Number of points/ 
measurements  
Anchors (words and 
numerical) 
Level of acceptance 
Facial Hedonic Scale (FHS) 
Dagan 
(1994) 
18-22 months Acceptance/compliance 
“willingness to swallow and 
occurrence of vomiting”  
“satisfaction”- defined as 
‘extremely satisfied/satisfied’  
“acceptability”- not defined 









6-12 years Taste/mouthfeel liking 7-point “super bad” to “super good” Anything rated >4 
Medeiros 
(2016) 
6 years and 
below 
Overall liking 7-point ‘hate it’ - ‘love it’  “acceptance to indifference”- 
Rated points 4-7 
Moniot-ville 
(1998) 
2-8 years Acceptability-  
“refusal of medication” 
6-point Bad (0) - Good (6) Points 3-6 
Jagani 
(2016) 
6-17 years Ease of swallowing 6-point Not difficult (0) - most difficult 
(6)  




6-11 years Patient preference, satisfaction, 
adherence, safety 
6-point Smiling face (6) - ‘frowning 
face’ (1) 




Avg. 2.9 years Taste 5-point Very good (5) > Very bad (1)  Points 3-5  
Sjovall 
(1984) 




3-16 years “overall acceptability”- Taste, 
smell, incident of vomiting, ease 
and willingness to take 




4-12 years Appearance, ease of 
swallowing, mouth-feel, taste 





Avg. 6.7 years Palatability 5-point Not defined Not defined 
Age-adapted FHS 
Orlu (2017)  
 
3-5 years Whether the child liked taking 
the tablet 
Willingness to take again 









Liked/disliked, willingness to take 
again, ease/difficulty to take 
5-point  Negative (1) - positive (5) Neutral (3) - 
Positive score (4 + 5) 
Nominal Scale (CareCAT) 
Blume  
(2018) 
0-5 years Swallowing 5-point Swallows well (1) - Not taken 
(5) 
Not defined  




6-59 months “ease of handling spacer” 
“control of asthma symptoms” 
“overall preference” 
100mm (10cm) Not defined  Clinically relevant if the VAS score 
preceded 60%, 
Statistically significant if VAS score 
preceded 95%, 










3-16 years Acceptability of treatment to 
patients 
100mm (10cm) Acceptable, stressful, very 
stressful, unacceptable 
Not defined  
Lottman 
(2007) 
5-15 years Safety, ease of use 100mm 
(10cm) 
I find it very easy to take (0) - I 







Avg. 6.7 years Satisfaction of route of 
administration  
100mm (10cm) Not defined Level of satisfaction was compared 
between patients in the two different 
routes of administration groups. 
Macdonald 
(2003) 
8-25 years Efficacy, safety, ease of use 100mm (10cm) Very easy to use (0) - very 
difficult to use (100) 
80% compliance  
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Three studies (Mulla, 2016; Ranmal, 2016; Moniot-ville, 1998) presented their scales 
with a negative anchor such as, “very unpleasant” or “not satisfied” on the left-hand 
side of the scale and the positive anchor on the right. Five studies (Orlu, 2017; Lopez, 
2018; Cohen, 2008; Bukstein, 2003; Jagani, 2016) presented the positive anchor/face 
on the left and the negative on the right. Five did not specify (Dagan, 1994; Thompson, 
2013; Medeiros, 2016; Sjovall, 1984; Verrotte, 2016). Moreover, there were also 
differences observed between the anchor and corresponding number on the scale. Six 
studies (Ranmal, 2016; Orlu, 2017; Mulla, 2016; Cohen, 2008; Bukstein, 2003, Moniot-
ville, 1998) presented the negative face/phrase corresponding to the lowest number 
on the scale (0, 1), whereas the remaining two studies (Jagani, 2016; Lopez, 2018) 
presented it the opposite way.  
 
One study (Sjovall, 1984) used the hedonic scale alongside the question ‘Which one 
of these figures do you think has tasted this medicine?’, and the children were then 
asked to indicate the figure on the form. This differs from the use of the hedonic scale 
in other studies which ask the child to indicate their own liking for the medicine by 
using the hedonic scale to do so (Thompson, 2013). The effect of the accompanying 
question to the results of the FHS is still relatively under-researched, and the impact 
of this could be beneficial in providing best practice recommendations to industry.  
There is little research or evidence regarding which scales for the acceptability of 
medicine assessment are preferred by or are more suitable for children, and the 
reliability and validity of one scale over another for children has not been tested and 
is still unclear. The Wong-Baker FACES Pain Rating Scale used in one study (Kendall, 
2001) has been validated for use in children. However, despite the number of hedonic 
scales used to measure the acceptability of medicines, it is still unclear whether any 
scale is more valid or reliable as this information is generally missing or not reported 
in the papers.   
 
2.4.6.3 Visual Analogue Scales (VAS) 
Visual Analogue Scales (VASs) are presented as a horizontal line, usually 10cm 
(100mm), with two opposing limits on either end. In the current review all the VAS 
included were 100mm which provides some consistency across paediatric 
acceptability testing (Figure 2.4). Six VAS were used, either as the sole measure 
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(Macdonald, 2003), or alongside another method (Van Riet-Nales, 2012; Akhavan-
Karbasi, 2012; Brand, 2001; Kendall, 2001; Lottman, 2007). 
 
Relating to the comprehension of VAS, phrases attached to the scale should be 
meaningful to research participants. In the current review, four of the six studies 
provided accompanying phrases (Van Riet-Nales, 2012; Lottman, 2007; Macdonald, 
2003; Kendall, 2001). However, two studies did not define phrases (Akhavan-karbasi, 
2010; Brand, 2001) The phrases were all different and matched the purpose of each 
study. For example, in the study by Macdonald (2003), the phrases 'Very easy to use' 
to 'Very difficult to use' were employed to measure ‘Ease of Use’ of a medicinal 
product. Whereas 'Very unpleasant' to 'Not at all unpleasant' was used to measure the 






Figure 2.8: Example of Visual Analogue Scale (van Riet-Nales, 2012). 
In the studies which used a VAS, two used a VAS to measure acceptability in a 
population group over the age of 6 years old (Akhavan-Karbasi, 2010; Macdonald, 
2003), whereas the remaining four studies included children aged 5 years or younger 
(Brand, 2001; Van Riet-Nales, 2012; Kendall, 2001; Lottman, 2007). Only one study 
(Macdonald, 2003) which recruited children aged 8 years and older, relied solely on 
children completing the VAS with no proxy reports from parents. The remaining five 
studies all had parents act as proxies to complete (Van Riet-Nales, 2012; Akhavan-
Karbasi, 2012; Brand, 2001; Kendall, 2001; Lottman, 2007). Whilst having parents to 
act as proxy reporters overcomes the issue of whether the VAS can be understood 
and appropriately used by a child in acceptability assessments, it further accentuates 
the discussion regarding whether the parent or child should be the one to provide the 
acceptability assessment. Studies did not report advantages or limitations of using 
VAS in child populations, however this is discussed in section 2.5 in context of wider 
literature.  
 
In five studies, the VAS was used alongside another assessment method to evaluate 
acceptability (Van Riet-Nales, 2012; Akhavan-Karbasi, 2012; Brand, 2001; Kendall, 
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2001; Lottman, 2007). However, the study which used the VAS as a lone acceptability 
assessment method (Macdonald, 2003) made use of alternative outcome measures 
rather than the VAS scores, such as 'compliance to treatment' to assess the overall 
acceptability of the new formulation. Preference was used in all five of the remaining 
studies alongside the VAS, as well as self-report diary methods which were used in 
one study (Brand, 2001); observations were used in two studies (Kendall, 2001; Van 
Riet-Nales, 2012); verbal self-reporting was used in one study (Van Riet-Nales, 2012); 
and the Wong-Baker FACES Scale which was also used in one study (Kendall, 2001).  
 
2.4.6.4 Observations 
Observations of children’s facial reactions, body language and/or amount of ingested 
product have also been used in testing the acceptability of medicines. Observations 
vary between studies as to who provides the observation assessment, which 
behaviour is observed to measure acceptability, and what observed behaviour is 
regarded as acceptable. Ten studies used parent observations to assess the child’s 
acceptability of the formulation (Blume, 2018; Giralt, 2017; Amirav, 2014; Kendall, 
2001; Spomer, 2012; Babbit; 1991; Cohen, 2008; Orlu, 2017; Rodd, 2011; Angwa, 
2020). Eight relied on the researcher or clinician to provide the acceptability 
assessment from the observation (Lopez, 2018; Beck, 2005; Kluk, 2015; Thompson, 
2013; Moniot-ville, 1998; Klingmann, 2018; Mekmullica, 2003; Klingmann et al, 2018). 
Eight studies used both caregiver and researcher observations to provide two 
separate acceptability assessments (Blume, 2018; Kendall, 2001; Orlu, 2017; Moniot-
ville, 1998; Klingmann et al, 2020; Ruiz et al, 2020; Giralt, 2019; Purchase et al, 2019). 
Only two of these studies provided information regarding the coherence between the 
two assessors, Orlu (2017) reported that caregiver and nurse observations showed 
excellent agreement to a figure of 95%, however no further details were provided. 
Whereas Blume (2018) reported that caregiver scores marginally differed to 
researcher observation scores, this study also video recorded the observation which 
allowed the researchers to standardise the scores provided in a blinded test a week 
later. This found that the scores were reproduced 81% of the time between observers.   
Five studies used the child’s facial expression/reaction to judge acceptability of the 
formulation (Thompson, 2013; Lopez, 2018; Moniot-ville, 1998; Kendall, 2001; Giralt, 
2017). Lopez (2018) evaluated issues with the palatability of a product based on 
negative facial expressions, whereas Moniot-ville (1998) and Kendall (2001) evaluated 
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positive (e.g. a smile) and negative facial expressions to assess the acceptability of a 
formulation. Seven studies observed the child’s ability to swallow, or swallowability of, 
a formulation as an outcome measurement for acceptance (Kluk, 2015; Orlu, 2017; 
Klingmann, 2018; Blume, 2018; Spomer, 2012; Van Riet-Nales, 2012; Mekmullica, 
2003). Lopez (2018) compared researcher observations to patient reported outcomes 
and reported that patient reported outcomes provided better discrimination between 
samples, and individual evaluation of a range of attributes including taste, texture and 
sample volume. Whereas the observation could only provide the overall judgement of 
acceptability.  
 
The majority of these studies measured the ability to swallow using terms such as 
“swallowed” to denote the formulation as being acceptable, and “refusal/not 
swallowed” as not acceptable. However, differences were observed with some 
endpoints. For solid oral formulations, Klingmann (2018) regarded ‘chewing or biting’ 
the formulation as acceptable, whereas others regarded this as not acceptable (Kluk, 
2015; Beck, 2005; Spomer, 2012). Similarly, a ‘choking reflex’ was also regarded as 
‘acceptable’ by Kluk (2015), provided the whole dose was subsequently taken, 
whereas in Medeiros’ (2016) study this was not acceptable. The remaining studies 
measured oral acceptance by observing physical behaviour with physical negative 
behaviour including turning head away, blocking with hands, clamping mouth shut 
(Beck, 2005), and crying (Rodd, 2011; Medeiros, 2016).  
 
Variance between the criteria for observations was also noted (Table 2.10), and three 
studies (Amirav, 2014; Mekmullica, 2003; Spomer, 2012) did not specify which criteria 
the observations were based on further than success or failure. Giralt (2017) reported 
that the observation was carried out systematically using detailed checklists, however 
no further information is supplied. Typically, acceptability in observations is based on 
an individual’s own judgement of a behaviour such as “acceptable, stressful, very 
stressful and unacceptable” (Kendall, 2001), or “facial expression” (Lopez, 2018), it is 
possible that the subjectivity of the observer will impact on how the behaviour is 
scored/judged, and therefore impact on the acceptability score provided. Having two 
external observers or recording the testing as in Kluk’s (2015) and Blume’s (2018) 
studies would allow for the retesting/scoring of the study and the inter-rater reliability 
of scores.  
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Observations were paired with questionnaires (Rodd, 2011; Orlu, 2017), hedonic 
scales (Lopez, 2018; Blume, 2018; Cohen, 2008; Moniot-ville, 1998, Orlu, 2017; 
Medeiros, 2016), VAS (Kendall, 2001; Van-Riet Nales, 2017), interviews/patient 
feedback (Giralt, 2017; Babbit, 1991; Rodd, 2011; Klingmann, 2018; Van-Riet Nales, 
2017), Likert scales (Rodd, 2011) and Wong Baker FACES Pain rating scale (Kendall, 
2001). Interestingly, the majority of studies paired observations with another form of 
acceptability evaluation, only one study (Mekmullica, 2003) did not.  
 
The use of more than one evaluative measure to assess acceptability may be 
necessary to provide a more reliable measurement of acceptability. 
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Table 2.10: Characteristics of observation studies 
Author (year) Behaviour(s) observed Acceptance threshold 
Observed by researcher/clinician 
Thompson (2013) Spontaneous facial 
reaction 
Sucked lozenge for 1 minute or spat out 





Smile = good or fairly good 
No face= acceptable  
Made faces/complained= poor  
Refusal= very poor 
Van riBeck (2005) Physical behaviour Acceptance= child allowed tablet to me in mouth for 10-seconds; 
Swallowability= child swallowed within 30 seconds; 
Chewed; expelled= removed/spat out tablet; Avoided= turning head, blocking with hands, clamping mouth 
shut  
Kluk (2015) Ability to swallow Acceptable: Smooth swallowing; swallowing with choking reflex or cough 
Not acceptable: biting or chewing; spitting out or refusal to take; choking without swallowing 
Orlu (2017) Ability to swallow Successful administration of ODF 
Total score on Medicine Acceptance Scale (MAS) (3 or above = acceptable) 
Klingmann (2018) Swallowability Acceptable: “swallowed” or “chewed and subsequently swallowed” 
Acceptability: defined as ‘everything swallowed’ or ‘partially swallowed’ 
Observed by parent/caregiver 
Kendall (2001) Pain 
Facial reaction 
Smiling to crying  
‘no obvious discomfort, mild reaction, winced or withdrew, cried, screamed’ 
‘acceptable, stressful, very stressful, unacceptable’ 
Cohen (2008) Pain (Observational 
Pain Scale) 
Nausea 
Nausea, dizziness, discomfort 
Giralt (2017) Infant's response  Adherence and handling of medicine 
Amirav (2014) Behaviour “did not awaken” “cry” “demonstrate fear” 
Medeiros (2016) Overall liking Positive reaction: Easy administration, sucking motions, licking lips, smile, stop crying, opening the mouth 
asking for more, nod positively 
No reaction: Had no reaction, does not woke up, woke up without crying.  
Negative reaction: Retching, nod negatively, cover mouth with hands, facial grimacing, crying, spitting, 
kicking, turning the head, refusing to swallow, cough 
Blume (2018) Swallowing “swallows well”, “refusal”, “spitting”, “vomiting”, “medication not taken” 
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Spomer (2012) Swallowability  Swallowed- acceptable 
chewed, spat out, choked on, refused- not acceptable  
Van-Riet Nales 
(2012) 
Swallowability Full dose swallowed, part-dose swallowed, dose not swallowed 
Mekmullica 
(2003) 
Ability to swallow Successful swallow of formulations  
Rodd (2011) Infant medication 
acceptance scale  
Reaction to supplement in mouth 
Swallowing of supplement 
Crying 
Facial expression 
Babbitt (1991) Noncompliance 
/nonacceptance 
Mild inappropriate behaviour  
Angwa (2020) Perception of taste Children’s expression/reaction 
Klingmann (2020) Amount 
taken/palatability 
“everything swallowed” or “chewed/partially swallowed” 
Ruiz et al (2020) Result of intake 
Patient reaction 
Time needed to 
prepare/administer 
Methods used to 
achieve administration 
Dose fully taken, partly, or not at all.  
Positive, neutral or negative reaction. 
Short (<1 min), medium (1-2.5 min), long (>2.5min) 
Dividing dose/using food or drink/patient reward/ restraint  





2.4.6.5 Verbal spontaneous reactions and patient feedback 
Verbal spontaneous reactions and patient feedback were used to assess the 
acceptability of formulations in four studies (Arapostathis, 2010; Medeiros, 2016; 
Cadwgan, 2017; Thompson, 2013). This feedback is often provided immediately after 
a formulation is administered (spontaneous) or following a question or prompt by the 
researcher (feedback). These reactions provide information about the subjective 
acceptability of a formulation to the individual. Additionally, understanding what 
aspects of the medicine are not acceptable and/or are disliked by participants is crucial 
to adapting the medicine for that individual (Table 2.11).  
 
Verbal reactions and feedback have been considered useful and effective ways to 
evaluate taste. However, some limitations with using these methods have been 
reported such as children being unable to articulate appropriately and the lack of 
standardisation of the verbal feedback. For example, one study (Thompson, 2013) 
measured children’s responses to the questions “would you be happy to take it (the 
medicine) again?” and “would you be happy for mum or dad to give you this flavour 
medicine when you get a sore throat?”. Differences were observed in responses to 
these two questions, despite the same medication being evaluated, 94% said yes to 
the first question but only 86% said yes to the second question. Whilst this difference 
was not statistically significant, it provides some evidence that the interpretation and 
understanding of a question may elicit different results depending on how the question 
is asked (Thompson, 2013). However, Sjovall et al (1984) compared spontaneous 
verbal judgements with results of a 5-point hedonic scale measuring the acceptability 
of a penicillin medication and found that for children under the age of 6 years old, 
verbal assessment discriminated between the formulations better than a hedonic 
scale, but that for children older than the 6 years no difference was shown between 
the two methods. Additionally, one study correlated verbal feedback to a rank score 
between 1 (very good/or similar) – 5 (very bad/or similar) (Sjovall, 1984) which allows 
for the testing and evaluation of these verbal judgements in a more statistical manner 






Table 2.11: Spontaneous verbal reactions 
Author (year) Verbal reactions Age of children 
Positive verbal reactions 
Medeiros (2016) "good," "I want", "liked", "tasty", 
"very good "or “better than the 
last one” 
<6 years 
Cadwgan (2017) ‘good’ ‘very good’ Avg. 4 years 
Negative verbal reactions 
Medeiros (2016) complain and say "bad" < 6 years 
Thompson (2013) ‘disliked’ 2-6 years 
Cadwgan (2017) ‘thought I was going to choke’ 
‘itching’, ‘unpleasant taste’ 
Avg. 4 years 
Sjovall (1985) Not defined  3-12 years  
 
2.4.6.6 Other measurements and tools  
Other tools have been used and adapted for the evaluation of acceptability of 
medicines in a paediatric population. The Caregiver Children’s Acceptance Tool 
(CareCAT) is a single page diary with a 5-point nominal scale. It allows the evaluation 
of the acceptability of medicine based on observable behaviour which can be used as 
a longitudinal measurement of behavioural responses to treatment duration for up to 
four weeks (Blume, 2018). The tool (Figure 2.9) consists of one positive behaviour 
(swallows well) and four negative behaviours (refusal, spitting up, vomiting, not taken), 
which caregivers complete when their child is given the medicine. The tool was 
developed to be used in clinical practice by health professionals and by parents/ 
caregivers for ‘at home’ use, within the study reliability of this scale was tested and 
reported to be a reliable tool to assess acceptance (Blume, 2018). It is intended to 
estimate the ‘general acceptance’ of a medication in a child population.  
 
Figure 2.9: CareCAT (Bloom, 2018).  
Similarly, The Medicine Acceptance Survey (MAS) (Kraus et al, 2001) is a 10-point 
summative tool which evaluates five behavioural responses in children when 
administered medicine (Figure 2.10). These responses are crying, facial expressions, 
body movement, reactions, and ingestion of the drug. The MAS was developed for 
caregivers/parents to use on infants, and so some of the responses (crying/body 
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movements) may be specific to infants. Whilst the MAS has content validity, internal 
reliability and interrater reliability, its efficacy and use outside of an infant population 
is unknown. Nevertheless, it has been adapted and used in newborns (Rodd et al, 
2011) and in a population of older children/ adolescents (Paloha, 2008).  
 
Figure 2.10: Medicine Acceptance Scale Adapted for Children/Adolescents (Paloha, 2008)  
Existing patient reported outcome measurement tools have been used to evaluate the 
taste, suitability and age-appropriateness of medicines in a paediatric population. 
These measures include Likert scales, the Treatment Satisfaction Questionnaire for 
Medication (TSQM) (Cadwgan, 2017) and the Wong-Baker FACES Pain Rating Scale 
(WBFP) (Kendall, 2001). The TSQM was initially developed for use in adult 
populations to evaluate treatment for chronic diseases, however, it has recently been 
used in paediatric populations (Cadwgan, 2017). It has been tested for reliability and 
validity in adult populations and scores highly on internal and construct validity, 
however reliability and validity is not reported in this study for children. The TSQM is 
a 14-item scale which aims to evaluate four key domains: effectiveness, side effects, 
convenience and global satisfaction. In Cadwgan's (2017) study, parents were asked 
to complete the TSQM through observation of their children.  
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Additionally, Wong Baker FACES Pain Rating Scale (WBFP, 2009) is a validated tool 
and was established as a self-assessment scale to measure the amount of pain an 
child may be in. It was originally developed with children, at least 3 years or older, to 
help them communicate their pain and improve assessment so that pain could be 
addressed and managed.  
 
Figure 2.11: Wong-Baker FACES pain scale  
In research use and to maintain the validity of the scale and its results, the Wong-
Baker FACES Pain Rating Scale should solely be used for pain assessment. The 
developers highlight that the scale should not be used in the assessment of emotions, 
moods, comfort or otherwise. However, one study in this review (Kendall, 2001) used 
the W-BFP Scale to measure the reduction of pain caused by the treatment as an 
indirect assessment of acceptability. Whilst the tool was used correctly (i.e. to measure 
pain), the extent to which a measure of pain can be used as an acceptability measure 
is debatable. 
 
That being said, measures such as the TSQM (2017) that evaluate more than one 
aspect of a concept may provide a more accurate picture of the overall acceptability 
of a medicine by accounting for the many different aspects that result in the “overall 
acceptability”. Ranmal (2016) used a multidimensional measure (Figure 2.12) to 
evaluate the overall acceptability of a formulation, accounting for personal preference 
(like/dislike), how easy or hard it was to take, and how likely the child would be to take 
the medicine in a real-life setting. Rather than using one end point such as preference 
or swallowability to evaluate the overall acceptability, this type of measure recognises 
that acceptability is the combined result of a number of different factors.  
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Figure 2.12: Ranmal (2016).  
2.5 Synthesis and Discussion of Review Findings  
In order to situate the findings of the review and draw conclusions, in this section the 
key findings from the reviewed papers are integrated into wider literature. The review 
demonstrates that whilst there are attempts in the literature to define acceptability, no 
common definition is applied. In line with current regulatory definitions (EMA, 2013), 
some studies used the willingness and ability of children and caregivers to administer 
and take medicines (Rodd et al, 2011; Ranmal et al, 2016; Angwa, 2020). However, 
this definition of acceptability is open to interpretation (Ranmal et al, 2018), and it was 
common for individual studies to use their own definition of acceptability that reflected 
the specific purpose of the study. For example, studies that compared medicines opted 
to use preference (Klingmann, 2017; van Riet-Nales, 2012), whereas studies that 
investigated tablet size or palatability generally opted to use swallowability (Lopez, 
2017; Jagani, 2016). The way that acceptability is defined or understood within the 
papers impacts on the criteria used to assess the acceptability of the medicine product. 
Whilst few studies provided the criteria used to assess acceptability, those that did 
were highly variable, ranging from criteria such as acceptance or rejection of a 
medicine, to a child’s body language such as “child-smiling” (Moniot-ville, 1998) or 
“swallowed with ease” (Kluk, 2015). This variability limits the extent that acceptability 
can be compared within or across studies.  
 
Overall acceptability is understood to be the combination of multiple factors, including 
appearance, palatability, swallowability and ease of administration (Korarewicz, 2016). 
However, there needs to be some guidance on which aspects of acceptability should 
be evaluated for which medicines e.g. swallowability, palatability and taste for oral 
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formulations; pain and appearance of medicine for injections etc. Focussing on only 
one or two of these factors in the evaluation of acceptability of paediatric formulations 
fails to account for the complexity of acceptability (Vallet et al, 2017; Kozarewicz, 2014; 
Ranmal, 2016). The simultaneous consideration of a number of these factors may 
provide a solution if conducted in a standardised manner. Similarly, whilst there was 
variance in the criteria used to assess acceptability, a universal threshold of 
acceptability is also dramatically lacking an evidence-base. Within the literature there 
were two main ways that investigators attempted to provide a threshold of 
acceptability. Firstly, the proportion of participants that express a willingness to take 
the medicine or provide a preference is transformed to a statistical limit, and an 
arbitrary percentage is recognised as acceptable (between 50%-100%). The approach 
of using a statistical limit to assess acceptability is observed within veterinary practice 
to judge palatability of medicine for animals, the EMA (2011) proposes a numerical 
limit of 80% (dogs) and 70% (other species) to judge whether a medicine can be 
regarded as acceptable or not. A requirement for a statistically agreed limit for the 
acceptability of medicine in children has been previously highlighted as necessary 
(Mistry & Batchelor, 2017). The second method used to provide a threshold of 
acceptability is through the use of a scale measure and defining acceptability as a 
point score or face on the chosen scale (Thompson et al, 2013; Medeiros et al, 2016). 
Again, guidance should be provided around which face or number on the scales is 
deemed to be acceptable as the current review highlights the variance between the 
accepted points.  
 
This review provides evidence that formulation developers and researchers are 
beginning to include children and young people in the evaluation and development of 
medicines for children, as called to do so by the EMA (2013). Whilst this demonstrates 
that steps are being taken to make medicines more acceptable for children, further 
work is still required. Specifically, further clarification is required regarding the age that 
children should be included in studies. Differences were observed in the current 
review, and few studies followed the age guidelines issued by the WHO (2007). 
Differences were observed for ages of children providing their own acceptability 
assessments and studies where adults/caregivers were used as proxy. Typically, 
children between the ages of 6-18years old reported their own acceptability 
assessment, however there were some exceptions with children aged from four years 
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old providing their own feedback in some studies (Mekmullica et al, 2003; Ogutu, 2014; 
Lottman, 2007), and parents providing acceptability assessment for older children and 
teenagers up to 13 years old (Munck et al, 2008; Babbitt, 1991). Further clarification 
about the age at which children and/or adults should provide feedback on acceptability 
is required if testing is to be standardised. Both healthy children and patients were 
tested in the studies included in the review. Following guidance from the EMA that 
testing should include the most relevant patient population (Kozarewicz, 2014) means 
that those children of the relevant age and disease status would be appropriate for 
testing. Patients’ past experiences in taking medicines and the nature of this treatment 
may also impact on children’s perceptions of acceptability (Giralt, 2017), therefore, 
whilst not every child may be a current patient, almost all children have taken some 
form of medication over their lifespan. Similarly, some features of acceptability, such 
as tablet size or appearance, can be considered disease-agnostic (FDA, 2015), and 
therefore testing in healthy populations of the appropriate age would also be beneficial 
rather than just testing adult populations.  
 
This review provides evidence that the measures that are used to assess the 
acceptability of medicines in children are widely varied and dependent on a number of 
factors. Methods used to assess acceptability differed depending on the focus of the 
study (see Table 2.7), as well as researcher decisions about the child’s age and 
assumed understanding, and the formulation and associated formulation factors (route 
of administration, dosing frequency) (Figure 2.13). The variance between these factors 
may mean that it is not possible for one global measure to evaluate acceptability of 
medicines in children as it is important that the measure used is suitable for the 
intended purpose (Mistry and Batchelor, 2018). However, this review highlights a 
number of issues with the currently used measures, not least that the children who are 
asked to use these measures have neither been included in their development and 
nor in the decision making when choosing a scale to use in practice. 
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Figure 2.13: Current practice: criteria that impact on the development and selection of methods used to 
assess the acceptability of medicine in children. 
Of the scales used to assess acceptability, Facial Hedonic Scales (FHS) were the 
most common and were demonstrated for use in children as young as four (Hofmaova, 
2020; Cadwgan, 2017). Hedonic scales are sometimes used with phrases or verbal 
descriptors when used in child populations and this is said to mitigate some of the 
issues with understanding and comprehension of the scales. FHS were age-adapted 
in two studies (Orlu, 2017; Ranmal, 2016), this related to the phrases used along with 
the images. However, Sjovall (1984) compared spontaneous verbal judgements with 
the results of a five-point hedonic scale measuring the acceptability of penicillin 
medication and found that for children under the age of six years old, verbal 
assessment discriminated between the formulations better than a FHS. For children 
over six years, no difference was observed. No studies provided information about 
how or why scales or response images were designed or chosen, and there is a gap 
in the literature about which image is the most meaningful or relatable to children. 
Similarly, the structure of the studies is also left up to the discretion of the researchers, 
as mentioned earlier studies differed on the presentation of the scales. Some 
displaying positive anchors/responses to the left of the scale, and others presenting 
these on the right. Similarly, studies on numerical scales also differed, with some 
presenting the negative face/phrase corresponding to the lowest number on the scale 
(0, 1), whereas other studies presented it the opposite way. It is not clear whether such 
issues have an impact on the outcome of assessment. Whilst this was not discussed 
within the papers, this has been explored in food preferences, and no differences were 
observed for presentation (Peryam & Pilgrim, 1957; Mistry & Batchelor, 2017). Visual 
analogue scales provide continuous data and may be better suited to comparing 
differences between samples, however Mistry & Batchelor (2017) report VAS are 
restricted by the age at which children are able to comprehend and use them. This is 
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reflected by the results of the current review which noted that parents/adult helpers 
completed the scale with the child in all but one study that used a VAS. Although not 
reported in the review papers, it is important to note that VAS can be misused when 
the anchor phrases and responses on the scales are not meaningful to participants 
(Bartoshuk, 2005). The degree to which the anchor phrases and responses were 
meaning to the children is unclear. 
 
In order for age-appropriate and acceptable medicines to be developed for children, 
the measures that are used to evaluate the acceptability of medicines must be shown 
to do just that. It has been demonstrated in pain studies that when given the choice 
children have opted to use hedonic scales over VAS (Luffy, 2003). Similarly, Bracken 
et al (2018) evaluated the age-appropriateness and acceptability of four different 
assessment tools with children and found children had preferences for specific scales 
and identified issues with the use of others. This provides evidence that different 
measures may be better suited to evaluate different aspects of acceptability of 
medicines (Preston, 2017).  
 
Based on the synthesis of the findings from this review it seems reasonable that a third 
domain should be added to the existing criteria used to assess the acceptability of 
medicine in children. This domain should relate to children and caregivers and should 
consider issues such as including children’s voices, acknowledging their 
understanding and considering factors such as including them in assessment of 
acceptability. Adding this third domain could be a move towards better practice in 
developing and selecting appropriate methods (Figure 2.14). 
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Figure 2.14: Proposed best practice: inclusion of criteria that should influence the development and 
selection of methods used to assess the acceptability of medicine in children. 
2.5.1 Conclusion  
The purpose of the review was to address the broad question about the methods used 
to assess the acceptability of medicine formulations for the population of children 
under the age of 18 years. It has highlighted the knowledge deficits and the potential 
benefits of inclusion of children in developing acceptability measures. The inclusion of 
children in research about children, particularly in a topic as subjective as medicine 
acceptability, has the potential to help industry and developers to obtain a better 
understanding and improve knowledge of age-appropriate formulation development. 
Obtaining the unique perspective of children about the appropriateness of measures 
used to evaluate the acceptability of medicine can only enhance understanding where 
multiple viewpoints are required (Figure 2.14).  
 
The literature review chapter has presented and discussed themes around the 
development of medicine for children and young people, the understanding of the 
acceptability of medicine, and the methods used to conduct acceptability testing with 
children and young people.  
 
This chapter has suggested that the current understanding of the acceptability of 
medicine is fragmented, which ultimately impacts the extent to which the methods that 
are used to evaluate acceptability can be deemed reliable or appropriate for use with 
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children and young people. These limitations originate from the fundamentally adult-
focussed assumptions that drive pharmaceutical development, and health care more 
generally (Tariq, 2013). There is an increasing recognition that children should occupy 
a more active role within research (Coulter, 2004), particularly where they can provide 
new types of knowledge in topics that concern them, such as their own healthcare 
(Stafford et al, 2006).  
 
The study presented in this thesis builds upon such work that has included children’s 
opinions and experiences of their own healthcare and complex health issues (Lidskog, 
2008; RCHP, 2012). It does so by providing children with the opportunity to engage in 
research for the co-construction of knowledge to improve the understanding of the 














































3 Methodology   
The review in Chapter 2 highlighted a gap in knowledge regarding the acceptability of 
paediatric formulations. It also demonstrated the limited and “fragmented” knowledge 
that exists about the best methods to conduct acceptability testing in paediatric 
populations (Ranmal et al, 2018, p18). This chapter will detail the research 
methodology that was employed to begin to address this gap in knowledge, prior to a 
detailed discussion in Chapter 4 of the methods employed in the current study to 
answer the research questions.  
 
This chapter begins by describing the generic qualitative research approach that 
underpins this project and examines the use of employing this approach over other, 
more specific, qualitative research methodologies. This chapter concludes with a 
critical examination of the ethical arguments for the competence and inclusion of 
children in research that concerns them.  
 
3.1 Aim 
The aim of this study was to: 
1. Explore the experiences of children in relation to medicines, to incorporate their 
views to develop a better understanding of the acceptability of medicine, and to 
relate this to the tools that are used to assess the acceptability of medicines. 
 
3.1.1 Objectives 
The objectives of this study were to: 
1. Explore children’s experiences of medicines to gain a better understanding 
about what is acceptable to children in formulations. 
2. Evaluate with children methods used to assess the acceptability of medicine. 
3. Use this new information to propose ways that existing tools used to assess 
acceptability of formulations in a paediatric population can be re-designed to 
better reflect children’s perspectives on the acceptability of medicine.  
 
3.2 Generic Qualitative Approach 
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A generic qualitative approach is reportedly best defined in the negative (Kahlke et al, 
2014), as it is “not guided by an explicit or established set of philosophic assumptions 
in the form of one of the known qualitative methodologies” (Caelli et al, 2003, p4) as 
seen in phenomenology, grounded theory or ethnography (Richard and Morse, 2007). 
Rather, generic qualitative research draws and builds on a range of tools, techniques, 
traditions and ideas from different approaches (Crotty, 1998), whether related to their 
epistemological, theoretical (Neergaard et al, 2009), or methodological stances (Hunt, 
2009). Drawing on the strengths of established methodologies, this approach remains 
flexible and reflexive. This approach aligns with the underpinning principles of the 
current study which involves exploring the ways in which children can be involved in 
this research, accounting for their personal preferences and strengths.  
 
As the current study sought to understand and explore children’s thoughts, feelings 
and perspectives, it was decided that employing a generic qualitative approach which 
carefully considers the positioning and engagement of children would be most 
appropriate in the current study. Qualitative research approaches have been 
previously found useful when undertaking research with young children, as they allow 
for a flexible approach that can be adapted to the individual children’s interests, needs 
and levels of engagement (Rogers & Evans, 2008). Additionally, qualitative research 
is described as an approach that explores social phenomena from the perspective of 
insiders, attempting to understand how people interpret and make meaning of their 
experiences and construct their worlds (Merriam, 2002;2009), by providing them with 
the means to express their voices (Lapan et al, 2012). These characteristics make it 
a suitable method of gaining a better understanding of children’s thoughts and 
opinions of the acceptability of medicine.  
 
Before deciding on a generic qualitative approach, number of other qualitative 
methodologies were considered- of particular note was phenomenology. However, 
each of the other methodologies had limitations in terms of their appropriateness for 
the current study. Whilst phenomenological enquiry is concerned with the “lived 
experience” of the individual, this approach focusses on the inner dimensions of the 
phenomena, the cognitive and psychological processes, inner qualities and structures 
(Percy, 2013, p13). The current study was interested in the children’s interpretation of 
acceptability in relation to their outward behaviours, their understanding and 
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construction of the term acceptability of medicine, and the appropriateness of the ways 
in which it is assessed.  
 
In terms of its design, generic qualitative research studies aim to understand how 
individuals interpret, construct, or make meaning of their worlds and experiences 
(Merriam, 2002). It relies on an interpretive approach (Marshall & Rossman, 2006) 
creating opportunities for the researcher to “access to another’s reality” (Silverman, 
1983; 17). As expressed by Berger and Luckman (1967), the reality of children’s 
experiences lies in their own construction, and therefore gaining an understanding of 
the reality of their world aligns to a social constructionist perspective. For this reason, 
the voices and explanations of the children are key to interpreting the data and the 
subjective interactions within this study are the primary means of accessing the social 
constructs. 
 
The epistemological position adopted in this study is primarily influenced by Guba and 
Lincoln’s (1985) conception of Naturalistic Inquiry, later acknowledged as a form of 
constructivism (Guba and Lincoln, 1988). This assumes that knowledge is maximised 
when the gap between the researcher and the participants is minimised, and, as a 
result, facilitates a better grasp on the socially constructed meanings. Therefore, 
generic qualitative research seeks to produce knowledge with individuals whose 
experiences are of interest to research (Clark, 2004), asserting that we “cannot know 
reality apart from our interpretations of it” (Clark, 2004; 473). Therefore, it is proposed 
that the adult academic will not be able to know the reality of a child without engaging 
with them to co-construct knowledge about their own lives and experiences. 
 
From this perspective, data can be seen to be both individually and socially 
constructed. Consequently, this study focusses on the construct of the acceptability of 
medicine from the perspectives of children. Therefore, core to this research was the 
necessity of providing children with the means to express and present their 
experiences, perceptions and opinions, while accepting that knowledge of social 
reality will always be influenced in some way by the interpretations of the researcher 
(Schutz, 1967; Gadamer, 1976; Patton, 1990). 
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The researcher, therefore, is an integral component to this approach, “attempting to 
interpret phenomena in terms of the meanings people bring to them” (Denzin and 
Lincoln, 2005, p3). Therefore, whilst the aim was to reduce the impact of the 
researcher on the study, it is acknowledged, as Schensul (2012) proposes, that the 
researcher will influence the study. This influence is related to the fundamental beliefs 
of the researcher, including their epistemological, ontological and theoretical 
orientation, that these beliefs may have influenced the assumptions brought to the 
research, and in turn, may have affected how the study was conducted. In order to 
minimise the extent of this influence, Flick (2007) suggests that the researcher be 
reflexive, considering their influence on the participants, data collection, practice and 
outcomes. This focus on reflexivity can be seen throughout the thesis.  
 
3.2.1 Challenges  
Conscious of the challenges associated with the use of generic qualitative research, 
particularly for neophyte researchers, Kahlke (2014) outlines three main critiques with 
generic qualitative approaches: theoretical void, lack of a robust literature/quality 
debate, and method slurring. Each of these is interlinked. 
 
The “theoretical void” that critics argue lies at the heart of much generic qualitative 
research arises because without clear alignment to or articulation of the underpinning 
specific epistemological and theoretical approaches the research framework is 
unclear. However, this criticism has been addressed in this study as although not 
theory driven, this research is, as Kahlke (2014) states, not “atheoretical” (p13) and its 
epistemological grounding is clearly stated.  This study is grounded within a social 
constructivist epistemology acknowledging that human experience is both constructed 
and contextual as well as allowing for shared realities (Thorne et al, 1997). This 
epistemological positioning fits well with the research question, aims and objectives of 
the study but also the positioning adopted in relation to the participatory and child-
centred approach. 
 
The argument of generic qualitative studies lacking a robust literature review or having 
a clear approach to study quality are also charges that can be refuted. The literature 
review presented in Chapter 2, provides a clear, comprehensive and robust review of 
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the literature. Also, the decision to adopt a generic qualitative approach was not taken 
lightly and it resulted from a considerable and conscientious reading of the 
methodological literature to ensure that a clear understanding of the impact of 
epistemological decisions on subsequent choices about methods. Rather than having 
a pre-determined framework to work within such as is available to researchers 
undertaking phenomenology for example, each choice has been considered carefully. 
This has required broad reading, the thinking through of issues and drawing on a 
number of different sources in order to identify and define the research methods. 
Rather than relying on pre-existing methodological rules or assumptions 
(Chamberlain, 2000) which has been reported to hinder the “thinking through” process 
(Kahlke et al, 2014, p44), the research choices have been reviewed and examined. 
Particularly in relation to the congruence of the methodology and methods, research 
questions, and the researchers own philosophical positioning. This has been 
extremely valuable to the development of the researcher and to the overall quality and 
robustness of this research study.  
 
The third major critique that Kahlke (2014) discusses is that of method slurring. This 
criticism is linked to the opinion, not always well-grounded, that generic qualitative 
research mixes methodologies without due consideration of the potentially varying and 
incompatible underpinning epistemological and methodological values and 
assumptions.  This can create issues related to the congruence of the research when 
the epistemology, methods and techniques are not working in harmony. However, the 
research methodology and methods were selected carefully, ensuring cohesion and 
harmony between these choices and throughout the research process. This aligns 
with Kahlke (2014) who refers to this as “building” (p46) the research framework, as 
opposed to a post hoc fitting together of the research questions, methods, 
methodology and theoretical underpinnings. Generic qualitative research is not, 
therefore, “free-floating theorising” (Thorn, 2004; p4), but instead a “critical 
examination within methodological guidelines that are consistent with [the 
researchers’] understandings and intended applications to practice”.  
 
The following sections of this chapter attend to the subjectivity of the researcher and 
the impact of her own beliefs and standings on the approach to this research, data 
collection methods, and the interpretive nature of the data analysis. This is followed 
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by a section considering the conceptualisation of children and the arguments for their 
involvement within research.  
 
3.3 Researcher Positioning, Subjectivity and Reflexivity 
An underpinning principle of this study was to facilitate the involvement of children in 
research in age appropriate ways that accounted for their strengths. This was crucial 
to being able to fulfil the aim of this study to explore the experiences of children in 
relation to medicines, to incorporate their views to develop a better understanding of 
the acceptability of medicine, and to relate this to the tools that are used to assess the 
acceptability of medicines. This, therefore, required the researcher to think in a new 
way, working outside of existing methodologies and resisting the traditional methods 
often employed to conduct health research with children. To achieve a more coherent 
understanding of the acceptability of medicine, Denzin and Lincoln’s (2000) statement 
is drawn on, that this improved understanding is only made possible by employing 
“many perspectives, [and] hear[ing] many voices” (p. 1054).  
 
The role of the researcher and their values within any research is becoming more 
widely recognised. Throughout life, knowledge is often constructed based on our own 
previous experiences, contextual, and cultural values (Greene and Hill, 2005). In terms 
of research, these experiences and values are drawn on to construct, for example, our 
participants’ identities. In research with children, these values are often shaped as pre-
existing ideas about childhood, which ultimately impact on which approaches, and 
methods used in the research process. Aligning with the idea that “the research 
process… cannot be considered as independent of the researcher” (Emond, 2005; 
126), the methods, approaches, and theoretical framings used are linked to the 
researcher(s) and their fundamental perspectives. Davis (1998) emphasises the 
importance of reflexivity in research with children, asserting that this encourages the 
researcher to question their assumptions, ideas and conceptions of childhood, and 
children as a population.  
 
Throughout this study the researcher’s role as a researcher, academic, children’s 
leader, and companion has had to be continually evaluated. However, before these 
roles are addressed, it seemed fitting to consider the positionality of the researcher. 
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The researcher is a white female in her early 20s who has consistently worked around 
children in some manner for the last 6 years. She grew up in a large family full of much 
younger children with whom she has always played and interacted. The interest in 
children’s research originated from previous practice studying developmental 
psychology, and the underlying cognitions, experiences and behaviours that take 
place during childhood and adolescence. This is furthered by her experience of 
working with a range of children from many different backgrounds and has also 
provided a particular perspective on the varying ways that children communicate, 
express themselves and behave. As a researcher, the positionality adopted is one of 
an early career researcher establishing her research profile, and conscious that she 
is still developing within health sciences and pharmaceutical research.  
 
All of these experiences and factors mean a personal and somewhat unique set of 
perspectives are brought to this research which will inform a particular interpretation 
when researching the social world of the children. Particular meanings or 
interpretations may be attached during social situations with children based on the 
researchers own psychological experience and values of working with children, and 
therefore it was crucial that this was something to be aware of when attempting to 
understand or interpret children’s behaviour, language and creations.  
 
Given the researchers experience of working with and interacting with children, she 
felt reasonably prepared and confident about being able to communicate with the 
children in the study and able to create an informal and friendly environment that the 
children would be able to trust. There were a few instances during data collection that 
would support this, for example, when one of the children in one of the school settings 
referred to the researcher using her name ‘Beth’, as opposed to “Miss”- which is typical 
of school age children within a school setting.  Similarly, when returning to one of the 
initial groups for the second workshop and having two of the children wave and run to 
greet the researcher when they saw her arrive at their group. These displays of 
behaviour perhaps show that the children who took part in the study did not only view 
her as a researcher, but also a friendly person, someone to trust and confide in. In this 




However, it has been argued that the display of emotions can influence a researchers’ 
interpretation of a situation (Widdowfield, 2000). This was something the researcher 
was conscious of, particularly when setting boundaries between herself and the 
children. The balance of roles between researcher and trusted adult was something 
that was worked hard on ensuring, conscious that becoming too ‘friend-like’ might 
negate the ethics of the research study, and too ‘researcher-like’ would not be 
beneficial to the collection of meaningful data. Assurances were taken in that the 
children were able to talk to the researcher like a friend, whilst at the same time asking 
questions about the study and remaining aware that she also had research duties to 
complete. This is particularly significant when considering the statement that 
“meaningful relationships” require a de-emphasis of “researcher only” knowledge 
(Bryne, 2009;68). As Hadfield-Hill and Horton (2014;148) explain, “we are never just 
researchers, just doing research”.  
 
The analysis of the interactions with children and the data collected is partially the 
interpretation of the researcher. Where children did not provide an explanation or 
assign meaning to certain aspects of their drawings and creations, it was attempted to 
interpret the possible meanings conveyed by the exploring children’s interests, 
motivations and individual differences. It is acknowledged that their drawings and 
creations can be complex to interpret, and attention is drawn to the interpretation of 
the images being “just that, interpretation” (Rose, 2001, p2).  
 
Referring back to the social constructionist epistemology adopted in this study, the 
primary objective was not to ‘find out’ objective truths, as we can never have the same 
perspective as another (Nagel, 1974), rather, it was attempted to construct an 
understanding of the concept of the acceptability of medicines. Similarly, with regard 
to drawings and creations, it is worth noting that there is no ‘correct’ answer when 
asking someone “what this means” (Hill, 1997). In particular, there is evidence to 
support that it may not the ‘finished’ product or its explanation that is meaningful in 
children’s drawings, but instead the process of the drawing or creating, and the 
actions, language and explanation that accompany this (Ring, 2001).  
 
The focus on reflexivity is particularly significant when considering what Dahlberg et 
al (1999) call ‘meaning making’ with children. This is the shared construction or 
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development of the underlying meaning of something such as a discussion, painting 
or creation. Here the earlier point that the views and voices of the children are not 
‘found out’ or uncovered is emphasised (Mauthner et al, 1998), and that the 
researcher, along with the children, research methods and data, are interdependent 
and interconnected when developing the meaning of a drawing, idea, or concept 
(Mauthner and Doucet, 2003).  
 
Furthermore, it is also crucial to acknowledge that whilst referring to the individuals in 
this study under the umbrella term of ‘children’, that the child population is not 
homogenous and individual children's perspectives on issues may be varied and 
complex. These individual perspectives are significant in themselves, and it is 
accepted “that children, as adults, may have different perspectives on the same 
issues” (Dockett and Perry, 2007;49), and that these are reflective of the individual 
contexts. Therefore, the aim of a continually reflexive approach in this thesis was to 
enable the researcher to step outside of her adult presuppositions and adopt an open-
minded and child-centred positionality. This leads on to the following section which 
highlights particular situations and issues that need to be considered when conducting 
research with children. 
 
3.4 Research with Children 
It is recognised that there are a number of methodological issues to be accounted for 
in research with children. Firstly, within the literature there is considerable discussion 
regarding whether research with children should be conducted differently to research 
with adults (Punch, 2002). Traditional research approaches have long viewed children 
as “transitional objects” (Maconochie, 2008, p2) to be studied, with the researcher 
conducting research “on” them (Hill et al, 1996), rather than “with” them (Mauthmer, 
1997). These traditional approaches grounded in positivist methodologies have 
focussed on the acquisition of large-scale quantitative data conducted and interpreted 
by adult researchers (Barker and Weller, 2003). This approach fundamentally 
disregards the child as possessing their own views and opinions and is instead 
underpinned by adult assumptions and interests (Hood et al, 1996; Valentine, 1999), 
which ultimately prevent adults from listening to children (Hendrick, 2000). However, 
over the last three decades there has been profound change in the way in which 
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children, their competencies, and rights, are represented at the social, political and 
academic level (Pagani, 2018).  
 
The reconceptualization of children as competent social actors (Pagani, 2018; James 
and Prout, 1990) who have the ability to valuably contribute to matters that affect them 
(O’Keane, 2008), has changed their role within research both theoretically and 
methodologically. This view of children, emanating from regulatory changes in 1989 
(UNCRC), along with work in the field of the new social studies of childhood, has 
worked to reposition children within society (Mayall, 1996) and particularly in research 
(Gallacher and Gallacher, 2008).  
 
There is a new appreciation for children as ‘valuable contributors’ to research 
(Willumsen, 2014; p332). With a recognition that children have a specific view on the 
world (James and James, 2001); that they may identify different issues to adults or 
view issues differently (Maconoshi, 2008), and that these views are worth listening to 
(Alaned, 2001). It is also recognised that children communicate in many different ways 
(Barker and Weller, 2003), and this has led to a critical examination of traditional 
research methods which are typically adult-focussed and a search for new methods 
that can serve as tools or frames that allow children’s experiences to be articulated 
and engaged with within research (Veale, 2005; Hill, 1996).   
 
Since these changes, researchers have attempted to account for children’s 
preferences by employing arts-based techniques and methods which Crivello et al 
(2009) regard as being ‘fun’. Whilst there is some discussion about using “fun” 
methods in the literature, the current study aligns to the perspective of Ford & Carter 
(2013) that the research and outcomes are still regarded as serious, even if the 
methods used are labelled as fun. In addition, there is then the discussion about what 
is “fun” and for whom? Conscious of these issues, the methods used in the current 
study are typically child-centred, and the children within the study had the option to 
interact, or not, with the methods and activities.  
 
Despite the challenges associated with designing child centred research, this was 
something thought to be crucial in the current study. As Christianson (2004) suggests, 
by using methods that are child-centred and that children are already familiar with, we 
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are able to enter their ‘culture of communication’ (p166). Children are therefore better 
equipped to participate meaningfully within the research. This is reportedly due to 
overcoming the adult-focussed assumptions that are ingrained in traditional research 
methods (Bradding and Horstman, 1999), and providing opportunities for children to 
present their actual experiences and knowledge (Wilkinson, 2015). Epistemologically 
it has been argued that child-centred methods and approaches to research generate 
better knowledge than traditional methods (Cahill, 2004), by producing more “authentic 
knowledge about children’s subjective realities” (Grover, 2004; Gallacher and 
Gallacher, 2008; p502). 
 
Within this study it is recognised that children can, and do, act as knowledgeable 
beings outside of the control of the researcher (Gallacher and Gallacher, 2008). This 
study was mindful that traditional methods, conducted with a value on word-based 
data such as structured interviews or focus groups can generate information with 
children from which adults “create knowledge” (Gallacher and Gallacher, 2008). 
Therefore, this study aimed to overcome the sole use of adult-centred word-reliant 
data collection techniques and instead also use a selection of arts-based methods to 
generate meaningful child-centred data.  
 
3.4.1 Children’s competence  
The notion of children’s competence is highlighted within academic literature (Horgan, 
2016). Traditionally, the assumption of many adults has been that children are not 
competent enough to express an opinion. However, theories of developmental 
psychology and socialisation have helped to inform understanding about how the ways 
in which children think differently to how adults think. For example, Piaget’s (1932) 
theory of cognitive development presents a four-stage process from birth to 
adolescence. Whilst there has been critique that the hierarchical progression of this 
theory suggests that “child thought” is valued less than that of the mature 
adolescent/adult (Maconochie, 2008; p3), ultimately this theory asserts that children 
think differently than adults. The theory states that children can be thought of as “little 
scientists”, who actively create their realities from what they know, their individual 
experiences and their mental representations of the world. Piaget, like many other 
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developmental psychologists (Erikson, 1958; Bandura, 1977) believed that children 
learn best through doing, and actively exploring.  
 
Building on this, socio-cultural psychologists have questioned the use of traditional 
methods in research with children. Several notable psychologists (Vygotsky, 1978; 
Donaldson, 1978; Hogan, 2005) have stressed that when subject to clinical interviews, 
tests and surveys in experimental settings, as opposed to being observed in their 
natural environments, children also appear less competent. This is not to say that 
children are not competent, but that the ways in which research is conducted with 
children does not enable them to present their competency. Hence, when conducting 
research concerned with understanding children’s views and experiences, a 
methodological approach and methods that account for children’s competencies and 
that can be conducted within familiar settings, is preferable (Alderson, 2004; Kellett 
and Ding, 2004).  
 
Even accounting for children’s preferences and strengths, there are still arguments 
regarding the reliability and validity of children’s accounts. When working with children 
in research, researchers generally have to account for a number of considerations that 
are relative to the stages of development and cognitive capabilities of the children in 
the study. For example, the use of appropriate language, concepts and speed of 
questioning can all affect children’s responses (Lamb et al, 1999; Scott, 2008). 
Children are also thought to be more suggestible than adults and may feel more 
pressured to conform to adult instruction and questioning (Flewitt, 2005; Tangen, 
2008). Therefore, simply the presence of the adult researcher may influence the 
children in their behaviour and responses.  However, this notion could be applied to 
any participant and not only children; adults are prone to many memory biases such 
as social desirability and third-person bias. Therefore, the issue is trading the benefits 
against the drawbacks of involving children in research. It is argued that even 
considering the potential for bias and influence, children are still better placed than 
any other person to tell us about their experiences, thoughts, opinions and views on 
the acceptability of medicine and the appropriateness of the methods used for 
evaluating the acceptability of medicine.  
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The study aligns to the principle that children are capable of providing both valid and 
insightful information, providing they are approached appropriately and that their data 
are interpreted carefully (Livingstone & Haddon, 2009). Therefore, it is important to 
consider factors related to the conduct of the researcher during the conduct of 
research with children. Recommendations from Zaman (2005) are drawn on, who 
argues that both observation and the opportunity for children to express their opinions 
and perceptions are necessary to provide a more accurate picture of children’s 
behaviour and beliefs. Useful techniques for generating a coherent understanding 
include the ‘think aloud’ method, where children are asked to commentate on their 
activity, the ‘active intervention’ where the researcher asks relevant questions during 
the task or activity, and ‘laddering’ in which the researcher asks the children why they 
like or dislike something (Zaman, 2005).  
  
Whilst this work was grounded in doing research with children, this was limited to the 
data collection phase. The methods that were used have been used with children in 
other areas of research (IDS, 2009) and have been used by researchers when 
interacting with children in their everyday lives (Literat, 2013; Biggeri and Anich, 2009; 
Chung and Gerber, 2010; Third et al, 2014; Driessnack, 2005). These methods are 
valued for their ability to uncover and access children’s views, and ultimately, enable 
the inclusion of children’s voices within research. In future research building on this 
work, the aim would be to include children across more phases of the research 
process, such as design, analysis and dissemination. 
 
3.5 Conclusion 
This chapter has provided a background to the underpinning philosophical, theoretical 
and methodological constructs that this study is grounded in. Reflexive considerations 
of the researcher’s role and the perceived positioning of the children with the study 
have been considered.   
 
This study uses a variety of methods to engage with children to learn and understand 
about their views, beliefs and experiences with medicine, and to try to improve the 
methods used to evaluate the acceptability of paediatric formulations. Their 
perspectives could lead to the development of more appropriate and effective methods 
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of assessment, which in turn would help to create better medicines for children. The 





























































4 Methods  
Building on the previous chapter in which the methodological grounding of this study 
was outlined, this chapter presents a detailed account of the empirical data collection 
for the current study. Firstly, it begins with a brief overview of the data collection 
process followed by an in-depth description of each stage including accessing the 
population, obtaining demographic information, the context of the data collection, the 
methods used to collect data, the development and use of the workshops, the ethical 




This study draws on the growing body of literature using mixed methods in healthcare 
research with children (Tariq, 2013). The research makes use of a range of qualitative 
methods including participant observation, participant-centred workshops, drawing 
activities, discussions with children, ranking exercises and scale measures. These 
methods were decided on as they are well suited to the child-centred nature of the 
study and lend themselves to the wide range of children and settings encompassed 
within this study. The methods were refined throughout the study following their 
application in practice and feedback from the children who participated in the study.  
 
The data collection process involved workshops and one-to-one sessions using a 
variety of visual and creative methods as well as activities and discussions with 
children. One of the primary drivers was to create a responsive research environment, 
which allowed children the opportunity to express dissent and/or preference when it 
came to participation in any or all activities. This approach presented the opportunity 
to minimise influence as the researcher, encourage shared control of the data 
collection and provide an environment that facilitated children’s choice of methods and 
amount of interaction with each method. The flexible nature of the workshops 
encouraged a child-led process that was responsive to the children’s behavioural and 
verbal cues relating to factors such as enjoyment, understanding, method preference, 





4.1.2 Target population and inclusion criteria 
The target population was children aged 5-12 years within the North West of England 
who met the inclusion criteria (see Table 4.1). No specific exclusion criteria were 
identified. 
 
Table 4.1: Inclusion criteria 
Table 4.1: Inclusion criteria  
• Children aged between 5-12 years 
• Attending one of the identified settings for recruitment  
• Physically and cognitively able to give informed assent and whose parent/caregiver 
physically and cognitively able to provide informed consent for their participation 
• Sufficient fluency in English to be able to understand and engage in the study 
 
The EMA guideline (2013) categorises children within different brackets and stipulates 
that school children within the 5-11 age bracket, other than newborns, are most 
affected by pharmacological differences such as drug absorption, distribution, 
elimination and excretion (EMA, 2013). It felt important to focus on this age range as 
the children in this age range are both most affected and are a very under-researched 
group in terms of their experiences and perceptions of the acceptability of medicine. 
However, despite this under-representation, they have appropriate cognitive and 
motor skills, are able to express their opinions and perspectives and have reading and 
comprehension abilities. A typically developing child begins to be able to read, 
recognise and understand simple words and stories at age 5 years (Morris et al, 2015). 
Since engagement in the study required the children to be able to understand the 
questions and purpose of the study and provide their written consent to take part, the 
age of 5 years old seemed a reasonable age for the lower age limit of eligibility for 
inclusion in the study. Although the EMA guideline notes the upper age of those school 
children who are 'most affected' as being 11 years, this study included children who 
were up to 12 years old.  
 
4.1.3  Settings 
Key settings were purposively identified which enabled the recruitment of children who 
met the inclusion criteria. Two main settings (1. Schools and clubs; 2. Clinical settings) 
were identified and designed into the study, and a third setting (Museum) was 
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incorporated into the study at a later date (see Figure 4.1).  Each of these three types 
of setting required data collection to be undertaken in a slightly different way. Each 
setting was decided on in order to increase the likelihood of recruiting from a wide 
population, accounting for socio-economic backgrounds, age, gender, children without 
clinical medicine use and children with experience of taking medicine in hospital. As 
outlined in the Introduction, Chapter 1, acceptability is a subjective concept and is 
often dependant on age, gender, background, culture and health status (EMA, 2012).  
 
By recruiting children from clubs and schools it was aimed to recruit children with 
different experiences of taking medicines and children within specific age brackets. 
The first clubs contacted were Rainbows and Brownies local to the researcher’s home 
as the researcher had pre-existing contact with them having been leader within 
Guiding since 2015. Through Rainbows and Brownies, information about the study 
was passed on to the leaders of local Cub and Scout packs.  
 
In order to account for differences in background and socio-economic status, contact 
with a school local to the researcher’s home was made via email explaining the study 
and they expressed interest in taking part. Another school also agreed to take part as 
a data recruitment site. Within this setting data collection was conducted by working 
with the children within small group-based workshops.  
 
It was also believed important to be able to recruit children who had a depth of 
experience in taking medicines, and who may have a different health status to children 
who do not typically attend a hospital. For this reason, one of the selected settings 
was a Children's Hospital. Within the hospital interviews were conducted on a one-to-
one basis. 
 
During the study, the opportunity to take part in a “Meet the Scientist” day as part of 
the Festival of Science event within the World Museum, Liverpool was provided. The 
researcher along with three colleagues attended the event and set up a ‘station’/table 
which acted as an information source about medicine development and also a base 
to recruit children and undertake data collection, the researcher and colleagues 
facilitating children on a one-to-one basis. This provided the opportunity to recruit 
children from a variety of socio-economic and cultural backgrounds.   
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Figure 4.1: Settings used within the study 
4.1.4 Sampling 
Sampling is the means of selecting a proportion of the target population to represent 
the wider group. It is more time saving and costs less than collecting information from 
the whole target population (Polit & Beck 2010). The North West of England, where 
this study was conducted, was chosen due to proximity to the researcher and because 
it encompasses a wide and varied area, including a large major city. The overall 
purpose was to generate an appropriate sample, with boys and girls of different ages 
to address the research question, aims and objectives (Plano et al, 2008; Hunt & 
Lathlean, 2015). A purposive approach for the selection of individual settings (schools, 
Rainbows etc.) was important, as it allowed me to target pre-specified groups, whose 
experience and knowledge were valuable to the study (Green & Thorogood, 2014).  
 
In order to sample the population within the settings, a convenience strategy was 
employed (Table 4.2). A convenience sample is “one that is available to the researcher 
by virtue of its accessibility” (Bryman, 2008, p183). This strategy was decided on given 
that the researcher had already identified and been granted access to the appropriate 
settings. This meant that any child within these designated settings, who fitted the 
inclusion and exclusion criteria, was eligible to participate. The selection of children 
within the settings depended on their availability on the days and times I visited the 
setting, whether the children themselves wanted to take part in the study, and in 
schools/clubs and clinical settings, parental consent was also required. Convenience 
sampling has limitations, the most obvious disadvantage is that the sample is likely to 
Schools/club settings: children are already familiar with one another
Children will engage in activities via workshops within these settings
Clinical settings in a Children’s NHS Trust setting: children unlikely to know each other 
Children will engage in activities individually
Museum setting: children will not necessarily know each other (unless attending in a 
friendship group)





be biased (Mackey & Gass, 2005) and not necessarily representative of a whole 
population.  
 
The debate surrounding the complexities of determining sample size in qualitative 
research has engaged social scientists from different fields for many years (Blaikie, 
2018). Acknowledging the complexities of predicting or stating sample size in 
qualitative research, as well as the requirement to justify sample size for the purposes 
of research processes and ethical review committees, the current research project 
followed recommendations for qualitative research which state that a sample size of 
15-20 participants can generate sufficient data (Vasilieou et al, 2018). Therefore, it 
was proposed that up to 40 children would be recruited from guiding groups (with four 
groups approached and an expected average of 10 children per group) and an 
expected 10-20 children from the leisure groups. Between 12-48 children were 
proposed from two-four primary schools (an expected 6-10 children from each school). 
Finally, it was expected that 10 children would be recruited from the hospital setting. 
Achieving the intended sample size was dependant on setting population sizes and 
availability, such as the number of guiding clubs and schools that agreed to participate. 
Therefore, it was intended that a minimum of 80 and maximum of 120 children would 
be recruited for this study.  
 
In total, two schools and four groups agreed, and one hospital was included. The 
addition of the museum event offered an opportunity to collect both data from children 
from a different setting and increase the number of children recruited. The recruitment 
via the museum event allowed sample sizes from the remaining settings to be lower 
whilst ensuring sufficient data was generated. 
Table 4.2: Sampling 
Settings Sampling of Site Sampling of Population Requirements 
Schools Primary school 
children (both boys 
and girls, aged 
between 5-12 years 
old) 
Teachers identified 8 
children in total. 4 children 
from Key Stage 1 (2 boys 
and 2 girls) and 4 children 
from Key Stage 2 (2 boys 
and 2 girls).   
Access to school granted by 
headteacher 
Child assent required 
Parental assent required  
Clubs Rainbows & 
Brownies (All girl 
groups, aged 
between 5-12), 
Approached each group 
and recruited children by 
convenience sampling. 
Access to group(s) granted by 
leader(s). 
Child assent required 
Parental consent required.  
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Scouts and Cubs 
(All boy groups, 
aged between 5-12) 
Every child in each group 
was eligible.  
Hospital Clinical sample of 
children (both male 
and female) 
between the ages of 
5-12 years old from 
a large regional 
Children’s Hospital. 
A member of the clinical 
team identified children 
(boys and girls, 5-12 years 
old) when the researcher 
was on the ward. Children 
recruited by convenience 
sampling as they were on 
the ward at the same 
time/day as the researcher. 
Access to the ward/hospital 
granted by Ward/Researcher 
manager(s).  
Child assent required. 
Parental assent required.  
Museum  A public 'Meet the 
Scientist' event 
(aimed at children 
between 4-12 years 
old) at the World 
Museum, Liverpool 
provided a setting 
from which to recruit 
children.  
The audience at the 'Meet 
the Scientist' event was fluid 
and entirely voluntary. 
Families turned up to the 
museum with the 
expectation of taking part in 
activities. Any child who was 
at the museum on the day 
could take part in the 
activities, however only the 
data from those children 
who reported their age as 
between 5-12 years old was 
included in the study. 
Access to the museum event was 
provided by the event organisers.  
The process of participation for 
the children from this setting relied 
on relied on a more limited form of 
consent/assent than within the 
other settings. The children were 
informed about the study before 
completing the activities, after the 
completion of the activities the 
children who wanted to take part 
in the study ‘posted’ their activities 
into a ‘letterbox’. Although this 
was not a written form of consent 
or assent, this was deemed to be 
consent on behalf of both child 
and parent/carer.  
 
4.1.5  Recruitment 
For the children recruited from the clubs and schools, they and their parents were 
provided with information and consent sheets by either the researcher or a gatekeeper 
in each group e.g. a teacher or leader. They were given at least a week to read through 
information sheets and consider taking part in the study. The researcher went back to 
each organisation at least one week later to collect signed consent forms. Before the 
visit back to the clubs and schools, a gatekeeper was contacted at each site to see if 
any parents or children had any questions, and if they did, to ensure they knew when 
the second visit was scheduled at each particular site. On the day of visit to collect 
consent forms from the guiding groups the researcher was available to both parents 
and children to answer any questions that they had. During this time, their rights to say 
no or withdraw from the study were reiterated. However, if a parent or child did not 
want to participate, they tended to tell the gatekeeper (contact at each group) who 
then updated me. At the school, no parent had further questions about the study and 
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those who wanted to take part returned their and their child/ren’s signed consent 
sheets to the school to be collected on the day of data collection. Before data collection 
commenced with any child or group, it was ensured that all consent and assent forms 
from both child and parent were provided. It was further ensured that each child at the 
group knew what they were taking part in by verbally asking and receiving a positive 
verbal or behavioural response (e.g. head-nod).  
 
At the hospital, children were recruited ‘on the day’. This meant that although 
information sheets and consent forms were provided and available to the parents and 
children to answer any questions, the decision about their participation was made on 
the same day. This compressed timeline for decision-making was undertaken as the 
study was deemed to have a low-sensitivity (i.e. was not believed to be upsetting or 
cause harm) and the aim was to make participation possible without adding burden to 
the children and parents. Gaining consent and assent on the same day aimed to make 
the research process as short and least time consuming as possible for these 
participants, and to ensure that the parents and children were not required to make 
any unnecessary trips to or from the hospital for the sake of the research. Prior to 
recruitment a relevant healthcare professional identified eligible children using the 
inclusion criteria for the study and checked with the child and parents if they were 
interested in talking to me about the study. They then introduced the researcher to the 
identified parents and children and time was given to answer any questions they had 
about the study. The parents and child/ren were then given between 10-15 minutes 
(longer if needed) to read through the information sheets and decide if they would like 
to take part. If they wanted to take part, they were given the option to either complete 
the research on the same day at a time convenient to them or take part on another 
day that the child/parent were scheduled to be in the hospital. Once the child/parent 
had decided about their involvement in the study, consent and assent forms were 
signed and collected by the researcher. No research took part before the forms were 
signed.  
 
Within the hospital setting it was more challenging to recruit children than in the non-
clinical settings. Reasons for lower numbers than anticipated being approached 
included the compressed timeline for recruitment following ethical approval and study 
end, the fact that recruitment coincided with ‘winter pressures’ within the hospital which 
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meant that the clinical settings were very busy, as well as the availability of healthcare 
professionals on the wards to introduce the researcher to the children. The initial 
proposed number of children to be recruited from the hospital was ten. However, within 
the available time frame only six children were identified within the agreed recruitment 
settings who were eligible and were approached to be recruited. Of these six children, 
only three participated. Of the three children and parents who were initially interested 
in participating in the study but who did not go on to participate, the researcher 
determined it would be unethical to ask for consent and assent due to the physical 
stress that the researcher observed the child was experiencing related to their hospital 
treatments. Two of the children’s parents declined to consider their child’s involvement 
due time constraints as their child was very preoccupied with treatment. These issues 
meant that recruiting the target of ten children from the hospital was not possible and 
therefore, this sample was lower than expected. 
 
Similarly, children attending the World Museum were also recruited ‘on the day’. In this 
setting, information sheets and consent forms were not provided as this event 
favoured a more fluid approach. Since the event was not pre-bookable by the public, 
neither the research team, nor the organisers, had any means of direct contact with 
the parents or children. Therefore, it was assumed that the people who turned up on 
the day were informed about the event, and that there would be activities they could 
part in. Information posters detailing the study were displayed, and flyers were 
available around the stand. As the children approached the data collection table, and 
before they completed the activities, they were told that the activities formed part of a 
research project and they were asked if they had read the posters. If parents 
accompanied the children to the activity table, they were also informed of the nature 
of the research and asked if they had read the posters or flyers. See Section 4.3.2 for 
full details of the consent/assent process.  
 
4.2 Data Collection Techniques 
The study was composed of two phases and on some occasions these phases were 
undertaken during the same period of data collection (e.g., when a return visit by the 
researcher was not possible). Phase 1 aimed to generate an understanding of 
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children’s acceptability and perceptions of medicines. Phase 2 built on this to refine 
ideas and focus on evaluating and refining the tools used to assess acceptability.  
 
As noted earlier, the data were collected in three main settings (clubs and school – via 
workshops), the museum and the hospital (on a one-to-one basis). Various methods 
were used (drawing, discussion, activity sheets, booklets and ranking activities) with 
the children. In this next section, the individual methods are presented, and this is then 
followed by how these were used within the workshops, at the museum and at the 
hospital. 
 
4.2.1 Rationale for selection of methods 
The overriding concern when choosing methods for this study was to enable the co-
creation of knowledge in a two-way ‘conversation’ with children aged 5-12 years old. 
Existing methods specific to the collection of data regarding children’s acceptability of 
medicine are typically adult-focussed and then adapted for children; this was not the 
approach the researcher wanted to adopt, instead it was aimed to use the best 
possible methods for enabling children's contributions. The Institute of Developmental 
Studies (IDS, 2009) provides best-practice methods for encouraging participation with 
children in research, these include mapping, listing, sorting, ranking, diagrams, 
digital/media use, and photography. Other authors have noted that creative visual 
methods such as drawing (Literat, 2013; Biggeri and Anich, 2009), storyboarding 
(Chung and Gerber, 2010) and writing (Third et al, 2014) are useful for engaging 
children in joint knowledge production, particularly when accompanied with discussion 
and spoken feedback (Driessnack, 2005).  
 
Prior to the research data collection methods being finalised, the researcher met with 
Alder Hey Children’s Hospital ‘Generation R-YPAG (Young Person’s Advisory 
Group)’, in order to inform the direction of the study. This is an established and 
experienced group of young people who regularly provide advice and input into a wide 
range of research studies. This session was designed to be engaging and informative 
for the young people whilst producing vital feedback for the researcher, children were 
offered the opportunity to interact with large A3 sheets, colouring, drawing and writing 
down their ideas using a selection of drawing materials. The group were also provided 
with sticky notes, stickers and empty packets of different medicines to evaluate and 
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use to target their ideas. Eleven young people, aged between 8 and 18 years old, took 
part in the session. The researcher explained the general area of the research and 
encouraged small group discussion about different ideas the researcher had about 
data collection methods as well as other aspects of data collection. In particular, the 
researcher was concerned with ensuring that the research topic was one of interest to 
the advisory group, obtaining an idea of how involved the YPAG believed children 
should be involved in data collection, and testing out preliminary questions and ideas 
for ease of understanding. Following this initial meeting, the researcher developed 
participant information sheets and consent forms, which were sent via e-mail to the 
YPAG facilitator to share with the group. These sheets/forms were reviewed by the 
YPA group and comments on wording, layout, and images were fed back to the 
researcher e.g. the group suggested changing the colours of the boxes on the 
information sheets, in order to make a distinction between the information sheets for 
the younger age group and the information sheets for the older age group. The group 
also suggested that removing some text to reduce the length of the information sheets, 
and increasing the size of text to make it easier for children to read would be better. 
 
Therefore, following the guidance provided by the IDS (2009), experience of working 
with children and PPI with children, a combination of child-centred qualitative data 
collection methods were selected and developed to be offered as a choice for data 
collection. These arts-based methods and activities involved drawing, colouring, 
discussion activities, ranking activities and scales/ questionnaires. It was intended that 
the use of these methods within the workshops and when working with individual 
children would facilitate them sharing and presenting their ideas, opinions and 
perspectives. Additionally, these methods enabled the collection of different aspects 
of children’s behaviour including visual, verbal and behavioural forms of expression. 
Table 4.3 provides a summary of research methods used and more detail about each 
method is presented in subsequent sections.  
 
Table 4.3: Research methods 
Method  Objectives and Rationale  
 130 
Drawing/Worksheets Used as a projective method- familiar and fun activity for most children in 
the age group. Different worksheets developed for different ages and 
preferences.  
Discussion Allowed for building rapport with children and allowing opportunities to 
express assent and dissent.  
Child-centred research method- child is the primary focus of interested, 
child allowed to vocalise and express preferences through direct interaction 
with researcher.  
Also allowed for the clarification and exploration of drawings which in turn 
facilitated data analysis including children’s own interpretations and 
meaning making.   
Activity booklets These included the main activities in an easily accessible and child-centred 
way. Children are familiar with activity booklets such as magazines and 
provide a novel and interesting self-contained data collection method.  
Ranking activities  Ranking activities are also a fun and child-centred method. They are easy 
to use, and it has been demonstrated that even very young children can 
understand them. Ranking activities were used to assist in the collection of 
data whilst maintaining novelty of the methods.  
 
The methods and the way they were presented to children might have shaped the 
contributions provided by the children. The rationale for using these methods is 
outlined in sections 4.2.2-4.2.4. Even though careful decisions were made about the 
selection of methods and the resources and materials available to children, the 
researcher has to critically consider how these choices both frame and potentially 
limit what the children contribute and can create.  
 
Materials such as props can trigger particular responses that might be helpful or 
could create a focus that is overly directed by the prop (Carter and Ford, 2012). So, 
for example in this study, the inclusion of potentially legitimate props such as 
medicine packets, blister packs and syringes could have overly directed the 
children’s attention to focus on these props, potentially limiting children’s 
imagination. The potential for misdirection, constraint or influence on the shaping of 
data by the use of props has not been a major focus of attention within health 
research. However, work from other fields, particularly forensic interviewing does 
provide some evidence of the need to be cautious and consider the influence of 
props (Poole et al., 2011, 2012).  For example, Nigro and Wolpow (2004) note that 
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whilst props may increase the quantity of data generated, it may decrease the 
accuracy of data and that prior experience of the props was influential. Work by 
Salmon (2006) also notes the importance of selecting developmentally sensitive and 
carefully considered toys as triggers within clinical settings. Other resources such as 
crayons and pencils result in the creation of two-dimensional outputs whereas the 
inclusion of collage materials can open up creativity into three dimensions; the use of 
toys such as Lego might create new opportunities for expression, although what can 
be built is restricted by the type of bricks, colours and so on (Carter and Ford 2012). 
The framing of children’s contributions by the choice of materials and resources is 
often overlooked but it is an issue that would benefit from future methodological 
research. 
 
4.2.2 Drawing and discussion 
Drawing has been described as a useful and fairly quick way to gain considerable 
amounts of data in a short period of time (Malet et al, 2010). Due to the wealth of 
research on the impact of drawing and the frequent use of drawing in child-centred 
interviews (Literat, 2013), it was decided this would be one of the main methods of 
data collection. A number of studies have demonstrated that drawings can be used to 
help researchers gain an insight into the child’s world, facilitating discussion about 
difficult or complex and important issues that would otherwise be difficult to talk about 
(Gross & Hayne, 1998; Pipe et al, 2002; Weinle, 2002; Wesson & Salmon, 2001). 
 
To develop child-friendly methods it was important that a variety of media such as 
drawing materials (pens, pencils, crayons), activity sheets and plain A4 sheets of 
paper, as well as novel materials such as stickers, glitter and scent pens were provided 
to facilitate the children's expressiveness (Malchiodi, 1998). A wide range of materials 
were developed and used in the drawing activities; mindful that the children in the 
study were different ages, at different developmental stages, and had different 
preferences and drawing styles. For instance, two activity worksheets were developed 
aimed at each age group, that were provided at the workshops for the children to 
interact with.  
 
It was also thought important to provide the children with a wide range of materials to 
use in the creation of their drawings. It was necessary to consider their own unique 
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preferences and drawing styles. For instance, drawing skills develop in stages and are 
dependent on children’s age and individual capability (Steel, 1997; Lowenfeld, 1978; 
Read, 1966). Whilst there are a number of proposed models, each agree on the typical 
age groups of development. Between the ages of 4-8 children are generally in the 
“schematic stage” and are still developing their fine motor skills but are beginning to 
draw more realistic pictures, following a particular schema, and creating stories to go 
along with their drawings (Steel, 1997). In the current study, the children in the younger 
age group (5-7 years) within this schematic stage did express a stronger interest for 
the thicker felt pens, gel pens and glitter pens, and typically chose to talk and discuss 
their drawings at the same time as they were creating them. Between the ages of 7-
12 years, children’s spatial perspective generally increases. During this ‘preteen stage’ 
children may draw more realistically, detailed and smaller drawings in an attempt to 
convey their ideas, rather than discussing the meanings out loud (Steel, 1997). For 
children in this stage fine line pens and sharpened pencils were provided so that they 
could create more intricate drawings. All of the children expressed particular interest 
in the scented pens and pencils provided, as they enjoyed the novelty of being able to 
physically display how their medicines would smell or taste. Figure 4.2 shows the 




Figure 4.2 Example of the range of materials provided at the workshops 
 
The variety of materials also enabled the children to decide on the tools they used 
(e.g. crayons/pencils/pens), as well as colours, therefore providing them with some 
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control within the workshop and over the activities they were completing. The younger 
children spent a lot of time working on their drawings, whereas the older children 
tended to draw small but detailed medicines accompanied by a large amount of writing 
describing what it was illustrating. It is key to note that the researcher was not solely 
responsible for interpreting the drawings, instead the children were encouraged to 
either write down or verbalise a short explanation of their drawing; this helped 
communication and conversation and the understanding of what the children meant.  
 
“Drawing and discussion” was used throughout the workshops, primarily to provoke 
conversation from the children about their drawings, but it was also used in the other 
activities such as the ranking exercises to uncover the meanings and decisions 
underlying their behaviour. Discussion is a method that often accompanies drawing 
(Driessnack, 2005) and is useful when working with children for a number of reasons. 
It helps to clarify the researcher’s interpretation of the drawing, it allows the researcher 
to ask about certain aspects of the drawing that is not necessarily clear to them, and 
it also allows the child to discuss the aspects of the drawing that are most meaningful 
to them (Pipe et al, 2002; Wesson & Salmon, 2001). Discussions with children are 
often more relaxed when conducted in group settings as it facilitates dynamic child-to-
child discussion in ways not possible in one-to-one interviews between an adult and a 
child (Hunleth, 2011). When drawings are used as a projective measure (i.e. focussing 
on what the child says, rather than what they draw), it helps to build rapport and 
reduces the defensiveness of the child by redressing the power imbalance between 
the adult and child (Hennessy & Heary, 2005).  
 
It is also thought that children attribute meaning not necessarily to the picture that they 
draw, but the action of drawing (Praiser, 2017), for example, in the study one child 
made straight lines on their drawing whilst making hand gestures depicting a ‘pop’ or 
‘bursting’, at the same time as explaining that these lines showed the fizzy medicine 
bubbling in the bottle. So, whilst the finished image looks like a bottle with lines at the 
top of it, watching the process, what the child said, and their body language, helps to 
better represent the intended image, and the researcher’ understanding of its 
















Figure 4.3: Image of a fizzing medicine (Child, aged 12).  
Furthermore, children are meaning-makers (Wright, 2007), and make use of many 
different forms of verbal and non-verbal communication. Often children will 
demonstrate meaning within their drawings by writing letters, words, numbers and 
symbols, by physically expressing through movement or body language, and by 
constructing verbal signs, noises and words in order to convey the intended meaning 
of their drawings. It has been stated that drawing along with the act of telling, talking 
or discussing, enrich and inform each other (Kendrick & McKay, 2004). Drawing and 
discussing affords children the opportunity to create and share meaning using a duality 
of modes: the non-verbal graphic description which stems from imagery and visual-
spatial memory; and the verbal description which involves talking about the drawing, 
events or graphic details. This crossover of modes is said to increase children’s 
capacity to mentally manipulate and organise images, ideas and feelings (Cox, 2005).  
 
The concept of using speech to accompany drawings is common in health research 
with children (Gauntlett and Horsley, 2004) and, in clinical and educational settings, 
drawing and discussion has been reported to produce twice as much information than 
talking alone (Driessnack, 2005; Patterson & Hayne, 2011). It has been observed that 
children aged 7-8 years appear to be able to illustrate their feelings and emotions with 
greater ease than they were able to articulate them (Wetton, 1999). Therefore, this 
may lead to richer data when both drawing and discussion are used together 
(Porcellato et al, 1999) as it is recognised that different ideas and perspectives might 
be presented depending on the methods used (Backett & Alexander, 1991). Horstman 
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et al (2008) suggest that current understandings of child development and the use of 
art may assist children in constructing complex ideas or recalling events, therefore, 
topics or issues that may otherwise have been avoided or ignored may be talked 
about, and a deeper understanding of the child’s actual feelings and perceptions may 
become known by the researcher. It has also previously been stated that children often 
know more than their drawings reveal (Griever, 1990), and that drawing alone 
generates fewer ideas and data than drawing and discussing (Pridmore & Lansdown, 
1997).  
 
4.2.3 Activity sheets and booklets 
The aim of the worksheets and booklets was to encourage the children to think about 
medicines and provide some information about which aspects of the medicine were 
most important. One worksheet was developed for the children aged 5-7 years and 
one for those aged 8-12 years. The 5-7-year worksheet (see Figure 4.4) is a one-page 
activity which asks the child to “Create their own medicine”, the main activity was the 
‘Drawing Box’ which the children could draw their medicine in. A smaller writing box 
next to the drawing box provided short sentence starters, typically used in schools with 
this age group, to facilitate some explanation of the children’s drawing. The sentence 
starters asked the children: I have chosen this shape because… I have chosen this 

















Figure 4.4: Activity sheet for the 5-7-year-old children    
 
Figure 4.5 Activity sheet for the 8-12-year-old 
children 
 
The 8-12-year activity sheet (Figure 4.5) aimed to facilitate the same information from 
an older age group. This was a two-page activity sheet geared toward older children’s 
reading and writing skills and interests. The first page began with a short description 
in the form of an e-mail, explaining what the task was. On the back of the worksheet 
was a small drawing box for the older children to draw in, along with the main activity 
which asked them to write a paragraph about their medicine. Ideas for them to include 
were written in the email so they had some direction if they needed it. Children were 
also provided with blank pieces of paper and template sheets, which were offered as 
an alternative to the activity sheets, or for the children to use once they had finished. 
It was up to the children to decide which drawing materials they used, although most 
of them opted for the activity sheets.  
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The activity sheets were designed to be a fun and child-centred option for children and 
a starting point for their engagement in the study. These sheets encouraged children 
to use their imaginations to create “marvellous medicine” and some guidance was 
provided as the children were asked to ‘think about shape, taste, colour and smell’ of 
the medicine. However, there was no expectation or guidance that these marvellous 
medicines would be either realistic or achievable. Giving free rein to their ideas and 
creativity mirrors to some extent the notion of ‘blue sky’ research which pushes 
boundaries and can sometimes be responsible for leaps forward in thinking. The aim 
of the exercise was to give the children no constraints in them being able to create the 
best possible medicine and to explore the characteristics and attributes that this 
marvellous medicine would have. In this activity, the discussions that accompanied 
these drawings were key to exploring what the children imagined a marvellous 
medicine to be, and what they believed would be helpful in a real medicine. The 
children were generally pragmatic and realised that some of the more magical, 
marvellous and unusual components of their designs might not be reasonable or 
realistic. However, the activity was successful in stretching their ideas and exploring 
key aesthetic issues of taste, shape, colour as well as aspects of related to the 
meaning and motivation for taking medicines. 
 
An additional data collection method was created as the workshops progressed, when 
it was realised that the existing activities would be difficult to use in smaller or more 
restricted settings, such as within schools and the hospital. An activity booklet was 
created which included the individual activities from both phase 1 and 2, in a more 
accessible form. The activity booklet consisted of 6 pages, with a separate activity on 
each page. The first page was an information sheet, asking the child for their ‘special 
name’ (pseudonym), their age and to circle if they were a boy or a girl, this was so that 
it was easy to match the activity booklet to a child and group them correctly into the 
relevant age and gender. Pages 2 and 3 (see Figure 4.6) aimed to elicit information 
about the children’s perceptions of the acceptability of medicines and the methods 
used to evaluate this acceptability. Pages 4-6 (see Figure 4.6) were focussed on 
refining the ideas from Phase 1 and to further the understanding of children’s 
acceptability of medicines. Pre-existing tools were evaluated in parallel to activity 3, 
which asks the children which scale they would prefer to use. In activity 5 the children 
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Figure 4.6: Activity booklet, pages 1-5  
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4.2.4 Ranking activities  
Task-based activities such as ranking exercises have been used by researchers in 
research with children and are said to "enhance children’s research imaginations" 
(Alderson, 2001, p147).  Grouping or ranking exercises are used in a number of 
studies with children (Brooker, 2001), for example Gadd and Cable (2000) 
demonstrate how happy and sad faces can enable young children to present how 
much they like or dislike a situation. Ranking exercises are also commended for their 
ease of use and the ability of the child to rank aspects or issues of the research in 
order of importance (Clark, 2005). Children under the age of five have demonstrated 
their ability to understand and use ranking exercises (Maconochie, 2008). However, 
there is also evidence to suggest that, when used as the lone method with children, 
ranking exercises can become tokenistic (Clark et al, 2003) or too simplistic, as they 
typically deal with a narrow range of issues (Bragg, 2007).  
 
In the current study the ranking activities were used as one way to understand which 
aspects of the medicines were most important, which flavours were preferred, and 
which acceptability measures were favoured. Small, laminated cue cards with the 
different aspects of medicine, flavours and scales were given to the children to interact 
and play with. In some workshops the children put them into their own order on the 
floor or on tables, whereas in others the children were able to use Velcro to arrange 
the cue cards on a game board (see Figure 4.7). The ranking exercises were intended 
to encourage a group consensus regarding which aspects of medicines were most 
and least important. However, these exercises ended up instead providing a useful 
prompt to encourage discussion due to the dynamics of the groups. For example, 
some of the group workshops were conducted in large spaces such as church halls, 
and this allowed children to break off into smaller groups and discuss the ranking game 
individually rather than together. Some children chose not to interact with the ranking 













Figure 4.7: Selection of ranking activities used in workshops 
 
4.2.5 Developing and undertaking the workshops 
Workshops were chosen as a way of collecting data from the children. Workshops 
were identified as a valuable approach in settings where the children already knew 
each other and had established relationships. These were conducted under the 
general guidance for running focus groups which states that participants should share 
similar characteristics and be acquainted with one another (Kitzinger, 1994; Krueger 
& Casey, 2000). The group dynamic created by working with a group of children from 
the same age and background and who are already acquainted with one another, aims 
to decrease researcher control over the study and encourage the free expression of 
ideas from the participants (Kitzinger, 1994; Wilkinson 1998, Madriz, 2003).  
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Whereas in a traditional focus group or interview the researcher would take control of 
the discussion by using a structured or semi-structured interviewing schedule, the arts-
based activities in the workshops offered prompts within a supportive environment 
(Kennedy et al, 2001). This provided the opportunity to gain information about the 
research topic. As Goss (1996) discusses, creating the opportunity for participants 
with similar characteristics to discuss the issues that they believe are relevant to their 
lives in relation to the activity, helps to ensure that the knowledge, language and 
concepts that are outcomes of the workshops are grounded in the voices and 
experiences of the participants. Arts-based methods were particularly useful for 
quieter or shy children as the workshop encouraged them to be confident to speak up, 
as also reported by McDonagh and Bateman (2012). Additionally, as noted by 
Richardson et al (2009), the children were able to build on each other’s responses and 
often came up with thoughts relating to things that others were saying, which may not 
have happened in an individual interview.  
 
It was intended that as the workshops progressed opportunities would be taken to 
review and modify the methods in collaboration with the children. Challenges that 
arose within the first workshops were evaluated and modified (such as adapting the 
work sheets and booklets), through discussion with the children and observation of the 
efficacy and limitations of various methods and approaches.  
 
4.2.5.1 A listener and observant participation approach 
The role of the researcher during data collection was varied and dependent on the 
group sizes and dynamics but it always involved some form of listening and observing 
the children and their interactions with the activities and, where other children were 
present, their interactions with one another. Listening and observation skills have been 
labelled as the basis for attaining a comprehensive understanding of a particular 
community or viewing social reality through the eyes of the participants (Venne, 2006). 
The decision to use the term ‘listener and observant participation’ instead of 
‘participant observation and listening’ is also influenced by work such as  Wilkinson 
(2013), and is based on the value placed on each role, whether that was as a 
‘participant’ or a ‘listener/observer’. At the same time as listening to, and observing the 
children and activities, the researcher was also consciously and intentionally 
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attempting to minimise her position as an ‘outsider’ who was there to observe and 
listen. This was achieved by being involved with the activities, for example, by taking 
up lying positions on the floor with them when they were drawing, interacting with them 
during the activities and talking with them rather than at them.  
 
Although there is diversity in the definition of listening, in this instance, listening was 
understood to be the active process of communication, which involves hearing, 
interpreting and constructing meanings (Clark, 2005), which is not limited to spoken 
word. Listening was used within this research to pick up on and encourage a dynamic 
process of discussion with the children about things they were talking about or 
highlighting as important to them, as opposed to simply extracting what they were 
saying. Whilst listening, observing children’s behaviours and interactions was also 
undertaken, mindful that children communicate in many different verbal and non-
verbal ways (Edwards et al, 1998).  Both the listening and observation helped to 
construct a more comprehensive understanding of their understanding, knowledge, 
thoughts and ideas about medicine development and assessment.  
 
Observations of the children were also important in complementing the listener 
participation by "giving importance to the interpretation of actions and words, in the 
contexts that they occur" (Grieg & Taylor, 1999, p81). Observation techniques have 
long been used in early years education as a tool to understand young children’s 
abilities and needs (Smidt, 2002), and are said to become increasingly important the 
younger a child is (Elfer & Selleck, 1999). The researcher was conscious of the risks 
of using observation such as her subjectivity as an adult researcher. There was a 
worry that behaviour, such as facial expressions and decisions (e.g. colour choices) 
might be interpreted an adult lens and that this might be incorrect or incomplete. 
Therefore, by actively involving the children in the  interpretation and analysis by 
asking them questions and asking them to explain things, they were able to help clarify 
whether the observations and preliminary analysis were in line with their own 
perceptions (Miller, 1997; Clark, 2004).  
 
4.2.5.2 Audio recording the workshops 
The main reason for choosing to audio record the groups was to allow the researcher 
to interact freely with the children rather than having the distraction of having to try and 
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write down their comments. Recording the children’s conversations and interactions 
with one another also aimed to help facilitate the subsequent interpretation of the 
physical outputs (pictures and drawings). The use of digitally recorded qualitative data 
has been commended for its “replayability” (Tessier, 2012, p449) this meant the 
researcher would have access to the original data that was “neither idealized or 
constrained” by a specific viewpoint or interpretation (Heritage, 1984, p 238). 
 
Given the size of some of the workshops the audio recordings allowed me to record 
conversations between children that might otherwise have been missed. Many of the 
conversations centred on why children made certain decisions about their drawings or 
ordering, and so during analysis the transcribed audio files helped me to interpret and 
give meaning to their outputs. By basing the analysis on the significance that the 
children give to the data, rather than solely on the researcher’s interpretation, it was 
aimed to lessen the chance of misinterpreting their meanings. 
 
Although the audio recorder was minimally intrusive, having the children acknowledge 
its use was necessary to obtain their informed assent to being recorded. However, it 
was important that their knowledge of being recorded did not impact their natural 
behaviour. Before the recording began, the children’s comfort and familiarity with the 
recorder was encouraged, by asking if anyone wanted to press the ‘on’ button and 
start or finish our recording. For most groups, the audio recorder was, at first, a novel 
‘toy’ that they each wanted to ‘have a turn’ at. Throughout the workshop the children 
lost interest in the device, and it was often only when it was time to turn off the recorder 
that the children again requested to press the button. Involving the children in the 
recording helped them to take some ownership of it, and rather than me recording 
them, it instead became within the children’s control. 
 
In some of the workshops, such as the large group museum events, it was not possible 
to audio record given the setting (a large and noisy environment and the potential for 
not only recording specific children but also surrounding conversations),  and the 
turnover of children attending the stall and taking part in the study. However, the focus 
of these busier workshops was on obtaining a large sample of children, as detailed in 
section 4.2.6. Instead, children were encouraged to write down their ideas and 
annotate their drawings. Additionally, in some of these busier workshops (e.g., within 
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the leisure groups when there were larger numbers of children within one room or hall) 
the children attending generally decided to sit in smaller groups to complete the 
activities, rather than sit in one large group together. Therefore, audio-recording each 
of the individual group discussions at all times was not feasible. The researcher carried 
the audio-recorder around the room with her and recorded only the information 
provided by the children when she was present. In future studies, it might be useful to 
provide each smaller sub-group with their own recorder to ensure no data is lost. 
 
See Table 4.4 for detail regarding the number of children who participated in each 
activity, and contributed to each aspect of the study. 
 
Table 4.4: Detail of number of children who participated in each activity. 
 Schools Clubs Hospital Museum Total 
Groups  S1G1 S1G2 S2G1 R1W1 R1W2 R2 B1 Ward  Museum  Total 
 Total 3 3 2 7 
 




8 19 3 81 111 
Activity 
sheets 
5 19 0 81 105 
Ranking 
activities 





5 11 3 0 19 
Audio 
recorded 
3 recordings. 4 recordings. 3 
recordings. 
0 10  
 
*Unknown engagement: Due to the conduct of the museum event, not all activities were monitored. 
Therefore, the ranking activity was presented more as a game or discussion point for children to interact 
with. No information detailing how many children engaged with this activity were kept.  
 
4.2.5.3 Undertaking the workshops  
Each group of activities was planned to last no more than 60 minutes, this aimed to 
mitigate boredom, and also reflected the time available within the settings. The group 
sizes ranged between 3-8 children, depending on the original group size and some 
groups were split into smaller groups in line with guidance suggesting that group sizes 
of 8 or fewer are appropriate (Horner, 2000).  
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Phase 1 activities aimed to generate an understanding of children’s acceptability and 
perceptions of medicines, and Phase 2 activities built on these to refine ideas and 
focus on evaluating and refining the tools used to assess acceptability. In Rainbows 
and Brownies where phase 1 and 2 were conducted separately, two visits were 
scheduled with each organisation. The workshops were carried out in a flexible and 
unstructured manner, each comprised of 3 key parts: introduction, main activity, 
debrief.  
 
4.2.5.4  Introducing the workshops 
Each workshop began by introductions to the children and having them all sit down 
together. The researcher explained who she was, what the workshop was about and 
what we would be doing for the next half an hour during the main activities. During the 
introduction and debrief parts of the workshop, which approximately lasted for 15 
minutes each, it was important that the children listened whilst it was explained, 
primarily so that any questions could be answered, issues identified, and a safe space 
was provided for children to assent or dissent to taking part. Larger groups were 
managed by using pre-existing methods such as a ‘talking stick’ or ‘Olivia’ (a doll used 
within guiding groups which is passed around the children for them to hold whilst they 
talk). This was a particularly helpful technique in the larger workshops and those with 
younger children.  
 
After the initial introductions and when assent had been gained, workshops began with 
an open discussion about the general area of medicine, what the children knew about 
it and if they had ever been given medicine; this aimed to be free flowing to allow for 
the natural progression of conversation. The children were all eager to share their 
stories of times when they had taken or been given medicine or stories about 
someone, they knew who took medicine. The discussions naturally progressed to what 
the children liked and disliked about medicine, and with some prompting such as “can 
you tell me more about that?”, the children discussed the different kinds of medicines, 
and the flavours, smells and other aspects that they liked or disliked.  
 
4.2.5.5  Main activity 
Following the introduction, the main activities were presented. Each activity was 
explained the drawing materials were introduced. Whilst most of the groups had their 
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own supply of materials, all of the children expressed an interest to use the pens and 
pencils that were provided. The activities are presented in more detail in the previous 
section 2.4.5. 
 
All of the children chose to interact with the drawing activities first and settled into a 
space in the room with a selection of pens and pencils to begin their drawings. The 
younger children actively involved one another in their creations and explained what 
they were drawing although some children chose to draw without input from their 
friends. In some cases, children asked for help to draw a shape or colour in, but mostly 
the children were more interested in explaining to me what they were drawing and 
why. Once the activity pages were complete, some children opted to continue drawing 
either on plain paper or by using the templates, and others engaged with different 
games that were not related to the workshop activities, such as skipping and playing 
together.  
 
The ranking activity was somewhat structured in some workshops and completely 
unstructured in others. In larger workshops the ranking activities were left for the 
children to interact with freely, they talked amongst themselves about where each card 
should be positioned. In the smaller groups, once the drawing activities were tidied 
away, we looked at the cards together and discussed some of the medicines. 
Following this the children were asked to order the cards in whatever way they 
decided. Most of the time the order of the cards was a straight line with the flavours 
on one level and forms of medicine (i.e. liquid or tablet or inhaler etc) on another, for 
example, in one workshop the children separated the flavours into ‘fruits’ and ‘sweets’.  
 
The third activity involved the children interacting with and evaluating different 
acceptability scales. Laminated scales and examples of currently used methods that 
are used to assess the acceptability of medicines were provided. The children played 
with these scales, circled their favourites, completed the example scales and 
discussed what they liked and disliked about them. The children were provided with 
post-it notes, stickers, emojis and novel templates such as empty ‘Top Trump’ cards 
and plain paper to re-design and develop the scales in ways they thought were more 
appropriate. Whilst the children were completing these activities, questions such as 
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“why did you choose that game/layout?” and “why have you decided to use (colour)?” 
were discussed.  
 
4.2.5.6 Debrief  
The workshops ended with a short debrief to give the children time and opportunities 
to ask any questions they had and to play with their friends before going back home 
or to their classes. The children were all told they could take their drawings home, if 
they wanted to do this, pictures were taken of their drawings. Most of the children 
decided to take their activities with them, along with certificates and debrief sheets 
with more information. They were each given the choice of a sticker and a small gift 
such as a rubber. Images of the children’s drawings can be found in the Findings 
(Chapters 5 and 6). 
 
4.2.6  Museum 
The World Museum event provided an opportunity to recruit a larger number of 
children than those attending the school and the clubs. The identification of the 
museum 'Meet the Scientist' event provided the chance to extend the initial recruitment 
sites to include this as a third site. These events are described as ‘interactive, hands-
on science days for all the family’, and are mainly attended by children between the 
ages of 4-12 years and their parents/carers. This seemed an ideal setting to recruit 
children for the study, so an area was provided for the researcher to set up a stall and 
be one of the 'scientists'. Members of the PMRU team at Alder Hey and colleagues 
from Edge Hill University accompanied the researcher to ensure that the children 
taking part on the day understood the study and were fully informed in how their data 
would be used for the study.  
 
The difference in the conduct of the study between the workshops and museum relates 
primarily to the participants and data collection techniques. The museum event was a 
much more fluid environment due to the fact that the event was not pre-bookable, and 
no prior contact was available with the families. However, as earlier mentioned there 
was a level of expectation that those present were attending the museum with the 
intention of engaging with the activities and getting involved in the day. Groups that 
arrived together such as school trips, families or groups of friends, and individual 
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children, were able to approach the stall and complete the activities. Therefore, the 
focus was less on the group dynamic and more about engaging a large number of 
children in a variety of activities simultaneously. The activities used within this setting 
were the same as within workshops although since the children had no set schedule 
for taking part, they could select whichever activity they wanted to. Each activity was 
clearly labelled and both children and parents were informed about the study before 
taking part in the activities. The research team present on the day aimed to ensure 
that each child had the opportunity to discuss with an adult about the study, although 
it was clear that the children were talking to their parents or guardians about the 
activities (Figure 4.8).  
 
Once the children had completed the drawing activities, someone from the team of 
researcher’s present would ask the children again if they wanted to take part in the 
study. If they did, they were able to post their drawing activities into Dr. Diamond's 
letter box. Following this they were provided with certificates of participation and 
stickers, along with debrief sheets which contained additional information regarding 
the study and contact numbers for them to get in touch with the researcher if required. 
 
 
Figure 4.8: Children discussing with parent and researcher about the activities (permission gained for 
use of photograph). 
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4.2.7 Clinical setting (Hospital)  
As opposed to the small group workshops conducted within the schools and clubs and 
the large event held in the museum, the hospital provided an opportunity to undertake 
one-to-one semi-structured interviews with children. The inclusion of a clinical setting 
provided an opportunity to recruit children who were likely to have more experience 
taking medicines than children recruited from the other settings and therefore could 
provide another perspective on the acceptability of medicines.  
 
The key difference between the workshops and hospital setting was that the data 
collection methods and techniques were adapted to suit the setting. Children were 
invited to take part in an interview rather than a workshop, as it was deemed that 
interviews would be more feasible and appropriate considering the setting. Although 
the benefits of the workshops could not be engaged in, the children were able to have 
one-to-one attention from the researcher who was able to tailor the interview to meet 
that child’s particular needs. Semi-structured interviews have long been used in 
qualitative research with children (Burnard, 2005), and are frequently used by nurses 
who conduct research within hospitals with children (Baumbusch, 2010). Semi-
structured interviews are said to facilitate rich description and personal accounts of 
children’s experiences and perspectives (Lambert & Loiselle, 2008) provided they are 
conducted in a way that allows for children’s spontaneous and in-depth responses 
(Ryan et al, 2009).  
 
In order to facilitate the rich description and accounts of children’s experiences, 
developing an interview guide is key (Ryan et al, 2009). The activities from the 
workshops were adapted and developed into an activity booklet (see Figure 4.6), 
which was used as a semi-structured guide for the interviews. A key benefit of using 
an activity booklet was that the child had control over which activities they engaged 
with, this helped to minimise the extent to which the researcher led the interview 
(Steubert & Carpenter, 1995). Additionally, the same techniques used within the 
workshops such as listening, observing and discussing were also used, creating a 
reciprocal environment that aimed to lessen power dynamics.  
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Each interview followed a similar pattern, the researcher was introduced to the child 
by a healthcare professional such as a nurse or ward manager who had identified the 
child as eligible. Following this, the study was explained to both parent and child and 
information was provided for them to read through (full details of the recruitment 
process can be found in section 4.1.5). After attaining consent and assent, each 
interview began with an open discussion about medicines which the children in the 
hospital generally took point on, explaining what medicines they had and why. In each 
case, the children were eager to start the activity booklet, and enjoyed having the 
choice of materials (such as different pens, pencils and crayons) to use. The adapted 
version of the ranking game worked well, and the children could number the aspects 
of medicines from 1 to 6 based on how important they were to the individual child. 
Finally, the children enjoyed interacting with the laminated scales, and used the pens 
to colour, draw and label the scales depending on their opinions.  
 
Following the completion of the activity booklet, the children were provided with a 
certificate and a debrief sheet, and each child seemed happy with this. Most children 
at the hospital chose to take their booklets home with them, and so before I left, I took 
pictures of their booklets with their permission to use for data analysis. The children 
were all provided with a choice of sticker and rubber as a small thank you and 
appreciation for taking part. The parents were provided with a copy of the consent and 
assent forms in line with the requirements of ethics approval for this setting.  
 
4.2.8 Photography 
Supplementary data were obtained through pictures and photographs of the 
completed activities. Some children opted to take their drawings and creations home, 
when this happened photographs were taken of each item - with their 
permission/assent - in order to document them. The photographs were also used to 
record the context of the drawings, activities and groups, and then used as reference 
points during analysis to inform interpretation of the children’s drawings.  
 
4.3 Ethics 
Ethics approval was obtained (FOHS 204) from the Edge Hill University, Faculty of 
Health and Social Care Research Ethics Committee (FREC) prior to conducting any 
fieldwork in the settings and ensured that the research was consistent with ethical 
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guidelines outlined in Edge Hill University's Ethical Guidelines for Undertaking 
Research with Children and Young People (UREC, 2012). As this study involved the 
collection of data from children within an NHS hospital, Health Research Authority 
(HRA) ethical approval was also necessary. HRA approval was granted on (date), 
following this a research passport form was completed for the participating NHS trust 
and a local capacity and capability letter of access was provided. Complete adherence 
to university and NHA policy and ethical documentation was followed at all times, 
however, as Horton (2008) notes, it is acknowledged that there is more to consider 
when doing research than described in the guidelines of ‘good practice’. Regardless 
of how ethically well designed or prepared a researcher is, it is recognised that as 
Morrow and Richards (1996) assert, it is impossible for researchers to foresee what 
ethical issues may arise throughout the research process, therefore ethics were 
considered situational and the researcher was responsive to ethics throughout this 
study.  
 
Many methodological and ethical issues that researchers are faced with when 
conducting research with children are no different to research with adults, for example, 
issues related to the risks and benefits of participation, confidentiality, interpreting and 
disseminating findings, as well as issues of participant protection and withdrawal 
(Dawson, 2009; Morrow, 2008). However, research with children also generates 
additional ethical issues such as power dynamics, competence and the inclusion of 
the child’s ‘voice’.  Power dynamics when conducting research with children have been 
recognised as a problem (Dorozenko, 2016), with children often perceived as a 
“powerless group in society” (Morrow, 2008, p16). Whilst it was not the intention to 
adopt these power roles, the researcher’s positionality as an adult academic and the 
lead researcher in the study, provided a position of power. However, the children were 
also perceived as ‘powerful’, as they have knowledge and experience that adults do 
not have.  
 
Related to this latter point is the notion of children’s competence (Horgan, 2016). 
Children have traditionally been viewed by adults as not competent enough to express 
an opinion (Maconochie, 2008). However, in the previous chapter it is argued that 
children think and communicate differently to adults (Piaget, 1932; Barker and Weller, 
2003), and that it is up to us, as adults, to account for children’s strengths in research. 
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In this current study methods typically reported as best practice with children were 
employed (Literat, 2013; Biggeri and Anich, 2009), these methods have been praised 
for enabling children to express their opinions and voices within research (Driessnack, 
2005).  
 
As a means of ensuring an awareness of the researcher’s responsibilities and to 
ensure that legal requirements were adhered to, a DBS check was obtained, along 
with the NIHR Introduction to Good Clinical Practice (GCP) eLearning training and 
NIHR Informed Consent in Paediatric Research training. 
 
4.3.1 Representation  
Representations are central to the process by which cultural knowledge is produced, 
exchanged and circulated in every instance of personal and social interaction (Gall, 
1997). The researcher was conscious that in order to effectively represent the children 
there would be required to account for the individual children and their experiences, 
age and gender.  
 
Representing children is not regarded as a straightforward task, the concept of 
childhood is dependent on how people view it and childhood is often (re)produced in 
relation to those cultural perceptions of childhood prevalent in the surrounding society 
(Ariès, 1962; Corsaro, 1997). However, it is necessary to represent and include 
children in research if meaningful data is to be produced (UNCRC, 1989). Accessing 
and representing children within research is not only difficult because of the adult 
presuppositions that we are naturally inclined to, but also due to methodological 
challenges and expectations the researcher faces (Sharp, 2001). It is widely 
understood that children communicate differently to adults, and so it becomes difficult 
for the researcher to recognise children’s views and voices when they are expected to 
provide adult typical data, such as long interview transcripts and detailed written 
accounts (Maconochie, 2008).  The researcher wanted to avoid simply listening to or 
extracting the views and voices of children within research (Mand, 2012), and instead 
“hear, interpret and make meaning” (Ebrahim and Muthukrishna, 2004; 85) with the 
children in a way that they are familiar with (Cook and Hess, 2007).  
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Although using child-centred methods can overcome issues of misrepresentation, 
these methods can generate data that are complex in terms of 'capturing' meaning. It 
is becoming popular to employ visual and creative methods of data collection to 
identify and evaluate children’s emotions, experiences and development (Burkitt, 
2004), as well as explore their conceptions and meaning making of activities (Ring, 
2006). These methods are also commended for their ability to maximise children’s 
involvement in research (Pfister & Vindrola-Padros, 2012) and to address sensitive 
topics. Nevertheless, there is still some resistance to using these methods. 
 
There are concerns that the authenticity of the children’s voice and views are nullified 
when the researcher attempts to interpret and re-present this child focussed data. This 
‘crisis of representation’ occurs when an adult researcher, who does not share the 
same views, experiences or ideas as the children, attempts to frame the child-made 
data within the study (Lincoln and Denzin, 2000). However, this crisis of representation 
is not unique to children, in fact, it is relevant across all qualitative research where an 
“other’s” voice is represented. Whilst it may be the case that issues of representation 
are more obvious with children, it is not the case that this inherently any more 
problematic than with adults (Maconochie, 2008). Therefore, the question is not “Can 
I rely on the child’s voice?” but instead, “Am I, as an adult researcher, presenting what 
the child has said, as expressed by them?”.   
 
It is not proposed that, because of the inclusion of children, this research resists adult 
interests or becomes child centred. However, by providing the children with tools and 
methods that are typically child-centred, the children and the researcher were able to 
co-construct and formulate ideas, views and understandings. It is also considered hat 
the co-constructed knowledge is not void of the researcher’s own influences. However, 
the study was conducted mindful of the issues that can arise when including children 
in the research and aimed to collaboratively produce information about the 
acceptability of medicine. The researcher was also conscious that the methods that 
are used to evaluate the acceptability of medicine are used by both children and adults 
and, like Dahlberg et al (1999), it is therefore emphasised that meaning making, rather 
than seeking to capture direct voices, acknowledges the values of interpretation, 
contextuality, and subjectivity, especially in the context of acceptability assessment 
development.   
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4.3.2 Gaining access, consent and assent  
One of the main challenges when conducting research with children is negotiating 
access at the varying levels with adults who have a responsibility for the child (Sime, 
2008). The multiple settings in this study required consideration of each setting, and 
individuals that would be required to obtain consent from in order to undertake the 
study. In each setting, the first person that was typically met with was the gatekeeper, 
these included the head teacher at the schools, event organiser at the museum, group 
leader at the guides or research and ward managers at the hospital. Throughout the 
study, each gatekeeper was provided with an Information Summary Sheet (Appendix 
35) and permission (along with any other necessary approvals) was granted by each 
adult gatekeeper to conduct the research at their organisations.  
 
A further level of access from parents or guardians is required when conducting 
research with children. The children’s well-being was of high importance throughout 
the study and consent and assent procedures followed current guidelines from the 
British Medical Association (BMA, 2016) which state that for under the age of 16, 
consent from a parent/legal guardian is first required.  
 
Parent information sheets (Appendix 8) and two Child Information Sheets, one for 
each age group (5-7, 8-12 years) (see Appendix 10 and 11) were developed; these 
had full details about the research study, potential risks and benefits of participation, 
confidentiality, and their right to withdraw. These documents were produced and 
amended in consultation with the Liverpool YPAG at Alder Hey. The group is a 
community of members between the ages of 10-15 years old who meet up every six 
weeks to support the design and delivery of health research in children and young 
people. This ensured that the documentation was presented in an accessible, 
interesting and appropriate way for the age groups relevant to the study.  
 
As all children in this study were under the age of 16, parents were asked to read 
through detailed parent information forms and consent sheets. Children were provided 
with child-friendly information forms and assent sheets and parents were asked to read 
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through these with their child/children to ensure that both parent and child were fully 
informed and in agreement to take part in the study. 
 
In the clubs and schools, the children and their parents were provided with information 
and consent/assent sheets by either the researcher or gatekeeper in each group. They 
were given at least a week to read through information sheets and consider taking part 
in the study. In the hospital setting parents were required to provide verbal permission 
before I could talk to their child about taking part in the study. Once their permission 
was attained, the child was provided with a child-friendly information sheet.   
 
In the museum setting the consent process was slightly different to the other settings. 
At the stall large information sheets were clearly displayed on boards and had a variety 
of parent and child information sheets on the tables. Before the children were given 
an activity sheet, parents were asked if they agreed to allowing their child to take part. 
Details about recruitment have been presented earlier in the chapter (section 4.1.5). 
 
Apart from the children at the Museum, all of the children who participated in the study 
provided written assent. At the museum, notions of implied consent were relied on 
(Stephen et al, 2008). After they had finished their drawing or activity, the children 
were reminded that if they posted it into ‘Dr Diamond’s Letter Box’ this meant that they 
were agreeing to be in the study. The physical act of posting the drawing was regarded 
as their assent.  
 
Throughout the data collection assent was viewed as a “process” (Heath et al, 2007, 
409), relying on the children's verbal and behavioural cues as their on-going 
willingness to participate (Flewitt, 2005). It was emphasised that their participation was 
voluntary by regularly reminding them that they could “play with something else” or “do 
a different activity” if they wanted to, highlighting their rights to withdraw at any time. 
This was particularly important when moving from one activity to another. The nature 
of the workshops allowed the children to participate when, and in what activities, they 
wanted to without them having to formally explain when they were leaving the 
activities. If the children re-joined the activities verbal assent was required to ensure 
they were happy to continue (Hall, 2009).  
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4.3.3 Confidentiality and anonymity 
The confidentiality of all children in this study, and their data, is assured as far as 
possible by using pseudonyms and the confidential storing of all data on secure and 
password protected computers (Article 5, General Data Protection Regulation, 2016). 
Any identifiable data including paper copies of information data containing the names, 
age and ID number, such as consent or assent forms, were stored in a sealed 
envelope in a locked drawer in the researcher’s office at the University. Any scanned 
documents were securely stored electronically on a password protected service at 
Edge Hill University. Physical copies of identifiable data that was collected at the 
Children’s Hospital were stored securely in sealed envelopes and in a locked filing 
cabinet at the hospital whilst the researcher was on site. At the earliest possible 
convenience, the researcher transported documents from the hospital to the research 
office at the University. Any data that had identifying or potentially identifying data were 
stored separately from the anonymous data. The device(s) used to record the audio 
data was not left unattended from the researcher, unless stored in a secure drawer 
within the researcher’s office. Audio files will be kept on a secure server until the thesis 
has been submitted and approved, in any case that the researcher may need to listen 
to the raw data. All personal data was anonymised at transcription, and all identifiable 
data was removed from the transcripts and observational data.  
 
It was made clear to the children that if a situation arose in which there was a 
reasonable cause for concern that more harm would come from maintaining 
confidentiality (e.g., in a situation where a child is the victim of harm), this would need 
to be reported to an independent adult at the venue, and appropriate action would be 
taken in line with the organisation’s and Edge Hill University's policies and procedures. 
Thankfully this was not a necessary procedure during the study.  
 
Rather than assign a pseudonym to the children to provide anonymity, children were 
asked if they would like to pick their own. Many of the children opted for non-typical 
names such as “popcorn” or “doo-doo” and the use of names of superheroes and 
princesses such as “Superman” and “Belle” was also common. Some of the children 
seemed resistant or unsure about choosing their own names and would ask “if that 
[name] was okay”. Following the example of previous work such as that by Moorefield-
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Lang (2010), the children naming themselves was welcomes as it was believed this 
was a ‘stamp’ of their identity and afforded them more agency in meaning-making and 
ownership. The children wore name badges in the workshops which had their chosen 
names written on them, these names were also put on their worksheets and drawings 
so that when we were talking it was easy to match up conversations to workshop 
outputs. A few children put their actual names on drawings and activities, and so 
before the workshops ended, they were asked whether they meant to do this, or 
whether they mistakenly put their actual name rather than pseudonym. This was 
believed important to clarify in case the children wanted to take ownership of these 
pieces of work or take them home with them. In most cases this was simply a mistake, 
and so before using the images these named were removed/covered.  
 
4.4 Data Analysis 
There is no one method specified for analysing research conducted using a generic 
qualitative approach. The literature provides a variety of data analysis approaches 
employed to undertake generic qualitative analysis. Some studies have relied on 
thematic analysis (Bellamy et al, 2016; Carter-Greene, 2019), whereas others have 
made use of inductive analysis (Liu, 2016), and framework analysis (Pope et al, 2000; 
Cross et al, 2005). Despite the variety of data analysis methods used in generic 
qualitative research, Merriam (2002) stresses that the purpose of generic qualitative 
research is to seek to understand how people interpret, construct or make meaning 
from their world and experiences. Building on this, Lim (2011, p52) adds that the 
methods used within this research are “highly inductive”, making use of open codes, 
categories and thematic analysis. Therefore, the use of thematic analysis in the current 
study aligns to the nature of generic qualitative research outlined above, accounting 
for the “rich description” (Lim, 2011, p52) and intentional flexibility of generic qualitative 
research (Thorne, Kirkham, & O’Flynn-Magee, 2004).   
 
Thematic Analysis is a widely used generic method of analysis which involves 
“searching across a data set – be that a number of interviews or focus groups, or a 
range of texts – to find repeated patterns of meanings” (Braun & Clark, 2006, p. 86). 
A primary advantage of thematic analysis is that it is a method, rather than a 
methodology (Braun and Clark, 2006; 2013), and so is not bound to any one 
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epistemological or theoretical perspective (Maguire & Delahunt, 2017). This offers a 
process of data analysis which allows for flexibility and that is compatible with many 
research approaches, this is a significant advantage when considering its use with 
generic qualitative research (Percy et al, 2015). King (2004) argues that the use of 
Thematic Analysis is beneficial when examining a large qualitative data set. It allows 
for the examination and comparison of different participants’ perspectives, and is 
useful in the subsequent synthesis, analysis and communication of results (Braun and 
Clark, 2006; Polit and Beck, 2008).  
 
Whilst offering advantages in its flexibility and accessibility (Braun and Clark, 2006; 
King, 2004), there are also disadvantages associated with this method of analysis. A 
key disadvantage relates to the flexibility of the approach. The variety of ways to 
approach thematic analysis has caused confusion and its validity has been questioned 
(Braun and Clark, 2014). However, such criticisms  are often related to a “lack of 
understanding about the potential of TA (Thematic Analysis)” (Braun and Clark, 2014, 
p2) and the 6-step framework recommended by Braun and Clark (2006) provides a 
systematic and robust method for coding and identifying patterns within a qualitative 
dataset. This framework is reported to be useful for those undertaking health research 
and is the approach adopted for analysis in this study.  
 
The aim of thematic analysis is to identify themes. Braun and Clark (2006) distinguish 
between semantic and latent themes. The process for identifying semantic themes 
(i.e. the things a participant has written, drawn or said- nothing more than the explicit 
or surface meaning of the data) is presented in Table 4.4 The latent level themes aim 
to look beyond what has been said and “… starts to identify or examine the underlying 
ideas, assumptions, and conceptualisations- and ideologies- that are theorised as 
shaping or informing the semantic content of the data” (p84). To overcome the 
criticisms of inconsistency and lack of coherence when developing latent themes 
(Holloway and Todres, 2003), it is important that the researcher is explicit about their 
epistemological position and that this is applied to the study’s analysis and is coherent 
with the study’s empirical claims (Holloway and Todres, 2003; Lorelli et al, 2017).  
 
The provision of structure and order that Thematic Analysis offers helps to guide the 
researcher through a well-structured approach to handling the data and therefore 
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allowing for greater transparency of the analysis (King, 2004). This focus on 
transparency is encouraged by Braun and Clarke (2006) to help the researcher 
understand and make clear their own theoretical position and how this might influence 
the analysis.  
 
Thematic Analysis can be used in both an inductive (bottom-up) and deductive (top-
down) way (Maguire and Delahunt, 2017). This study used an inductive approach as 
this made sense in terms of the focus on meaning-making, in-depth perspectives, 
views, feelings and the reality of children in respect to the acceptability of medicine. 
The semantic analysis therefore was not driven by the researcher or research 
questions, but by the data itself as its focus was on what each group of children had 
to say about the acceptability of medicine. However, it is not claimed that the research 
questions did not influence the data analysis at all, as the researcher was conscious 
that themes identified would be influenced by the research aims. The researcher 
worked hard to ensure that the analysis moved beyond simply describing what was 
said, and into latent analysis of the data by interpreting and explaining it.  
 
Following Braun and Clarke’s (2006) six phase framework of Thematic Analysis, 
themes were identified both within and across participant groups. This framework 
provided a systematic process of analysis which was followed closely throughout the 
data analysis in this study.  
Table 4.5: Six phase framework of Thematic Analysis (Braun and Clarke, 2006) 
Phase 1: 
Familiarisation  
Is common to all forms of qualitative analysis – the researcher must immerse 
themselves in, and become intimately familiar with, their data; reading and re-
reading the data (and listening to audio-recorded data at least once, if relevant) 
and noting any initial analytic observations. 
Phase 2: 
Coding 
Also a common element of many approaches to qualitative analysis (see Braun 
& Clarke, 2012a, for thorough comparison), this involves generating pithy labels 
for important features of the data of relevance to the (broad) research question 
guiding the analysis. Coding is not simply a method of data reduction, it is also 
an analytic process, so codes capture both a semantic and conceptual reading 
of the data. The researcher codes every data item and ends this phase by 





A theme is a coherent and meaningful pattern in the data relevant to the 
research question. If codes are the bricks and tiles in a brick and tile house, then 
themes are the walls and roof panels. Searching for themes is a bit like coding 
your codes to identify similarity in the data. This ‘searching’ is an active process; 
themes are not hidden in the data waiting to be discovered by the intrepid 
researcher, rather the researcher constructs themes. The researcher ends this 




Involves checking that the themes ‘work’ in relation to both the coded extracts 
and the full data-set. The researcher should reflect on whether the themes tell a 
convincing and compelling story about the data and begin to define the nature of 
each individual theme, and the relationship between the themes. It may be 
necessary to collapse two themes together or to split a theme into two or more 
themes, or to discard the candidate themes altogether and begin again the 





Requires the researcher to conduct and write a detailed analysis of each theme 
(the researcher should ask ‘what story does this theme tell?’ and ‘how does this 
theme fit into the overall story about the data?’), identifying the ‘essence’ of each 




Writing is an integral element of the analytic process in TA (and most qualitative 
research). Writing-up involves weaving together the analytic narrative and (vivid) 
data extracts to tell the reader a coherent and persuasive story about the data 
and contextualising it in relation to existing literature. 
The six stages in the table above were followed during the data analysis in this study. 
Some initial analysis of the data occurred during the data collection process during 
discussions with children about what they had drawn, their proposed rankings, their 
intended meanings and contextualisation of their data. 
 
Familiarisation (Phase 1) occurred whilst the task of transcribing the audio recordings 
was carried out. Each workshop and interview was independently transcribed as soon 
as possible following its completion, in order to capture not only the spoken word but 
also any non-audio data such as: facial expressions, body language, movements and 
pauses that would otherwise be lost in the audio recording. This was completed 
through listening and re-listening to each recording, transcribing each time, and 
verifying the transcript whilst listening to the raw audio file a final time. In an attempt 
to maintain the authenticity of the children’s voices as far as possible, their words were 
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transcribed verbatim in order to ‘capture’ the children as they are, and as they 
presented their ideas and thoughts. 
 
After immersion in each individual data set through repeated reading of the transcripts 
and through line by line analysis, the data was preliminarily coded (Phase 2). Although 
there is an argument to use online software for this step in the analysis process (Smith, 
2017), the researcher believed this process took away the authenticity and immersion 
that qualitative analysis calls for. Therefore, it was decided that analysis would be 
conducted using hard copies of the transcripts, as suggested by Smith, Flowers & 
Larkin (2009). This was an active process, facilitated by the notes made during and 
after each data collection session based on the discussions with children (Paton, 
1990). Having these notes available helped to contextualise the children’s responses 
and highlight key concepts and ideas that they identified as important in each age and 
gender group. Transcripts were initially coded as individual documents, initial ideas, 
codes, and themes were identified and transferred into a table. Coding the interview 
and workshop transcripts individually allowed for the individual child’s or group’s 
perspectives to be identified without trying to fit each transcript into a set of codes or 
themes from other interviews. This meant that different codes were identified and 
complements the inductive approach of data analysis adopted in this study.  
 
The process for coding was in depth and ongoing and began by identifying semantic 
codes. These codes were easily identified through the labelling of surface meanings 
of what the children did or said, for example in one interview a child explained that 
they liked Calpol, so a code for Calpol was created along with ‘like’ or ‘positive’. 
Following this, latent codes, which capture the interpretations, assumptions and 
underlying ideas of the data were identified. In this example, the child’s positive view 
of Calpol seemed to originate from past experiences of taking the medicine, referring 
specifically to a time they could recall when Calpol helped them to get better. These 
codes were then grouped into themes. 
 
Once these codes had been identified on hard copies of the individual transcripts, 
word files on the computer were created for each emerging theme (Phase 3). These 
files acted as ‘master themes’ where the relevant participant quotations were copied 
and pasted along with which transcript they were originally from and line number in 
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order to make identification a more structured process, as suggested by Smith (2009). 
This enabled the collation of quotations, searching for commonalities and differences 
between different participants perceptions in each workshop and interview. It also 
allowed an overview of how big each proposed theme was, with the frequency of 
supporting statements easily observable.  
 
After each transcript had been coded and organised into one of the theme files, sub-
ordinate and super-ordinate themes were refined and re-organised into a table (Phase 
4). This process began by grouping all similar themes together and condensing 
themes where there was overlap or repetition, however this was an iterative process 
and as the themes developed consideration was given to the richness of data and its 
relevance to the research questions. It was evident from the analysis that the findings 
would be split into two sections- the first focussing primarily on what children had to 
say about the acceptability of medicines, and the second focussed on children’s 
drawings, re-development and new ideas for assessing the acceptability of medicines. 
Therefore, two separate ‘master’ tables were developed, and it was decided that it 
would be beneficial for the clarity of the findings to display these independently with 
the discussion chapter (Chapter 7) linking between the two.  
 
Once the narrative of each theme began to take shape it was then evaluated how 
these themes fitted together into the overall story of the data. The theme tables were 
reviewed by the supervisory team to ensure that sub-ordinate and super-ordinate 
themes were understood and grounded in data (Phase 5).  
 
Themes were condensed and organised further and pulled together into a more 
simplified table. A narrative was then formed around the themes to explain the story 
in more detail, using verbatim quotations from the participants as pillars for the story 
to build on (Phase 6).  
 
To ensure the trustworthiness of the process of Thematic Analysis in this study, I 
followed Lincoln and Guba’s (1985) criteria for evaluating trustworthiness, presented 
in Table 4.5. 
 
Table 4.6: Lincoln and Guba's (1985) Criteria for Trustworthiness 
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Credibility Confidence in the ‘truth’ of findings based on the research design, 
subjects/informants and context. 
Transferability Applicability of the findings in other contexts. 
Dependability Consistency and replicability of the findings with the same subjects or in 
a similar context. 
Confirmability Degree of neutrality or the extent to which the findings of a study are 
shaped by the respondents and not researcher bias, motivation or 
interests.  
 
4.4.1 Image analysis  
Drawings in this study were used primarily as a way to facilitate discussion (Gross & 
Hayne, 1998; Pipe et al. 2002). It is believed that children attribute meaning not 
necessarily to the picture that they draw, but the action of drawing (Praiser, 2017), 
therefore observations were made of the children drawing and notes were made to 
provide context for the drawings within the discussion. Therefore, drawing was used 
more as a projective measure of data collection. That being said, in line with the data 
analysis approach outlined above, drawings were broadly analysed based on what 
the children talked about. Kuhn (2003) provides a method of thematic analysis to 
analyse children’s drawings. This method proposes a broad and interpretive model 
based on observations, focussing on 1) the descriptive evaluation of the drawing, 2) 
the evaluation of the image, and 3) the thematic evaluation of the drawing.  
 
4.5 Overview  
In this chapter the aspects related to the inclusion criteria, sample, recruitment and 
methods of data collection have been discussed, along with the conduct of the 
workshops, ethical considerations and data analysis. The aim of this chapter was to 
provide an open and structured explanation of the research process. However, this 
process was not linear, instead it was an ongoing iterative learning experience.  
 
The generic qualitative approach and subsequent Thematic Analysis provided the data 
that underpinned the findings chapter. The development of the following chapter was 
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highly dependent on a sensitive and interpretative effort to present the co-constructed 
reality of the acceptability of medicine, whilst maintaining the authenticity of the 
































































5 Exploring Children’s Perspectives to Improve the Understanding 
of the Acceptability of Medicines 
This chapter presents an overview of the demographic information of the children who 
participated in the study and the findings relating to children’s perspectives of the 
acceptability of medicines. The findings are organised into three super-ordinate 
themes: What Children Can Tell Us about the Acceptability of Medicines; What Helps 
Improve the Acceptability of Medicines to Children; and What Reduces the 
Acceptability of Medicines to Children. These themes were formed following the data 
analysis process described in section 4.4 of the previous chapter. 
 
5.1 Demographics: Participant Characteristics 
In total 111 children participated in the study within three main settings: schools/clubs, 
hospital environment and museum.  
 
Overall similar numbers of girls (n=66) and boys (n=45) were recruited into the study, 
and more children (66%) were in the younger age bracket (aged 5-7-years; n=73) than 
in the older age bracket (aged 8-12-years; n=38). In total, 27 children participated via 
either the two primary schools (n=8) or via two Rainbow and one Brownie groups 
(n=19). No boy scout groups gave access, so no boys were recruited from these 
groups. Within the hospital, children (n=3) were recruited from two wards and the 
museum setting accounted for the majority of children (n=81) recruited to the study. In 
Table 5.1 the participant recruitment settings are broken down into more detail to 
provide a more comprehensive overview of the recruitment process.  
 
Table 5.1: Total number of children by setting, sub-group and participant characteristics.  
 Schools Clubs Hospital Museum Total % 







ws 1  
Rainbo
ws 2 
Brownies Ward Museum Total % 
Total 3 3 2 7 4 8 3 81 111  
Age (years)  
5-7 3 0 0 7 4 0 0 59 73 66% 
8-12 0 3 2 0 0 8 3 22 38 34% 
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Gender  
Girls 1 1 0 7 4 8 2 43 66 59% 
Boys 2 2 2 0 0 0 1 38 45 41% 







Not known 3 not known 8 7% 
ainhaler; bcetirizine, cmedication for ADHD 
 
In order to provide some context for the presentation of quotes and artwork, each 
quote or image is presented using the child’s chosen pseudonym (if appropriate), their 
gender, age, and the setting (school/club, museum, hospital) they were recruited from, 
e.g., Alex, Boy, 8-12yrs, Hospital. If the child did not provide a name, or in group 
sessions where it was difficult to distinguish the individual contributions of specific 
children, then the information provided is less detailed, e.g., Girl, 8-12yrs, School 1. 
All of the quotes are presented verbatim using the spelling the children used in their 
written comments or reflecting the language and word usage in their verbal 
communications.  
   
Three super-ordinate themes and six sub-ordinate themes were developed and are 
summarised in Figure 5.1. These themes are presented in the form of a narrative 
supported with the most pertinent quotes from the data.  
 
  
•Children's understanding of the acceptability of medicine 
•Medicines help children and children need help with 
medicines 
What children can tell 
us about the 
acceptability of 
medicines?
•Aspects of medicines that children like, love or believe are 
fine
•Practical factors that influence the acceptability of medicine










Figure 5.1: Summary of three superordinate (dark blue bubbles) and six subordinate (light blue bubbles) 
generated from the data collected from the children in the study. 
5.2 What Children Can Tell Us About the Acceptability of Medicines 
The first super-ordinate theme identified in the data was regarding what children know 
about the acceptability of medicine. This included how children defined acceptability, 
the factors they believe impacts the acceptability of medicines, and the belief that 
medicines help children. This was organised into two sub-ordinate themes Children’s 
Understanding of the Acceptability of Medicines, and Medicines Help.  
 
5.2.1 Children’s understanding of the acceptability of medicines  
During the initial discussions, and following prompts from the activity booklets, children 
talked about what they understood about the acceptability of medicines. Most children 
provided an explanation of acceptability that was broadly similar to definitions of 
acceptability used by clinicians and academics within current research work with Alex 
explaining: 
 
‘It means like if it’s ok for you, like yes or no. If you’re fine taking it” (Alex, Boy, 
8-12yrs, Hospital).  
 
This broad understanding was evident across most children, including those who take 
medicine regularly, children who take medicine occasionally for minor health reasons 
(e.g. common cold) and those taking medicines such as daily vitamins. It was common 
for children to describe acceptability using words such as ‘OK’, ‘accept’ and ‘agree’ 
and whilst their descriptions were generally accurate they often framed them in a way 
that was seeking confirmation that this was the case: “Does it mean like if it’s ok for 
you?” (Belle, Girl, 8-12yrs, Hospital), “How you accept medicine?” (Anika, Girl, 8-
12yrs, Brownies), and “I think it means when you accept something… it means when 
you agree with something” (Girl, 5-7yrs, Rainbows 1).  
 
Other children were less sure of their understanding, “Acceptability means… no I don’t 
get that” (Girl, 8-12yrs, Brownies) or were clear that they did “not know what 
acceptability means” (Girl, 5-7yrs, School 1). However, some guessed what it meant, 
as demonstrated by one child who asked if acceptability “is it like, what it does?” (Girl, 
8-12yrs, Brownies). A couple of children who had difficulty explaining what an 
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acceptable medicine was explained it as something “that you’re, erm, not allowed to 
take it on your own” (James, Boy, 8-12yrs, School 1), or something “that you can’t use” 
(Joy, Girl, 8-12yrs, School 1).  
 
Children who did not seem to understand the concept of acceptability of medicines 
tended to think in terms of experiences and examples of where they had heard the 
words ‘acceptable’ or ‘not acceptable’ being used before, even if this was not 
necessarily related to medicine. For example, one child explained acceptable as “if 
you are being bad or not” (Boy, 5-7yrs, School 1). A boy talked about past experience 
of their parents using the word and explained that “Ex-cept-able [spelling it out] means 
if you are bad it says that’s NOT acceptable, and that’s what your mummy or daddy 
uses they say “that’s NOT acceptable” if you hit or kick someone” (Boy, 5-7yrs, School 
1). Millie talked about how their “teacher said unacceptable to [child] because he 
always be’s [sic] naughty” (Millie, Girl, 5-7yrs, Rainbows 1).  
 
There were variations in how the acceptability of medicines was interpreted by 
children. Whilst the majority of children had a good perception about the acceptability 
of medicines, relating it to either agreeing or accepting something, some children did 
not or could not provide a coherent explanation of acceptability. 
 
Expanding on their understanding, children talked about their thoughts and ideas of 
medicines and the acceptability of medicines. Many children explained the concept of 
acceptability as indicating practicalities of taking the medicine, and the idea that an 
acceptable medicine is something “that someone is allowed to use it a bit” (G, Boy, 8-
12yrs, School 2). The idea of being allowed to take medicine was a recurring idea with 
Brooke explaining “Does it mean if, if you’re allowed to take it on your own?” (Brooke, 
Girl, 8-12yrs, School 1).  
 
The children also discussed whether a medicine’s acceptability would relate to 
whether “you’re not allergic to it” (James, Boy, 8-12yrs, School 1), “…if you like it” (Joy, 
Girl, 8-12yrs, School 1) and/or if you are “old enough” (Brooke, Girl, 8-12yrs, School 
1) to take it. The fact that the children discussed the practical requirements for the 
person taking the medicine suggests that they think about the practicalities of taking 
medicines and the positive and negative effects that medicines can have (see Figure 
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5.2). Children also considered the difference between knowing what acceptable 
means and the limitations of being asked whether or not a medicine was acceptable, 
with one girl explaining that “I wouldn’t know if it was acceptable if I had never had it 
before” (Girl, 8-12yrs, School 1).  
 
Some children’s ideas about acceptability addressed areas that are not typically seen 
as being part of conventional notions of evaluating the acceptability of medicine, such 
as bravery, “Acceptable? Umm that means you have to be brave if you are having 
something that hurts” (Girl, 5-7yrs, Rainbows 1). Others explained the acceptability of 
medicine as something that “you really don’t like, and you really don’t want to have to 
do it again” (Girl, 5-7yrs, Rainbows 2).  
 
Whilst there were differences between children who had a good understanding of the 
acceptability of medicines and children who did not, it was clear that each child 
responded to the idea of the acceptability of medicine as something unique to them, 
whether accounting for appropriateness (age, allergies or usability), or whether it was 
an individual like or dislike. Acknowledging the tentative nature of providing numbers 
of children who could/could not provide a definition of acceptability, out of the thirty 
children who attended a workshop or interview in a school, club or hospital, over half 
(18 children) provided an understanding or discussion of acceptability broadly similar 




Figure 5.2: Image of medicine (Girl, 8-12yrs, Museum). 
 
Ingredients: penecilin, water, sugar, paracetamol (it 
cures stomachache) 
 
Dear Dr. Diamond… my medicine is called 
yummious tabletious. I chose the colours because 
you don’t want to put people off with strange colours 
or make people want to eat them all the time. I have 
chosen this shape because you can break parts off 
the medicine for different doses. This medicine 
would taste like strawberry so that people would like 
the taste but not like it so much that it will make you 
want to take the medicine all the time. I hope that 
you will try my medicine out.  
 
From “SRLQ” [sic] 
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5.2.2  Medicines help children and children need help with medicines 
One of the first topics children discussed during the workshops was that they “know 
medicine helps lots of children” (Popcorn, Girl, 5-7yrs, Rainbows 1). This idea was 
commonly held, and many children referred to how medicines “help” (Girl, 8-12yrs, 
Brownies). The topic of helping was initiated by the children when they were asked 
“has anyone had medicine before?”.  
 
The idea that medicines help was discussed by children whether they were taking 
medicines regularly or not, showing that they understood that medicines help children, 
with one girl explaining “it helps us” (Girl, 8-12yrs, Brownies). A key idea was that 
“medicine helps you to stop being poorly” (Katie, Girl, 5-7yrs, Rainbows 1) with some 
children elaborating on how medicines help across a range of different conditions, for 
example: 
 
“it [medicine] helps you get better if you’re not well, if you’ve got chicken pox or 
spots or anything like that” (Girl, 5-7yrs, School 1). 
 
Building on this idea that medicines help improve your physical condition was the idea 
that medicines also “make you feel [emotionally] better when you’re poorly” (Girl, 8-
12yrs, Brownies) showing that they understood that medicines could help in two ways. 
The recognition that medicines make them feel better was also found in children’s 
drawings from the museum group, in Figure 5.3 a boy wrote about and had drawn his 
medicine as a marshmallow because he thinks ‘children will want to eat marshmells 
[sic]’, and that ‘medisen [sic] will make children feel better’.  
 
 
Figure 5.3: Image of marshmallow medicine (Boy, 8-12yrs, museum). 
 
Ingredients: marshmellow, medisen, medisen 
for tummy ache 
 
“Dear Dr. Diamond… because I think children 
will want to eat marshmells [sic] and medisen 
[sic] will make children feel better” 
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Children also talked about the preventative role of medicines as they knew they were 
not only given when “actually if you are poorly” (Girl, 8-12yrs, Brownies) but also 
helped to “make you not get really sick” (Girl, 8-12yrs, Brownies), revealing insight into 
the consequences of not having medicine:  
 
“Sometimes if you don’t have it then you will get more poorly” (Girl, 8-12yrs, 
Brownies) 
 
Building on the idea that medicines can help to overcome or prevent illness, many 
children referred to their routine of having a “vitamin every morning” (Pineapple, Girl, 
5-7yrs, Rainbows 1) and the association that “medicine keeps you healthy” (Girl, 5-
7yrs, Rainbows 1). The link between children’s experience and holding a particular 
viewpoint about medicines was common and, arguably, linked to how children knew 
that medicine would make you feel better as well as knowing that it was helpful. This 
link was observed in the following dialogue between Pineapple, who is allergic to cats 
and dogs, and the researcher: 
 
“Pineapple: I know a medicine... Piriton 
Beth: do you know what that’s for? 
Pineapple: stopping people from itching or getting itchy eyes 
Beth: do you like it? 
Pineapple: yeah because I’m allergic to cats and they make my eyes itchy” 
(Pineapple, Girl, 5-7yrs, Rainbows 1). 
 
Here, Pineapple explains how she knows a medicine, Piriton, and how this medicine 
helps by “stopping people from itching or getting itchy eyes” (Pineapple, Girl, 5-7yrs, 
Rainbows 1). She then goes on further to explain how she “went to Mark’s and they 
have a little dog and I’m allergic to dogs and my eyes went a little bit funny, and then 
I had Calpol” (Pineapple, Girl, 5-7yrs, Rainbows 1). The belief she holds of medicines 
helping appeared to come from the association of her experiencing itching when she 
is around cats and dogs and how, in her experience, Piriton and Calpol has helped 
her eyes stop being itchy. Although she has made a link between Calpol and it helping 
her itchy eyes, Calpol’s use is not intended to help itching. However, its pain relief 
characteristics and her perception that medicines help could have led to this link.  
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A similar view is also expressed by Alex, who explains why an “acceptable” medicine 
for him would be Calpol because “it also helps me” (Alex, Boy, 8-12yrs, Hospital). Alex 
explains that he would choose Calpol and, although many other children have 
explained that they like the “strawberry Calpol” (Boy, 5-7yrs, School 1) referring to its 
taste, Alex explains he would choose it because it helps him. Again, the view that 
‘medicine helps’ was initiated by the child, and perhaps highlights that not only is the 
efficacy of the medicine a priority for the child, but also positive past experiences with 
medicine are key to facilitating a child’s positive belief system and their constructed 
knowledge about medicines. Another child from the museum group also drew a 
medicine and explained that this would be the best medicine to create because it would 




Figure 5.4: Image of soothing, orange medicine (Boy, 8-12yrs, Museum) 
Building on this, a distinguishing feature relating to the acceptability of medicines was 
that not only did children know that medicine helps them, but a number of children 
explained that they “accept medicine because it helps me” (Girl, 8-12yrs, Brownies) 
and therefore the driver for them accepting medicine was the knowledge that it helped 
them: 
“I accept medicine because it helps you when you’re poorly” (Girl, 8-12yrs, 
Brownies)  
 
The belief children hold that medicine helps was also used to explain how children can 
weigh up the advantages and disadvantages of taking medicine. Children are 
observed accepting the negative aspects of medicine, such as taste, in the belief that 
it will be beneficial for them. Alex talked of a medicine he was given when he was 
being put under general anaesthesia at the hospital, and although he mentioned that 
it didn’t taste nice, he knew that it was given to him to help and therefore accepted it.  
 
Ingredients: Soothing smells, orange flavour, 
well serum, round, hard 
 
“Dear Dr. Diamond… I have chosen this 
meadeacene [sic] and its ingredience [sic] 
because it sounds helpful” 
 
 175 
“even if it tastes horrible. Like when I went to sleep on the 23rd the taste in my 
mouth was horrible- but it helps” (Alex, Boy, 8-12yrs, Hospital).  
 
5.2.2.1 Medicines help you join in  
As well as medicine helping children to get better and feel better, they also talked 
about how medicine helps children to take part or join in. Some conditions make it 
difficult for children to take part in typical daily routines at school or with friends. This 
can lead to isolation for the child, being unable to do the same things that their friends 
do. In his interview, Alex explained that his medicine helps him by allowing him to take 
part in the daily mile, a school activity that he could not take part in without his 
medicines: 
 
“Yeah and it also helps me. Usually I wouldn’t be able to walk in the mile, but I 
can with it… in school. My friend, well best friend actually, he usually finishes it 
really quick cos he’s one of the fastest in the class” (Alex, Boy, 8-12yrs, 
Hospital) 
 
To provide context for the significance of this, the aim of the daily mile is to improve 
physical, social, emotional and mental health, and wellbeing of children. Alex explains 
how his ability to join in with the daily mile is because of his medicines, he explains 
that it helps him take part and be with friends. The notion that Alex attributes his ability 
to join in the daily mile to his medicines is crucial in understanding the extent of the 
help provided by his medicines.  
 
5.2.2.2  Adults help children with medicines 
Overall, aside from specifically talking about adults helping them with medicines, the 
children talked more generally about the ways in which adults help them when they 
are poorly or hurt:  
 
“do you know a doctor called Doctor [name]? He helps me… he always helps 
me!” (I, Boy, 8-12yrs, School 2).  
 
This was also reiterated in another workshop where the children talk about how 
Popcorn’s mum helped another child when they hurt themselves: 
 
Rosie: isn’t your mum a doctor Popcorn?” 
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Popcorn: Yeah my mum’s a doctor… a school nurse, my mum is a school nurse! 
How did you know?! 
Rosie: my brother broke him [sic] finger and your mum had a look at it… 
because I saw it!” (Rosie and Popcorn, Girls, 5-7yrs, Rainbows) 
 
Adults were also talked about as helping with the various processes associated with 
medicines administration. One boy describing how her mother used a syringe to get 
liquid medicine out of a bottle explained “my mum put it on a um... a special thing, you 
can get orange or purple, and then you slide it into the bottle… yeah you slide it into 
the medicine and then you just slide it into your mouth” (Boy, 5-7yrs, School 1). 
Another boy explained that adults were helpful as children “would have to have an 
adult to get the water for them” (G, Boy, 8-12yrs, School 2) if they were taking a tablet. 
Another boy builds on this, stating that is “because children aren’t allowed to get them 
on their own they have to have an adult” (I, Boy, 8-12yrs, School 2). However, a boy 
who frequently takes medicines for Attention Deficit Hyperactivity Disorder responds 
to this explaining that although at school he can use his medicine on his own, at home 
he needs help with his medicines from an adult: 
 
“yeah, they are, I do. I do when I’m in school. Just at home I have no clue where 
it is, so nanny has to get it for me at home” (G, Boy, 8-12yrs, School 2). 
 
The idea that children need help from adults with their medicine administration 
depending on the environment they are in is one which was mentioned a number of 
times and is important to highlight. When asked if it would be better if a child could 
take their medicine on their own some agreed that this would vary with one boy 
explaining that they: 
 
“would still need help, I need help but sometimes I don’t because I can just puff 
it on my own without the inhaler thing (spacer) like I have to do… erm, like 
before I have my football match today. I have to do my own blue one because 
I play football” (Boy, 5-7yrs, School).  
  
5.3 What Helps Improve the Acceptability of Medicines to Children? 
Throughout the interviews and workshops, children spoke positively about many 
factors relating to medicines. The factors found to facilitate acceptance fall into two 
sub-ordinate themes: Aspects of Medicine that Children Like, Love or Believe are Fine, 
or; Practical Factors that Influence the Acceptability of Medicines.   
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5.3.1 Aspects of medicines that children like, love or believe are fine  
All children talked about things they liked, loved or believed were fine about medicines; 
typically, these aspects related to taste or smell, and/or the form of the medicine. 
 
5.3.1.1 The taste and smell of medicines 
The idea that the acceptability of a medicine “depends on flavour” (James, Boy, 8-
12yrs, School 1) was common. Mainly for those children who did not take medicines 
as part of a daily routine “what it tastes like is important” (Girl, 5-7yrs, School 1). 
Interestingly, one of the main reasons for this importance was that “it might be the 
wrong medicine, you need to check”, with the suggestion being that the taste of the 
medicine would enable the child to identify the ‘right’ medicine.  
 
Some children thought that medicines with no taste would be a good idea and that an 
acceptable medicine would be one “you wouldn’t taste” (Girl, 8-12yrs, Brownies). 
Inhalers were often talked about positively as they had ‘no taste’: 
“If you swallowed it your tummy wouldn’t feel any taste… I know because it’s 
just only air that’s going into your mouth. And cos in your tummy is like nothing. 
It just taste like air… it taste like anything but not taste. It tastes good, I like it” 
(Girl, 5-7yrs, School 1). 
 
However, children also talked about liking or loving the taste of some medicines, 
specific medicines such as Calpol were talked about as “tasting nice” (Alex, Boy, 8-
12yrs, Hospital). When asked what would improve Calpol, children explained that 
“nothing” (Girl, 5-7yrs, School 1) would make Calpol better. A number of children 
referred to wanting the taste of Calpol specifically, one child from the Museum drew 
their medicine (Figure 5.5.) explaining that it would ‘have the taste of strawberry calpol 
because I like the taste of calpol [sic].’  
  
 
Figure 5.5: Image of 'easy to swallow' tablet (Girl, 8-12yrs, museum) 
Ingredients: (general helpful medicine stuff), 
strawberry flavour 
 
Dear Dr. Diamond… I have chosen the 
shape and size as it would be easy to 
swallow. It would be wite and have the taste 
of strawberry calpol because I like the taste 
of calpol [sic].  
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Other children suggested that the flavour “strawberry or any other flavour like that” 
(Girl, 5-7yrs, School 1) would be good for other medicines; one boy explained that 
they: 
“take two (medicines), one is a gummy bear and one is these (tablet)… it’s like 
a peppa pig and it taste like strawberry! No, my peppa pig taste like raspberry… 
I like both of them” (I, Boy, 8-12yrs, School 2). 
 
“Strawberry” (Girl, 5-7yrs, Rainbows) was the taste that the children commonly talked 
about as one they loved: “I love them ones because they taste like strawberries” (Boy, 
5-7yrs, School 1). When asked what would make medicines better, it was suggested 
that “if you could make it like, make it, it would be like… the ingredients would be 
strawberries!” (I, Boy, 8-12yrs, School 2). This was common in all groups, particularly 
within the pictures from the museum, with most of the children explaining that they 
would choose a strawberry flavour for their medicines (Figure 5.6).  
  
Figure 5.6: Image of rainbow medicine (Girl, 5-7yrs, museum) 
 
Children also talked about liking orange tasting medicines “I take it orange and I did 
actually like it” (Girl, 5-7yrs, School 1). However, a couple of children associated the 
taste of strawberry medicines to spice, which negatively affected their opinions as can 
be seen in the following conversation between three children:  
 
“Boy: it wasn’t like normal strawberry; it was like it was spicy 
Girl: that’s why I didn’t like it 
Boy: too spicy” (Boy and Girl, 5-7yrs, School 1) 
 
The perception that medicine was “a bit spicy” (Boy, 8-12yrs, School 1) originated from 
children’s experience with medicine, whether it was through their own experience with 
taking medicines, or whether they observed someone else taking medicines and drew 
Ingredients: lemon and lime flavouring, 
strawberry dust, rainbow, red water, ruby liquid, 
snow, ice, sweet orange and mango scent 
 
Dear Dr. Diamond… I chose these ingredient 
because lemon and lime taste great. Strawberry 
also tastes delisios [sic]. 
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conclusions that because their “mum takes one and drinks water because it’s like, 
spicy” (Girl, 5-7yrs, School 1).  
 
Apart from taste, children talked about the impact of smell and this was often linked to 
the flavour such as “mine smells like… strawberry” (Boy, 5-7yrs, School 1). Explaining 
that “sometimes they [medicine] can be smelly… they can smell nice and not nice” 
(Girl, 5-7yrs, School 1). The smell of strawberry was generally talked about positively, 
one girl explained that they “have a medicine at home and it smells like strawberries 
and I love it” (Girl, 5-7yrs, Rainbows 1).  
 
5.3.1.2 The feel of the medicine 
Children also talked about the feel of medicines and explained that if they were 
designing an acceptable medicine “it would not be bumpy” (Girl, 8-12yrs, Brownies) 
and that “it would be smooth” (Girl, 8-12yrs, Brownies). Another child reiterated this 
idea and explained that an acceptable medicine “wouldn’t have like bits in it” (Girl, 8-
12yrs, Brownies). Mouthfeel was thought to be important to some children at the 
museum who drew a picture of a medicine with a spoon (Figure 5.7). She explained 
that the most important thing was that it was “esy to swally [sic]”. The idea that a 
medicine should be easy to swallow was also reiterated by another child from the 
museum who explained that they ‘have chosen the shape and size as it would be easy 
to swallow’ (see Image 5.8). However, other children did not think that it being easy to 
swallow was as important as the imperative was just to take the medicine: “because 
you need to swallow it, so that doesn’t matter because you just swallow it without 
feeling. You just have to…” (Girl, 5-7yrs, School 1). 
 




Figure 5.8: Image of 'easy to swallow' medicine (Girl, 5-7yrs, museum) 
 
5.3.1.3 Real, normal or adult medicines  
Children’s perception of the medicines also seemed to be a factor influencing how 
acceptable they found them. A lot of children expressed positive views about taking 
‘real’ tablets, Bella explained “I love them... I love real tablets!” (Bella, Girl, 5-7yrs, 
Rainbows 1). Real tablets were talked about in a number of different ways; some 
children talked about real tablets as those which they had observed adults taking, 
others referred to the form and colour of real medicines in comparison to a typical 
children’s medicine (e.g. a white tablet compared to a chewy orange or purple 
medicine).  
 
Although Bella did not expand on what she meant by ‘real tablets’ when prompted, the 
idea that children liked medicines because they were real was common. Some 
children perceived real tablets as being like those they had observed their parents and 
other adults taking: 
“what my mum does, she takes two tablets when she’s poorly” (Girl, 5-7yrs, 
School 1)  
 
Other children in the same workshop added “that’s what my mum does” (Girl, 5-7yrs, 
School 1) … “my dad and my mum do that too” (Boy, 5-7yrs, School 1). Additionally, 
children explained that they “saw my grandad and my nan take them (tablets). I’ve 
saw my mum and my dad take them” (Girl, 5-7yrs, Rainbows 2). Children’s perceptions 
of these ‘real’ medicines were generally positive, with one boy explaining that he 
wished he “could taste them (capsules) one day” (Boy, 5-7yrs, School 1).   
 
Children associated the idea of ‘adult medicines’ with the colour and form of a ‘normal’ 
medicine: 
“I have chosen the shape and size 
as it would be easy to swallow” 
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“I think… tablets? Um... look like white like normal tablets” (Boy, 5-7yrs, School 
1).  
In contrast to these ‘real medicines’, children distinguished between medicines made 
for adults and medicines made specifically for children: “it was like a kid’s one… but 
not like the orange one, like a purple” (Girl, 5-7yrs, Rainbows 2). 
 
As well as distinguishing certain features such as colour and form, children also 
distinguished between adult and child medicines by the mode of delivery (whether the 
tablet was to be swallowed whole or chewed). When showed a picture of a white round 
tablet, one child explained: 
“you know like you showed the tablet you showed, you don’t chew it do you? 
You just swallow it… but my peppa pig gummy bear you can’t swallow it you 
have to chew it” (I, Boy, 8-12yrs, School 2). 
 
However, when asked if they had ever taken a tablet, one child explained “no because 
sometimes they’re… because some are for adults…” (Girl, 5-7yrs, Rainbows 2). 
 
5.3.1.4  Not really like medicine, sometimes like sweets 
In contrast to the perceptions of ‘adult’ or ‘real’ tablets, chewable tablets were 
mentioned frequently as a ‘child’s medicine’, and were also talked about positively 
across the workshops: 
 
 “I have one for health like, it has um vitamins in them, and they are quite nice” 
(James, Boy, 8-12yrs, School 1).  
 
Talking about chewable tablets some children explained that they “love them ones” 
(Girl, 5-7yrs, School 1), explaining that they “like them… I think I have vitamin D and 
vitamin C” (Girl, 5-7yrs, School 1). The way that children’s perception of medicines 
can improve acceptability can be noted where children believe that some medicine is 
“not really like medicine” (Boy, 5-7yrs, School 1). This was explained by one child 
where she did not “even realise they’re vitamins, you can only tell on the box” (Girl, 5-
7yrs, Rainbows 1).  Other descriptions of chewable tablets included being “kind of like 
gummy bear things but they’re like jelly babies” (Girl, 5-7yrs, Rainbows 1), like 
“chocolate” (James, Boy, 8-12yrs, School 1), or “like chewing gum” (Joy, Girl, 8-12yrs, 
School 1). When asked to create their own medicines, at the museum, children 
continued the sweet tasting theme often drawing something that “makes me happy” 
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for example, a cheerful unicorn, a smiling gingerbread person or a dinosaur in the 
images (Figures 5.9-5.11) and linked these to sweet tastes and treats such as 
cupcakes, sweets , chocolate and gingerbread. Whilst these sweet-like perceptions 
are different for most children e.g. a jelly baby compared to a gingerbread man; the 
children’s associations were generally positive.  
 
 
The children made associations between some medicines and sweets and many 
medicines were described as looking “like sweets” (Girl, 5-7yrs, Rainbows 1) or 
described as specific sweets such as “like little gummy bears” (Boy, 5-7yrs, School 1) 
or “like a peppa pig gummy bear” (I, Boy, 8-12yrs, School 2). Some children explained 
that they “pretend they [medicines] are like sweets” (Girl, 5-7yrs, Rainbows 1). The 
idea that medicines were like sweets was also talked about in relation to the efficacy 
of the medicine in that efficacious medicine would not be horrible to take: 
 “It would make you better when you are poorly, and it would be like a 
sweet so that it’s not horrible, it wouldn’t be horrible” (Anika, Girl, 8-
12yrs, Brownies). 
The idea that sweet-like medicines would improve the acceptability of medicine was 
also talked about when children were asked to use their imaginations to develop their 
very own medicine. One child explained that: 
 
“I love chocolate gingerbread 
men. Chocolate is easy to eat and 
tastes nice” 
 “Cupcakes because it tastes 
nice and makes people 
better” 
The dinablet- because I like 
dinosaurs and sweets” 
   
Figure 5.11: Image of unicorn 
medicine (Girl, 8-12yrs, 
Museum 
Figure 5.10: Image of dinosaur 
medicine (Boy, 5-7yrs, museum) 
Figure 5.9: Image of gingerbread-




“one thing that would make medicine better and make younger children like it 
is if it was a bit more nicer and not yucky” (Anna, Girl, 8-12yrs, W6, Line 23). 
 
Figure 5.12 shows an “iTablet” designed to taste like a gummy bear and “phone 
shaped because everyone is always on their phone”. 
 
 
Figure 5.12: Image of iTablet (Boy, 8-12yrs, museum).  
 
Other children talked about the ‘sweetie’ flavour being important and Jo-jo talked 
specifically about how having “a lolly-pop flavour” (Jo-jo, Girl, 5-7yrs, Rainbows 1) 
would be the best for her medicine. The sweets idea was continued with Katie 
describing an ideal medicine with “sweeties inside it… the sweets are inside the 
medicine… and at the bottom there’s a lolly pop and you get to eat the lolly pop! (Katie, 
Girl, 5-7yrs, Rainbows 2). Children at the museum frequently drew sweet-like 
medicines, one child explained they created the ‘roll on bubble-gum to fool kids so 
they would take it’ (Girl, 8-12yrs, Museum) (see Figure 5.13 for Roll on Bubble-gum). 
 
Despite the idea that “you can pretend they are like sweets” (Girl, 5-7yrs, Rainbows 
1), the children knew “they are not actually” (Girl, 5-7yrs, Rainbows 1) sweets. A couple 
of children explained that even though “they look like sweets… they’re not” (Girl, 5-
7yrs, Rainbows 1). Another explained: 
 
“Also, my mum said don’t take them from strangers because you think they’re 
sweets but they’re really not” (Girl, 5-7yrs, Rainbows 2).  
 
Ingredients: a gummy phone  
 
Dear Dr. Diamond… my medicine is phone shaped 
because everyone is always on there phone. It will 
taste like gummy bears. It feels soft and squishy 
and will smell really fruity. The size would be about 




Children also had an awareness of the safety around medicines and accepting 
medicines from strangers.  
 
5.3.2 Practical factors that influence the acceptability of medicines 
Children also talked about the practical aspects of medicines that they believe are 
important to medicine acceptance. When asked which aspects of medicines were 
important, the children talked about ease of use and appearance as key factors. Alex 
summed things up explaining: 
 
“umm mainly how easy the medicine is to use, the size of the medicine, it’s just 
really them three… actually it might be how it feels in my mouth as well” (Alex, 
Boy, 8-12yrs, Hospital) 
 
Alex also thought of an additional factor, that he did not say out loud, which was ‘how 
often you have to take the medicine’. These factors were reported by other children 
across the workshop groups and interviews and will be discussed below.   
 
5.3.2.1  How easy medicines are for children to use  
The idea that it is important that medicine is easy to use was a common finding. When 
asked to rank the factors from most important to least important, children across all 
age groups and settings, explained that they “would put it that’s how easy it is to use” 
(Boy, 5-7yrs, School 1) as the most important or “that’s the second importance” (Girl, 
5-7yrs, School 1).  
 
Whether medicine was easy to use depended on whether the medicine required any 
other aid to take it (e.g. a glass of water or a spoon) and whether the child could take 
the medicine on their own or if they needed help from someone else such as parents 
and grandparents (section 5.2.2.2). When children discussed whether a medicine 
would be easier to use if taken on a spoon or a syringe most children explained that a 
syringe was “better than a spoon because then you just don’t have to like pour it into 
the spoon and you can just suck it out of the syringe” (Boy, 5-7yrs, School 1). Having 
the appropriate tools such as their preferred tool to dispense the medicine (e.g. a 
syringe) increased the acceptability of the medicine as it prevented issues such as 
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spilling the medicine and ensured you got the “right amount” of medicine as James 
clearly explained: 
 
“Syringe because, cos with a spoon it’s quite easy to spill. And if you spill some 
you might not get the right amount” (James, 8-12yrs, School 1). 
 
However, although using the syringe was generally the preferred method, children also 
considered that taking medicine from a syringe could cause issues, as it could be 
difficult to “fit the syringe in it [bottle]” (Girl, 5-7yrs, School 1). James, who noted the 
potential problem with fitting the syringe, also noted that both spoons and syringes 
had their own challenges:    
 
“Umm if it was a syringe it’s quite hard and if it’s a spoon it’s hard. Because you 
might spill the spoon and you might not get the syringe in right” (James, Boy, 
8-12yrs, School 1). 
 
Children at the museum who were asked to create a new medicine also considered 
how easy the medicine would be to use, often drawing their liquid medicines along 
with a spoon. However, some children created new forms of dispensing medicine that 
they believe would be easier or more appropriate to use, such as Roll-on Bubblegum 
medicine (Figure 5.13) 
 
 
Figure 5.13: Image of Roll-on Bubblegum medicine (Girl, 8-12yrs, museum). 
 
The idea that adult help could improve acceptability by making the medicine easier to 
use was discussed by many of the children. Although this has been explored in section 
5.2.2.2, it is important to bring attention to it here to show how not only can adults help, 
but also that this help is pivotal for a lot of children feeling competent or comfortable 
taking their medicines.   
Ingredients: strawberry, bubblegum flavouring, normal 
medicine stuff 
 
Dear Dr. Diamond… Its roll on because it’s easier than 




Boy: Maybe that one’s it, how easy is the medicine maybe, that one is number 
1 too 
Beth: How easy it is to use? So, is it important that you can take your inhaler 
on your own? 
Boy: Not for me because I can’t do it 
Beth: Would it be better if you could use it on your own? 
Boy: I would still need help, I need help… (Boy, 5-7yrs, School 1) 
 
For children who take medicines as part of a regular routine, it was common to see 
that the perceived acceptability and influence of ease-of-use were dependent on the 
particular context or situation. Typically, at school they have to take more responsibility 
for their own medicine administration whereas at home their parents take on the 
responsibility.  
 
5.3.2.2 What the medicines look like  
There was an overall agreement across the workshops and interviews that “the 
colour… and what it looks like” (Girl, 5-7yrs, School 1) were the least important factors 
influencing the acceptability of a medicine. This is highlighted in a conversation 
between two children in one of the age 5-7-year group workshops: 
 
Boy: that one’s deffo got to be number 6 
Beth: which one?  
Boy: that one, what it looks like that doesn’t even occur 
Girl: colour?? colour??! That’s not important that, that’s number 6 that, colour 
(Girl and Boy, 5-7yrs, School 1) 
  
Some of the older children from other workshop groups further reiterated that the 
colour of medicine was not important, and this was summed up by Brooke who said 
“mm nope not important” (Brooke, Girl, 8-12yrs, School 1). The idea that colour was 
“not really” (Alex, Boy, 8-12yrs, Hospital) important was observed both in children 
taking medicines more frequently and those inexperienced in taking medicines, with it 
being described as “not even a little tiny bit important” (Boy, 5-7yrs, School 1). 
 
However, the images that children drew were almost all colourful, or presented in 
colourful packaging. Within the museum images, children explained they had designed 
their medicines with certain colours because they like it, or because it was their 
favourite colour. Children associated certain colours with medicines they had 
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experience with such as “medicine is green” (Boy, 8yrs, Museum) and “purple because 
this is the colour of the medicine at home” (Boy, 5yrs, Museum). Additionally, children 
associated colours with certain tastes and smells, one child explained they would 
choose an orange colour because “it looks like honey” (Boy, 6yrs, Museum), or yellow 
because “it like banana [sic]” (Girl, 7yrs, Museum).  
 
Similarly, there were some conflicting ideas about the importance of what the 
medicines look like. Despite most children believing that appearance was not of high 
importance to acceptability, some children considered that appearance might be 
important if that is how you identify your medicine. When asked whether how the 
medicine looked like was important, one child explained: 
 
“maybe if you buy the wrong kind of medicine and you eat it without realising 
you might not be well and you might need a different kind of medicine” (Girl, 5-
7yrs, School 1). 
 
It is interesting to note that this comment did not concern the influence of appearance 
on perceived acceptability, but rather the appropriateness of the medicine to treat the 
health issue. The child had considered that if the medicine did not look a certain way, 
there was a chance of getting confused and becoming sick if they took the wrong 
medicine by mistake.  
 
However, some children associated the look of a medicine with what they thought it 
might taste like. Capsules were described as looking “even nicer than ice cream 
because they look, they don’t even look spicy” (Girl, 5-7yrs, School 1), another child 
continued explaining that: 
 
“It looks like they don’t have spice in them because the tablets look like they 
have teeny weeny bits of sugar on them, and it [capsule] doesn’t look like that!” 
(Boy, 5-7yrs, School 1).  
 
Therefore, the perception of medicine appearance could improve acceptability, with 
one child explaining that they “wish they could taste them one day” (Boy, 5-7yrs, 
School 1). The idea of certain medicines appearing more acceptable than others was 
also identified in the pictures drawn by the children at the Museum. In Figure 5.14 a 
girl has drawn two, small capsule-like medicines and she explained that they were “to 
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swallow, they would taste like bubble-gum because it’s so tasty. Red to match bubble-
gum” (Girl, 8-12yrs museum).  
 
Figure 5.14: Image of bubble-gum capsules (Girl, 8-12yrs, museum). 
As seen in other sections, children’s perception seems to be a strong indicator of how 
acceptable a child considers medicines.  
 
5.4 What Reduces the Acceptability of Medicines to Children?  
Children generally used “hate” (Alex, Boy, 8-12yrs, Hospital) or “dislike” (James, Boy, 
8-12yrs, School 1) to describe certain unpleasant or difficult characteristics of 
medicines such as size, horrible taste or its disruption to daily routine. These created 
both practical and/or psychological barriers influencing the acceptability of medicines. 
Practical barriers included disruption to routine, side effects and some of the physical 
characteristics of the medicines such as mouth feel or tendency to disintegrate as well 
as a nasty taste. Medicines were often described as being “horrible” (Popcorn, Girl, 5-
7yrs, Rainbows 1) and “disgusting” (Pineapple, Girl, 5-7yrs, Rainbows 1) and children 
explained that they “didn’t like medicine” (Lex, Girl, 5-7yrs, Rainbows 1) because it 
“tasted so horrible” (Popcorn, Girl, 5-7yrs, Rainbows 1) or it “turns into little bits” (G, 
Boy, 8-12yrs, School 2) or was “oversized” ” (Alex, Boy, 8-12yrs, Hospital). 
 
Psychological barriers related to worries and fears around taking medicines, 
sometimes these two factors were independent and other times physical barriers 
created psychological barriers, and vice versa.  
 
5.4.1 Practical barriers 
5.4.1.1 How many times and where you have to take your medicine  
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The disruption caused by some medicines was an important barrier for some children 
who thought that “how many times you have to take medicine that’s important” (Girl, 
5-7yrs, School 1). Children at the hospital were most likely to talk about how frequency 
and location was important, both Belle and Alex, despite knowing that their medicine 
was necessary, did not like that they had to go into hospital to have it and “basically 
miss school or weekends” (Alex, Boy, 8-12yrs, Hospital). 
 
“umm because I have to take megatrexate [sic] every week I don’t really like it, 
‘cos that means I’d have to come into here [hospital]” (Alex, Boy, 8-12yrs, 
Hospital) 
 
5.4.1.2 The feel of the medicine in your mouth 
A frequently mentioned reason was the feel of the medicine in the child’s mouth, a 
factor addressed in research as mouthfeel. This aspect of acceptability focussed on 
liquid and tablets (including chewable tablets). The idea that the way medicine feels 
can influence the acceptability of medicine was mentioned by some of the children. 
Alex explained how “…actually, it might be how it feels in my mouth as well cus I don’t 
want it feeling all rough and not able to swallow” (Alex, Boy, 5-7yrs, Hospital).  
 
The disintegration of tablets could reduce their acceptability, with ‘G’ (pseudonym) 
noting “when the tablet melts it turns into all little bits and it’s horrible” (G, Boy, 8-12yrs, 
School 2). The idea that the medicine breaking down into “little bits” was a prominent 
issue, as ‘G’ explained: 
 
“…but when my medicine that I take melts in my mouth it tastes like, it just taste 
like someone’s pooed in it ……. Yeah it taste horrible, so you have to have 
water and make sure it doesn’t start to melt” (G, Boy, 8-12yrs, School 2).  
 
The theme of disruption was again present, with the same child explaining that his 
medicines needed to be taken with a drink to help him swallow it or protect him from 
the bad taste when the tablet started to disintegrate.  He explained that even though 
his tablet is “made out of strawberries, when my medicine that I take melts in my mouth 
it taste… horrible” (G, Boy, 8-12yrs, School 2) which means “you have to have water 
and make sure it doesn’t start to melt”. The inconvenience for ‘G’ is to remember his 
medicines three times a day as well as “my water” (G, Boy, 8-12yrs, School 2), and 
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that he has to “have an adult to get the water” (G, Boy, 8-12yrs, School 2) for example, 
“nanny has to get it for me at home” (G, Boy, 8-12yrs, School 2). As well as causing 
an additional disruption that he needs to remember his medicine and his water, having 
to rely on an adult’s help also reduces his self-efficacy and ability to use his medicines 
on his own.  
 
Interestingly, one girl who only took medicines for minor coughs/cold and allergies, 
explained that mouthfeel was not important as the imperative was to take the medicine 
“because you need to swallow it, so that doesn’t matter because you just swallow it 
without feeling. You just have to…” (Girl, 5-7yrs, School 1). She views taking medicine 
as something you just have to do and therefore does not believe that the feel of 
medicine is important. Whilst this is interesting, her belief that “you just have to” 
perhaps reflects her experience with medicine, and with what she has been told when 
she has needed to take medicines.  
 
5.4.1.3 Size or amount 
Children talked about how the amount or “the size of the medicine is important” (Girl, 
5-7yrs, School 1) to acceptability. Many children talked about their previous 
experiences with medicines and how these experiences have led to their beliefs about 
what makes a medicine an acceptable size. Typically, children disliked medicine being 
too big or having to take too much/many and both aspects were seen as a negative 
factor in terms of acceptability. James summed up his dislike of tablets by mentioning 
both the size and number of tablets they had once taken which has led him to having 
an aversion for tablets:  
 
“I don’t really like getting the tablets to swallow because once, I think, once I 
had this really bad cold and they [the tablets] were like that big [showing me 
with his finger] and I had to take eight at a time” (James, Boy, 8-12yrs, School 
1) 
 
The idea that the size or amount of the medicine can cause an issue for children was 
reiterated by another child who explained that “if you have it oversized it can make you 
feel ill if you have too much medicine” (Alex, Boy, 8-12yrs, Hospital).  
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 Although ‘volume issues’ such as the size or amount of the medicine were seen as 
problematic by some children, emotional and psychological responses such as worries 
and fears, were also important to the overall acceptability. These feelings were often 
coupled with a physical and/or behavioural response when taking medicines such as 
“I choke a lot… because I don’t like it” (Girl, 5-7yrs, School 1) or kicking off when taking 
medicines too frequently, as Alex explained: 
 
“Sometimes you can start to kick off…I usually do that because I haaate 
megatrexate (sic) and taking it” (Alex, Boy, 8-12yrs, Hospital).  
 
Alex’s behavioural response of kicking off is in retaliation to having to take that specific 
medicine, because of the frequency of having to take it, and the fact that he has to go 
into hospital to take it which in effect means he has to miss school or his weekends to 
have the medicine. His kicking off would suggest that this disruption to his daily life 
causes an issue in the acceptability of this medicine for him. Although volume factors 
and affective (emotional and psychological) responses overlap, the emotional and 
psychological responses are addressed discretely in the following sub-theme. 
 
5.4.2 Psychological barriers 
5.4.2.1 Worry  
Children talked about worry in relation to taking medicines. These worries related to 
the incorrect administration of medicines, negative side effects of taking medicines 
(such as being sick and choking or the pain associated with injections), and the 
appearance or perception of the medicines. In one workshop where some of the 
children were talking positively about tablets and how they enjoy taking their vitamins, 
Doo-doo who had previously talked about how taking medicines was “scary” 
exclaimed “Why does everyone love taking tablets?! I hate them!!” (Doo-doo, Girl, 5-
7yrs, Rainbows 1).  
 
Common worries were related to side effects, including coughs, vomiting and that “you 
might even be sick” (Girl, 5-7yrs, School 1). James explained a physical side effect 
that “some of my inhalers after I’ve had them I come up with a cough” (James, Boy, 8-
12yrs, School 1). Whilst the inhaler is used to help his health condition it appears that 
an issue for this child is that he “stops wheezing and starts coughing” (James, Boy, 8-
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12yrs, School 1).  This worry or apprehension was typically related to what the child 
already knew about medicines, their actual experience with medicines or their 
experience of being told about medicines. Children expressed various worries about 
swallowing a tablet whole. One worry was that doing this would make them vomit: 
 
“if you swallow it and then if you like swallow it whole, you might be sick in case 
it gets stuck in your bones” (Boy, 5-7yrs, School 1). 
 
Other worries included the danger of having a tablet stuck or choking on a tablet, and 
another child explained it was “because you might choke, if you don’t chew it you might 
choke” (Girl, 5-7yrs, School 1). Their response to this danger was to chew the tablet. 
However, this belief might cause problems if there was a time where they were asked 
to swallow a tablet whole.  
 
The fear of feeling unwell was also associated with taking too much medicine: 
 
“yeah cos if you have oversized… it can make you feel ill if you have too much 
medicine” (Alex, Boy, 8-12yrs, Hospital). 
 
Children also expressed the worry that “if you buy the wrong kind of medicine and you 
eat it without realising you might not be well” (Girl, 5-7yrs, School 1) or “if you pick the 
wrong medicine… and you have it you might be sick” (Girl, 5-7yrs, School 1), this is 
an important consideration in understanding why children might be opposed to taking 
medicines. Children believing that their medicine is the right medicine for them seems 
an important consideration in making a medicine acceptable. The potential influence 
of past experiences is important to understand as it may explain why some children 
might have worries about certain medicines being associated with being sick or unwell: 
 
“sometimes actually, when you have medicine it might actually make you sick, 
I can remember that from in an assembly a long time ago…” (Boy, 5-7yrs, 
School 1). 
 
Another worry that was mentioned by children was about having an overdose. This 
was mentioned by James who did not have a lot of experience with medicines, and so 
it is perhaps indicative that their lack of experience with medicines leads to them 
becoming worried when they do take it:  
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“I just get worried about having an overdose every time I use it…” (James, Boy, 
8-12yrs, School 1). 
 
Some of their worries were associated with administration or use of medicines and this 
worry has an impact on the factors the children believed to be important in the 
development of medicines. James explained that liquid medicines are “quite hard. 
Because you might spill the spoon and you might not get the syringe in right.. and it 
might spill everywhere” (James, Boy, 8-12yrs, School 1).  These worries reflect the 
child’s altering belief in their own abilities to perform the task of administering 
medicines on their own, some children are required to take responsibility for their own 
medicines at school or where their primary caregiver cannot help. This is therefore 
something to consider when evaluating the factors that influence the acceptability of 
medicine. 
 
In contrast to the beliefs that children hold (Section 5.3.2) that medicines “makes you 
not get really sick” (Girl, 8-12yrs, Brownies) the worries expressed about overdose, 
choking and oversized medicines highlight an alternate view to consider when 
evaluating the acceptability of medicines.  
 
5.4.2.2 Fear  
The main cause of fear in children in the study was medication given by “needle”, 
although, some children expressed fear about taking tablets with Pineapple explaining 
that taking tablets was “scary” (Pineapple, Girl, 5-7yrs, Rainbows 1). Fear of a 
medicine influenced the acceptability of a medicine.   
 
The majority of children showed an aversion to needles, saying things such as “don’t 
even show me that” [picture of a needle] (Lex, Girl, 5-7yrs, Rainbows 2), “definitely 
not, no way hosay a needle!” (Boy, 5-7yrs, School 1) and “I do not want an injection” 
(Girl, 5-7yrs, School 1). The main reason for children finding needles scary related to 
their appearance, with children explaining that they “don’t like the pointy bits” (Doo-
doo, Girl, 5-7yrs, Rainbows 1) and that the reason they did not like them was because 
they were “sharp” (Popcorn, Girl, 5-7yrs, Rainbows 1). In order to explain how sharp 
needles were, a few children used figurative speech to describe how they viewed 
them. One child explained it by showing me a small space between her thumb and 
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pointing finger, “if it was likeee… that… it wouldn’t really hurt would it?... like that 
wouldn’t hurt” (Girl, 5-7yrs, School 1). She continued and showed me two pencils, one 
with a sharp point and the other blunt (Figure 5.15) “if it was like that (the blunt pencil) 
it wouldn’t really hurt you, it would be really really fine wouldn’t it? Because it wouldn’t 
be sharp” (Girl, 5-7yrs, School 1). 
 
 
Figure 5.15: Image of blunt pencil and sharp pencil (Girl, 5-7yrs, School 1) 
 
The pencil analogy was also used in another workshop where ‘EV’ explained that “it’s 
like a sharpened pencil… it’s pointy” (EV, Girl, 5-7yrs, Rainbows 1). Needles were also 
described as scary “because it like, looks like a mountain top but smaller” (Boy, 5-7yrs, 
School 1) and “yeah it looked spikey like that” (Girl, 5-7yrs, School 1). The way that 
needles look seems to be the main cause of fear in children in this study, with the 
belief that if you “have to have a needle… it really hurts” (Girl, 5-7yrs, School 1). Most 
children talked about how needles are “painful” (Girl, 5-7yrs, Rainbows 1), and 
Pineapple explained the cause of this pain is “because of the needle thing” (Pineapple, 
Girl, 5-7yrs, Rainbows 1).  
 
Some children had personal experience with needles and vividly recalled this:  
 “one day I had an injection when I was about 2 or 3 and it was right there 
[pointing to his arm] and I screamed like this [child demonstrated by 
‘screaming’, showing his mouth wide open and eyes tightly shut but with no 
noise]” (Boy, 5-7yrs, School 1). 
 
Other children, like Millie, had experience of a family member with a needle “my mum 
had to have one on her arm” (Millie, Girl, 5-7yrs, Rainbows 2).  Depending on whether 
their experience of injections was positive or negative, seemed to influence children’s 
 195 
opinions about whether the medicines given by injection were positive or negative. 
Pineapple explained that she was “going to get one of them [needle] done anyway, for 
when I get my ears pierced” (Pineapple, Girl, 5-7yrs, Rainbows 1), and when another 
child replied that they “didn’t want one” (Girl, 5-7yrs, Rainbows 1), Pineapple told her 
that her “nan said it only stings for a minute” (Pineapple, Girl, 5-7yrs, Rainbows 1). Jo-
jo explained that when she was much younger her “hip wasn’t in the right order and I 
had to have a needle… I was only one” (Jo-jo, Girl, 5-7yrs, Rainbows 1) and although 
she said she could not “remember”, she said that needles “only hurt when you have it 
on your hip” reflecting a belief based on her own experience.  
 
Experiences that children had observed had a similar effect to ones they had 
personally and directly experienced. Some children had seen younger siblings have 
an injection “that’s what my brother was like, [brother’s name] was like screaming and 
screaming” (Girl, 5-7yrs, School 1), which led to the belief that “if you’re little and you 
have something sharp in your arms or legs and you’re only like little you would like 
scream” (Girl, 5-7yrs, School 1). However, children noted a distinguishing line for 
screaming as a response, explaining that “when you are only three or two” (Boy, 5-
7yrs, School 1) it would be okay to “scream like this” (Boy, 5-7yrs, School 1) whereas 
it would not be okay when older.  
 
Some of the older children associated having a needle with needing to be “brave” (Girl, 
5-7yrs, School 1). Most of the children who talked about needles, talked of bravery 
explaining that “I had a needle because I was so brave” (Girl, 5-7yrs, School 1), “you 
have to be brave” (Girl, 5-7yrs, Rainbows 1) or associated bravery with rewards “I was 
brave and then I had chocolate buttons” (Boy, 5-7yrs, School 1). Even children, like 
Katie, who had not had an injection thought that it would be painful and experienced 
a sense of dread with children explaining that “I would dislike a needle a lot” and the 
expectation of a negative behavioural response “so I would cry” (Katie, Girl, 5-7yrs, 
Rainbows 1). This is clearly evident in the following conversation between Popcorn 
and Lex in a workshop: 
 
Beth: so why don’t you like needles then?  
L: Because they painful and I scream  
Beth: How do you know they are painful if you’ve never had one? 
L: Errr I don’t know 
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P: because I told L, because I had one and they are painful”  
L: you scream, and it hurts! (Popcorn and Lex, Girls, 5-7yrs, Rainbows 1) 
 
The fear and negative experiences of others having needles or medicines can lead to 
a sense of dread for children who have not yet experienced the treatment. Children 
like Lex clearly projected this fear saying, “I would dislike a needle a lot” and the 
expectation of a negative behavioural response “so I would cry” (Lex, Girl, 5-7yrs, 
Rainbows 1).  
 
In order to understand how to overcome some of these psychological barriers to 
acceptability of injections, children were asked what would make needles better. The 
response from each workshop was that “if they weren’t sharp and they were just like 
plastic” (Doo-doo, Girl, 5-7years, Rainbows 1), the belief was that “if it wasn’t that 
sharp… then it wouldn’t actually really hurt you” (Boy, 5-7yrs, School 1). However, in 
contrast to the majority of children who had infrequent experience of needles, Alex, a 
child who had injections frequently, explained that “umm the injections… basically the 
(medicines) I’ve had” are okay. Similarly, one child in a workshop responded to a 
comment that needles “really hurt” (Girl, 5-7yrs, School 1) with a defensive tone “EY, 
I have them!” (Boy, 5-7yrs, School 1). The children, like James, who had needles 
regularly tended to say that they were OK: 
 
 “yep I have… I had an injection and I didn’t cry… my most recent one was two 
or three months ago” (James, Boy, 8-12yrs, School 1).  
 
5.5 Conclusion  
In this chapter findings generated from the first activities from the interviews and 
workshops which focussed on generating insight and knowledge of children’s 
understanding of the acceptability of medicines have been described. These findings 
have been grouped into three sub-ordinate themes 1) What Children Can Tell Us 
About the Acceptability of Medicines; 2) What Helps Improve the Acceptability of 
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6 Exploring Children’s Perspectives on Improving the Methods 
Used to Assess the Acceptability of Medicines  
6.1 Introduction 
This chapter will present the findings from the activities and discussions related to the 
re-development and design of the methods that are used to assess the acceptability 
of medicines. As described in the methods chapter, during the activities and 
discussions children were shown a range of the most commonly used scales from the 
literature (n=14); these scales included 11 faces scales, one numerical scale and two 
scales with both images and numbers on. As in the previous Findings chapter (Chapter 
5), the demographics, participants, and analysis all remain the same. This chapter is 
organised into three key themes, the first two focus on children’s responses to the 
scales and the final theme focuses on their ideas for improving the methods for 
acceptability testing:  Children’s Experience and Understanding of Scales, Children’s 
Preferences for Scales and Improving Acceptability Testing.  
 
In total, three superordinate themes and eight subordinate themes were developed 
and are summarised in Figure 6.1 below. These themes are displayed as a narrative 
supported with the most pertinent quotes from the data.  
 
Figure 6.1: Summary of the superordinate and subordinate themes related to improving acceptability 
assessment. 
 
• Previous use of scales
• Children's understanding of the scales
• Children’s interpretation of the ‘neutral’ middle 
Children's experience 
and understanding of 
scales
• Scales needed to be easy to use
• Thumbs up for emoji scales
Children's Preferences 
for Scales
• Designing better scales: images and colour
• Presentation of acceptability tests/scales




6.2 Children’s Experience and Understanding of Scales 
The first super-ordinate theme developed from the data related to children’s 
understanding of the current scales that are used in assessing the acceptability of 
medicines. This included whether or not children had used scales before and the 
implications of this, what children understood about the scales and about using the 
scales to evaluate medicines, and finally how children interpreted current scales and 
whether this was aligned to the purpose of the scale. This is organised into three sub-
ordinate themes Previous Experience of Using Scales, Children’s Understanding of 
the Scales, and Children’s Interpretation of Response Categories.  
 
6.2.1 Children’s previous experience of using scales  
Following initial discussions with each group and individual child it became clear that 
children had differing levels of knowledge and information about assessment scales 
used to evaluate medicines. It generally seemed that children’s previous use of an 
assessment scale influenced their ability to use and understand the scales provided. 
Typically, children who had previously used or seen assessment scales before were 
more easily able to identify scales, with Lexi explaining ‘I recognise that one’ (Lexi, 
Girl, 5-7yrs, Rainbows). This was common both in children at the hospital ‘I think it 
was this one [that he had used before], it’s either that one or that one… 9 or 10’ (Alex, 
Boy, 8-12yrs, Hospital), and also those children from other settings who had either 
been in hospital or had some experience of hospitals: 
 
“I’ve used that! I’ve used the happy face one because Dr.*Name* gave me a 
sheet and on the 29th October, I’m going to have an operation!” (I, Boy, 8-12yrs, 
School).  
 
As well as demonstrating an awareness of being able to identify scales and know what 
they were used for, these children also showed that they had a good understanding 
about how the scales were to be completed: 
 
“Oh I know what these are, they tell you from 1-10 and then you put a dot where 
they ask you if it’s nice” (G, Boy, 8-12yrs, School).  
However, children who had not previously used them or had any experience with 
paper scales struggled to understand what they were. In one group, after being shown 
the scales to evaluate, Katie explained that ‘they don’t look like scales’ (Katie, Girl, 5-
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7yrs, Rainbows 2) and the other children in this group agreed, explaining that they had 
never seen one before. This meant that children sometimes got confused or did not 
properly understand what the scales were asking them. This therefore led to differing 
understandings of the scales and the meaning of the categories used on each of the 
scales (explored in 6.2.2 and 6.2.3).  
 
6.2.2 Children’s understanding of scales 
When looking at and evaluating the scales, most children explained that they 
understood what the two end anchors of the scales (0 and 10, or Very Happy and Very 
Unhappy) meant, ‘One means bad and ten means great’ (G, Boy, 8-12yrs, School 2). 
Most children used their own faces and expressions to display their interpretation of ‘I 
like it’ or ‘I dislike it’ or drew what they thought the face would look like ‘Like this! Like 
this!’ (Girl, 5-7yrs, Rainbows).  
 
Figure 6.2: “I like it a lot”  
Starting with ‘I like it a lot’, (Figure 6.2) the children explained that this anchor would 
be ‘a big smiley face’ (Girl, 5-7yrs, Rainbows) and when asked what they thought it 
meant, most of the children agreed that it meant something like ‘they really enjoyed it’ 
(Girl, 8-12yrs, Brownies). A lot of the children displayed an awareness between the 
end anchors and the category options, explaining that ‘that one’s a big smiley face and 
that one is just a little smiley face’ (Katie, Girl, 5-7yrs, Rainbows). The ‘little smiley 
face’ was attributed to the ‘I like it’ response category, and it was agreed that this 
category would be ‘a smiley face’ (Millie, Girl, 5-7yrs, Rainbows 2), it would look 




Figure 6.3: “I like it” 
When explaining the ‘I don’t like it’ (Figure 6.4) categories there was more of a variety 
in responses, however each had negative connotations. With some children explaining 
that it was a ‘sad face, that would look sad’ (Girl, 5-7yrs, Rainbows), and ‘that’s a sad’ 
(Millie, Girl, 5-7yrs, Rainbows 2). When asked what they thought it meant, this face 
was described as being ‘unhappy’ (Girl, 5-7yrs, Rainbows). However, other children 
thought that this face meant ‘dislike it’ (Girl, 5-7yrs, Rainbows) and expressed this 
dislike using ‘ewwww’ (Girl, 5-7yrs, Rainbows).  
 
Figure 6.4: “I dislike it” 
However, this was not always the case, and some categories on particular scales (see 
figure 6.5) caused some confusion. Typically, children were confused about 
distinguishing between some negative categories, seeing little difference between the 
categories. This was apparent in both the younger children ‘I dislike it and I dislike it a 
lot are the same’ (Girl 5-7yrs, Rainbows) and the older children (8-12yrs) and in 
children who had and had not used the scales before. Alex, summed up the difficulties 
that some of the other children experienced:  
 
Figure 6.5: Dislike faces 
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Alex: “I don’t really get what’s different… oh yeah now I see 
Beth: The difference between the two sad faces? Wouldn’t you be able to tell? 
Alex: I didn’t see cos the smiles are like each other” (Alex, Boy, 8-12yrs, 
Hospital)  
 
Other aspects of scales caused confusion, for example, when looking at a numerical 
scale that displayed zero as the most positive answer and ten as the most negative 
answer, children were quick to think it was the other way around. This is really clear in 
my conversation with Jo-jo: 
Beth: What do you think zero means?  
Jo-jo: Not very good 
Beth: And what do you think ten means? 
Jo-jo: AMAZING 
Beth: Well… 
Jo-jo: You know, really liked it? 
Beth: So this one is a little bit different. So this one says that zero is… 
Jo-jo: Realllly good and ten is really bad?? (Jo-jo, Girl, 5-7yrs, Rainbows 2) 
 
Whilst Jo-jo understood that the numbers on the scale related to the acceptability of 
the medicine being evaluated, the order of the scale did not initially make sense to her. 
Similarly, in another workshop children were confused about whether the zero meant 
that the medicine tasted horrible or that the medicine did not taste of anything- 
interpreting the ‘0’ as a neutral response: 
 
“I: zero means urr disgraceful 
G: yeah, zero means it doesn’t taste of anything 
I: yeah doesn’t taste of anything, taste disgraceful 
Beth: Oh. So does zero mean it doesn’t taste of anything or that it’s not very 
nice? 
I: ummmm 
G: just that it doesn’t taste of anything” (G and I, Boys, 8-12yrs, School 2) 
 
Whilst G, one of the boys in this conversation, had earlier explained that ‘one means 
bad and ten means great’, here he seems to interpret this scale differently. This could 
reflect a struggle to understand the scale without other descriptors such as images, or 
words he understands. Additionally, although G had previously demonstrated an 
awareness of how to complete numerical scales, when he used a facial scale, he 
interpreted the meaning of a scale anchor to relate to the size of the medicine rather 
than its acceptability.  
 
“G: *circles a big smiley face* this is a big medicine  
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Beth: so is the smiley face because it’s good that it’s big or is the smiley face 
telling us that it’s big? 
G: yeah because it’s big” (G, Boy, 8-12yrs, School 2).  
 
Referring back to the section Adults Help in the previous findings chapter (Section 
5.2.2.2), at another point in the interview G explains that the scales would be easier to 
understand with somebody else helping the child to use it. He drew the picture below 
(Figure 6.6) and explained it: 
 
 
Figure 6.6: Adults help 
“see look, look, I’ve drawn glasses so it shows that somebody else is helping 
them and here’s the person that can’t see or understand. See that person 
helped them read it” (G, Boy, 8-12yrs, School 2) 
 
So, whilst G earlier displays an awareness of how to complete these scales, it may be 
that the scales he is evaluating are different to one he has previously used. This 
suggests that children would benefit from the current scale being used being explained 
to them, to ensure their comprehension of the scale is in line with the meaning of the 
scale. This also links to section 6.2.1, where children who have previously used a scale 
and have already had information about particular scales, are more likely to 
understand the scales and categories.  
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6.2.3 Children’s interpretation of the ‘neutral’ middle  
When evaluating the scales, the ‘extremes’ i.e. very happy or very unhappy, were 
talked about first and it seemed that most children had a good idea about what they 
meant. However, although generally the children had a good understanding of what 
the categories in the middle of the scales meant, they tended not to spontaneously 
talk about the middle categories, and so these answers were typically prompted by me 
asking the initial question ‘what about these, the middle ones? What do you think they 
mean?’ (Beth, Interview 7, Alex, Hospital).  
 
Children from four of the workshops and interviews described the middle face as being 
‘just okay’ (Girl, 8-12yrs, Brownies), ‘not bad’ or ‘in the middle’ (Girl, 5-7yrs, Rainbows), 
‘the middle face means it’s just okay’ (G, Boy, 8-12yrs, School 2), ‘yeah okaaay’ (I, 
Boy, 8-12yrs, School 2), and ‘just like, good and bad’ (Alex, Boy, 8-12yrs, Hospital). 
When drawing what they thought this middle face would look like, one child explained 
that they were ‘doing a straight one’ (Girl, 5-7yrs, Rainbows) (Figure 6.7).  
 
Figure 6.7: Straight face 
However, the middle category caused confusion for some of the other children, and 
there was a greater variety in what the children interpreted the middle face to mean. 
When asked to draw a picture of a face that they thought would be in the middle, 
labelled ‘okay’, Jo-jo decided on a squiggly face (Figure 6.8) and asked ‘what about 
that one?’ (Girl, 5-7yrs, Rainbows). When she was asked to draw a picture of a face 
that looked ‘acceptable’, she drew ‘a tiny smiley face for it’ (Jo-jo, Girl, 5-7yrs, 
Rainbows) (Figure 6.9). Interestingly, acceptable and ok are often used 
interchangeably to talk about the middle categories on acceptability scales. However, 
this could imply that the language used has a greater effect on how children interpret 
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and respond to acceptability scales, and therefore an effect on which category 
represents the level to which children find a medicine acceptable.  
 
Figure 6.8: Squiggle face 
 
Figure 6.9: Small smile 
In one workshop, children had differing opinions on what the middle face meant, with 
one child explaining ‘that is like confused’ (Girl, 5-7yrs, School 1), and another saying 
that they ‘would choose that one if I didn’t like it, because I would go like [shows a 
facial expression matching the middle face]’ (James, Boy, 5-7yrs, School 1). Another 
child from a different workshop explained they were ‘doing a thinking face’ (Girl, 5-
7yrs, Rainbows) for the middle category. It is clear that different children attribute 
different meanings to the categories when they are not clearly explicit in their meaning 
i.e. ‘very happy’.   
 
6.3 Children’s Perceptions on, and Preferences for Scales  
The second superordinate theme relates to children’s preferences for scales and the 
aspects that influence this preference. One of the key things that children talked about 
was how the scale needed to be easy to use, and those scales deemed as ‘easier’ to 
use were preferred over other scales. Similarly, children had preferences for specific 
types of scales, including what type of response category was used, whether this was 
displayed with or without words, and the number of response categories on the scale.  
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6.3.1 Scales needed to be easy to use and age-appropriate  
One of the first reasons children gave for choosing a scale was that ‘it’s easier to use’ 
(G, Boy, 8-12yrs, School 2) (scale 11). Children explained how different scales would 
be the easiest to use for them, giving reasons for their choices. Most children talked 
about how the response categories on each scale would improve a scale’s usability. 
In particular face scales were deemed as easier to use: 
 
“G: it’s easier! So so I know what that means, so if it’s sad it means it tastes 
rubbish and if it’s that one [points to small smile] it means it tastes a little bit 
good…” 
“I: and that’s just great [big smiley face]” (I and G, Boys, 8-12yrs, School 2).  
 
Other children chose different scales for other reasons. In particular, when asked 
which scale would be best for him to use, James explained he ‘thinks that one [Likert 
scale], because I find it a bit more exact’ (James, Boy, 8-12yrs, School 1). Similarly, 
another child from a different workshop asked if the Likert scale was ‘maths? Can we 
do more maths?’ (Anika, Girl, 8-12yrs, Brownies). The Likert scale was deemed 
preferable for the children in the older age group (8-12yrs), and for those children who 
chose it, it was because they liked numbers and maths, or found the numbers more 
exact than the images on the facial scales. However, not all children agreed with this, 
and Joy explained that she thought the Likert scale ‘was too difficult, I think that one 
[with faces] is easier’ (Joy, Girl, 8-12yrs, School 1).  
 
Despite this, Joy was conscious that older children ‘might be ten or something, so they 
might be able to use it [Likert scale]’ (Joy, Girl, 8-12yrs, School 1). Most of the children 
in the study were conscious that no one scale would be the best fit for every child, and 
age and ability were factors that children considered would change the 
appropriateness of a scale. When evaluating the emoji scales, despite already 
explaining which scale would be the best for him, Alex talked about how: 
 ‘the emojis kinda help the small ones [children] and they might just get 
confused [with stars], they might just think you’re putting bigger stars on’ (Alex, 
Boy, 8-12yrs, Hospital). 
 
Emojis were talked about being the easiest of the response categories to understand, 
G explained how ‘emojis are actually the easiest to use, cos cos you can tell if it’s 
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angry easier, this one is number 12. You can tell what they mean easier’ (G, Boy, 8-
12yrs, School 2) (see Figure 6.11: Scale 12).  
 
Similarly, a number of children talked about how words would either help or hinder the 
appropriateness of a scale. Alex explained how the words ‘helped a bit, but say my 8-
year-old sister is still reading year two books’, he chose three scales which he thought 
‘would be good’… 
 
“I think I would prefer mainly the ones without the words… because if little ones 
ever did that test and they didn’t really know how to read them I think that one 
would be best because it has no words and it has clear expressions” (Alex, Boy, 
8-12yrs, Hospital).   
However, G explained that he would not like a scale without words because if it has 
‘got no words, what if you don’t know what the faces mean?’. Both children show an 
awareness of considering other children and whether or not the response categories 
would be understandable. Whilst G explains he would prefer both words and images, 
he also goes on to offer a solution to what Alex describes as an issue if the person 
completing the scale could not read, ‘if it’s got words then an adult could read the 
words, somebody else could come and read the words’ (G, Boy, 8-12yrs, School 2). 
This idea that words would help children to understand was also reiterated by a girl in 
a different workshop group, she explains that the scale is ‘really clear and has words 
so you know just what they all mean’ (Girl, 8-12yrs, Brownies).  
 
6.3.2 Thumbs up to emoji scales 
As well as emojis being talked about as making the scales easier to understand and 
use, overall, they were the preferred option for response categories on the facial 
scales. Children gave a number of reasons for this, including the additional 
expressions and hand gestures, the clarity of the scales and how well children believed 
the emojis reflected their own responses. When presented to the children, the scales 
were labelled 1-12 (full list of scales can be found in the methods section), these 
numbers will be referred to in the following section to distinguish which scales are 
being talked about.  
 
Of all the scales, the scales referred to as the ones with ‘the emojis’ (Girl, 8-12yrs, 
Brownies) (Scales 9, 10, 11, 12) were mentioned most often as being preferred. Key 
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reasons for these scales being chosen was ‘because I like the emojis on it’ (I, Boy, 8-
12yrs, School 2) (Figure 6.10: Scale 11), and ‘that’s like maybe they’re emojis’ (Boy, 
5-7yrs, School 1) (Scales 9,10,11).  
 
Each of the scales had emoji-type faces on them, some in colour and some without. 
So, whilst there were other options of ‘emoji’ faces, children showed preference to a 
select few. One child preferred scale 12 (Figure 6.11) because of the colour of the 
images specifically, and whilst this was the only time colour was mentioned as a 
reason for choosing an existing scale, colour was mentioned in each workshop when 
re-designing scales (See section 6.4). 
 
“There’s more like colour and dislike is like an angry face’ (Joy, Girl, 8-12yrs, 
School 1)”.  
 
6.3.2.1 Happy and smiley 
As well as colour, other reasons children liked scales related to the emojis used, in 
one workshop the children talked about how they liked Scales 9, 10 and 11 because 
‘they are all happy and smiley… AND that one is putting a thumbs up!!’ (Boy, 5-7yrs, 
School 1) (Figure 6.10). The fact that children chose these scales because they ‘like 
this faces’ [sic] (Girl, 5-7yrs, Rainbows), and one of the key reasons given for this 
choice was because of the ‘smiley face’ (image 6.13: scale 8) (Girl, 8-12yrs, Brownies). 
‘I like 11 because I like the faces’ (Girl. 8-12yrs, Brownies).  
 
Figure 6.10 Scale 11 
6.3.2.2 Children like emojis because they are clear  
Another child added that she liked scales 10 and 11 ‘because there’s all sorts of 
different things on them’ (Girl, 5-7yrs, School 1), and the children generally agreed 
that they ‘like the scale, I can do that’ (James, Boy, 8-12yrs, School 1). The idea that 
the children liked a scale because they could ‘do’ it, links to how easy they found it to 
use, and Anika explained why she decided on scale 12 (Figure 6.11): 
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“Cos it’s got like just like really just like very clear, really dislike and like and I 
like that it’s got different things like if you dislike it but didn’t dislike extremely 
you could go for that one and if you liked it but didn’t like it extremely you could 
go for that one and then if you if you erm, it was not good but not bad just in the 
middle you’d go for this one” (Anika, Girl, 8-12yrs, Brownies).  
 
 
Figure 6.11: Scale 12 
 
Being able to differentiate between the faces seemed like an important factor of the 
scales, one child explained that the emojis would be a good scale to use ‘because 
they’ll know that’s happy and that one is less happy’ (Girl, 8-12yrs, Brownies). 
Similarly, in another workshop one of the children explained that he would chose 
number 5 (see Figure 6.12: Scale 5) ‘because it’s quite clear and bold, and things like 




Figure 6.12: Scale 5 
6.3.2.3  Other factors 
Two children in one of the workshops chose scale 8 as their preferred scale to use 
when assessing acceptability because they thought that it was ‘good that they have 
done a girl and a boy’ (Anna, Girl, 8-12yrs, Brownies). These children explained that 
they would choose this scale because: 
 
“Anna: girls might understand the girl one and boys might understand the boy 
one…  
Anika: because little girls might think, if they aren’t a boy they might not 
understand that one but if they are a girl they might understand that one. So it’s 
better.” (Anna and Anika, Girls, 8-12yrs, Brownies) 
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However, two other children in this group disagreed, explaining that they ‘don’t think it 





Figure 6.13: Scale 8 
Scale 8 was also specifically highlighted as inappropriate for some children and other 
scales 6 and 7, were described as being unclear by some children. Alex thought scale 
8 (Figure 6.13) was particularly unclear: 
 
“But I wouldn’t really suggest this one (pointing to number 8) because, that one 
[middle faces] it looks like they’re just thinking and they’re not saying good or 
bad. It just looks like they are thinking about what they are going to answer” 
(Alex, Boy, 8-12yrs, Hospital).  
 
The children also considered other factors, such as how accessible the scales were 
to other children, and Alex explained that he would pick the emoji scale 10 (Figure 
6.14) in case a child could not talk: 
 
“I mean like, say if someone couldn’t talk and they didn’t know how to, they 
could only do sign language and they didn’t know how to say it they could just 
point or tick it” (Alex, Boy, 8-12yrs, Hospital).  
 
 
Figure 6.14 Scale 10 
Systematic data were not collected regarding children’s preferences for specific 
scales. However, some children commented that scale number 12 (Figure 6.11) was 
the most common scale chosen by children, the main reason for this being that 
children both liked and understood the emojis. Children also acknowledged that having 
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both pictures and words would be useful and helpful, as discussed in section 6.3.2.2. 
The second most common scale preferred by children was scale 8 (Figure 6.13). This 
was mainly chosen by younger children who expressed that they liked that the male 
and female options. However, this scale was not as popular with older children and, 
earlier in this chapter (Section 6.3.2.3), a discussion of the advantages and 
disadvantages of this scale was presented. 
 
6.4 Improving Acceptability Assessment 
The final super-ordinate theme was developed from what the children talked about 
regarding their thoughts and opinions of improving acceptability assessment. The 
children evaluated the currently existing methods of assessing acceptability and talked 
about their ideas to improve these for children. They also discussed ways that 
acceptability assessment could be improved, and this is explored in the following 
sections.   
 
6.4.1 Designing better scales: images and colour 
Firstly, children explained the different ways that they believed the assessment scales 
could be improved, these were organised into two key sections: Improving the images 
used on the response categories and Using colour to improve the scales.  
 
6.4.1.1 Improving response category images 
When looking at the scales almost all children redesigned or developed new faces and 
emotions for the response categories on the scales. These typically included additional 
behaviours or facial expressions that they believed would be easier to understand and 
use, which were generally more emotive. 
 
Children mainly added to the negative end of the scales ‘dislike it’ or ‘dislike it a lot’ 
with the inclusion of tears and crying as can be seen from Jo-jo and Katie’s discussion: 
 
“Katie: No I dislike it a lot- So that’s reaaaally bad 
Jo-jo: Waaah im crying [facial expressions to match the face she is drawing] 
Katie: I want him to cry 
Beth: Oh did you put him crying? 
Katie: If I dislike it a lot, I would dislikeeee a needle a lot so I would cry 
Jo-jo: Don’t talk about them” (Katie and Jo-jo, Girls, 5-7yrs, Rainbows) 
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In this exchange Jo-jo explains that she is crying as she draws the face, saying that if 
she disliked something a lot she would cry. Conversely, Katie explains that she wants 
him to cry, referring to the face she is drawing. Interestingly both children were given 
the same task and yet have interpreted it differently, with one of them drawing 
themselves on the scale, and the other drawing how they would expect someone else 
to react if they disliked something a lot. Katie then continues and uses her own 
experience, e.g. if she disliked a medicine she would cry, as a justification for why she 
had drawn the face crying. Similarly, in other workshops when asked what a face 
would look like if it was ‘I dislike it a lot’, the children showed me with their own 
expressions and body language, this included children crossing their arms, pursing 
their lips and frowning. The children then continued drawing the faces on the scale 
asking ‘crossed arms? They might be crying… that’s what my friend does’ (Girl, 5-
7yrs, Rainbow 2). Similarly, in another workshop one of the children explained that ‘my 
face would like when it was not acceptable for needles, I would go [demonstrates]’ 
(Girl, 8-12yrs, School 1). In each of these examples, the children use their own 
experiences, or their experience of another child taking medicine to base their belief 
of how they would look or act when they ‘dislike it a lot’ (See Figure 6.15).  
 
Figure 6.15: I dislike it a lot 
As well as physical actions such as crossing arms and crying, children in this workshop 
also talked about specific facial expressions such as ‘I’m doing a shocked face’, ‘I’m 
doing a straight face’, ‘I did a frown’ and ‘I’m going to do this one a frown’ (Girls, 5-
7yrs, Rainbows 2). Each of these ideas are different and perhaps display children’s 
differences depending on their experiences and how they believe they would act. 
Additionally, some of the faces that the children decided on such as ‘a straight face’ 
are used in pre-existing scales as indicating acceptability or the middle response. This 
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has implications for the validity of the results of these scales when there is so much 
variance in children’s interpretations.  
 
Reiterating the earlier point that some children found it difficult to distinguish between 
the response categories, a number of children explained that they ‘don’t know what I 
dislike it’ would be (Millie, Girl, 5-7yrs, Rainbows). One of the children explained that 
for ‘I don’t like it… [they would be] sad and grumpy’ (Girl, 5-7yrs, Rainbows 2). In a 
different workshop, Jo-jo thought that it would be ‘a sad face but like a lighter one, look 
like that [points to a face]’ (see Image 6.16) (Jo-jo, Girl, 5-7yrs, Rainbows). 
 
Figure 6.16: I dislike it 
Katie, from the same workshop. explained that she would ‘put it with tears in my eyes 
but I’m not crying yet’ (Katie, Girl, 5-7yrs, Rainbows) for ‘I don’t like it’, in comparison 
to crying in ‘I don’t like it a lot’.  
 
For the middle response category ‘acceptable’, children talked about a range of 
emotions and behaviours that they believed would represent acceptable. A number of 
children, like Alex, used a ‘thumbs up for acceptable’ (Alex, Boy, 8-12yrs, Hospital), 
adding the thumbs up hand gesture to their drawings.  
 
Additionally, children also included a smile on their ‘acceptable’ faces or picked ‘the 
cool one with sunglasses’ (Boy, 8-12yrs, School 1) from the emoji sticker sheet. Whilst 
the child did not explain why he had picked the one with sunglasses, he explained that 
he ‘likes that one… it actually looks like superman a bit because of the goggles 
glasses’ (Boy, 8-12yrs, School 1). In this workshop it became apparent that the child 
chose that specific face because he thought it was ‘the coolest there’ (Boy, 8-12yrs, 
School 1).  
 
6.4.1.2  Impact of colour  
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Whilst the colour of scales was only mentioned as a reason for one child choosing a 
scale (section 6.3.2.1) a majority of children incorporated colours into their re-designed 
scales and explained that different colours meant different things. In one workshop, 
Katie explained that she was using different colours for the faces ‘because it shows 
how they actually feel’ (Katie, Girl, 5-7yrs, Rainbows). However, when asked why she 
had picked the colours she said that she did not know. Despite this, the concept that 
colours could display how a person, or face, ‘felt’ continued in another workshop where 
Ruby told me that she was ‘going to choose yellow for happy face and red for sad’ and 
when asked why, she explained ‘cos red is for angry and yellow is for happy’ (Ruby, 
Girl, 5-7yrs, Rainbows 2).  
  
There was a recurrent theme around why children chose red or yellow to display their 
unhappiness or happiness with a medicine. One child explained that she ‘is the 
confused one’ and asked if there was a red pen anywhere, when asked why she 
coloured it in red, she explained ‘oh, because it’s like your lips for red isn’t it?’ (Girl, 5-
7yrs, School 1). It is clear that the colour red had different meanings for each child, 
one using it to display unhappiness and the other using it to indicate that their face 
had red lips. The colour yellow was sometimes used ‘for happy’, and other times 
children used it for all of the response images, rather than having the scale without 
colour or a skin tone. Children talked about how they ‘like the colours’ (Jo-jo, Girl, 5-
7yrs, Rainbows) of certain scales, and scales without colours were described as 
‘stinky, it doesn’t have any colours on’ (Katie, Girl, 5-7yrs, Rainbows). One child 
explained that they would ‘want to change the colour of this one (scale)’ and when 
asked to which colour, she said ‘yellow’ (Girl, 5-7yrs, Rainbows 2). Only one child 
explained that the colour would not make a difference, when drawing his face he used 
the orange pen and without prompting said ‘I’m not saying it has to be orange’ (Alex, 
Boy, 8-12ys, Hospital), and continued saying it could be any colour.  
 
6.4.2 Presentation of acceptability tests/scales  
When re-designing and developing the existing scales, the children thought that the 
presentation of the scales could improve how appropriate the scales were to children. 
The typical format of an acceptability assessment page (Figure 6.17), was described 




Figure 6.17: Typical scale used in acceptability assessment deemed to be “boring” 
 
Most of the children expressed a preference for the scale which had been designed to 
look like an activity map (Figure 6.18); the individual scales remained the same but 
were displayed across the page, with a dotted line for the children to follow from one 
question to another. 
 
 
Figure 6.18: Acceptability assessment with activity map design 
 
The children engaged well with this scale, most children expressed positive opinions 
on this presentation such as ‘I love this one’ (Girl, 8-12yrs, School 1), and ‘I like it this 
one’ (G, Boy, 8-12yrs, School 2), following the line and answering the questions by 
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circling the face that they thought best represented their feelings. In workshop 2, all of 
the children explained that they: 
 
“would choose this one, I would choose this one… because there’s loads of 
activities to do and you get your hands working and that one (original 
presentation) you have to think about a lot of it but this one you can play along” 
(Katie, Girl, 5-7yrs, Rainbows).  
 
The idea that this presentation was ‘fun’ was reiterated by another child who described 
it as being ‘like a game’ (Girl, 5-7yrs, Rainbows). Building on this, Joy and other 
children explained that this presentation was ‘just more fun and it’s good for like little 
kids to do’ (Joy, Girl, 8-12yrs, School 1). There was a recurring idea that presenting 
the scales this way was ‘easy’ (Girl, 5-7yrs, School 1) and more appropriate for all 
ages of children, with other children explaining the reason they liked it was because 
they could ‘draw on it… I like following the map with felt tips’ and ‘because we get to 
draw on it… children like to draw’ (Girl, 5-7yrs, Rainbows 2).  
 
James said that he would be ‘in the middle’ with this option, and when asked why he 
explained that ‘it would be better if it was like a map but with the number scale on it’ 
(James, Boy, 8-12yrs, School 1). This is an important consideration, as James has 
separated his thoughts on the presentation of the scale and the individual scales 
themselves.  
 
Continuing with the game theme, some children explained that the scale designed to 




Figure 6.19: Game scale 
James and Brooke gave this presentation a ‘thumbs up’ (James and Brooke, Boy and 
Girl, 8-12yrs, School 1), and Joy said it was a ‘winner winner’ (Joy, Girl, 8-12yrs, 
School 1).  James explained his reasoning for Top Trumps being good was: 
 
“Um because Top Trumps is quite fun and lots of kids play it and they find it 
quite easy to read” (James, Boy, 8-12yrs, School 1) 
 
Children from other workshops agreed that they would ‘like the Top Trumps one’ (Girl, 
5-7yrs, Rainbows), and Anika explained it was ‘because children like to play games 
and Top Trumps they all play and I think they would understand it’ (Anika, Girl, 8-
12yrs, Brownies). However, although children explained that they liked this style, not 
all children knew about Top Trumps and some children did not complete the scale 
correctly (i.e. with numbers), instead writing in the space that the medicine was ‘OK’, 
as can be seen in Figure 6.19.  
 
A couple of children preferred the ‘iPad’ design (Figure 6.20), and Joy explained this 
was because ‘loads of kids go on their iPads so if they saw this they might think it’s 
okay’ (Joy, Girl, 8-12yrs, School 1). This was reiterated in the Brownies group, where 
two children said that they would choose ‘the iPad one because children use iPads a 
lot’ (Girls, 8-12yrs, Brownies). James, who previously expressed a liking for numbers, 
explained that although he liked the presentation, he ‘just finds it easier with the 
numbers (scale)’ (James, Boy, 8-12yrs, School 1).  
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Figure 6.20: iPad scale 
 
6.4.3 Other ways of acceptability testing  
Children talked about the other ways that acceptability testing could be conducted. 
When asked how acceptability assessment could be improved, the main things 
children talked about was having a choice, being asked how they feel first, and being 
included.  
 
Children are often included in acceptability testing at later stages of the approvals 
process but are rarely included in decisions about the ways that acceptability 
assessment is conducted. However, in this study children discussed how they believe 
it is important for them be involved in these decisions. Alex explained that he thought 
it would be useful if children were offered a choice of assessment scales so that each 
individual child could pick which one was most appropriate to them, taking into 
consideration whether the scale had words or did not have words: 
 
“Umm not really, well they could have like a separate one where they 
copy it and it’s the same, but it just doesn’t have words and then the child 
could choose which one they use” (Alex, 8-12yrs, Boy, Hospital).  
  
Other children were also conscious that having a choice or option would be helpful ‘G’ 
explained that “because [that] has got no words and what if you don’t know what the 
faces mean? If it’s got words somebody else could come and read the words” (G, Boy, 
8-12yrs, School 2). The children explained that not only did they think it was important 
for them to be involved, but that also that they thought it was important for children of 
different ages and abilities to be accounted for. Alex provided a detailed response: 
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“Beth: So, can you think of any ways to improve these to make them better? 
Alex: Well, I mean you could put an extra one with three on so that one (hand 
gesturing) for maybe bad and good? 
Beth: Oh, so with the thumbs up and down? 
Alex: The little ones could do that (thumbs up and thumbs down gesture) in 
reception 
Beth: So that is a little bit like this one- thumbs down and thumbs up 
Alex: But I think they should probably be a bit bigger” (Alex, Boy, 8-12yrs, 
Hospital) 
 
Here it is suggested that having a choice of an extra scale with just three images on, 
(a thumbs up, thumbs down and thumbs to the side) would be more appropriate for 
younger children, because they can ‘do that’ with their own hands. He also suggested 
that these should be bigger than the hand gestures that typically appear on the current 
scales.  
 
Similarly, children in another workshop also believed it was important that children 
were involved in decisions about acceptability assessment because ‘they can see if 
they actually like it or not and if it helps them’ (Girl, 8-12yrs, Brownies). Children also 
considered that this assessment should come from both children in the hospital and 
children who are not in the hospital ‘because they [adults] can just choose one child 
that is not actually like ill, and they can taste it… because if someone is really ill and 
then if the medicine makes them worse’ (Girl, 8-12yrs, Brownies). However, children 
in this workshop also showed an awareness that the medicines should not be tested 
on children initially ‘because it could make them really poorly if it’s not right’ (Girl, 8-
12yrs, Brownies).  
 
However, they all agreed that children should have some say in their medicine and 
assessment. Here the children showed an awareness of the safety and effectiveness 
of the formulation to ‘help them or make them worse’, and the ability to separate this 
from the taste and feel of the medicine for children. It is clear that children understand 
that the medicine should be tested initially on adults to ensure its safety. However, 
they also demonstrated that it is important that children are involved in the 
development of the acceptability aspects of the medicines.  
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Children talked about how they thought it was important that adults ‘ask how you feel 
about doing it [the assessment] first’ (Joy, Girl, 8-12yrs, School 1). They considered 
that: 
 “it [the medicine] might be like hard, it might be horrible if an adult tastes it 
because adults have different tastes to children” (Girl, 8-12yrs, Brownies).  
 
This is an important point, and one that all formulators undertake. It was also 
interesting that this was something that children chose to talk about, without any 
prompting. This finding demonstrates that children often have more of an insight to the 
process of medicines development and differences in preferences than we, as adults, 
sometimes consider. There was a belief from the children that ‘people who are older 
than children are more important because like they have an adult brain’ (Girl, 8-12yrs, 
Brownies), in the context of the development of medicines. However, another child’s 
response to this was, ‘but as a child, as a kid they would understand more’ (Girl, 8-
12yrs, Brownies). The idea that ‘a kid would understand more’ is a prominent reminder 
that children might be better placed about their own preferences and acceptability in 
regard to medicines and acceptability assessment and that this is something that 
should be considered in greater depth.  
 
6.5 Conclusion  
This chapter has explored the findings from the activities and discussions relating to 
the methods that are used to assess the acceptability of medicines and to the re-
development and design of these methods. These findings have provided much 
needed insight and information about children’s thoughts and opinions about the 
acceptability of medicine assessment and will help to expand knowledge about these 
assessment methods can be improved. This chapter has highlighted the wide range 









































7 Discussion  
7.1 Introduction  
In this chapter the findings are discussed in relation to the aim and objectives of the 
study. The aim of this study was to explore the experiences of children in relation to 
medicines, to incorporate their views to develop a better understanding of the 
acceptability of medicine, and to relate this to the tools that are used to assess the 
acceptability of medicines. Crucially this study reveals the importance of involving 
children in improving acceptability and considering their ideas for the redevelopment 
of tools used to assess acceptability of medicines. This has been achieved by working 
with children and learning from them. 
Three objectives were proposed to ensure that the overall aim of the study was 
achieved. These were to: 
1. Explore children’s experiences of medicines to gain a better understanding 
about what is acceptable to children in formulations. 
2. Evaluate with children methods used to assess the acceptability of medicine. 
3. Use this new information to propose ways that existing tools used to assess 
acceptability of formulations in a paediatric population can be re-designed to 
better reflect children’s perspectives on the acceptability of medicine.  
This chapter begins with a recap of the reasons underpinning the need for this study, 
and how the methods used were the most appropriate way of involving children in this 
research to achieve the study’s aim and objectives.  
7.1.1  A lack of theoretical frameworks  
The importance of being able to develop acceptable medicines for the paediatric 
population is recognised in literature and regulations and outlined in Chapter 1. In 
order to develop acceptable medicines, it is important that formulators are aware of 
what is being referred to when talking about the acceptability of medicine, and how it 
can be measured.  
 
Inconsistency and lack of clarity in how the acceptability of a medicine is defined and 
operationalised can be problematic for formulators attempting to develop an 
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acceptable medicine (Lallemant, 2018). Within the literature, many studies claim to 
assess the acceptability of medicines but fail to include a definition of the concept, this 
therefore limits the results if they cannot be interpreted or compared across studies 
(Chen et al, 2019). Furthermore, acceptability is often conflated with other constructs, 
such as palatability, usability, and swallowability (Table 2.5 presents a full synthesis). 
Whilst these factors are recognised as potentially relating to, or impacting on 
acceptability, they are not synonymous (EMA, 2018). Because of this inconsistency 
many studies fail to report how acceptability is assessed, and little to no information is 
provided about how data capture tools and measures are developed or validated. 
 
It is widely acknowledged that the inconsistency in defining the acceptability of 
medicine can cause an issue when developing assessment measures. Within health 
psychology, it is recognised that applying a theory to a complex concept or intervention 
can enhance understanding (Rimer and Glanz, 2005).  However, when searching the 
medicines-related literature no theoretical model or framework that defines or outlines 
the construct of the acceptability of medicines could be identified.  
 
Broadening the search to wider health literature, the Theoretical Framework of 
Acceptability (TFA) developed by Sekhon, Cartwright, & Francis (2017) was identified, 
and presents a theoretical underpinning of acceptability specific to healthcare 
interventions. This was the only healthcare-related framework identified within the 
literature that provided specific sub-constructs of acceptability. The authors 
synthesised and systematically reviewed 43 papers, and applied Hox’s (1997) four 
step process of theorising to provide a definition and theoretical framework. The four 
steps included: 1. Deciding on a concept to measure; 2. Defining the concept; 3. 
Describing the properties and scope of the concept; and 4. Identifying the empirical 
indicators and subdomains (constructs) of the concept. In order to do this, Sekhon et 
al. (2017) reviewed and evaluated the definitions and the end-point variables used to 
assess healthcare intervention acceptability within the 43 papers. By doing this they 
proposed the following conceptual definition of healthcare intervention acceptability: 
“A multi-faceted construct that reflects the extent to which people delivering or 
receiving a healthcare intervention consider it to be appropriate, based on 




They then described the properties and scope of the concept of healthcare intervention 
acceptability, by reviewing the literature and identifying the variables that were 
reported to be measured by either observations or self-report techniques in 
acceptability assessment. The variables they identified were then operationalised and 
provided with definitions. This led to the proposed Theoretical Framework of 
Acceptability Version 2 (TFAv2) (Figure 7.1), composed of seven different sub-
constructs: affective attitude, burden, ethicality, intervention coherence, opportunity 
costs, perceived effectiveness and self-efficacy (Sekhon et al, 2017).   
 
Figure 7.1: Theoretical Framework of Acceptability (TFA v2) (Sekhon et al., 2017) 
 
Sekhon et al. (2017) propose that theorising the concept of acceptability provides the 
foundations required to improve and develop more appropriate measures to assess 
healthcare intervention acceptability. However, the TFA also provides a basis for 
operationalising of the concept of acceptability across all health care. Since the 
framework was published in 2017 it has been validated within complex intervention 
acceptability studies (Kioskli, 2017) and applied to mobile health applications (health 
apps) (Chen et al, 2019), mental health programs (Murphy and Gardner, 2019), and 
healthcare delivery system interventions (Strait, 2018).  However, to date, no paper 




Whilst acknowledged that there are differences between the acceptability of medicines 
and the acceptability of healthcare interventions, the current study demonstrates how 
the theorised concept of acceptability as proposed by Sekhon et al (2017) can be 
applicable in the context of medicines. The definition that Sekhon proposes considers 
acceptability as multi-dimensional, something which is already acknowledged in the 
acceptability of medicines (EMA, 2018). Additionally, Sekhon’s definition indicates that 
acceptability is reliant on the individual’s attitudes, perceptions and own assessment. 
Within wider healthcare definitions acceptability is also defined as relating to an 
individual’s attitudes and perceptions (Sidani et al, 2009’ Staninszewsa, 2010). 
Similarly, the inclusion of the child and their perceptions, beliefs and emotions toward 
medicines was found to impact acceptability in the current study. Finally, Sekhon’s 
(2017) TFA describes seven domains, all of which were also identified in the findings 
as impacting on the acceptability of medicines in the current study.  
 
Therefore, within this discussion I apply the theoretical understanding of acceptability 
developed by Sekhon (2017) to the acceptability of medicine and, based on the current 
study’s findings, and I present: 
a) a definition of the acceptability of medicine accounting for children’s 
perceptions,  
b) a framework of the acceptability of medicine with consideration of the user, and  
c) recommendations for how these two factors can improve the assessment 
measures used to assess the acceptability of medicine.  
 
7.2  A New Definition of the Acceptability of Medicines  
In the following section the general understanding of acceptability is explored, 
accounting for children’s experiences and perceptions. The factors reported by the 
children that influence acceptability are presented in the Framework of Children’s 
Medicine Acceptability (Section 7.3). The discussion of these two key areas 
demonstrate the achievement of the first objective of the study which was to explore 
children’s experiences of medicines to gain a better understanding about what is 
acceptable to children in paediatric formulations. 
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In relation to the acceptability of medicines, the findings of the study presented in 
Chapter 5 (Exploring Children’s Perspectives to Improve the Understanding of the 
Acceptability of Medicines), demonstrate that most children, whether they were 
familiar with taking medicines or not, understood that acceptability (a medicine was 
acceptable) meant the medicine was ‘ok’. This is in line with the terminology used 
within the acceptability of medicines assessment studies (Mistry et al, 2018). 
Interestingly and perhaps not expectedly, children were quick to explain that different 
characteristics of medicines influenced how ‘ok’ medicine was.  
 
The findings also show that children perceive the acceptability of medicines as a multi-
dimensional concept. Whilst the children had differing interpretations of what was 
acceptable regarding specific characteristics, their perceptions included five of the 
seven dimensions outlined by the EMA (2013). In addition, children also discussed a 
range of other factors that they perceived as impacting on acceptability (referred to 
hereafter as User Aspects). Thus, children demonstrated they had a complex 
understanding of the acceptability of medicines and were able to contribute to the 
existing pool of knowledge regarding the concept (this is discussed in section 7.3).    
 
However, current guidelines, papers and definitions focus heavily on the acceptability 
of the product, and little consideration is given to the user (see Figure 7.2). In a 
reflection paper, the EMA (2016, p4) reports capability as a potential influence on 
acceptability and state that the ability of a child to use a medicine product “will relate 
principally to age, physical development and ability to co-ordinate” but also “to 
psychological development and understanding” (p4). Whilst this is an important 
consideration and one that the current study considers, it is not expanded on within 
the guidance and no information regarding how this influence could be assessed or 
measured is provided.  A major limitation of these existing definitions, models and 
guidelines is that there is little to no consideration of how children may contribute to, 
or influence, the acceptability of medicines. Without knowing the total extent of 
acceptability, it is a challenge for pharmaceutical companies, researchers and 
formulators to assess the complete concept of acceptability.  
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Based on the findings of the study, it was considered that the original EMA definition 
of acceptability might have to be adapted to encompass the perceptions and 





















Key to colours used in domains 
 
 Sufficient evidence generated; additional research beneficial 
 Some evidence generated; additional research needed 
 Minimal evidence generated; additional focused research needed 
 
Figure 7.2: Characteristics of each aspect assessed during acceptability testing (EMA, 2018).  
 
In a recent paper produced with the EuPFI, the requirement for additional information 
relating to the child is recognised (Lallemant, 2018). Lallemant (2018, p12) proposes 
that primary research involving the user should be undertaken by academic and 
formulation scientists and with the users of the formulations (children, caregivers, 
families, health professionals, and public health stakeholders), “to better understand 
the use of drugs in the economic, geographic and cultural context of their use”. It is 
also argued that methodological research is required in order to validate the tools used 
for collecting acceptability data across age groups with a focus on developing  
“standardised, universal, objective, simple metrics… to evaluate the acceptability of 
Age 
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Primary and secondary 
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existing paediatric forms and optimise formulations under development… this 
research must necessarily involve concerned populations” (Lallemant, 2018, p13).  
 
Children are often left out of initial stages of medicines development, and parents and 
caregivers are asked to provide acceptability evaluations as proxy (Angwa et al, 2020; 
Klingmann et al, 2020; Giralt et al., 2019). The concern within the pharmaceutical and 
medicines development industry that children do not, or cannot, understand what the 
acceptability of medicine is, produces a cycle whereby children are not involved. This 
was made clear to me when one of the doctors reviewing the patient information 
leaflets for this study had concerns that the word ‘acceptability’ was included on them, 
that the children would not know what was meant by acceptability. However, findings 
from this study demonstrate that children can and do, understand what the 
acceptability of medicine refers to and more importantly, are able to meaningfully add 
to the conversations regarding the acceptability of medicine.  
 
Within the Literature Review (Chapter 2), although it was recognised that there are a 
multitude of definitions used within the literature, the EMA’s (2017) definition of the 
acceptability of medicine was established as the most reliable and widely used 
definition: 
“Patient acceptability can be defined as the ability and willingness of a patient 
to self-administer, and also of any of their lay or professional caregivers, to 
administer a medicinal product as intended.” (EMA, 2017, p3). 
 
This definition of patient acceptability is crucial to explaining what acceptability is, as 
without it there would be no understanding about what acceptability refers to and how 
it should be evaluated. However, the findings from this research highlight additional 
component constructs (building blocks) that influence acceptability and argue that 
these should be included in a definition of the acceptability of medicine (see Section 
7.3).  
 
Therefore, the current study proposes an extended definition that can be 
operationalised for the purpose of measurement. This is grounded in the initial 
understanding provided by the EMA as well as the findings produced by the children 
in the study and is closely aligned with the definition of healthcare intervention 
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acceptability as proposed by Sekhon et al. (2017). This definition accounts for the 
newly identified constructs in 7.3.2 and explains how specific variables can be used 
as indicators to assess acceptability in order to provide a definition that will allow 
researchers to effectively measure the concept of acceptability.  
 
The following definition of the acceptability of medicine is proposed: 
 “A multi-faceted construct that reflects the extent to which a child self-
administering, or a parent or person administering, and a child receiving a 
medicine considers it to be appropriate, based on their anticipated or 
experienced cognitive and emotional responses to the medicine, resulting in 
the child’s intention to engage with the medicine”.  
 
This proposed definition draws on Sekhon et al. (2017) and incorporates the newly 
identified component constructs of acceptability (cognitive and emotional responses- 
see Section 7.3.2). It proposes that cognitive and emotional responses are likely to 
influence behavioural intent to engage with the medicine. Involving children emotional 
and cognitive responses to medicines aims to account for the full extent of 
acceptability, rather than solely focussing on product aspects. This definition is also 
more aligned with the definition proposed by Drumond (2017), who defines 
acceptability of medicine as the “sum of positive and negative experiences of a patient 
and/or caregiver with a pharmaceutical drug product before, during and after use, 
which will affect the ability and willingness to take or use the drug product as intended” 
(p296). 
Whereas the original definition includes the willingness of the child, the definition 
developed from this study proposes that it is the child’s intention rather than 
willingness that plays a bigger part as a predictor for engaging in the treatment. The 
intention of the child is driven by the characteristics of the user identified as impacting 
on acceptability in the current study. Willingness and intention have been reported as 
synonymous (Chen et al, 2018), however, whilst they are similar, there are distinct 
differences between intent and willingness that should be considered. Firstly, 
willingness is defined as “an individual’s openness to opportunity, that is, his or her 
willingness to perform a certain behaviour in situations that are conducive to that 
behaviour” (Pomery et al, 2009, p3), however behavioural willingness is said to involve 
“little precontemplation of the behaviour or its consequences” (Pomery et al, 2009., 
Gerrard et al, 2002., Gerrard et al, 2009). Within the current study, it is clear that a 
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child’s decision to take a medicine is not a passive act, children do consider whether 
or not to take a medicine, and the consequences of either taking, or not taking, the 
medicine. Therefore, behavioural intention seems a better fit. Azjen (1991) defines 
behavioural intention as, “Intentions are assumed to capture the motivational factors 
that influence a behaviour; they are indications of how hard people are willing to try, 
of how much of an effort they are planning to exert, in order to perform the behaviour” 
(p. 181). It is therefore argued that the intention of the child to engage in taking 
medicine is arguably more important than the willingness of the child. Furthermore, it 
is proposed that the user aspects influencing the acceptability of medicine within the 
model could be predictors (motivational factors) of the child’s intention to take the 
medicine, and therefore by including these in acceptability assessment is more likely 
to result in a more accurate and valid acceptability rating. These motivational factors 
or constructs are discussed in section 7.3.2 Children and user aspects. Following this 
a discussion of the influence of product factors on acceptability can be found in Section 
7.3.3.  
7.3 Theoretical Framework of Children’s Medicine Acceptability 
The previous section outlined the newly developed definition of the acceptability of 
medicine, this definition was produced drawing on past literature and incorporating the 
data from the current study. The following section will discuss the newly developed 
framework, and its purpose in providing a conceptual model of the constructs that 
influence the acceptability of medicine. 
 
As referred to in the previous section, current understanding of user aspects that 
influence acceptability is limited, and the findings from this study propose a number of 
aspects that should be considered. The Framework of Children’s Medicine 
Acceptability proposes an additional seven constructs that influence acceptability. 
These constructs were identified by applying inductive methods to review the empirical 
data provided during data collection with the children (see Appendix 36 for preliminary 
framework).  
 
7.3.1 Developing a new framework: Framework of Children’s Medicine 
Acceptability  
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The Framework of Children’s Medicine Acceptability accounts for the pre-existing 
constructs of the acceptability of medicine that relate to the user and product 
characteristics as outlined by the EMA (2018). This provides a framework that 
encompasses both: characteristics of the product and characteristics of the user and 
presents a structure to assess these factors together. Therefore, whilst the TFA 
(Sekhon, 2017) has been used as a basis for the theoretical underpinning of this model 
and has been applied to the new user constructs identified in the study, the new 
framework developed from this study is an updated and re-developed model (Figure 
7.3). These findings, particularly those relating to user aspects, were also used to 















Figure 7.3: Framework of Children’s Medicine Acceptability 
This section will firstly discuss the necessity for the additional constructs to be included 
in a framework of the acceptability of medicine, it will then outline how both of these 
aspects (product aspects and user aspects) work together and can be evaluated as a 
whole.  
 
7.3.2 Children and user aspects  
Within this study children talked about discrete emotions, issues, beliefs and 
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already mentioned, acceptability is often viewed from the perspective of adults and 
typically focusses on the product characteristics. However, as the Framework of 
Children’s Medicine Acceptability highlights, there is a need for the inclusion of 
additional user characteristics as children reported that these influence the overall 
concept of acceptability. However, unlike the existing characteristics of the user which 
have been reported as important by adults (age, ability, disease type and state), the 
additional factors are inherent to children’s experiences with medicine. The inclusion 
of these factors has the potential to improve how acceptability is viewed and ultimately 
assessed.  
 
The following factors relate to either children’s cognitive or affective responses to 
medicines or their impact on whether a medicine is deemed acceptable or not. The 
first four factors: treatment coherence, perceived effectiveness, self-efficacy and 
opportunity costs relate to cognitive factors, and the following three: affective attitude, 
burden, and ethicality relate to affective responses (the definitions provided for use in 
the Framework of Children’s Medicine Acceptability can be found in Table 7.1). Within 
social psychology it is proposed that humans rely on affect, cognition and behaviour 
to effectively manoeuvre and make sense of life (Jhangiani & Tarry, 2014). Cognition 
helps people to understand and predict the behaviour of themselves and others. Over 
time, sets of knowledge are developed which allow quick judgements to be made 
about a person, object, or in this case a medicine. For example, a child’s knowledge 
could be that needles hurt, or that medicines help. A person’s set of knowledge and 
interpretation of events is dependent on past experience, for example: a child who 
takes a tablet every day might interpret the benefits of the medicines as more 
significant than a child who takes tablets less frequently, as they might not understand 
the benefits they provide.   
 
Similarly, affect refers to the feelings that are experienced in day to day life (Shouse, 
2005). Emotions can be strong and caused by specific events (such as taking a 
medicine) and are often accompanied by high levels of arousal (Steimer, 2002). They 
can serve as adaptive purposes, for example, being afraid of a needle because you 
believe they cause pain will lead to avoiding needles to protect yourself from the hurt. 
However, this can become harmful when it is left unregulated and unchecked i.e. a 
child’s belief that needles are painful could adversely impact on them receiving 
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treatment for a condition that requires this mode of administration. Research has found 
a positive influence between affect and behavioural intention (Phua, 2012), if a person 
approaches a subject or experience with a positive attitude, they are more likely to be 
more prepared and willing to display more accepting behaviours (Selwyn, 1997).   
 
The domains of the framework are used to structure the following sections of the 
Discussion.  
Table 7.1: Framework of Children's Medicine Acceptability: User domains.  




Treatment coherence The extent to which the child understands the purpose for 
the medicine, and how the medicine works. 
Perceived effectiveness  Extent to which the child perceives the medicine as likely to 
achieve its purpose.  
Self-efficacy  A child’s confidence in being able to use the medicine alone 
or with help.  
Opportunity costs The extent to which the benefits of the medicine outweigh 
the negatives.  
Affective 
factors 
Affective attitude How a child feels about the medicine.  
Burden The perceived amount of effort required for the child to take 
the medicine.  
Ethicality  The extent to which the intervention has good fit with an 
individual’s value system. 
 
7.3.2.1 Treatment coherence  
Treatment coherence is defined as the extent to which the child understands the 
purpose for the medicine, and how the medicine works.  
 
Coherence and understanding of an illness or medical intervention has been reported 
as an indicator of intervention acceptability (Huddleston, 2012), and in his definition of 
treatment acceptability, Kazdin (1981, 2000) includes the extent to which a consumer 
finds an “intervention to be fair, appropriate, reasonable and consistent with their 
expectations of treatment”. Similarly, Sekhon (2017) also included intervention 
coherence as an influencing factor in acceptability. By drawing on health psychology 
literature, Sekhon (2017, p9) provides a definition of intervention coherence as “the 
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extent to which the patient understands the intervention, and how the intervention 
works”.  
 
The findings from this study demonstrate that children’s perceptions of acceptability 
are dependent on their understanding of their medicines and the purpose of medicines 
use in relation to the medical problem. In contrast to previous studies (Kameen-Anttila 
et al, 2006; Menacker et al, 1999), children in the current study had a good 
understanding about how medicines work and what they were used for. Older children 
in the study (8-12yrs) were more conscious of how medicines work in general, 
whereas younger children could explain about how they thought medicines they had 
specific experience with worked. This may be related to the cognitive development 
across different ages, and previous studies have demonstrated that the understanding 
of illness follows a cognitive development pattern (Bibace & Walsh, 1980; Hameen-
Anttila & Bush, 2008). Therefore, a child may understand some topics of medicine use 
more easily depending on their operational stage of cognitive development (Hameen-
Anttila & Bush, 2008).  
 
Similarly, sources of children’s knowledge about medicines was also varied in the 
current study and could also explain why coherence or understanding of medicines 
was so varied. Most children referred to their own prior experiences with specific 
medicines, or their observation of a family member using medicines. This is in line with 
studies from the US, Canada and Finland that report that parents, specifically the 
mother, is a child’s primary source of information about medicines (Menacker et al, 
1999; Bozoni et al, 2006; Chambers et al, 1997). In contrast to Stoelben et al (2000) 
children in the current study did not mention medicine packaging as a source of 
information.  
 
7.3.2.2 Perceived effectiveness  
Perceived effectiveness is defined as the extent to which the child perceives the 
medicine as likely to achieve its purpose.  
 
The effectiveness of medicines was one of the first things that children discussed. 
Children, whether they had experience taking medicines or not, talked in general about 
how medicines help. In the current study, children generally viewed medicines 
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positively and discussed how medicines improve health; this is in accordance with 
other literature (Hameen-Anttila & Bush, 2008). Similarly, children also reported that 
medicines should mainly be used when you are sick to help you get better or when 
they were really needed, these findings are similar to that of work from Garcia et al 
(1996) and Hameen-Anttila et al (2006). However, children in the current study not 
only mentioned that medicines could help an existing illness but also reported the 
preventive value of medicines such as vitamins. This is at odds with previous literature; 
a systematic review (Hameen-Anttila & Bush, 2008) found that in most studies, 
children generally talked about medicines helping cure an existing illness rather than 
prevent an illness. The idea that positive past experiences might facilitate a child to 
develop a positive belief system about medicine is presented in the previous chapter 
and reiterated here. This aligns with work from the field of cognitive psychology which 
argues past experience influences our beliefs, attitudes and future behaviour 
(Albarracin & Wyer, 2000). Arguably, how effective a child believes a medicine to be 
is a key driver in children accepting a medicine, with a number of children explaining 
that they accept medicine because it helps, or because they believe that it helps.  
 
As well as past experience, children also evaluated the effectiveness of a medicine 
based on how it looked. A systematic review (Hameen-Anttila & Bush, 2008) found 
that young children often identify a medicine by referring to its appearance (colour, 
form). The impact of colour and form is discussed as a product factor in section 7.3.3.2. 
However, studies have found that children often relate the efficacy of the medicine to 
external characteristics (Menacker et al, 1999; Bush et al, 1985). For example, 
children believe that the size, taste or colour of a medicine is related to how well the 
medicine works (Menacker et al, 1999; Bush et al, 1985).  
 
7.3.2.3 Self-efficacy  
Self-efficacy is defined as a child’s confidence in being able to use the medicine alone 
or with help.  
 
Children’s participation in the medicine-taking process was regarded as an important 
influence on acceptability by children. This is in line with past research that has found 
that children regard themselves as active participants in their medicine use and report 
they are more autonomous in using medicines than parents indicate (Hameen-Anttila 
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& Bush, 2008). Autonomy was frequently mentioned in the current study, and children 
talked about a range of actions from knowing where medicine is kept in their homes, 
to administering and taking a medicine by themselves. These are in line with 
behaviours included on an 11-item medicine autonomy scale, used within previous 
research (Bush & Davidson, 1982). It is reported that autonomy, or self-efficacy, is one 
of the most influential cognitive variables on behaviour (Martos-Mendez, 2015). A 
number of psychosocial models include self-efficacy, such as The Attitude, Social 
influence and Self-efficacy model, which suggests that the patient (user) should have 
“sufficient self-efficacy to perceive herself/himself as being able to take the medicine 
as prescribed” (Lopez et al, 2003; in Martos-Mendez, 2015., p21).  
 
A child being able to use a medicine independently improved acceptability of medicine 
for children who were required to take a medicine frequently for a condition such as 
Attention Deficit Hyperactivity Disorder. Self-administration and taking ownership of 
treatment is reported as fairly common for conditions that children are knowledgeable 
about (such as taking paracetamol for headaches) (Chambers et al, 1996). However, 
in the current study restriction by external factors, such as being at school or requiring 
a glass of water, reduced acceptability. Self-administration or autonomy in medication 
was related to children’s knowledge and skills of their condition and treatment; this is 
also reported in a systematic review (Hameen-Anttila & Bush, 2008). Children who 
had more experience with a condition or treatment voiced a greater amount of 
empowerment and knowledge about their medicines, and for these children 
acceptability was improved when they could use their medicine independently. For 
other children with less experience of medicines and reduced awareness about the 
risks of medicines, having an adult involved in the process was fundamental to how 
they viewed the medicine taking process. 
 
7.3.2.4 Opportunity costs 
Opportunity costs are defined as the extent to which the benefits of the medicine 
outweigh the negatives.  
 
Children discussed opportunity costs as the benefits of the medicine outweighing the 
negatives. This has been referred to in intervention acceptability as “the extent to 
which benefits, profits, or values must be given up to engage in an intervention” 
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(Sekhon et al, 2017, p8). Within healthcare this is often referred to as balancing the 
risk/benefit ratio. In the current study, children generally explained that they would 
accept negative aspects of a medicine, such as a bad taste, if they believed that taking 
the medicine was beneficial to their health, for example, one child described a time 
that he was in hospital for a procedure which required him to be put under general 
anaesthetic where the medicine was horrible but he understood that it helped him. His 
knowledge about the benefits of the medicine outweighed his emotional response to 
the bad taste.  
 
The acknowledgement that people, both adults and children, should have access to 
the possible benefits and risks of a medicine has been recognised within the last 
decade (DoH, 2012), and this focus on health literacy has improved the access of 
information for patients. Raynor (2012) reported that low health literacy leads to worse 
mortality in the UK, and research has shown that for children the provision of patient 
information that is accessible, understandable and usable can reduce worry and fear 
about medical procedures (Bray et al, 2019).  
 
In order for children to assess the opportunity costs of their medicines, it is crucial that 
they are informed about the reason they are taking their medicines. The findings from 
the current study suggest that if a child is not fully informed about the benefit of taking 
their medicine, or if they are administered a medicine without having its purpose 
explained, it could lead to children’s affective responses dominating their behavioural 
response. Whereas if a child understands why they are being administered a 
medicine, they are more likely to use their knowledge and their cognition to evaluate 
the benefits and risks and make a behavioural decision rather than act on an emotional 
reaction. This has also been demonstrated in a study from Berry (2007), who found 
that parents who are fully informed are more likely to fully assess the benefits and risks 
of their child’s treatment.  
 
7.3.2.5 Affective attitude  
Affective attitude is defined as how a child feels about the medicine.  
 
Affective attitude, in relation to the findings of this study, can be understood as how an 
individual feels about taking the medicines. Children in the current study displayed that 
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they had developed attitudes towards medicine, this has previously been found in a 
study with 7-year-old children (Hameen-Anttila et al, 2006), and in 6-12-year-old 
children (Syofyan et al, 2019). These attitudes were either positive or negative, and 
specific factors of medicines were related to these attitudes. Positive attitudes were 
generally attributed to the clinical value and effectiveness of the medicine, as well as 
characteristics related to the palatability and appearance of the medicine. Children’s 
attitudes toward medicine have been reported in a number of other studies (Dawood 
et al, 2011; Sharaideh et al, 2013) however reasoning was not provided (Syofyan et 
al, 2019). Similarly, children also expressed negative affective attitudes towards 
medicines, related to a bad prior experience or perceived risk of negative side effect 
(such as adverse drug reaction or choking), this is also reported in Syofyan et al 
(2019). 
 
7.3.2.6 Burden  
Burden is defined as the perceived amount of effort required for the child to take the 
medicine.  
 
Whilst how easy the medicine was for children to use has been discussed in relation 
to self-efficacy in 7.3.2.3, children also talked about amount of effort required in using 
a medicine. Children talked about the frequency of taking their medicines being a 
burden, as well as the disruption caused to their routine such as when their medicine 
regime required regular attendance at hospital. It is clear that burden influences 
acceptability, with children expressing negative affective attitudes about their dislike 
for the amount of effort required in taking certain medicines. It is also clear that both 
burden and the associated emotions, can cause negative behavioural responses such 
as “kicking off”. Whilst the behavioural response is typically used as the base for 
assessing acceptability (Blume et al, 2018; Rodd et al, 2011; Beck et al, 2005), 
understanding the reasons for the behaviour, and the ways in which this can be 
counteracted could be crucial to understanding and improving acceptability.  
 
As well as practical burdens, psychological burdens were also referred to. Some 
children expressed fears about taking medicines, this is also reported by Bush & Joshi 
(2002). These fears were related to the dangers of medicines, such as taking a wrong 
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medicine or someone else’s medicine (Menacker et al, 1999; Bush & Joshi, 2002). 
Children were also conscious of the dangers of taking a medicine for a condition that 
they do not have, being allergic to the medicine, or taking too much medicine for your 
age. These factors are also reported within a systematic review (Hameen-Anttila & 
Bush, 2008).  
 
Finally, children were conscious of the safety of testing of medicines during the 
development process. They stated that medicines should be assessed with healthy 
adults and children before they were given to a sick child to ensure the medicine does 
not make the sick child’s condition worse. Furthermore, the children in the current 
study were aware of adverse reactions such as being sick or not taking enough 
medicine, this finding is similar to the results provided by Stoelben et al (2000) who 
reported that 79% of German children (15-17 years) were aware that medicines can 
have harmful effects. The children in the current study were younger than the sample 
in the study from Stoelben et al (2000), and so this might imply that children of a 
younger age may also have an awareness of the risks associated with taking 
medicines.  
 
The psychological burden of medicine-related pain in children has been extensively 
researched (Birnie et al, 2018), and research reveals that the past experience has a 
significant impact on children’s perception. Findings from the current study reveal 
psychological burden and memory, particularly in relation to needles. Some children 
reported needles or tablets as scary and recounted traumatic past experiences of 
some medicines, some recalling episodes when they were younger and of which they 
had little clear memory but which they still talked of as being painful. Research by 
Chambers (2019) acknowledges this burden but states that “it’s not so much how 
much pain children have from an injection, but how much pain they remember having, 
that impact their subsequent experiences”. Noel (2012) builds on this proposing that 
when children remember previous pain as more severe, they experience future pain 
as more intense (Noel, 2012). Additionally, Chambers (2019) also reported that pain 
perspectives can be socially constructed and influenced largely by family members, in 
particular parents and siblings (Chambers, 2019). This was true for the children in the 
current study who had observed someone else, such as a sibling, in pain, or those 
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children who had been told about the pain by a friend or family member who had 
primed them with the awareness that needles are painful.  
 
7.3.2.7 Ethicality  
Ethicality, in the current study, is defined as the extent to which the medicine is a good 
fit with individual child’s value system. Children in the current study displayed an 
awareness that taking medicines was the right thing to do to help them to get better. 
They demonstrated that they understood that taking medicines was the right course 
of action, even when they did not necessarily like the medicine. Ethicality was also 
reported as a factor in Sekhon’s (2017) framework of intervention acceptability. There 
is little supporting evidence for ethicality in decision-making to take medicines in past 
literature, and no studies have asked children about this as yet. The current literature 
base is sparse in this area and a focus on this in future research would be beneficial.  
 
7.3.3  Children and product aspects 
In addition to the seven user aspects identified in the data and applied to the 
framework, children also discussed product aspects that influence acceptability. As 
outlined within the literature, the acceptability of a medicinal product is said to be 
dependent on the palatability/swallowability, the appearance, complexity, 
volume/amount, frequency and duration, administration device, primary/secondary 
container, and the mode of administration of the medicine (Kozarewicz, 2014; Ranmal, 
2016). Children’s perceptions of the acceptability of medicines related to specific 
aspects of medicines that either improved or reduced acceptability. Within this section 
the findings that relate to these aspects are discussed and provide a much-needed 
child’s perspective on the product factors that influence acceptability. The aspects 
which improve or reduce acceptability are discussed in five sub-themes: 
palatability/swallowability, mode or form of administration, complexity/ease of use, 
size/volume/amount, frequency and duration. 
 
7.3.3.1 Palatability/swallowability 
Children reported that the smell, taste, and feel of a product would each improve the 
acceptability of a medicine. This finding is in line with the wider literature, with the 
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palatability of a medicine regarded as one of the most important factors relating to the 
product in paediatric medicine development (Mistry & Batchelor, 2016).  
 
It was clear that taste and flavours were factors that dominated children’s discussions 
and figured in their drawings and their responses to the activities; taste and flavours 
were considered by the children to be important measures of acceptability. However, 
it is worth reflecting on why these factors came through so strongly. As previously 
discussed (section 4.2.1) the nature of the activities that the children engaged with 
may have created a particular expectation and frame that might have triggered the 
children to talk about taste and flavours. In the Marvellous Medicine activity, the 
children were guided to think about shape, taste, colour and smell although no limits 
or constraints to their imagination were imposed (beyond only being able to access 
the colours of pencils that were available). Similar sorts of prompts were present in the 
other activity booklets. Although the activities provided a degree of direction, they did 
not prioritise particular factors, so the emphasis on taste and flavour can be reasonably 
confidently deemed to arise from the children rather than any bias within the research 
design or design of the tools. With the previous points in mind, the children reported 
that the smell, taste, and feel of a product would each improve the acceptability of a 
medicine. This finding is in line with the wider literature, with the palatability of a 
medicine regarded as one of the most important factors relating to the product in 
paediatric medicine development (Mistry & Batchelor, 2016). 
 
Palatability has been defined as “the overall appreciation of a (often oral) medicine by 
organoleptic properties such as vision (appearance), smell, taste, aftertaste, and 
mouth feel (e.g. texture, cooling, heating, trigeminal response), and possibly also 
sound” (Kozarewicz, 2014, p245-248). Within the current study, whilst children did not 
specifically refer to the palatability of a product, they did talk about a number of these 
factors defined within palatability. Taste and palatability are reported as key barriers 
to completing treatment (Batchelor & Marriot, 2015; Milne & Bruss, 2008), and this is 
further complicated when considering the diversity of taste preferences in the 
paediatric population. Children in the current study had different ideas about what 
tastes would make a medicine acceptable, and one of the main ideas was that ‘no 
taste’ would be best. The taste of Calpol and strawberry flavours were also frequently 
mentioned and talked about in a positive way. These findings could reflect children’s 
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biology, with past research revealing that children between the ages of 3-10 years 
reject bitter tastes (Mennella et al, 2005; Mennella et al, 2014) and unpleasant textures 
(Mennella et al, 2013), and favour sweet or pleasant tastes (Mennella et al, 2011).  
 
7.3.3.2 Mode or form of administration 
The mode and form of the medicine was also discussed as impacting on acceptability. 
Liquid formulations, often labelled as the formulation of choice for children, particularly 
by parents (Mennella et al, 2015), were talked about as being difficult to use and had 
more negative mouthfeel associations than other formulations. This is in line with prior 
research reporting that children find liquid formulations problematic to take (Mennella 
et al, 2015). In contrast, children talked more positively about tablets. In research 
about the acceptability of mini-tablets, it has been reported that children (aged 
6months-6years) prefer mini-tablets in comparison to syrups (Musiime et al, 2014). 
Specifically, in the current study children liked tablets as they viewed them as a ‘real’ 
medicine that adults have, or perceived tablets as sweets or sweet-like. In recent years 
significant attention has been paid to the impact that ‘sweet-like’ medicine can have 
on paediatric adherence to treatment, and studies have already started to create three-
dimensional tablets in the shape of sweets, such as Starmix ® (Scoutaris, Ross & 
Douroumis, 2018). However, there were also negative perceptions of tablets, and 
consistent with prior reports (Czynewski et al, 2000) some children voiced concerns 
about the fear of being sick or choking on tablets.  
 
Whilst children generally regarded the colour and what the medicine looks like as the 
least important factor influencing acceptability (see Section 6.4.1.2), colour seemed to 
be an influencing factor in children’s drawings. The majority of children explained their 
colour choices because it was their favourite colour, it made children feel magical, or 
it was the colour associated to the smell or taste of the medicine, or sweet. Within 
psychology, it is well understood that people make judgements based on colour 
(Morton, 2016). Colour of medication has been found to influence our emotional 
reaction to the medicine, a systematic review has found that different colours illicit 
different emotional responses to medicines, for example: red, yellow and orange are 
generally associated with stimulating medicines, whereas blue and green were 
generally regarded as tranquilising (Craen et al, 1996). The impact of a medicines 
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colour on patients’ attitude is well reported in the literature (Craen et al, 1996), and 
one study has found that the colour of medication has an influence on patient’s 
adherence (Fitzgerald, 2013). Differences in perception of medication colour has been 
reported between age and genders (Strivastava & More, 2010). Therefore, whilst 
children did not report the colour of medicine to be an important factor influencing on 
acceptability, this could be due to associations being subconscious and not something 
children are generally aware of. When developing medicines for children, being aware 
of the association’s children have to certain colours is an important consideration.  
 
7.3.3.3 Complexity/Ease of use 
The complexity or ease of use of a product was voiced by the children as being one 
of the most important factors when considering the acceptability of a medicine. 
Children perceived medicines that they could use on their own, or without help from 
anyone else as more acceptable. Medicine that did not require any additional help 
(such as by parents or teachers administering or helping) were reported as more 
acceptable by some children who frequently used medicine (such as for ADHD), 
whereas other children who only used medicine when they were sick (such as calpol 
in a syringe or spoon) talked frequently about adults helping to administer medicines. 
This is supported by literature that reports that when children are unwell, autonomy in 
using medicines is not important (Gerrits et al, 1996). This suggests that the context 
around the medicines use could be an important factor to consider when prescribing 
medicines for children.  
 
7.3.3.4  Size/volume/amount 
The size or amount of medicine was also related to the acceptability of medicines, with 
most children explaining that a medicine that was too big or too much would reduce 
its acceptability. Tablet size is a frequently considered factor in formulation 
development, and tablet size has been deemed the most important factor relating to 
the acceptability of tablets in a feasibility study (Bracken et al, 2018). The size and 
amount of a medicine was the key reason for children voicing fears about the 
formulation, as reported in previous research (Czynewski et al, 2000) which reported 
that fears about choking or the medicine getting stuck in their throat reduced its 
acceptability. However, tablets up to 10mm in diameter have been demonstrated to 
be acceptable to children between the ages of 4-12 years when swallowed whole 
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(Bracken et al, 2018), and therefore it could be argued that the fear of the tablet is the 
cause of the issue rather than the formulation itself (fear as a barrier is discussed in 
detail in 5.4.2.2). Pill-swallowing training has been found to be related to improved 
medication adherence (Garvie, Lensing & Rai, 2007), and a recent systematic review 
reported that pill swallowing difficulties can be overcome with a variety of interventions 
(Patel et al, 2015).  
 
7.3.3.5  Frequency and duration 
Children reported that the extended frequency or duration of treatment would 
negatively affect acceptability. For children who were treated in hospitals, longer 
duration of treatment meant that they missed out on other aspects of their lives, such 
as school or weekends at home. The impact on longer duration of treatment has been 
reported as a barrier to compliance in adult treatment (Menzies et al, 1993; Dhanireddy 
et al, 2005). Whilst treatment duration was not reported as a barrier for children outside 
of hospitals, the frequency of having to take an inhaler or tablet each day to manage 
a condition was discussed by this group. Dosing frequency is reported as a 
consideration of acceptability in formulation development (Kozarewicz, 2014).   
 
In summary, Section 7.3 has discussed how the conceptual TFA model developed by 
Sekhon et al (2017) has been applied to the empirical data collected from the children 
in the study, in order to better understand children’s acceptability of medicine. This 
consideration of the TFA allowed the creation the Framework of Children’s Medicine 
Acceptability which addresses both user aspects and product aspects which can be 
applied to the development and assessment of medicines. The Framework of 
Children’s Medicine Acceptability is the first attempt at applying theory to the defining 
and operationalising of the acceptability of medicine.  
 
7.4  Improving Acceptability Assessment 
Involving children in this research regarding the understanding of the acceptability of 
medicines aimed to improve understanding of how children approach taking medicines 
and the barriers to an acceptable medicine. It is argued within the literature that 
“ensuring that formulations are suitably designed and acceptable to end-users reduces 
the risks that medicine quality could be compromised, supports patient adherence and 
consequently leads to safer and effective use of medicines” (Ranmal, 2018, p 2).  
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However, despite the wealth of literature and guidance provided about product aspects 
or characteristics of medicinal products that are said to impact acceptability (Liu, 
2015), there is a recognised lack of empirical evidence on the suitability and end-user 
opinions of medicines in the child population (Ranmal, 2018).  
 
In 2009, NICE published an extensive guideline about the inclusion of patients in their 
own healthcare. This outlines that “informed patient choice, rather than ‘compliance’ 
is the desired outcome” (NICE, 2009, pp53-54). It states, “facilitating informed choice 
involves more than the provision of information. Informing should be an active 
process… it also entails eliciting the patient’s beliefs and identifying whether pre-
existing beliefs might act as a barrier to an accurate interpretation of the evidence” 
(NICE, 2009, p53). In the current study, the findings demonstrate that children’s beliefs 
and emotions about treatment and medicines impact on their perception of the 
acceptability of medicines. This therefore may impact their adherence to the treatment.  
 
Involving children in this study has led to a better understanding of some of the 
influences that might play a part in a child regarding a medicine as acceptable or not. 
The NICE (2009, p56) guideline states that “the decision to take medicines and the 
continuing taking of medicines should be considered as a complex behaviour… 
internal factors represent the beliefs and experiences of the patient. These include the 
patient’s beliefs about medicines in general and their own reaction to medicines. 
These will influence their intention to take a medicine as suggested by a health care 
professional.”  This mirrors the findings from the current study, which show that 
children’s beliefs and experiences impact their intention to take a medicine. Similarly, 
the current study also demonstrated that factors such as prior experience, 
communication with family and friends, and information provided by other people who 
have had the same medicine or treatment also impacts on a number of the user factors 
and therefore children’s intention to take a medicine. This is also reported in NICE 
guidelines (2009). Furthermore, within health risk-behaviour literature, ‘experience’ is 
reported as a moderator for engagement in behaviour. Individuals with more 
experience are reported as more likely to be increasingly aware of the consequences 
of engaging, or not engaging, in a health behaviour (Pomery et al, 2009). 
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A child’s decision about the acceptability of a medicine is made within their own frames 
of reference and make sense within their own understanding. However, a key issue 
with this is that these factors are not currently given attention when developing or 
administering medicines for children. Researchers and healthcare professionals are 
generally focussed on improving the product, and rarely acknowledge that the child’s 
reluctance to take medicine, or disagreement with the prescriber’s recommendations 
may stem from the child’s beliefs and attitudes and can be the cause of the issue for 
acceptability. NICE (2009) state that the onus is on health professionals to “elicit and 
explore patients’ beliefs and experiences, and facilitate the patient making an informed 
choice about whether or not to take a prescribed medicine” (p56). Therefore, in order 
to do this, children need to be effectively involved in these discussions, and 
appropriate tools are required to facilitate this involvement; this was the focus of 
objectives two and three in the study.  
 
As previously discussed, the ways that the acceptability of medicine is currently 
assessed in children is limited and often does not capture the total extent of 
acceptability. Throughout this discussion it has been argued that the inclusion of 
additional factors relating to the child would improve understanding of acceptability. 
The following section will discuss how measures can be improved to facilitate the 
effective involvement of the child in acceptability assessment.  
 
7.4.1 Inclusion of user factors 
The Framework of Children’s Medicine Acceptability highlights additional constructs 
that should be considered during the acceptability assessment and proposes that 
these can be applied within the development stages of paediatric products. In 
guidance provided by the WHO it is stated that the “window of opportunity during which 
acceptability can be assessed and the formulation modified is short” (WHO, 2019, 
p92). This is because the “characteristics of the product only begin to be known when 
the paediatric investigation plan (PIP) or paediatric study plan (PSP) is submitted, and 
it is only when the first formulation prototype is available that acceptability can be truly 
evaluated in the target population” (WHO, 2019, p92).  
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However, in contradiction to this notion of a short window of opportunity, it is proposed 
that the Framework of Children’s Medicine Acceptability can be applied both 
quantitatively and qualitatively to the development process. This would lengthen 
and/or widen that window of opportunity by enabling the assessment of acceptability 
prior to the development of the formulation prototype. At the planning stage of 
developing formulations, it is reported that little is known about specific needs of 
children (WHO, 2019, p95). However, the characteristics of the user outlined in the 
new framework provides additional information for formulators and developers to refer 
to in order to provide a more appropriate formulation. The framework also provides a 
method of considering the acceptability of a formulation prior to the formulation being 
developed. With the prospective assessment of medicine acceptability, children can 
provide their judgement of a potential medicine based on the user and product 
characteristics outlined in the framework.  
 
It is theorised that patient acceptability will change across these time points (Sekhon, 
2017) and therefore it is important within acceptability of medicines work for 
formulators and researchers to outline at what time point acceptability is assessed 
(e.g., prior to commencing medicine, whilst taking medicine, after completion of 
medication course) to ensure accurate acceptability assessments. It is a key feature 
of the framework that children can make a judgement about whether or not they expect 
the medicine to be acceptable prior to having had the medicine. These judgements 
are argued to be as a result of past experience influencing the new user factors 
outlined in the Framework of Children’s Medicine Acceptability. Being able to 
effectively assess anticipated acceptability by evaluating these factors would provide 
the ability to highlight which aspects of the medicine would need to be changed or 
modified to improve acceptability or children’s responses to the medicine.  
 
Anticipated acceptability could encompass a timespan from the development stage 
through to clinical trials or a time close to the ‘routine’ administration of the medicine 
to a child. This would be significantly beneficial to pharmaceutical companies and their 
research divisions that often invest many years and funding into developing a medicine 




In the knowledge that it would not be possible to assess product factors and user 
factors separately during the acceptability of medicine assessment, Table 7.2 
demonstrates how it might be possible to assess the collective acceptability of the 
medicines accounting for both the user aspects and product aspects.  
 
Table 7.2: Proposed Framework of Children’s Medicine Acceptability methods applicable to the 







Qualitative Qualitative Qualitative 
e.g. semi-structured interviews 
or workshops based on 
constructs from Framework of 
Children’s Medicine 
Acceptability with children to 
help guide development of 
formulation 
e.g. semi-structured interviews 
based on constructs from the 
Framework of Children’s Medicine 
Acceptability with children and 
deliverers about anticipated 
and/or experienced acceptability 
during the administration or 
treatment duration.  
e.g. semi-structured interviews/focus 
groups based on constructs from the 
Framework of Children’s Medicine 
Acceptability with children to assess 
experienced acceptability post-
administration/treatment.  
Quantitative Quantitative Quantitative  
e.g. questionnaires or child-
centred rating scales based on 
constructs from the 
Framework of Children’s 
Medicine Acceptability to 
assess anticipated 
acceptability of the medicine or 
treatment.  
e.g. questionnaires or child-
centred rating scales based on 
constructs from the Framework of 
Children’s Medicine Acceptability 
to assess acceptability during 
trials or administration with 
children.  
e.g. questionnaires or child-centred 
rating scales based on constructs 
from the Framework of Children’s 
Medicine Acceptability to assess 
acceptability post 
administration/treatment to assess 
retrospective acceptability.  
 
The WHO states that “At the earliest conception of the strategy for developing 
formulations for children, all the dimensions of acceptability must be considered.” 
(2018, p10). This might help to facilitate the consideration of acceptability earlier in the 
process. Furthermore, the findings from the current study also reveal that children 
have the agency to meaningfully contribute to these discussions about the 
acceptability of medicine. Children demonstrated not only that they believe they should 
be involved, but also how and why it was important for them to be involved in 
medicines development and assessment. They discussed the necessity of being 
involved in medicine development, and how assessment measures could be improved 
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through the involvement of children. It has been reported that children benefit from 
shared decision making in healthcare decisions in a number of ways. By influencing 
their wellbeing (Spinetta et al, 2002), improving effectiveness of services and 
enhancing communication skills (Cohen and Emanuel, 1998). The findings from the 
study reflect wider conversations regarding the inclusion of children, or the opportunity 
to participate, in decisions that affect their healthcare (Hinds et al, 2001).  
 
7.4.2  Involving children in acceptability research improves knowledge  
The EMA (2013) provides recommendations for the improvement of assessment 
measures and noted that the tools used to collect acceptability data need to be 
“developed… and validated… [and] must necessarily involve the concerned 
populations” (Lallemant 2018, p13). In the current study children provided their own 
input, and by drawing on their own experiences with acceptability assessment 
measures they worked to evaluate, and re-design current self-report measures used 
to assess the acceptability of medicines.  
 
Children said that being involved in the development of assessment measures would 
be more appropriate than having the measures developed solely by adults. There were 
a number of reasons given for this, firstly children argued that there were distinct 
differences between adults and children in relation to the acceptability of medicine. 
Children have explained that “adults have different tastes to children”, and it “might be 
horrible” if the testing of the medicine was left solely down to adults. Furthermore, 
there was a recognition that children would understand more about the acceptability 
of medicines to children than adults would, acknowledging the differences between 
the two population groups. Differences between adults and children in regard to 
acceptability of medicine is well recognised, and a number of studies demonstrate this 
(Lopez et al, 2018; EMA, 2013).  
 
However, the findings also show that children had an awareness of the importance of 
the safety and effectiveness of the formulation, with the understanding that adults 
should initially ensure it was safe for use, with the assertion that adults were more 
important to medicine development than children. This was discussed in relation to the 
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formulation of medicines and children demonstrated an awareness that children are 
not equipped on their own to develop medicines.  
 
7.4.3  Child-friendly design: Improving response categories 
The findings of the Literature Review in Chapter 2 highlight considerable variety in the 
response images, words and anchors that are used on acceptability assessment 
measures (see Chapter 2). When evaluating and exploring ideas for re-designing 
these measures with the children in the study, children gave consideration to additional 
behaviours and facial expressions that they thought were easier to understand and 
use. The language used on the scales also seemed an important consideration, with 
the words ‘ok’ and ‘acceptable’ eliciting different responses from the children despite 
them being used interchangeably within acceptability assessment (Medeiros, 2016; 
Sjovall, 1984).   
 
There were differences between how children interpreted and presented each of the 
response categories, and this seemed to be particularly dependent on the child’s 
interpretation of how the question was posed and what wording was used. Although 
differences in children’s responses were not clearly correlated to age in the current 
study, past research has considered the capacity of children to respond to scales, and 
wording has been identified as something to be carefully considered in research with 
children (e.g Piers-Harris Self-Concept Scale, 2002). In some studies, wording has 
been re-written depending on the population group to account for reading level (Mellor 
& Moore, 2014), and other studies have substituted the words entirely (Mellor et al, 
2004). Interestingly, children in the current study voiced that having the choice 
between two scales- one with words and one without words, would mitigate issues 
regarding whether words were appropriate for children to read and understand.  
 
The differences between how children interpreted and presented the response 
categories was particularly evident for the middle response/face which is generally 
assumed to be ‘acceptable’ in measurement (Medeiros, 2016). A number of children 
interpreted the middle face as a positive response, whereas some children explained 
that this face was ‘in the middle’ and this was accompanied by the use of a straight 
mouth on the face. Other children decided on a ‘confused face’ with a wavy mouth. 
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Interestingly, when re-designing the faces, some children chose to draw a straight line 
for the mouth of the faces labelled ‘I don’t like it’. Typically, in current assessment 
scales straight mouths are used to indicate the middle response- e.g. ‘ok’ or 
‘acceptable’ (Thompson, 2013; Medeiros, 2012). Therefore, there are implications for 
the use of the straight face to indicate acceptability if the children using the scales 
interpret this to mean something else.  
 
The variety of responses in relation to the wording on the scales may be related to 
children’s cognitive development. The findings demonstrated that children in the study 
could more easily interpret the end anchors, or the most positive and negative 
responses. This is in line with findings from wider literature that has found children 
between the ages of 5-12 years have a tendency to choose the extreme ends of the 
scales when presented with Likert scales (Chambers & Johnstone, 2002; von Baeyer 
et al, 1997). Similarly, when asked to re-design the faces on the scales, children 
generally added features to the ‘extremes’, such as making them more emotive, 
displaying more exaggerated body expressions, for example, a little smiley face, 
smiling with mouths open, crossing arms, frowning, and adding tears to the faces. 
 
Another consideration when using scales with children is whether the results provide 
valid and accurate data (Chambers, 2014). The findings from the current study show 
that the child’s response depends on how the question on the scale is phrased. For 
example, past research has found that some scales refer to the questions in third 
person “What would this face look like if the medicine was good” (Sjovall, 1984), 
whereas the majority present the scales asking for a child’s subjective judgement “how 
would you feel if the medicine was good” (Thompson, 2013). Further research 
exploring this would be beneficial, as limited literature provides any conclusion to 
which format or phrasing is best for children. Other research by Chambers & Johnson 
(2002),  has found that children between 5-11years old are able to accurately report 
judgements about physical objects and this accuracy did not change the younger the 
child was, or whether they were responding using a 3-point or 5-point scale. However, 
subjective judgements, such as emotions or judgements of the self, are more difficult 
for children to report accurately (Tyng et al. 2017). Suggesting that it is not the capacity 
of the child to use a scale, but what the scale is asking that might cause problems. 
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This has implications for the wording of questions on scales, particularly when the 
scale is asking for a response about a subjective feeling or judgement.  
 
Cognitive developmentalists such as Piaget (1954) propose that between the ages of 
7-11 years, children are able to make concrete judgements about physical objects, 
whereas from 12-16 years children enter the formal operation stage, in which abstract 
thinking typically evolves and judgements can be made about feelings and emotions. 
However, these are generalisable concepts and may not apply to every child. It is 
interesting to note that when children were discussing the faces and wording on the 
scales, many of the children referred to personal experiences and drew images that 
matched how they believed they would act when they did not or did like a medicine- 
rather than drawing how they would feel. It could be argued that this reflects the 
literature regarding cognitive development and children’s capacity to report their 
subjective judgements, as a child would be able to make a judgement more easily 
about their behavioural reaction (physical and objective action), as opposed to 
reporting their emotional response or internal feelings (subjective reaction).  
 
There was also an awareness from some of the older children that children younger 
than them might require additional help or different types of information in order to 
understand and use a measurement scale. In the current study children talked about 
how acceptability assessment could be improved if children were provided with a 
choice in which measures were used to assess acceptability, if they were asked how 
they felt about the measures, and if they were included in the development of the 
assessment measures. This has also been found in a study by Hall et al (2017), who 
found that children communicate judgements differently to adults and that in order to 
provide an appropriate differentiation in the sale points, scales need to be adapted to 
children’s emotions. Children also explained that scales would be easier to understand 
if somebody helped to explain what the scales and responses meant. Some of the 
children considered that others might not be able to see, read or understand the 
images and words and therefore having someone help them before being 
administered the assessment measure would be useful. Bell (2007), reports that whilst 
having an adult on hand to help children make sense and understand the questions 
on the scales, it is important that the researcher is aware of potential biases.  
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7.4.4 Presentation of self-report acceptability assessment measures  
When re-designing and developing the existing scales, the children thought that 
changing the presentation of the scales could improve how appropriate the scales 
were to children. The presentation of response scales has not been explored in the 
literature on children’s acceptability of medicine and research is also limited in wider 
literature, with most papers focussing on adults. Wording, presentation and layout of 
a scale has been found to impact on adults (Dillman & Christianson, 2005; Schwarts 
& Oyserman, 2001; Hartley & Betts, 2010). In wider literature, the adaptation of likert 
scales for children has provided evidence that simple sentences and a lower number 
of responses improves children’s participation in the scales (Royeen, 1985). Similarly, 
Royeen (1985) also found that presenting assessment scales in a game format was 
found to reduce anxiety in children. Whilst the current study did not measure the 
outcomes of using different formats, the children in the study generally demonstrated 
a preference for a game format scale. However, it is important that these factors are 
also studied in the wider child population (Betts & Hartley, 2012).  
 
The current study demonstrates that the presentation of scales could be improved in 
a number of ways, specifically, the format of the scale (including scale items, anchor 
points and response images), and the layout of the whole self-report measure 
(positioning of the questions and response categories). The findings from the current 
study demonstrate how simply altering the design or layout of a measure or scale can 
take it from a boring scale and make it more engaging, interesting and child-friendly 
Bell (2007) notes that questionnaire format can help to avoid confusion, boredom and 
cognitive overload. This study shows that developing scales with children is possible 
and that their input could overcome some of these issues with engagement. Landoni 
et al (2017) also note that the inclusion of children in scale development provides 
unique insights and knowledge. This is important in terms of the quality of data 
collected and Betts & Hartley (2012) report that the format of children’s questionnaires 
has the potential to influence data quality. However, further work needs to be 
undertaken on the presentation of assessment scales for children in relation to 
acceptability of medicines  
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An additional consideration of the findings relates to the cognitive ability of the children 
to use the scales effectively. Research has reported that children’s ages and cognitive 
abilities may influence understanding of scale items and anchor points (Fuchs, 2005). 
However, in the current study, most children, regardless of age, identified the scales 
with pictures on as most appropriate. Whilst this was not quantitatively studied, it is in 
accordance with findings from Betts & Hartley (2012) who found that no differential 
effects were found for any of these factors in children aged 9, 10, and 11 years old. 
This is something that should be explored in future research.  
 
7.5 Original Contributions to Knowledge 
As earlier stated, the overall aim of the current study was to explore the experiences 
of children in relation to medicines, to use their views to develop a better understanding 
of the acceptability of medicine, and to re-develop the tools that are used to assess 
the acceptability of medicines. In this respect it has been successful. The study 
proposes three original contributions to knowledge.  
 
The first original contribution is that this study proposes a new definition of the 
acceptability of medicine, which can be operationalised for use in practice. This is 
based on the engaging with children and drawing on their experiences to enhance 
current knowledge and understanding of the concept. From the review of past 
literature, this is the first study that has involved children in this way.  
 
The second contribution to knowledge is the development of the “Framework of 
Children’s Medicine Acceptability”. This framework provides a conceptual contribution 
to knowledge. To date, this is the first study that has attempted to theorise the 
acceptability of medicine. This framework provides the foundations required to better 
define the concept and improve the assessment tools used to measure acceptability. 
An important contribution of this model is that it demonstrates that the acceptability of 
medicine is influenced by additional factors relating to the user that are not currently 
accounted for when developing and assessing the acceptability of medicines. Due to 
the nature of the model, there is clear scope for its potential transferability across other 
populations (e.g. older children, adolescents and adults), thus contributing to the 




The third contribution to knowledge is that this study provides a much-needed 
methodological contribution to existing knowledge regarding child-centred measures 
and assessment tools used to assess acceptability. Given the inconsistency in 
methods used to evaluate the acceptability of medicine, the improvement of this area 
is crucial to enhance medicines for children. This study contributes to improving 
assessment measures in two ways. Firstly, the study proposes new recommendations 
for the development of child-centred, child-friendly tools that could improve children’s 
engagement, understanding and use of measurement tools. Secondly, the Framework 
of Children’s Medicine Acceptability provides new and relevant items that should be 
included on assessment tools and measures that better reflects the acceptability of 
medicine to children, therefore providing an argument for a more valid set of items to 
assess acceptability.  
  
7.5.1  Conclusion 
The aim of this chapter was to discuss the findings in context of the broader body of 
literature. This study aimed to explore the perceptions and beliefs of children about 
the acceptability of medicine and the acceptability assessment measures. No previous 
research has focused on this in this population group and therefore the current study 
aimed to bridge this gap in knowledge. The original contributions to knowledge 
demonstrate that the aims and objectives of the study have been achieved. Knowledge 
has been developed in relation to children’s perceptions of the acceptability of 
medicines and this has led to presenting a new definition of the acceptability of 
medicines. In addition, the study demonstrates new knowledge in relation to the 
factors that are thought to influence acceptability. Finally, the study has increased 
knowledge about children’s perspectives of acceptability assessment measures. The 
following chapter offers strengths and limitations, reflections, and recommendations 
























































This concluding chapter will explore the quality of the study, its strengths and 
limitations, before offering recommendations for future research, researcher 
reflections and providing a final conclusion to close this thesis.  
 
8.2 The Quality of the Study, Strengths and Limitations 
When discussing the topic of evaluating quality in qualitative research, the current 
study draws on criteria from Lincoln and Guba (1985). These criteria are regarded as 
the “gold standard” (Whittemore, Chase and Mandle, 2001., p527), and represents the 
most used standards for evaluating qualitative research. It is suggested that quality 
should be evaluated on the study’s ‘trustworthiness’, i.e. how closely a study 
represents the perspectives of the research participants. In order to assess 
trustworthiness, four concepts are highlighted: credibility, transferability, auditability 
and confirmability (Lincoln and Guba, 1985).  
 
8.2.1 Credibility 
The credibility of a qualitative study refers to the extent “to which a study’s findings 
represents the meanings of the research participants” (Lietz & Zayas, 2010., p191). 
This relates to how authentic and accurate the study interpretations are to the 
descriptions provided by the participants (Drisko, 1997). In order to achieve credibility, 
it is reported that qualitative researchers should manage research reactivity and bias 
(Padgett, 2008). Research reactivity refers to any influence that either the researcher 
or the study procedures might have on the participants, whether that relates to the 
conduct of the study, questions asked, verbal and non-verbal communication and 
degree of participation (Lietz & Zayas, 2010). In order to manage this, it is proposed 
that researchers remain mindful of the research procedures and the potential 
influences.  
 
In the current study the researcher was conscious of the imbalances that may be 
present between the child and adult, and the researcher aimed to balance their own 
roles between researcher, leader, and friendly person. This, in part, took shape in 
being conscious of the environment in which the data were collected, as well as the 
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conduct and behaviour engaged with during the study. Research has found that 
children perform more competently in environments they are familiar with (Alderson, 
2004; Kellett and Ding, 2004), therefore each interview and workshop was purposely 
conducted in settings that the children were familiar with, whether this was the ‘chill-
out room’ in the schools, or other spaces such as the church halls and public spaces 
for the larger groups. Children took pride in their schools and group meeting rooms, 
explaining why certain rooms are used and showing around. Similarly, consideration 
was given to how susceptible children are to adult influence, and the pressure of the 
child to conform to adult instruction or questioning (Flewitt, 2005; Tangen, 2008). 
Therefore, it was attempted to build rapport with the children before conducting the 
research by visiting each data collection site, where possible, prior to carrying out data 
collection. The researcher attempted to enter into the children’s “culture of 
communication” (Christianson, 2004; p166), from introducing herself to the children by 
using her first name, rather than ‘Miss’ or an un-named visiting adult, to sitting on the 
floor alongside the children rather than sitting on a chair like the other adults or 
standing up like the other adults in the room might be.  
 
As well as research reactivity, qualitative researchers should also be aware of how to 
minimise researcher bias and build self-awareness. Researcher bias relates to the 
perspectives, worldview, and preconceived ideas of the researcher that may influence 
the research process, design of the study, data analysis, and presentation of the 
findings (Lietz, Langer and Furman, 2006). In research with children this is particularly 
important, and in the current study particular consideration was given to ensuring that 
the children were viewed as meaningful contributors in the study, rather than being 
included in the study as research subjects or “transitional objects” (Yardley, 2000; 
Maconochie, 2008, p2). 
 
In the current study the researcher was conscious of her position as a neophyte 
researcher, with little experience in healthcare, medicines, or research on the 
acceptability of medicine. It was initially feared that her lack of experience within this 
research topic would represent a significant limitation, not having the background or 
experience to connect with the children about their healthcare. However, the ‘outsider’ 
healthcare perspective became more a strength, as this allowed the researcher to 
engage in the research process with the belief/ orientation that the children were the 
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experts in the room. It was common during the process for the researcher to be 
unfamiliar with the names or purpose of particular medicines and would often end up 
asking the children to explain and expand when discussing certain topics regarding 
their experiences with medicines. This was found to encourage the children to take a 
more central role in the discussions, and this helped to balance the power between 
the researcher and the children. As well as this being a strength during the data 
collection in this study, it is also believed that this ‘outsider status’ in relation to 
healthcare also provided a strength during data analysis. Having never worked within 
pharmaceutical development the researcher did not come to analysis with any 
preconceived ideas about the typical considerations regarding medicines 
development and acceptability assessment and was therefore able to analyse the data 
without these views impacting on the interpretation.   
 
Similarly, researcher bias also includes the influence of subjective interpretation 
(Bradshaw, Atkinson and Doody, 2017). This was considered extensively for the 
current study in the methodology chapter (Chapter 3) and it was recognised from the 
outset that “the research process… cannot be considered as independent of the 
researcher” (Emond, 2005; p126). The influence of the researcher on any study is 
becoming more widely recognised, and so in the methodology chapter of this thesis 
(Chapter 3) the underpinning philosophical stance is transparent. This research was 
conducted under the constant awareness that “reflexivity is not an activity that occurs 
at one point in time, but instead represents a process that unfolds throughout the entire 
research process” (Lietz & Zayas, 2010). Evidence of reflexivity is apparent throughout 
this thesis, from the earlier chapters regarding philosophical underpinnings and data 
collection techniques, to reflections regarding assumptions and preconceived ideas of 
the child population, and the interpretation of their data (Davis, 1998). This reflexivity 
was particularly useful when interpreting the data, and this was accompanied by 
‘Listener and Observer” techniques in order to ensure as far as possible that the 
interpretation of what the children said and drew made sense in the context in which 
they occurred (Leavitt, 1995).  
 
Strategies to increase credibility include triangulation, member checking and thick 
descriptions (Padgett, 2008). For triangulation, Padgett (2008) defines it as the use of 
multiple sources to achieve a comprehensive picture. Therefore, by using a number 
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of sources to gather data qualitative researchers can achieve ‘completeness’ (Drisko, 
1997). In the current study, triangulation was achieved through the use of number of 
sources to collect data, including small group workshops, large events and one-to-one 
interviews. Similarly, member checking was also undertaken, by “corroborating the 
research findings by seeking feedback from the research participants” (Lietz & Zayas, 
2010; Creswell & Miller, 2000). Whilst this was not part of the formal data analysis 
process, the children were sought to be actively involved in the reviewing of 
observations or conclusions during the workshops and interviews, and were asked 
follow-up questions or for additional explanations in order to help clarify whether the 
researcher’s observations were in line with the children’s own perceptions (Clark, 
2004). This is in line with how Shenton (2004) describes member viewing, providing 
participants with draft ideas of the analysis and ascertaining their sense of agreement 
with the findings (Lietz & Zayas, 2010).   
 
Finally, within this thesis it is acknowledged that not all characteristics of the child 
population were measured, factors including health status, ethnicity and culture were 
not collected from the children. This therefore impacts on the extent that the study’s 
findings represents the meanings provided by the research population, and limits the 
transferability of the conclusions made within this thesis. Recommendations for further 
research on this topic addresses this issues, and provides recommendations for the 
framework to be studied in other child populations.  
 
8.2.2 Transferability 
As well as credibility, displaying that the study can be applied, or of use, to theory, 
practice and future research is also important (Lincoln & Guba, 1985). This refers to 
how transferable the study findings are to situations outside of the study, and how they 
can fit in to other contexts in a meaningful way (Sandelowski, 1986). As reported in 
Lietz & Zayas (2010), qualitative studies cannot be generalised by quantitative 
standards, due to the fact that the sampling employed in qualitative research is 
generally purposive and not probability. However, whilst generalisability is not 
something sought in qualitative research, “transferability is achieved when the findings 
have applicability to another setting, to theory, to practice, or to future research (Lietz 
& Zayas, 2010., p195). Therefore, in order to demonstrate how a study is transferable 
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it is suggested that the researcher identify key aspects of the study and evaluate the 
extent that these might be applicable to other contexts (Devers, 1999). In the current 
study, the acceptability of medicine has been evaluated in a child population. The 
findings suggest a new definition and theoretical underpinning of the concept of the 
acceptability of medicine. This definition and proposed theory may be applicable to 
other population groups, such as adolescents, adults and older adults. Similarly, 
suggestions made in Section 8.4 demonstrate how the study findings can be applied 
to regulations, practice and to future research.  
 
Race and ethnicity are being increasingly used as variables in health research 
(Sheldon & Parker, 1992), and the importance of recognising racial and ethnic 
differences is both a reflection of good science and social justice (Perez-Stable, 2018). 
In medicines research it is recognised that cultural differences influence perception of 
colour, shape and texture on the taste of a product (Wan et al, 2014), and therefore a 
limitation of this research is that race, ethnicity and culture data was not collected. 
However, this research relied solely on children self-reporting information about 
themselves, and the only data that was collected was their age and gender, both of 
which they could circle easily on the consent sheets. Following FDA guidance for 
collecting race and ethnicity data in clinical research, the children in the current study 
would have had to either self-report their race and ethnicity information, or a detailed 
race and ethnicity category page would have had to be included on patient consent 
forms (FDA, 2016). This was not thought to be appropriate, particularly when guidance 
for schools and local education authorities reports that parents should supply this data 
for children (Department for Children, 2009).  
 
It could also be argued that the inclusion of caregivers and adults may have provided 
a more holistic view of medicines acceptability when considering that acceptability is 
defined as the ability and willingness of both the child and caregiver to administer a 
medicinal product. However, the current study was focussed specifically on the beliefs, 
perceptions and understanding of children regarding the acceptability of medicines. 
This study was conscious that the gaps in current knowledge are specific to 
considerations of children, and the methodology and methods section provides 
detailed information regarding why the focus on children’s knowledge is so crucial to 
this topic area. Therefore, whilst the inclusion of parents and caregivers were outside 
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the scope of the current study, this is proposed as a recommendation to future 
research.  
 
Finally, it is acknowledged that data were not collected from the children about factors 
including health status, ethnicity and culture. This absence of this data therefore limits 
the transferability of the findings and the framework that was proposed. It is 
recommended that future research on this topic should include data collection of these 
key demographic factors. 
 
8.2.3 Auditability   
The third of consideration of quality as identified by Lincoln and Guba (1985) is 
auditability. This refers to the extent that the study procedures are documented, 
allowing for another person outside of the study to follow and evaluate the process 
(Padgett, 2008). The qualitative process does not adhere to strict procedures, and it 
has been suggested that a flexible and iterative process is what makes for a high-
quality qualitative project (Davies and Dodd, 2002; Morrow, 2007). Being iterative and 
allowing the process to change as the study went on was a key part of the development 
of the current study, as outlined in Chapter 4 Methodology the methods and data 
collection instruments were adapted for the different settings and individual children 
that took part. Data collection methods were adapted and revised as per feedback 
during the initial stages of the study (this is discussed in chapter 4), and sample sizes 
were flexible allowing for the recruitment of an additional data collection site following 
the commencement of the study (discussed in section 4.1).  
 
In order to document the changes that occur during the process, it is suggested that 
the researcher keeps an audit trail (Lietz & Zayas, 2010). This is a written account of 
the research process, outlining what happened during the study and the 
accompanying reflexions of the researcher. Within Chapters 3 and 4 of this thesis, the 
study process is outlined and the researcher maintained a reflexive approach whilst 
outlining this. Furthermore, the researcher met with the supervisory team and kept a 
detailed account of each research meeting at least once a month over the three years. 
These meetings are also referred to as peer debriefing (Padgett, 2008), where 
members of the team can leave comments and discuss the project, as well as be the 
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place of research decisions, data analysis discussions and study feedback. The 
conduct of meetings such as these can enhance the quality of a project (Shenton, 
2004). Peer debriefing is also said to promote reflexivity, generate new ideas and 
identify potential issues. In order to increase reflexivity and accountability in the current 
study, the research team consisted of both experts in academia, who were key in 
advising of the study set up and write up, as well as professionals in paediatric 
medicine and acceptability who could provide a more in-depth, expert view during 
certain points of the study (such as clinical data analysis and knowledge). 
 
The literature review followed a search strategy that could be replicated but the search 
terms and strategy did not include all methods of assessment. For example, search 
terms such as ‘visual analogue scale’ and ‘questionnaire’ were not included. The 
absence of these search terms potentially limits the findings of the review as this 




Finally, confirmability refers to the findings being confirmed by others (Drisko, 1997; 
Lincoln & Guba, 1985). To achieve confirmability, a study must demonstrate that the 
findings and data are clearly linked, “that the works’ findings are the result of the 
experiences of the informants, rather than the characteristics and preferences of the 
researcher” (Shenton, 2004., p72).  
 
This can be achieved through a number of methods, see Table 5 for a summary of 
strategies. In the current study audit trails and peer debriefing have already been 
mentioned in Section 8.2.3, however member checking is also useful in allowing other 
collaborators that are external to the research team an opportunity to influence the 
research procedures. As outlined in the introduction chapter (Chapter 1), there is a 
growing interest in the acceptability of medicines, and the role of children in improving 
this. The current study was developed with patient and public involvement from the 
YPAG at Alder Hey Children’s Hospital. In the first year of this study, research ideas 
were taken to one of the YPAG meetings, where the children and young people 
discussed, edited and contributed to the topics they thought would be useful to 
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research. Incorporating the perspectives of children and young people from the YPAG 
helped to ensure that the study was built with their ideas and perspectives in mind 
from the outset. This group was also fundamental in the reviewing and editing of the 
patient information leaflets and consent sheets, ensuring that the outward facing 
information was appropriate. The children at the YPAG thought that this study was 
important. 
 
Table 8.1: Research strategies for increasing trustworthiness of qualitative research (Lincoln and Guba, 
1985; Padgett, 2008; Shenton, 2004). 
Reflexivity A thoughtful consideration of how a 
researcher’s standpoint can influence 
the research. 
Observer Triangulation Using more than one researcher to 
analyse the data. 
Data triangulation Collecting data from multiple sources 
such as interviews and focus groups.  
Prolonged engagement Conducting multiple interviews or 
spending extended time with participants 
to achieve an exhaustive look at the 
experience. 
Member checking Including participants in analysis or 
returning to a sample of participants to 
corroborate the findings. 
Thick descriptions A thorough representation of the 
phenomenon of inquiry and its context as 
perceived and experienced by study 
participants. 
Audit trail Keeping a detailed written account of the 
research procedures. 
Peer debriefing Meeting with mentors or other 
researchers engaged in qualitative 
research to dialogue regarding research 
decisions. 
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Negative case analysis Seeking contrasting evidence through 
sampling and analysis.  
 
In order to demonstrate trustworthiness and quality as outlined by Lincoln and Guba 
(1985), a qualitative research project must be shown to demonstrate some of the 
outlined strategies in Table 8.1. It is argued that whilst not required to employ all of 
these strategies, there should be evidence that the researcher has addressed 
research reactivity and bias and has addressed transferability, auditability and 
confirmability (Creswell & Miller, 2000). It is believed that the current study addresses 
these criteria of quality and provides evidence of this throughout this thesis.  
 
8.3 Strengths Through Contributions to Knowledge 
Although not a specific component of Lincoln and Guba’s (1985) criteria it is proposed 
that the original contributions to knowledge can be seen as strengths. These 
contributions have been explored in depth in the discussion chapter (Chapter 7) but a 
summary of them is presented here as evidence of the quality and rigour of the study.  
1. This study proposes a conceptual contribution based on a new definition of the 
acceptability of medicine, that can be operationalised for assessment.  
2. The “Framework of Children’s Medicine Acceptability” has been developed 
from this study. This model provides the operationalisation of the concept of 
acceptability in relation to children’s medicine.  
3. This study contributes to the methodological grounding of the acceptability of 
medicines for children. Involving the child in the re-development and design of 
acceptability assessment measures.  
4. Finally, findings from this study indicate the importance of widening the window 
of opportunity to consult with children and young people at earlier stages of 
product development in order to improve product acceptability. 
 
8.4 Recommendations  
As mentioned in Section 8.2, the recommendations of a study are presented as a 
strength of quality, particularly in relation to the transferability of the study. The 




8.4.1 Recommendations for regulators 
Based on the findings of this study, two recommendations are made for regulatory 
bodies to consider.  
1. Currently, there is no extended guidance or suggestions about how formulation 
developers and researchers can address the user-related factors. The factors 
identified from this study relating to experience, psychological and affective 
responses should be considered in acceptability assessment as this would help 
provide a better measure of the acceptability of medicines. 
2. Policy on acceptability assessment should include a definition that considers 
the acceptability of the user and of the product. The current study recommends 
a definition that has been developed from the findings and that can be 
operationalised for use in the development and assessment of acceptable 
formulations.  
3. Existing policy should be reconsidered to include children’s involvement in 
aspects of acceptability assessment in the early development stages.  
8.4.2 Recommendations for practice  
Based on the findings of this study, two key practice recommendations are presented:  
1. Children should be included in acceptability assessment.  
2. Acceptability testing with children should be carried out at an earlier stage of 
formulation development.  
 
8.4.3 Recommendations for further research  
The findings from this study are an important starting place for the inclusion of children 
in research related to the development of acceptable paediatric formulations and 
assessment of the acceptability of medicines.  
Three key recommendations for further research are presented:  
1. Research about the applicability and value of using the Framework of Children’s 
Medicine Acceptability in acceptability assessment should be undertaken as this 
framework has the potential to improve the acceptability of medicine for children.   
2. Research should investigate parents and caregivers’ experiences of medicinal 
products and the factors contributing to the acceptability of medicine for children. 
This should build on the qualitative methods outlined in the current study. 
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3. Research is needed to develop and design acceptability measures suitable for 
use with children’s formulations; these studies should involve children.  
4. There is a need for future research to explore acceptability in more detail and also 
to examine the value of the proposed Framework of Children’s Medicine 
Acceptability with a more focused population of children than those recruited to 
this study; this population would be with children with long-term conditions who 
require medication as this represent a group of children with a greater depth of 
experience in taking medicines. This would enable a wider exploration of 
acceptability and adherence. 
5. Research is also needed to examine acceptability with children from a range of 
ethnicities and cultures.  
 
8.5 Conclusion 
In conclusion, the study reveals that children perceive the acceptability of medicine as 
a multi-dimensional construct related to two key aspects: the product and the user. 
The findings imply that improving knowledge and understanding about children’s 
perceptions and beliefs of medicine, and its acceptability, can guide researchers and 
clinicians in better defining the concept of the acceptability of medicine.  
 
Based on the literature underpinning this study it was apparent that children were 
largely omitted from acceptability research regarding medicines (Mistry & Batchelor, 
2017; Ranmal et al, 2018). This research has explored the perceptions, experiences 
and knowledge of children in the acceptability of medicines and assessment 
measures. It is concluded that: 1) children are generally knowledgeable about their 
treatment and medicines; 2) children’s beliefs and attitudes influence their 
acceptability of medicines; 3) children want to be involved in their medicines, and the 
improvement of their knowledge about the benefits of treatment may be a facilitator to 
improving acceptability and adherence; 4) children have contributed to the 
understanding of the acceptability of medicines; 5) the “Framework of Children’s 
Medicine Acceptability” has the potential to improve medicine development and 
assessment; and 6) acceptability assessment measures can be made more child-
friendly and age-appropriate by including children in their design and development.  
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It is hoped that this research will contribute to the limited literature that has involved 
children in medicines development and acceptability assessment. It is also hoped that 
this study emphasises that children can improve knowledge and understanding in 
topics that concern them, and their inclusion of the child contributes positively to such 
research. Finally, it is hoped that this study will help current practice, regulations and 
research to consider that multiple perspectives can only enhance understanding on 
topics such as these.  
 
8.5.1 Final word 
It seems fitting at the end of this child-centred thesis to hand the very final word back 
to the children as a reminder that they have much to say about the acceptability of 
medicines. So, this thesis ends with some wise words from three of the children. 
Alex clearly understands acceptability when he says:  
 
“Acceptability means like if its ok for you, like yes or no. If you’re fine taking it”.   
 
And two of the girls I interviewed via Brownies sum up what is important to them in 
terms of the acceptability of medicine by mentioning taste, magic, children’s 
preferences, children’s understanding and the importance of choice: 
 
 It would have the taste of strawberry Calpol because I like the taste of Calpol, 
and people will feel magical with this medicine. It might be horrible if an adult 
tastes it, because adults have different tastes to children. But as a child, as a 
kid they’d understand more,  
 
And then the child could choose. 
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Appendix 37: Table detailing the number of children who participated in 
each activity  
 Schools Clubs Hospital Museum Total 
Groups  S1G1 S1G2 S2G1 R1W1 R1W2 R2 B1 Ward  Museum  Total 
 Total 3 3 2 7 
 




8 19 3 81 111 
Activity 
sheets 
5 19 0 81 105 
Ranking 
activities 




5 11 3 0 19 
Audio 
recorded 
Yes, 3 recordings. Yes, 4 recordings. Yes, 3 
recordings. 
No 10  
 
